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CHAPTER 1 
General introduction 
1.1 Introduction 
Congenital heart malformations (CHM) are among the most common congenital defects, occurring in 
8 out of 1000 live-births 1• In the past decade significant progress has been made in the identification 
of genes implicated in the signaling pathways involved in cardiovascular development. A major con-
tribution has come from the study of model systems from fruit fly to mouse. Additionally, multiple dis-
ease genes implicated in genetic forms of human CHM have been identified, mainly through positional 
genetics in multiplex families. Especially human syndromes with CHM ("syndromic" CHM) have been 
instrumental in the elucidation of these disease genes, but recently also a number of disease genes 
implicated in "non-syndromic" CHM have been identified. 
In this chapter the most important forms of syndromic CHM with the different signaling pathways 
involved, and the genetic and environmental factors contributing to non-syndromic CHM are sum-
marized. Several recent reviews have addressed the progress in the identification of these genes and 
pathways H. 
1.1.1 Genetic pathways in cardiac development 
1.1.1.1 Transcriptional regulators of cardiac precursors 
Heart development starts in early gestation when a crescent of mesodermal tissue originating from 
the anterior lateral plate commits to the cardiac lineages, and differentiates into two pools of progeni-
tors known as the first heart field (FHF) and the second heart field (SHF) (see Figure 1 from ref"). FHF 
cardiomyocyte progenitors arise from the splanchnic mesoderm and are mainly involved in formation 
of the heart tube and left ventricle. The right ventricle and outflow tract are derived from the SHF pro-
genitors, originating from the pharyngeal mesoderm 11 •12• Both the development of the FHF and SHF 
appear to be regulated by complex signaling networks involving members of the bone morphogenetic 
proteins (Bmp), sonic hedgehog (Shh), fibroblast growth factor (Fgf), Wnt, and Notch proteins'-"·"·". 
A core set of evolutionary conserved transcription factors and regulators (Nkx, Mef2, Gata, Tbx and 
Hand families) controls heart development from early on by determining cardiac cell fate and expres-
sion of cardiac effector genes. These encode contractile proteins such as sarcomeric proteins and other 
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unknown target genes regulating morphogenesis 13 (Figure 1 from ref 10). Many of these transcription 
factors and regulators, including Nkx2-5 and Gata4, operate in both the FHF and the SHF, whereas oth-
ers are preferentially expressed in one of these two fields: Hand1 and TbxS in the FHF, and lsl1, Tbx1, 
Foxh1 and Fgfin the SHF 15.Two important upstream regulators in theSHF are lsl1, a UM-homeodomain 
transcription factor, and Foxhl. Several studies have indicated that lsl1 expression defines a multi potent 
cardiovascular SHF progenitor that can differentiate into specific mature cardiac, pacemaker, smooth 
muscle, and endothelial cell types 16,17• Both lsl1 and Foxh1 are required for the proliferation and survival 
of SHF cells and the regulation of many other transcription factors and signaling pathways 13,18• lsl1 
regulates Mef2 expression, a myogenic transcription factor that is known to be associated with differ-
entiation of all muscle types. Foxh 1 interacts with Mef2c and is required for right chamberformation 19• 
GATA factors and Nkx2.5 are essential for Mef2c expression in the SHF. The latter interacts with Hand2, 
and is required for proper development of the right ventricle 20• Another important cardiac transcription 
factor isTbx20, which controls expansion ofFHF- and SHF-derived cells and outflow tract development, 
possibly by regulating Nkx2.5 and Mef2c 21 • Also several microRNAs (miRNAs) functioning as negative 
regulators of target RNAs, are expressed in the developing heart, including MiR1-1, MiR1-2, MiR133a-1 
and MiR133a-2. These noncoding RNAs play a role in "fine-tuning" the amount of key proteins during 
cardiogenesis 10• 
Figure 1 I Pathways regulating cardiac morphogenesis. 
Transcription factors, signaling proteins, and miRNAs that play a role in different regions ofthe developing heart are shown. Positive effects are indicated by 
arrowheads, and negative effects by bars. Physical interactions are indicated by dashed lines. The FHF is the dark and medium gray area of the atria and left 
ventricle. The SHF is the white area. The conotruncus is also partly in gray: this represents the area where the cardiac neural crest cells migrate into the outflow 
tract from the neural folds to septate the outflow tract and panem the bilaterally symmetric aortic arch arteries (Ill, JV, and V!)). From ref 1G with permission 
from Dr. Deepak Srivastava. 
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1.1.1.2 Left·right asymmetry and the NODAL signaling pathway 
The molecular network regulating left-right (LR) asymmetry of the body plan has been studied exten-
sively, and more than 80 genes involved in this process have been identified 22-28• The NODAL signaling 
pathway is essential in LR patterning. Four essential proteins in this pathway are the highly conserved 
proteins Nodal, Lefty1, Lefty2 and Pitx2, which are all expressed asymmetrically near the midline or 
in the left lateral plate mesoderm at comparable developmental stages 5•28• Both the Nodal and the 
sonic hedgehog (Shh) signaling pathways converge on the transcription factor Pitx2. Pitx2 is initially 
expressed asymmetrically along the LR axis in the linear heart tube, but this asymmetry translates into a 
dorsal-ventral polarity in the looped heart tube. The precise downstream cardiac targets of the NODAL 
signaling pathway remain unknown. The NODAL signaling pathway and related CHMs are further de-
scribed in paragraph 1.1.2.4 of this Chapter and in Chapter 2. 
1.1.1.3 Formation of the cardiac outflow tract 
Following rightward looping of the heart tube, cardiac neural crest cells migrate into the outflow tract 
to septate the outflow tract and pattern the bilaterally symmetric aortic arch arteries 29• Second heart 
field derived myocardial cells interact with these neural crest cells via Tbx1-dependent secretion of 
growth factors such as Fgf8 30• 
1.1.1.4 Valvulogenesis 
Signal transduction pathways including Wnt/~- Catenin, Vegf, Notch, Bmp- Tgf~, and Erb, and tran-
scription factors including different Gata, Fox and Sox transcription factors have all been implicated in 
heart cushion and valve formation in mice. These different signaling pathways exhibit extensive cross-
talking, resulting in a complex integrated process of cardiac valve morphogenesis (for review: see ref 
31
.32). Genetic pathways implicated in cardiac valve formation and human CHM with cardiac valve de-
fects are further described in Chapter 3. 
1.1.2 Syndromic congenital heart malformations 
CHM occur in many human syndromes, which reflect the multitude of genes involved in cardiovascular 
development. Such syndromes might be due to chromosomal imbalances. Genomic deletions detect-
able by conventional cytogenetics are found in approximately 13% of children with CHM, and include 
trisomy 21, 13 and 18, Turner syndrome and Cri-du-Chat (Sp-) syndrome 33.34. Submicroscopic deletions, 
including 22q11.2 deletion syndrome, Williams syndrome (7q11.23 deletion), Smith Mag en is syndrome 
(17p11.2 deletion) and Wolf-Hirschhorn syndrome (4p- deletion) comprise a considerable subgroup of 
syndromic CHM. Recent CGH array studies demonstrate a high frequency of chromosomal imbalances 
in syndromic CHM 35, and a lower frequency in non-syndromic CHM 36• 
Positional genetics studies in humans have led to the identification of many disease genes that are 
implicated in monogenic forms of syndromic CHM. Here we only review the more frequent syndromes 
that led to the discovery of different pathways involved in cardiovascular development. 
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1.1.2.1 Transcription factors in Holt-Oram syndrome and related disorders 
The first identified single gene mutation associated with inherited CHM was identified in the T-box 
transcription fator TBXS gene, and was shown to cause Holt-Oram syndrome 37•38.1ndividuals with Holt-
Cram syndrome display great phenotypic variability with mild to severe limb defects, and various types 
of CHM, including atrial septal defect (ASD), ventricular septal defect (VSD), tetralogy of Fallot (TOF) 
and atrioventricular conduction defects 37.38• Truncating mutations cause substantial cardiac and limb 
defects, whereas missense mutations lead to either more prominent heart or more severe limb defects 
depending on the specific gene domains affected 39• Soon after the discovery ofTBXS mutations in Holt-
Oram syndrome, mutations in another transcription factor gene NKX2.5 (NKX2E) were discovered in 
families with inherited ASD and atrioventricular block.w. Murine models have shown thatTbxS and the 
homeoboxtranscription factor Nkx2.5 interact physically and synergistically to induce downstream tar-
gets 41 A2• TbxS and Nk.x2.5 both interact with the zinc finger transcription factor Gata4, and in humans 
GATA4 mutations lead to non-syndromic CHM, including septal defects, PS andTOF. This transcriptional 
network was further extended by the identification of the Sa!l4 gene whose gene product has been 
shown to interact with TbxS in a mouse model 43• In humans the SALL4 gene is implicated in Okihiro 
syndrome, a malformation syndrome with cardiac septal defects and radial ray defects clinically over-
lapping Holt-Oram syndrome 44-46. Recently, mutations in the T-box DNA-binding domain ofTBX20 were 
implicated in cardiomyopathy and septal defects in humans 47• Murine Tbx20 also interacts with the 
Nk.x2.5-Gata4-Tbx5-Sall4 complex 48A9• Patients with mutations in all these transcription factor genes 
mainly show septal defects, providing further evidence this transcriptional network is essential for sep-
tal development. Other transcription factor genes that interact with this network, such as ISL1, TBX2, 
GAT AS, HAND2, MEF2c, as well as downstream targets might be additional functional candidate genes 
for human CHM 19•48•50•51 • 
1.1.2.2 TBX1 gene in 22q11.2 deletion syndrome and related disorders 
The 22q11.2 deletion syndrome is one of the most common human microdeletion syndromes with an 
estimated prevalence of one in 4000 live births 52• CHM in this syndrome include outflow tract anoma-
lies such as interruption of the aortic arch (IAA), persistent truncus arteriosus {PTA), transposition of the 
great arteries (TGA), Tetralogy of Fallot (TOF), and double outlet right ventricle (DORV) "· Disruption of 
one or two copies ofthe Tbx1 gene in mice results in heart defects similar to those seen in 22q11.2 de-
letion patients 5455, providing evidence that TBX1 haploinsufficiency is the cause of the cardiac defects 
seen in 22q11.2 deletion patients. Subsequently, human TBX1 mutations were demonstrated to cause 
non-syndromic CHM including VSD and IAA 56..57, and also most of the anomalies seen in the 22q11.2 
microdeletion patients ss-.6o. 
TBX1 is needed for the proliferation of SHF cells before they differentiate into cardiomyocytes, and in-
teraction ofSHF cells with neural crest cells that migrated into the outflow tract.Tbx1 is a direct target of 
Foxc1 and Foxc2, two closely related Fox transcription factors 61•62• Mutations in the human FOXC2 gene 
cause Lymphoedema-distichiasis syndrome, which is associated with CHM, including abnormalities of 
the outflow tract such as TOF, in 6% of patients 63• Murine Tbx1 expression regulates the proliferation 
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of the splanchnic mesoderm and the expression of FgfB. FgfB mutations in mice result in CHM similar to 
those with neural crest interruption, including PTA, DORV, and VSD 64• Also mutations in other signaling 
pathways affecting neural crest cell migration, including the endothelin and semaphoring pathways, 
cause outflow tract anomalies {for review: see ref 29). 
1.1.2.3 RAS·MAPK signaling pathway in llloonan syndrome and related disorders 
Noonan syndrome, LEOPARD syndrome, Cardia-facio-cutaneous {CFC) syndrome and Costello syn-
drome are clinically and genetically heterogeneous conditions with overlapping clinical features, in-
cluding dysmorphic features, short stature, and cardiac defects such as hypertrophic cardiomyopathy 
(HCM) and pulmonary valve stenosis (PS) 65•66• Molecular studies of these syndromes have revealed a 
signaling pathway referred to as the RAS·MAPK signaling pathway, which includes the PTPN11, 5057, 
KRA51, RAF7, BRAF, MEK1 and MEK2 genes. Mutations in all of these genes can lead to cardiomyocte 
hypertrophy and pulmonary valve anomalies, predominantly by increased signaling leading to sup-
pression of calcineuric/NFAT transcriptional activity 67•68• 
Noonan syndrome is an autosomal dominant condition caused by mutations in PTPN17 in approximate-
ly 50% of patients 69.1n a minority of patients with Noonan syndrome, mutations have been found in 
the 5057 (17-28%) 70•71 , KRA5 (2%) n,n or RAF1 (3-17%) 74•75 genes. Mutations in 50$1 are associated with a 
milder phenotype characterized by normal stature and absence of cognitive deficits. Mutations in KRA5 
72.73 on the other hand may lead to a more severe phenotype resembling CFC syndrome. 
LEOPARD syndrome (Lentigines, ECG abnormalities, Ocular Hypertelorism, Pulmonary valve stenosis, Ab-
normalities of the genitalia, Retardation of growth, Deafness) shares several clinical features with Noonan 
syndrome, including facial dysmorphism, short stature and CHM, but is characterized by pigmentary 
abnormalities such as lentigines as seen in Neurofibromatosis type 1 patients. LEOPARD syndrome is 
caused by heterozygous mutations in PTPN11 in 90% of cases and RAF1 mutations in a minority of 
cases (3%) 76•77• The Leopard syndrome-associated PTPN11 mutations are distinct from PTPN17 muta-
tions found in Noonan syndrome: Leopard mutations lead to dominant-negative effects that disrupt 
the growth factor activity of Ras effectors, whereas Noonan mutations are gain-of-function mutations 
that lead to enhanced phosphatase activity, resulting in activation of the RAS-MAPK pathway 78• 
Cardia-facio-cutaneous (CFC) syndrome is caused by an autosomal dominant mutation in the BRAF (37-
78%), KRA5 (5%), MEK1 or MEK2 (1 0-15%) genes encoding additional proteins in the same RAS-MAPK 
pathway 79-81• Although the clinical features of CFC syndrome overlap with Noonan and Costello syn-
drome, skin disease (eczema, hemangioma, hyperkeratosis and keratosis pilaris), mental retardation, 
seizures and optic nerve hypoplasia may be key features to discriminate CFC syndrome from Noonan 
syndrome or Costello syndrome 82• 
Costello syndrome phenotypically overlaps with Noonan syndrome and CFC syndrome, and is charac-
terized by failure to thrive, cognitive impairment, tumor predisposition, loose skin, nasal papillomata, 
and cardiac anomalies including HCM and atrial tachycardia 83•84• Costello syndrome is caused by het-
erozygous mutations in the HRA5 gene in over 80% of patients 80.84-ll6. 
The main CHM seen in individuals with Noonan syndrome, LEOPARD syndrome, CFC syndrome, and 
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Costello syndrome are PS and HCM, but also VSD and TOF can be found. PSis less frequent in Costello 
syndrome than in the other 3 syndromes. RAFJ mutations in Noonan syndrome and LEOPARD syn-
drome lead to HCM in many cases 74•75•87• Arrhythmias are observed in over 30% of patients with Costello 
syndrome 88,and might be a discr"1minating cardiac feature with Noonan and CFC syndrome, as cardiac 
rhythm abnormalities are infrequent in the latter 2 syndromes 82• CHM seem to be less frequent in CFC 
patients with a MEK7 or MEK2 mutation 81 • 
Although there is an unconfirmed suggestion that PTPN17 mutations may play a role in non-syndromk 
PS, mutations in the RAS-MAPK pathway have not been convincingly found to cause non-syndromic 
CHM a9,9o. 
1.1.2.4 NOTCH signaling pathway in Alagille syndrome and related disorders 
Alagille syndrome is an autosomal dominant disorder characterized by liver disease, vertebral anoma-
lies, dysmorphic features, and various types of CHM. CHMs include PS, TOF and peripheral pulmonary 
arterial stenosis. In approximately 90o/o of patients a mutation is found in the JAG1 gene encoding Jag-
gedl 91-93.Jagged1 is a member of the NOTCH signaling pathway and is expressed in a specific popula-
tion of endocardial cells of the outflow tract that undergo epithelial to mesenchymal transformation. 
JAG7 mutations have also been found in patients with non-syndromicforms ofTOF with PS, pulmonary 
atresia and absent pulmonary valve 94,9s. 
NOTCH signaling is dependent on the interaction between Notch ligands (delta-like 1,3,4 and Jag-
ged1,2) and receptors (Notch 1-4) enabling the transduction of signals between neighbouring cells. 
The NOTCH signaling pathway is involved in many steps in both vascular and cardiac development, 
including cardiomyocyte differentiation, boundary formation of the atrioventricular canal, valve de-
velopment, ventricular trabeculation, and outflow tract remodeling 8•96• Not surprisingly, mutations in 
other components of this pathway also lead to CHM. NOTCH2 mutations have been found in a minority 
of patients with Alagille syndrome with renal disease representing a differentiating feature between 
patients with JAG7 and NOTCH2 mutations 97• NOTCH7 mutations have been identified in individuals 
with bicuspid aortic valve (BAV) and aortic valve stenosis (AS) although the CHM spectrum included 
also mitral atresia, hypoplastic left heart (HLH) and DORV". 
1.1.25 TGFB signaling pathway in Marfan syndrome and related disorders 
Aortic aneurysms represent a common vascular malformation with life-threatening implications. Aortic 
aneurysm can be part of syndromes including Marfan syndrome (FBN7 gene) 99"101 , Loeys-Dietz syn-
dromes (TGFBR1/2 genes) ,,.,,.,, Ehlers-Danlos syndromes (COL3A 1 gene and FLNA gene) "'·"' and 
arterial tortuosity syndrome (SLC2A10 gene) "'·"'· Upregulation of the TGF~ signaling pathway plays 
a central role in the pathogenesis of Marfan syndrome, Loeys-Dietz syndrome and arterial tortuosity 
syndrome (ATS), making this pathway the primary pharmacological target for the development of new 
treatment strategies for arterial wall disorders. In transgenic mouse models Losartan, an angiotensin II 
type 1 receptor, inhibitsTGF~ signaling and results in a rescue ofthe aortic pathology"'· Although the 
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results of human trials with Losartan have to be awaited, a preliminary report suggests that Losartan 
therapy will benefit young patients with severe Marfan syndrome 110• 
Non-syndromic aortic aneurysms can be due to mutations in sarcomeric protein genes such as the 
MYH11 gene encoding the smooth muscle cell myosin heavy chain 111 and the AUA2 gene encoding 
smooth muscle cell a-actin 112.1t is currently not known whetherTGFj3 signaling is increased in patients 
with mutations in these sarcomeric protein genes, but interaction between the TGFI3 pathway and sar-
comeric protein genes has been reported 113• 
1.1.3 Non-syndromic congenital heart malformations 
The majority of CHM with monogenic inheritance is associated with other malformations and consti-
tutes syndromic forms of CHM.In contrast, most cases of non-syndromic CHM occur sporadically. Fami-
lies with clear monogenic inheritance of non-syndromic CHM are scarce, thereby impairing the identi-
fication of disease genes involved in non-syndromic CHM by a classical positional genetics approach. 
The low percentage of single gene mutations with high penetrance argues against a prominent role of 
these mutations in sporadic cases of CHM. However, only a limited number of human genes involved 
in cardiogenesis are currently known. Taken into account the large number of genes that play a role in 
murine cardiogenesis, many human genes are expected be identified within the coming years. Next-
generation sequencing most likely will play an important role in identifying these genes. 
Overall, the recurrence risk of non-syndromic CHM (defined as the risk of a child with CHM after a previ-
ous child with CHM) is usually in the order of2-1 0 o/o. The traditional hypothesis to explain this relatively 
!ow non-Mendelian recurrence risk suggests that the majority of sporadic cases with non-syndromic 
CHM are due to multifactorial inheritance involving a multitude of susceptibility genes with reduced-
penetrance mutations superposed on unfavorable environmental factors. The different environmental 
factors, disease genes with monogenic mutations, susceptibility genes with reduced-penetrance muta-
tions and somatic mutations implicated in the development of non-syndromic congenital heart malfor-
mation are reviewed extensively in Chapter 1.2 114 and are briefly discussed below. 
1.13.1 Environmental factors 
The environmental factors inducing CHM include mainly maternal embryotoxic factors, including ma-
ternal diabetes, hyperphenylalaninemia, hyperhomocysteinemia, medication, alcohol abuse, exposure 
to solvents, and nutrient deficiencies 11 s. 
Also a few paternal risk factors have been reported, including cannabis and cocaine use and exposure 
to organic solvents. 
1.13.2 Rare variants with high and reduced penetrance 
The fetal developmental program of the heart involves many signaling pathways with ligands-receptor 
interactions, secondary signal transduction pathways and transcription factors that determine the ex-
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pression of cardio-specific genes. Significant ligand-receptor promiscuity and cross-talking between 
the different signal transduction pathways exists. Germline mutations contributing to non-syndromic 
CHM have been identified in a multitude of genes belonging to these pathways, including genes en-
coding ligands (NODAL, LEFTY7, GOF7, JAG7), receptors (CFC7, TOGF7, ACVR2, NOTCH7), transcriptional 
regulators (CITE02, FOG2, MYOCO), transcription factors (ZIC3, NKX2.5, TBX1/5!20, GATA4, FOXH1), and 
down stream targets (AUC7, MYH6). However, in only a minority of patients with non-syndromk CHM 
a mutation can be identified (for reviews: see refs 2•9•114•116).1n most CHM genes both high- and reduced-
penetrance mutations have been identified. The high-penetrance mutations result in pedigrees with 
clear autosomal dominant inheritance. The reduced-penetrance mutations are not only found in the 
patients with CHM, but can also be present in asymptomatic first-degree relatives, resulting in pedi-
grees with a non-Mendelian inheritance pattern. Determination of the degree of penetrance of such 
mutations is very difficult, as it requires a combination of DNA analysis and careful cardiologic examina-
tion in many family members. 
1.1.3.3 Common variants with low penetrance 
A number of susceptibility genes with common variants with low penetrance of CHM have been identi-
fied, usually by association studies. Most of these genes, including the MTHFR, MTHF07, MTRR, TCN2, 
SLC19A 1, and NNMT genes, are involved in the methylation cycle through the conversion of homo-
cysteine into methionine. Some of these studies have not been replicated or have provided contra-
dictory results. Other susceptibility genes including the NPPA gene encoding atrial natriuretic peptide 
(ANP) "',the N053 gene encoding endothelial nitric oxide synthase (eNOS)"', the VEGFgene encoding 
vascular endothelial growth factor 119•120, and the NFATC7 gene encoding a calcineurin-dependenttran-
scription factor 121 have been described, but the exact functional significance of these remains unclear. 
Genome-wide association studies (GWAS) have not yet been reported in CHM. 
1.1.3.4 Somatic mutations 
Somatic mutations not present in the germ line may also contribute to non-syndromic CHM. This might 
explain why the candidate gene approach for non-syndromic CHM usually performed in constitutional 
DNA derived from blood has had little success. Many years after Knudson's theory about somatic muta-
tions gained universal acceptance, this concept remains largely confined to tumor biology. Only recent-
ly somatic mutations confined to affected cardiovascular tissue have been reported in CHM. The group 
of Reamon-Buettner and Borlak m-m has reported the majority of somatic mutations in CHM, including 
mutations in the cardiac transcription factors NKX2.5, TBXS, GATA4, HEY2 and lately HAN07. The abun-
dance of somatic mutations reported by this group contrasts with the limited number of mutations in 
other studies: no NKX2.5 gene mutations were found in cardiac tissue from patients with BAV and as-
sociated aortic aneurysm 128, and no somatic 22q11.2 deletions could be identified in heart tissue from 
patients with conotruncal heart defects without germ line 22ql1.2 deletion 129• Therefore, the concept 
of somatic mutations in the heart leading to CHM awaits further confirmation. 
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Abstract 
The genetic defect in most patients with non-syndromic congenital heart malformations (CHM) is un-
known, although more than 40 different genes have already been implicated in non-syndromic CHM. 
Only a minority of CHM seems to be due to monogenetic mutations, and the majority occurs sporadi-
cally. The multifactorial inheritance hypothesis of common diseases suggests that the cumulative effect 
of multiple genetic and environmental risk factors leads to disease. 
We review here the different environmental factors, monogenic disease genes with high-penetrance 
mutations, susceptibility genes with reduced-penetrance mutations, and somatic mutations implicat-
ed in non-syndromic CHM. 
Introduction 
Congenital heart malformations (CHM) are among the most common human congenital defects, oc-
curring in 6 to 8 out of 1000 live-births 1• The majority of CHM with monogenic inheritance is associ-
ated with non-cardiac malformations, and thereby constitutes syndromic forms of CHM. These include 
. well known examples such as Holt-Oram syndrome, Alagille syndrome, and Noonan syndrome, among 
many others (for review: see refs 2-4). Many of these syndromes have a monogenic mode of inheritance. 
In contrast, most non-syndromic CHM occurs sporadically, and families with clear monogenic inherit-
ance of non-syndromic CHM are scarce s..a. This precludes the identification of human disease genes in-
volved in non-syndromic CHM by a classical positional genetics approach. The sporadic nature of most 
non-syndromic CHM is traditionally explained by the multifactorial inheritance model which involves a 
multitude of susceptibility genes with low-penetrance mutations (common variants) or intermediate-
penetrance mutations (rare variants) superposed on unfavorable environmental factors 9 • Although 
widely accepted, this hypothesis remains difficult to proof, and only a handful of studies on accumulat-
ing and/or interacting effects in CHM have been reported 1 0-1:~. 
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Here we review the different etiological factors implicated in the development of non-syndromic CHM, 
including environmental factors, disease genes with high-penetrance mutations, susceptibility genes 
with intermediate- or low-penetrance mutations, and somatic mutations. 
Environmental factors 
Environmental factors associated with an increased risk forCHM include mainly maternal factors, there-
by suggesting that the majority of these environmental noxes are teratogenic or embryotoxic and not 
mutagenic (for review: see refs 14,15). The main maternal factors include hyperhomocysteinemia, diabe-
tes, hyperphenylalaninemia, alcohol, and medication (Table 1) 15• 
Especially homocysteine-methionine metabolism has been studied in CHM- in parallel to studies in 
neural tube defects- in view of the observations that: i) both maternal deficiency of folic acid 16 and 
vitB12 17 are associated with an increased risk for CHM, ii) folic acid antagonists, including medication 
such as trimethoprim, triamterene, carbamazepine, phenytoin, phenobarbital, and primidone, increase 
the risk for CHM 18, iii) maternal hyperhomocysteinemia is asso-ciated with an increased risk for CHM 19, 
iv) the risk of CHM can be reduced by supplementation during pregnancy with folic acid or multivita-
mins containing folic acid and vitB 12 (for review: see ref 20), and v) animal studies have implicated ma-
ternal folate deficiency in CHM "-".Different enzymes including SCL 19A 1, MTHFR, MTHFD1, MTRR, and 
NNMTareactive in the"methylation cycle"through the conversion of homocysteine into methionine by 
a 1-carbon (methyl) transfer. This cycle is essential in the methylation of deoxyuridine monophosphate 
(dUMP) to generate the thymidylate (dTMP) needed for DNA synthesis. Some common genetic variants 
in the genes encoding these enzymes represent low-risk factors for CHM. Folic acid antagonists might 
increase the risk of CHM by interfering with the action of dihydrofolate reductase (DHFR), thereby in-
hibiting the synthesis oftetrahydrofolic acid (THF) 18• As the methylation cycle is both determined by 
maternal and fetal genetic factors on one hand, and environmental factors on the other hand, both the 
maternal and the patient's genotype combined with maternal intake of nutrients such as folic acid and 
VrtB12 might influence the CHM risk. This makes the"methylation cycle" to a true multifactorial model 
for CHM. Periconceptional folic acid supplements have led to the prevention of more than SO% of cases 
neural tube defects 23• Similarly, a number of studies suggest that the risk for CHM can be decreased 
by the use of folic acid (alone or in multivitamin supplements) during gestation (for review: see ref2°). 
Maternal pregestational diabetes is associated with specific types of CHM, such as conotruncal defects 
24
.25 and heterotaxy 26-28• Heterotaxy is also seen in progeny of the NOD mouse, a model of insulin-de-
pendent diabetes mellitus 29-'11 • The pathogenic mechanisms leading to these specific CHM are unclear. 
The prevention of diabetic embryopathy by antioxidants in diabetic pregnancy in mice suggests that 
oxidative stress might play a role in this process 32• 
Maternal hyperphenylalaninemia is associated with an increased risk of CHM 33' 35• Although different 
types of CHM are seen, coarctation of the aorta (CoA) and hypoplastic left heart syndrome (HLHS) are 
overrepresented in children with CHM born after exposure to high levels of phenylalanine during preg-
nancy 34• Implementation of a strict diet before conception and in early pregnancy reduces the risk of 
CHM ""·The mechanism of hyperphenylalanine-related CHM is still unclear. 
Table 1. Environmental factors contributing to CHM 
Maternal 
Diabetes 
Hyperphenylalaninemia 
Hyperthermia 
Hyperhomocysteinemia 
Alcohol abuse 
Drug abuse 
Medication 
Chemical exposures 
Nutrient exposures 
Nutrient deficiencies 
Viral infections 
Paternal 
Age 
Drug abuse 
Chemical exposure 
Hyperglycemia 
Hyperphenylalaninemia 
High temperature 
Hyperhomocysteinemia 
Alcohol 
Cannabis 
Cocaine 
ACE inhibitors 
Thalidomide 
Retinoids 
Phenytoin, phenobarbital, carbamazepine, 
valproic add 
lithium 
Trimetraprim, triamterene, sulfasalazine 
Aspirin 
lndometacin 
Ibuprofen 
Organic solvents 
Pesticides 
Vitamin A 
Vitamin E 
Folate 
Vitamin B12 
Nicotinamide 
Rubella 
Influenza 
Unknown 
Cocaine 
Cannabis 
Organic solvents 
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Heterotaxy, conotruncal defects, HLHS 24.27,212-215 
TOF, HLHS, CoA 33)4)16 
ASD, HLHS, PS, TA 211.217·219 
Various 
" 
ASD, VSD J6;J7,22G.l21 
VSD, Ebstein 
"'" 
PS, PDA, VSD, heterotaxy 
'"'' 
ASD, VSD, PS, PDA 
'" 
Conotruncal defects 411.41 
Conotruncal defects 42,41 
Various 18.123-m 
Ebstein # 
Various 
" 
IAA, HLHS 45,46 
PDA 
" 
TGA, AVSD, VSD, BAV • 
Various 46.211.226-228 
TGA "' 
TGA, PS, outflow tract defects 230·232 
Various m 
Various 
" 
Various 
" 
Various 
" 
VSD, PDA, pulmonary valve anomalies 2J.t)l5 
Conotruncal defects, TGA, TA, CoA, VSD 
"' 
, 
VSD 
" 
VSD so 
CoA, HLHS • 
ASD, atrial septal defect; AVSD, atrioventricular septal defect; BAV, bicuspid aortic valve; CHM, congenital heart malformation; CoA, coarctation of the 
aorta; PS, pulmonary valve stenosis;VSD, ventricular septal defect; HLHS, hypoplastic left heart syndrome; lAA, interrupted aortic arch; PDA, patent ductus 
arteriosus; TA, tricuspid atresia; TAPVR, total anomalous pulmonary venous retour, TGA, transposition of the great arteries; TOF, tetralogy of Fa !lot 
The teratogenetic effect of alcohol on the developing heart is well established, as neonates with fetal 
alcohol syndrome have a high risk of CHM, mainly atrial septal defects (ASD) 36.37• Also mice exposed to 
ethanol exhibit CHM, particularly ASD 38>'. 
Medication known to be associated with an increased risk of CHM in offspring includes 
thalidomide 40.41, retinoids 42•43, lithium 44 , aspirin 45•46, indomethacine 47, ibuprofen 48, ACE inhibitors 49 
and folic acid antagonists 18• 
Only a few paternal factors have been reported to be risk factors for CHM in offspring: the use of can-
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nabis and cocaine by older fathers increases the risk for a child with a VSD 50, and also paternal age on 
itself is a risk factor for CHM 51 • Fathers exposed to organic solvents have an unexplained increased risk 
of children with left-sided heart malformations 46• It has been postulated that this teratogenic effect is 
due to dominant mutations in spermatozoa 52• 
Disease genes with high-penetrance mutations 
Many syndromic forms of CHM exist, and for many the primary gene defect has been identified. In re-
cent years an increasing number of families with monogenic forms of non-syndromic CHM have been 
reported, which has facilitated the positional cloning of several disease genes, including ZIC3, GATA4, 
NKX2S, NKX2.6, JAG1, TBXS, FLNA, MYH6, AaC1, NOTCH1, and ELN. Other disease genes were found 
through a candidate gene approach: these include TBX1, TBX20, CFC1, CITED2, CREL01, FOG2, LEFTY2, 
NODAL, GDF1, FOXH1, TDGF, MYOCD, TLL1, THRAP2 and ANKRD1 (Table 2). The majority of monogenic 
forms of non-syndromic CHM are caused by a single high-penetrance autosomal dominant mutation. 
Nevertheless, the majority of mutations reported in many of the human HCM genes are missense muta-
tions of which the pathogenic, let alone the monogenic nature, has not been formally demonstrated, 
and some of these mutations have reduced (intermediate or !ow) penetrance (Table 3). 
Many of the genes implicated in non-syndromic CHM are transcriptional regulators of heart morpho-
genesis. The fetal developmental program of the heart involves multiple pathways with extensive 
cross-talking and promiscuous ligand-receptor interactions, secondary signal transduction pathways 
and a network of transcription factors that determines the expression of cardia-specific effector genes 
(Figure 1). Various ligands in the circulation or the extracellular space of the heart, including hormones, 
cytokines, and growth factors, stimulate receptors in the cell membrane of cardiac cells. These ligand-
receptor complexes include JAGGED/NOTCH, TGFB-BMP/TGFBR, VEGF/FLTl-FLKl, NODAUACVRA-
ACVRB, and RTK/RAS. These membrane complexes (in)-activate different signal transduction pathways 
converging on a network oftranscriptional factors and regulators. Phosphorylation I dephosphorylation 
by kinases such as mitogen-activated protein kinase (MAPK), extracellular signal-regulated kinase 1/2 
(ERK1/2), cJUN, GSK, and calcineurin further controls these transcriptional networks. The transcriptional 
regulators of heart morphogenesis include several T-BOX transcription factors (TBX1, TBXS and TBX20), 
various GATA transcription factors (GATA4, FOG2), myocyte enhancer factor 2 (MEF2), nuclear factor of 
activated T cells (NFAT), serum response factor (SRF), homeobox transcription factors (NKX2.5, NKX2.6), 
basic helix-loop-helix (bHLH) transcription factors (HAND1, HAND2), and various SMAD transcription 
factors. These transcription factors regulate the expression of numerous cardiac effector genes, includ-
ing atrial natriuretic factor (ANF), b-type natriuretic peptide (BNP), myosins including a-myosin heavy 
chain (a-MHC) encoded by the MYH6 gene, and cardiac actin encoded by the AaCJ gene. 
Most high-risk mutations occur in 2 different groups of genes eg. transcription factors-regulators and 
cardiac effector genes. Several transcriptional regulators, including GATA4, FOG2, NKX2.5, NKX2.6, ZIC3, 
CITED2, TBXl, and TBX20, have been implicated in non-syndromic CHM. Recently, also mutations in sar-
comeric protein genes MYH6 53,AGC7 54 and MYH7 55 have been shown to cause various CHM 56• A simi-
Jar signal transduction pathway, referred to as the NODAL signal transduction pathway, is involved in 
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the establishment of left-right asymmetry: NODAL, LEFTY! I LEFTY2 and GDFl are ligands for a recep-
tor complex consisting of CFCl, TDGFl, ACVR2A /ACVR2B and ACVRl B. This complex determines the 
activity of transcription factors including FOXH1 that have cardiac-specific downstream targets such as 
PITX2 (Figure 1). Mutations in the NODAL pathway are not only involved in laterality defects but also in 
heterotaxy-related CHM such as tetralogy of Fallot (TOF), transposition of the great arteries (TGA) and 
double outlet right ventricle (DORV) "· 
The different disease genes with high-penetrance mutations implicated in non-syndromic CHM are 
discussed below (Tables 2 and 6). 
LEFTYl NODAL 
LEFTY2 GDFl 
ZIC3 
BMP 
1GFB 
Sarcomeric proteins; ACTC1, myosins 
Vasoactive proteins: ANF (NPPA), NOS3 
JAGGED1 
Figure 1 I Signaling pathways in heart morphogenesis involved in non-syndromic CHM 
HANDl 
Extracellular ligands 
Regulators 
Transcription factors 
Downstream cardiac 
effector genes 
The fetal developmental program of the heart involves many pathways with ligand-receptor interactions, signal transduction pathways and interacting 
transcription factors that determine the expression of cardio-spedfic effector genes. The figure is simplified to focus on genes implicated in non-syndromic 
CHM. The disease genes encode members of all compartments of the pathway, including ligands (LEFTY2, NODAL, VEGF, GDFl, JAGGED1), receptors (CFCl, 
TDGfl, ACVR2B, NOTCH1), t~nscription Moo-regulatoo (CITEDZ, TFAPZB, ZIG, FOXH1, FOGZ, MYOCD, NKX2.5-2.6, TBX1·5-20, GATA4, HEYl), and 
downstream effectortargets including sarcomeric proteins (AGC1, Myosins) and vasoactive proteins (ANF, NOS3), Significant ligand-receptor promiscuity and 
cross-talking between the different signal transduction pathways exists. 
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ligands and receptors 
NOTCH1 
Bicuspid aortic valve (BAV) +/- severe valve calcification, the most common CHM, can be caused by 
autosomal dominant mutations in the NOTCH7 gene in a minority of patients 58• BAV may be part of left 
ventricular outflow tract obstruction (LVOTO) that can also be caused by NOTCH1 mutations 59-61 (Tables 
2 and 6). NOTCH proteins are single-pass transmembrane receptors that regulate many developmental 
pathways (Figure 1 ). Mutations in the genes encoding NOTCH2 and its ligand JAGGED1 lead to Alagille 
syndrome, a syndromic CHM characterized by peripheral pulmonary artery stenosis and septal defects. 
Mouse embryos that are double mutant for the Notch1 and Notch2 receptors exhibit defects in left-
right (LR) asymmetry, indicating that the Notch signaling pathway plays a primary role in the estab-
lishment of LR asymmetry, this by directly regulating expression of the Nodal gene 62• Up to now no 
NOTCH1 mutations have been reported in patients with laterality defects. 
NODAL 
Five % of patients affected with either heterotaxy or heterotaxy-related HCM such as looping defects 
indudingTGA and DORV have a mutation in the NODAL gene 57 (Tables 2 and 6).1n mice Nodal is asym-
metrically expressed in the left lateral plate mesoderm, and Nodal signaling specifies left-sidedness by 
activation of Pitx2. Nodal-deficient mice die prior to the establishment of the LR axis, lack the primitive 
streak and do not form mesoderm 63.54. NODAL a member ofTGF!3 superfamily of developmental regu-
lators, is part of the NODAL signal transduction pathway, which regulates the establishment of the LR 
axis. Mutations have also been found in other components of the NODAL signal transduction pathway, 
including the GDF7 65,LEFTY2",ACVR28", CFC1 "·69, FOXH7 10 and TDGF7" genes (Figure 1). 
GDF1 
Mutations in the GDF1 gene have been found in 2% of a large group of patients with a wide spectrum 
of CHM, including TGA, DORV, TOF and interrupted aortic arch (IAA) 65 (Tables 2 and 6). Mice Jacking 
Gdfl exhibit a spectrum of defects related to LR axis formation, including visceral situs inversus, right 
pulmonary isomerism and looping defects such as TGA and DORV 70• GDF1 is a growth differentiation 
factor that belongs to the transforming growth factor-beta (TGF~) superfamily. it is a ligand of ACVR2, 
and part of the NODAL signal transduction pathway 71 (Figure 1 ). 
LEFTY2 
In two patients with heterotaxyand left isomerism mutations in LEFTY2 have been described, but over-
all LEFTY2 mutations are uncommon in heterotaxy 66 (Tables 2 and 6). Mice with targeted deletion of the 
Lefty2 asymmetric enhancer (which regulates LR expression of Lefty2) show left isomerism 72• LEFTY2 
and the very homologous LEFTY7 encode TGF~-Iike proteins that are ligands in the NODAL signal trans-
duction pathway (Figure 1). 
ACVR28 
In 3 patients with heterotaxy mutations in the ACVR28 gene have been reported" (Tables 2 and 6). 
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Acvr2b -1- knockout mice show abnormal LR axis development, ASD and ventricular septal defects 
(VSD), right-sided morphology of the left atrium and left lung, and spleen hypoplasia"· Pitx2 -/-knock-
out mice have cardiac defects similar to Acvr2b knockout mice 74, supporting the evidence that Pitx2 
is a downstream target of the Acvr2b signal transduction pathway. ACVR2B belongs to the family of 
Activins, transforming growth factor-beta-related proteins that act as receptors for ligands such as 
LEFTY1, LEFTY2, GDF1 and NODAL in the NODAL signaling pathway (Figure 1). 
CFCI 
A minority of patients with heterotaxy 68, TGA and DORV 75 or TOF 10 show mutations in the CFC1 gen 
(Tables 2 and 6). Mutant Cfc7 mice have heterotaxy 76• The CFC7 gene encodes Cryptic, which belongs to 
the EGF (epidermal growth factor)- CFC family of proteins (consisting of Cripto, Frl1, and Cryptic). These 
proteins are membrane-associated NODAL co receptors in the NODAL pathway (Figure 1 ). 
TDGFI 
Only 2 patients with CHM (TOF) " have been reported to have a TDGF7 mutation (Tables 2 and 6). Tar-
geted disruption of the Tdgf7 gene is lethal. TDGF1 (CRIPTO) is an EGF-CFC family member like CFC1. It 
acts as a co-receptor in the NODAL signaling pathway (Figure 1 ). 
FOXHI 
Several patients with CHM (mainlyTOF, few with heterotaxy) have been reported to have a FOXH1 mu-
tation 10 (Tables 2 and 6). Foxh1-/- mutant mouse embryos fail to form the outflow tract and right ven-
tricle n. FOXH1 is a forkhead DNA-binding transcription factor in the NODAL signaling pathway. It is 
essential in the development of the second heart field (SHF) and derivatives (the right ventricle and 
outfow tract), during looping morphogenesis of the heart (Figure 1 ). 
Transcription factors and regulators 
GATA4 
Mutations in the GATA4 gene have been reported in familial cases of ASD +I_ pulmonary stenosis 
(PS) 8•78-<~0, and in a minority (1-4 %) of sporadic patients with septal defects or conotruncal anomalies 81 -84 
(Tables 2 and 6). Homozygous Gata4 knockout mice die in utero and develop two symmetric promyo-
cardial primordia that fail to migrate ventrally and form two independent heart tubes 85.s6• Mice with 
heterozygous Gata4 mutations exhibit septal defects and endocardial cushion defects 83• The different 
members of the GATA zinc-finger transcription factor family (GATA 1-6) recognize the consensus target 
sequence (T/ A)GATA(NG) in downstream targets, and play critical roles in various developmental proc-
esses, including cardiac and coronary vasculature development. The transcriptional activity of the GATA 
transcription factors is modulated through interaction with multiple nuclear proteins, including other 
zinc finger proteins such as the FOG family, the NKX2 family, the NFAT family, and coactivators such as 
p300 and CBP "-"'(Figure 1 ). 
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Table2 I Germline mutations contributing to non~syndromic CHM 
Ligands~ receptors 
NOTCH7 BAY, AS R1108X, H1505del, T596M, P1797H, P1390T, A683T, 6661$ 58-61 
em Heterotaxy R112C, R189C 68,{i9 
T6A Splice donor site duplication intron 4 ); 
TOF IYS4+2T>C 
" 
TA IYS4+2T>C 
" 
AYSD IYS4+2T>C 
" 
L£FTY2 Heterotaxy R314X, SJ42K 
" 
ACVR28 Heterotaxy R40H,Y4941 
" 
GDF7 TOF 6162D,SJ09P, PJ12T 
" 
T6A Q27X,A318T 
" 
DORY Q67Y 
" 
AYSD 62625, R68H 
" 
NODAL Heterotaxy E20JK, 6260R, R275C, Y284F, R234_P241delinsLTS, IVS1-16>T, 0 
IVS2+1G>A 
TDGF7 TOF P125L 
" 
JAG7 PS, TOF 6274D, E228~ 146,147 
PTPN77 AVSD L4JF m 
Transcription factors 
GATA4 ASD S52F,6296S,SJ58del, EJ5~, Q316E,A411V 8l8-S1,84.23IJ,ll9 
TOF E216D, D425N, A 118_A 119insA, P407Q 81.82.84 
ASD± PS 6296$, 5358~, 6296( B,79,M 
VSD A411V, EJ59K,A6V, S46del, A 125_A 126insAA, S429T, A422V .,~ 
HRY L40JM 
"' 
PAPVR A411V "' 
FOG2 TOF 806,56576 
"' 
NKX2.5 ASD-AV block Q149X, R1896, T178M, Y259X, Q170X, Q198X, Q160P, 5,78,93· 
IVS1+ 16> T+ 1T, c.215_221del7, A75~, ASS~, R190C, Y256X, 99.1~1.240-143 
Q170X, E160P, Y256X, K104fs,A127E, R142C, Q817H,N188K, 
R1896, Y191C, c.701_702ins5, C264X, E109X 
TOF Q22P, R216C, R142C, Al23T, Q149X 93,99-101.244,245 
HLHS, CoA, IAA T178M, R25C, P275T 97,101 
Heterotaxy c.215_221del7 ); 
T6A A6JV 101 
DORY N291del 101 
VSD Y191C, Q149X, Y259X, E1 09X 99,243 
Ebstein A42P 
'" 
NKX2.6 PTA F157l 
'" 
TBX20 
C/T£02 
FOXH1 
l/C3 
TBX5 
TBX1 
ANKRD1 
Sarcomeric proteins 
MYH11 
AUC1 
MYH6 
MYHl 
MYBPC3 
Miscellaneous 
FLNA 
ELN 
TLL1 
THRAP2 
ASD,CoA 
VSD 
PDA 
DCM 
MS, HLV 
VSD 
ASD 
TOF 
CHM 
Heterotaxy 
TGA 
ASD,PS 
ASD, VSD, AVSD 
VSD 
IAA 
TAPVR 
PDA, aorta aneurysm 
ASD, VSD 
ASD 
ASD, Ebstein 
ASD, VSD 
XMVD 
SVAS 
ASD 
TGA 
1152M,Q195X 
I 152M 
I 152M 
Q195X 
Q195X 
5170_G178del 
G178_5179del, 5198_G199del 
V112M, D350G, P336l, 53396, 5113T/5346G 
516l, G267R, T2421, D328E 
Various mutations 
W255G, K467X, K405E 
A217P 
GSOR 
A379_G381del 
A466_A476dup 
T116M 
L 1456_N1526del, R1241_L1264del 
M123V, c215_231del17, E101 K, G99l 
1820N 
R281T, F2JOS 
Various mutations 
G288R, V711D, P637Q, deletion exons 16-19 
Various mutations 
M182l, A238V, L627V 
R1872H, D2023G 
*Mutations in the open reading frame are described at the protein level. 
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'" 
'" 
" 
" 
150,246 
148-150 
"" 
"' , 
'" 
"" 
111 
54,122,123 
5l 
117-119 
m 
'" 
AS, aortic valve stenosis; ASD, atrial septal defect; AV, atrioventricular; AVSD, atrioventricular septal defect; BAV, bicuspid aortic valve; CHM, congenital 
heart malformation; CoA, coarctation of the aorta; DORV, double outlet right ventricle; HLHS, hypoplastic left heart syndrome; HLV, hypoplastic left 
ventricle; HRV, hypoplastic right ventricle; IAA, interrupted aortic arch; MS, mitral valve stenosis; NS, not specified; PA, pulmonary atresia; PAPVR, partial 
anomalous pulmonary venous retour; PDA, patent ductus art-eriosus; PS, pulmonary valve stenosis; PTA, persistent truncus arteriosus; RV, rightventride; 
SVAS, supravalvular aortic stenosis; TAPVR, total anomalous pulmonary venous retour; TGA, transposition of the great arteries; TOF, tetralogy of Fa!lot; VSD, 
ventricular septal defect; XMVD, X~!inked myxomatous valvular dystrophy 
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FOG2 
A minority of patients with TOF have a mutation in the FOG2 gene 89, whereas patients with chromo-
somal breakpoints at 8q22, possibly involving FOG2, often show TOF 90 (Tables 2 and 6). Also Fog2 
knockout mouse embryos exhibit TOF 91•92• FOG2 (Friend Of GATA) is a multi-zinc-finger transcription 
factor modulating the transcriptional activity of GATA4 (Figure 1 ). 
NKX2.5 
Mutations in the NKX2.5 (NKX2~ CSX) gene cause various CHM, including ASD and VSD, atrioventricular 
conduction defects, TOF, subvalvular aortic stenosis (AS), pulmonary atresia, Ebstein anomaly, ventricu-
lar hypertrophy, cardiomyopathy and ventricular non compaction 5•78•93-101 (Tables 2 and 6). Most NKX2.5 
mutations are found in familial atrioventricular block with ASO 5•93•99 andTOF 100•101 .1n other CHM NKX2.5 
mutations are uncommon 101 • Nkx2.5 knockout mice lack the primordium of the AV node 102, whereas 
ventricular-restricted Nkx2S knockouts display complete heart block and massive trabecular muscle 
103
• NKX2.5 is a homeobox transcription factor contributing to diverse cardiac developmental pathways 
through interaction with the network of transcriptional regulators of heart morphogenesis (Figure 1). 
NKX2.6 
Only a single mutation in the NKX2.6 gene has been associated with CHM, in a consanguineous family 
with persistent truncus arteriosus (PTA) 104 (Tables 2 and 6). Targeted disruption of Nkx2.6 in mice did 
not result in an abnormal cardiac phenotype 105• NKX2.6 is a homeobox transcription factor with great 
homology to NKX2.5, but its transcriptional targets are unknown (Figure 1). 
TBX20 
Mutations in the TBX20 gene have been found in a minority(< 1 o/o) ofCHM patients 7• A missense mu-
tation has been found in a family with autosomal dominant inheritance of septal defects 7• A truncat-
ing mutation was present in a family with autosomal dominant inheritance of septal defects, LVOTO 
anomalies including mild CoA, mitral valve stenosis, hypoplastic left ventricle (HLV) and cardiomyopa-
thy 7 (Tables 2 and 6). Heterozygous Tbx20 knockout mice show atrial septal abnormalities and dilated 
cardiomyopathy, whereas homozygous mutants show a rudimentary heart that lacks chamber myocar-
dium 106• TBX20 is a cardiacT-box factor that interacts with other cardiac transcription factors, including 
NKX2.5, GATA4, and TBXS "'(Figure 1 ). 
C/TED2 
Mutations in the C/T£02 gene have been identified in about 1 %of sporadic patients with various CHM, 
including ASD andVSD,and anomalous pulmonary venous return 108 (Tables 2 and 6). Cited2 -/- embry-
os die with ASD and VSD, overriding aorta, DORV, PTA, and right-sided aortic arches 109• These mutant 
mice lack expression of Pitx2c that is a target gene in the Nodal pathway. CITED2 (CBP/p300-interacting 
transactivatorwith E/D-rich c-terminal domain, type 2) is a member of the CITED family of cofactors that 
are involved in regulating a wide variety of CBP/p300-dependent transcriptional responses. CITED2 is 
a transcriptional co-activator ofTFAP2 (Figure 1). One oftheTFAP2 transcription factor genes TFAP28 is 
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involved in Char syndrome, which is a syndromic CHM characterized by patent ductus arteriosus (PDA) 
(Figure 1 ). 
ANKRD1 
In a patient with total anomalous pulmonary venous return (TAPVR) showing a de novo 1 0;21 balanced 
translocation, the ANKRD1 gene was found disrupted 110• An ANKRD1 missense mutation has been 
found in another sporadic patient with TAPVR, suggesting that ANKR01 gene possibly plays a role in 
TAPVR 110• The ANKRD7 gene, encodes a transcriptional regulator that belongs to the muscle ankyrin 
repeat protein (MARP) family. 
Sarcomeric protein genes 
MYH11 
Mutations in the MYH71 gene encoding the myosin heavy chain 11 are responsible for a specific form of 
familial thoracic aortic aneurysm and/or dissection (TAAD) with PDA 111 (Tables 2 and 6). Patients with a 
MYH11 mutation exhibit a severe decrease in the elasticity ofthe aortic wall. This is consistent with the 
role of myosin heavy chain 11 in smooth muscle cells in maintaining the mechanical properties of the 
thoracic aorta. The perinatal changes of the ductus arteriosus require smooth muscle cells to migrate, 
proliferate, differentiate, and contract 112• As evidenced by the presence of PDA in these patients and 
in Myh11-l- mice 113, myosin heavy chain 11 is also involved in the perinatal closure of the ductus ar-
teriosus. Myosin heavy chain 11 is a sarcomeric protein that is expressed in smooth muscle cells of the 
ductus arteriosus and arterial walls (Figure 1 ). 
MYH6 
A single missense mutation in the MYH6 gene has been found in an autosomal dominant family with 
ASD 53 (Table 2 and 6). Knockdown expression of Myh6 in chicken prevents atrial septum formation 53• 
Myh6 cardiac expression is regulated by the transcription factorTbxS in physical interaction with Mef2c 
114
• Mutations in TBXS reduce activation of the MYH6 promotor and lead to ASD in Holt-Oram syndrome. 
Similarly, GATA4 mutations associated with ASD also affect MYH6 promotor activation 8 (Figure 1 ). In 
heterozygous mice, ablation of the Myh6 gene leads to focal fibrotic lesions and cardiac myocyte disar-
ray with impairment of both contractility and relaxation, but no septal defects 115• MYH6 encodes the 
alpha-myosin heavy chain, a cardiac sarcomeric protein that is part of the contractile unit of cardiovas-
cular muscle and expressed at high levels in the developing atria. 
MYH7 
Recently, mutations in the MYH7 have been shown to cause CHM including Ebstein anomaly and septal 
defects 55 (Tables 2 and 6). MYH7 is a cardiac sarcomeric protein gene frequently involved in different 
forms of cardiomyopathy. Homozygous mutant mice die within a week after birth, while heterozygous 
mice display hypertrophic cardiomyopathy (HCM), but no CHM 1".MYH7 encodes the beta-myosin heavy 
chain, a cardiac sarcomeric protein that is part of the myosin thick filament of cardiovascular muscle. 
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MYBPC3 
Whereas heterozygous mutations in the MYBPC3 gene are a frequent cause of HCM, compound hetero-
zygosity or homozygosity for truncating mutations in the MYBPC3 gene not only causes lethal forms 
of cardiomyopathy, but also septal defects. Several Old Order Amish with lethal HCM, PDA and septal 
defects (apical muscularVSD, and ASD) have a homozygous truncating mutation in MYBPC3 117•118• Sep-
tal defects were also present in neonates with severe HCM due to compound heterozygous truncating 
mutations 119 (Tables 2 and 6). Transgenic mice with mutant Mybpc3 exhibit mild ventricular hyper-
trophy, but no septal defects or other CHM 120• MYBPC3 encodes a cardiac sarcomeric protein cardiac 
myosin-binding protein C that modulates myosin, assembly actin-myosin interaction in sarcomeres 
and stabilizes thick filaments 121 • 
ACTC7 
ACTC1 is another sarcomeric protein gene implicated in HCM, dilated cardiomyopathy (DCM),and non-
compaction cardiomyopathy (NCCM). A founder mutation E1 01 Kin Spanish families with apical HCM/ 
NCCM also causes secundum ASD or atrial septum aneurysm in multiple patients, and VSD in one pa-
tient 54• In another family with apical HCM due to a ACTC7 missense mutation (G99K) one patient also 
had ASD 122• In two large Swedish families with autosomal dominant inheritance of ASD without car-
diomyopathy a founder mutation M 123V was identified "' (Table 2). However, the frequency of ACTC7 
mutations in ASD overall is low (1-2 %), and no ACTC1 mutations were found in various other types 
of CHM 123• Actin knockdown in chick embryos produces less developed atrial septa 123• Mice lacking 
cardiac actin do not show gross cardiac anomalies, but increased apoptosis in the atrial and ventricular 
septa 124• Also in the pathogenesis of human secundum ASD apoptosis may play an important role 125• 
The ACTC1 gene encodes the cardiac actin protein that is an essential structural component of the thin 
filaments of sarcomeres. One end of the actin filament forms cross bridges with myosin to generate 
force, whereas the other end is immobilized and anchored to a-actinin in theZ disc.ACTC7 mutations in 
patients with ASD seem to reduce affinity of actin for myosin 123• 
Miscellaneous genes 
GJA1 
Mutations in GJA 1 have been reported in various forms of CHM by the group of Britz-Cunningham 126• 
However, several other groups were unable to find Cx43 mutations in CHM patients 127•132, and it has 
been suggested that the mutations identified by the Britz-Cunningham group were not located in 
GJA 7, but in the highly homologous GJA 7 pseudogene. Complex mutations indicative of illicit recom-
bination between GJA 1 and the GJA7 pseudogene have been found in heart tissue from patients with 
HLHS 133• Cx43-null mice show delayed looping 134• GJA 7 encodes a gap junction protein connexin 43 
(Cx43t which facilitates cell-to-cell adhesion and intercellular communication. 
FLNA 
Four different mutations within the same region (repeat 1 to 7) of the X-linked FLNA gene encoding 
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Filamin A have been identified in families affected by valvular dystrophy 135 (Table 2). Loss-of-function 
FLNA mutations are lethal in males, while in females they result in periventricular nodular heteroto-
pia associated with aortic aneurysms, valve regurgitation and overlapping features of Ehlers-Danlos 
syndrome 136•137• Mutations that conserve the reading frame lead to a broad range of syndromes, in-
cluding frontometaphyseal dysplasia, Mel nick-Needles syndrome, and otopalatodigital syndrome type 
1 (OPD1) and type 2 (OPD2). Flna-null mice die at midgestation with widespread hemorrhage from 
abnormal vessels, PTA, and septal defects 138• The FLNA gene encodes filamin A, a large cytoplasmatic 
protein that crosslinks actin filaments and participates in the anchoring of the actin cytoskeleton to 
membrane proteins. 
Elastin 
A common microdeletion within chromosomal band 7q11.2 encompassing the ELN gene causes Wil-
liams syndrome, a syndromic CHM with supravalvular aortic stenosis, poststenotic aortic aneurysms, 
sometimes associated with arterial stenosis, mainly of pulmonary arteries. !ntragenic ELN mutations re-
sult in the same spectrum ofCHM 139•140 (Table 2). Some patients with ELN mutations also show bilateral 
inguinal hernias, cutis laxa, pulmonary disease, and aortic aneurysm and dissection 141 • Transgenic mice 
hemizygous for the elastin gene show a compensatory increase in the number of elastic lamellae and 
smooth muscle in their arteries, resulting in arterial stenosis 142.The ELN gene encodes elastin that forms 
the amorphous component of elastic fibers that are abundantly present in arteries. 
THRAP2 
Mutations in the THRAP2 gene are present in 3% of patents with non-syndromic TGA 143 (Table 2). The 
THRAP2 gene encodes a TRAP240-like protein, which belongs to the TRAP complex of proteins associ-
ated with the thyroid hormone receptor. 
TLL1 
Missense mutations in TLL1 have been described in patients with ASD, although the significance of 
these mutations is not clear as only a limited group of 15 healthy control were screened, no family 
members were screened for these mutations and no functional analysis of these mutations was per-
formed 144• Mice with a disrupted T//7 gene display incomplete formation of the muscular interventricu-
lar septum and abnormal positioning of the heart and aorta 145• The TLL 1 gene encodes Tolioid-like-1, 
an astacin-like metalloprotease that is highly similar to the morphogenetically bone morphogenetic 
protein-1 (BMP1 ). 
Genes implicated in syndromic CHM 
Some genes implicated in syndromic forms of CHM have also been found to cause non-syndromic CHM 
with no or subtle non-cardiac features. These genes include JAG1 (Aiagille syndrome), ZIC3 (X-Iinked het-
erotaxy), TBX1 (22q11.2 deletion syndrome), TBXS (Holt-Oram syndrome) and TFAP2{3 (Char syndrome). 
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JAG! 
JAG7 (JAGG£07) mutations have not only been found in patients with Alagille syndrome, but also in 
non-syndromic right-sided heart defects such asPS and TOF 146.,47 {Tables 2 and 6).Jagged 1 is a ligand 
for the NOTCH receptors (Figure 1 ). Also NOTCH2 mutations have been shown to cause Alagille syn-
drome, but not non-syndromic CHM. 
ZIC3 
ZIC3 mutations typically result in X-Jinked heterotaxy, a combination of left-right asymmetry defects, 
including complex cardiac anomalies, altered lung lobation, splenic and hepatobiliary abnormalities, 
and gut malposition. ZIC3 mutations have also been found in non-syndromic CHM such as TGA, ASD 
and PS 148•150 (Tables 2 and 6). Zic3 mutant mice, exhibit heterotaxy, neural tube defects, and vertebral 
and rib anomalies 151 • ZlC3 is a zinc finger transcription factor that acts as an enhancer of the NODAL 
signaling pathway (Figure 1 ). 
TBX! 
A common microdeletion within chromosomal band 22q11.2 encompassing the TBX1 gene causes the 
velocardiofacial syndrome (22q11.2 syndrome), which is a major cause of CHM. Although intragenic 
TBX1 mutations have later been shown to cause most of the anomalies of the microdeletion patients 
151
-
154
, they can also be associated with non-syndromic CHM, includingVSD and lAA 155•156• TBX1 encodes 
aT-box transcription factor which is expressed in neural crest cells (Figure 1 ). 
TBXS 
Whereas TBXS null alleles usually lead to classical Holt-Oram syndrome, some patients with a TBXS mis-
sense mutation (eg. the GSOR mutation) have non-syndromic CHM with very limited limb anomalies, 
but severe cardiac defects "'·158 (Table 2). TBXS belongs to the Brachyury (T) family, which encodes 
transcription factors sharing a common DNA-binding motif, the T-box. The TBXS protein associates with 
other cardiac transcription factors including GATA4 and NKX2.5, and synergistically activates different 
cardiac effector target genes (Figure 1 ). 
TFAP2P 
Char syndrome is caused by mutations in the TFAP2{3 gene. Although most TFAP28 mutations lead to 
PDA associated with typical facial dysmorphism, patients with the P62R mutation show PDA with only 
mild facial features 159•160 (Table 2). TFAP2/3 is a transcription factor expressed in neural crest cells {Figure 1 ). 
Reduced-penetrance mutations in susceptibility genes 
The hypothesis of the multifactorial inheritance of common diseases suggests that multiple genetic 
risk factors with reduced penetrance (intermediate or low) superposed on unfavorable environmental 
factors lead to disease. These risk factors can be rare variants with intermediate penetrance (Table 3) or 
common gene variants with low penetrance (Table 4). 
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Rare variants with intermediate penetrance 
Rare variants with intermediate penetrance have been associated with CHM, but for most of them there 
is only limited evidence that they contribute to CHM {Table 3). Most of these mutations are missense 
mutations in sporadic patients with CHM whose unaffected family members {usually one of the par-
ents) also show this DNA variation; in other cases the mutation is also present in the control population, 
albeit with a lower frequency. The latter is then considered circumstantial evidence of low penetrance. 
However, in many cases the functional significance of such missense mutations is unknown, and they 
could be either nonfunctional polymorphisms or disease mutations with reduced penetrance. Addi-
tionally, multiple rare variants sometimes can be found in a single patient, implying a cumulative effect 
and consequently a reduced penetrance for the individual mutations, as shown for the NODAL path-
way 10• Most studies involve mutation analysis of the open reading frame of genes already implicated 
in CHM by the presence of high-penetrance monogenic mutations leading to the respective CHM. As 
variations can also be located in gene control regions the mutations described below might underrep-
resent the overall amount of intermediate-penetrance mutations. 
The different rare variants with intermediate penetrance implicated in non-syndromic CHM are dis-
cussed below (Table 3). 
CRELD1 
Several CRELD1 missense mutations have been reported in patients with isolated atrioventricular septal 
defect (AVSD) 16, 162 and in 2 patients with Down syndrome, which is the main cause of AVSD 163• These 
missense mutations were also found in unaffected parents or other family members, indicating incom-
plete penetrance of these mutations 161•162 (Table 3). The CRELD1 gene located on chromosome 3p is also 
deleted in patients with the 3p- syndrome, which is often associated with CHM, typically AVSD 162,164• 
The CRELD family of genes encodes for cell adhesion molecules containing cysteine-rich epidermal 
growth factor (EGF)-Iike domains, which mediate interactions between proteins of diverse function. 
NKX2.5 
The identification of NKX2.5 missense mutations in normal parents of children affected with CHM (and 
in some cases also in healthy controls) indicates that some of these mutations might have reduced 
penetrance 100•101 {Table 3). 
NOTCH1 
In a large series of patients with BAV and/or LVOTO a NOTCH1 missense mutation with functional signifi-
cance was demonstrated in almost 7% of patients. Some of these mutations were also present in unaf-
fected parents although echocardiography was only performed in approximately one third of cases. 
These mutations could therefore represent rare variants with reduced penetrance 61 (Table 3). 
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GATA4 
GATA4 missense mutations in patients with ASD 81, or AVSD 83 were also found in some of their non-
affected parents or family members, indicating that some of these mutations might have reduced pen-
etrance (Table 3). 
NODAL 
Jn 10% of Hispanic patients with heterotaxy a G260R mutation in the NODAL gene was found, which 
was shown to exhibit significant impairment of NODAL signaling. As this mutation was also pres-
ent in one unaffected parent and a control, it must be considered as a rare variant with reduced 
penetrance 57 (Table 3). Mutations in different genes involved in the NODAL signaling pathway (NODAL, 
FOXH7, CFC7 and GOF7 10) co-occur, suggesting a cumulative effect of mutations leading to reduced 
NODAL signaling. 
CFCJ 
The R78W mutation in the CFC7 gene, which is common in African-American patients with heterotaxy6875, 
significantly impairs NODAL signaling, but is also found in controls, and must therefore be considered 
as a rare variant. Also other CFC1 variants with reduced penetrance have been reported 10J 5,165 (Table 3). 
Patients with a CFC1 mutation may show a second mutation in other NODAL pathway components, in-
cluding the GOFJ and FOXH1 genes 10• Altogether these findings suggest that rare variants in CFC7 may 
represent genetic factors with reduced penetrance for heterotaxy and other CHM. 
FOXHJ 
FOXH1 mutations are among the most common mutations found in CHM (mainly TOF), but several of 
these patients show a second mutation in the CFC1 gene, another component of the NODAL pathway, 
indicating a cumulative effect of mutations leading to reduced NODAL signaling 10 {Table 3). 
GDFJ 
A single patient with undefined CHM has been reported to have both a missense mutation R68H in 
the GDF1 gene and a missense mutation F162L in the CFC7 gene 10 (Table 3). Assuming functional sig-
nificance of both mutations, this further indicates a cumulative effect of different mutations leading to 
reduced NODAL signaling. 
MYOCD 
A single MYOCD missense mutation has been found in a patient with PS. This functionally important 
variant was also present in 0.5% of Hispanic controles (Table 3). Selectively ablation of the Myocd gene 
in neural crest-derived smooth muscle cells in mice resulted in PDA 166• MYOCD encodes for Myocardin, 
a transcriptional coactivator of serum response factor (SRF) that plays a role in myocardial and vascular 
smooth muscle cell differentiation. 
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THRAP2 
The missense mutation reported in a patient with TGA was also present in the healthy mother of this 
parent, indicating reduced penetrance 143• 
Common variants with low penetrance 
Susceptibility genes with low-penetrance mutations (commen variants) are being identified at high 
speed for various common disorders using genome-wide association studies (GWAS). In these studies 
hundred thousands of SNPs (Single Nucleotide Polymorphisms) are analyze simultaneously in large 
numbers of patients and controls using high-technological platforms. GWAS studies have not yet been 
performed in CHM. However, small-scale case-control studies have identified common variants con-
tributing to CHM. As the numbers of individuals (both patients and controls) included in most of these 
studies are limited the conclusions are often tentative; furthermore, many studies are contradictory 
and have not been replicated. The different common variants with low penetrance implicated in non-
syndromic CHM are discussed below (Table 4). 
Table 3 I Rare variants with intermediate penetrance contributing to non-syndromic CHM 
CRELD1 Matrice!lular protein AVSD R329C, T3111, P162A, E414K 16H63.248 
AVSD, dextrocardia R107H 
'"' 
NKX2.5 Transcription factor TOF R25C, E21Q, A219V 100,101.245 
A5D-AV block K151 
'" 
DORV N291del tnt 
NOTCH I Transcription factor LVOTO A683T, G661 S " 
GATA4 Transcription factor ASD D425N, G93A 
" 
AVSD P163S, A346V 
"' 
NODAL Ligand Heterotaxy·CHM G260R ~ 
THRAP2 Receptor associated TGA E251G 
'" 
protein 
MYOCD Regulator PS K259R 
'" 
CFC7 Receptor TGA R78W 75,105 
TOF R78W, G174fs 
" 
IAA R78W 
" 
DORV G174fs, N21H, R47Q 75,1G5 
*Mutations in the open reading frame are described at the protein level. 
ASD, atrial septal defect; AV, atrioventricular; AVSD, atrioventricular septal defect; CHM, congenital heart malformation; DORV, double outlet right ventricle; 
IAA, interrupted aortic arch; LVOTO, left ventricular outflow tract obstruction; PS, pulmonary valve stenosis; TGA, transposition of the great arteries; TOF, 
tetralogy ofFallot 
44 I CHAPTER I 
Folate .....,,_----- Folate intake 
Dihydrofolate (DHF) 
Tetrahydrofolate (THF) 
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S~Methyl THF 
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Homocysteine Methionine 
TCN2- _1 
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dTMP dUMP 
DNA synthesis 
MTHFR 
Figure 2 I Methylation cycle with different 
environmental and genetic risk factors for 
CHM Nutritional factors such as reduced folate 
and vitB12 intake, and common variants in the 
SLC79A7, MTHFD7, MTHFR, MTRR, 
NNMT. and TCN2 genes might lead to 
decreased availability of methionine necessaryfor 
DNA synthesis. Folic acid antagonists, induding 
medication such as trimethoprim, triamterene, 
carbamazepine, phenytoin, phenobarbital, and 
primidone, may increase the risk for CHM by 
inhibiting Dihydrofolate reductase {DHFR). 
Different enzymes including MTHFR, MTHFD1, MTRR, SLC19A 1 and NNMT are implicated in the meth-
ylation cycle through the conversion of homocysteine into methionine (Figure 2). 5,1 0-Methylenetetra-
hydrofolate reductase (MTHFR) is an enzyme that converts methylene THF into 5-methyiTHF. The latter 
is a cofactor for methionine synthase (MTR) and MTR reductase (MTRR), two enzymes that convert ho-
mocysteine into methionine. Several studies have reported inconsistent associations between MTHFR 
variants and CHM, but a meta-analysis of published studies concluded that the common MTHFR vari-
ants A222V (c.677C> T) and E429A (c.1298A>C) on patient or maternal genotypes were not significantly 
associated with CHM 19• 
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MTHFD1 
The MTHFD7 gene encodes a trifunctional protein involved in the interconversion of folate to methy-
lenetetrahydrofolate (THF). The latter is converted to 5-methyl THF by MTHFR (Figure 2). The c.1958G>A 
variant, leading to the missense mutation R653Q in MTHFD7, decreases MTHFD1 enzyme stability and 
activity. Homozygosity for this variant (present in approximately 20 % of the European population) is 
associated with an increased risk for CHM, particularlyTOF and AS 167• This effect could only be demon-
strated for the R653Q mutation on the patient's genotype, but not on the maternal genotype (Table 4). 
MTRR 
The MTRR gene encodes the MTR activator methionine synthase reductase enzyme. MTRR restores the 
activity of methionine synthase (MTR), the enzyme that converts homocysteine into methionine using 
5-methyl THF as a cofactor (Figure 2). Homozygosity for the 122M variant (c.66A>G) in the mother"' in 
combination with low maternal serum vitB12 12 is associated with an increased risk for different types 
ofCHM in offspring (Table4). 
SLC19A 1 (RFC1) 
Transport of folate compounds into mammalian cells can occur via receptor-mediated or carrier-medi-
ated mechanisms. One of the genes involved in carrier-mediated transport is the SLC79A7 gene encod-
ing the reduced folate carrier-1 (Figure 2). Offspring carrying the G allele for the c.80A>G variation have 
been reported to show an increased risk for CHM 169 (Table 4). 
NNMT 
Apart from the MTHFR, MTHF07, MTRR and SLC19A1 genes that are involved in folate metabolism, also 
the nicotinamide N-methyltransferase (NNMn gene may be a genetic determinant of plasma homo-
cysteine levels. Nicotinamide N-methyltransferase catalyses the methylation of nicotinamide and other 
pyridines using methyl groups generated in the methylation cycle of homocysteine-methionine (Fig-
ure 2). A G>A variant in intron 1 in both the maternal and fetal NNMT gene are associated with an 
increased CHM risk, but only on a background ofpericonceptional exposure to medicines and/or a low 
dietary nicotinamide intake 11 (Table 4). 
TCN2 
The TCN2 gene encodes transcobalamin 2, which is the main transporter ofvitB12 (cobalamin), an es-
sential vitamine in the synthesis of methionine (Figure 2). Maternal and fetal homozygosity for the 
P259Rvariant (c.776C>G) in combination with low maternal serum vitB12 have been reported to cause 
an increased risk for different types of CHM in offspring 12 (Table 4). 
NPPA 
The NPPA gene encodes atrial natriuretic peptide (ANP) that has natriuretic-diuretic activity important 
in the control of extracellular fluid volume and electrolyte homeostasis. ANP is a cardiac effector hor-
mone secreted from the cardiac atria to decrease blood pressure and cardiac hypertrophy by interac-
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tion with different transcription factors and sarcomeric proteins (Figure 1). The G664A variant in the 
NPPA gene is reported to cause an increased risk for conotruncal defects 170 (Table 4). 
N0 53 
Endothelial nitric oxide synthase (eNOS) encoded by the NOS3 gene converts !-arginine into nitric ox-
ide, which plays a role in vasodilatation and in the regulation of cell growth and apoptosis (Figure 1). 
Homozygozity for the common c.894G> T (E298D) variation in combination with maternal smoking 
causes an increased risk ofCHM 13 (Table 4). 
VEGF 
VEGF (vascular endothelial growth factor) is a mitogen that specifically acts on endothelial cells and 
belongs to a family of regulatory peptides controling blood vessel formation by interacting as a ligand 
with the endothelial tyrosine kinase receptors FLTl and KDR!FLKl (Figure 1 ). The MG haplotype of 
three variants -2578A, -1154A, and -634G located in the promoter and leader sequence of VEGF are 
known to lowerVEGF levels. These common VEGFvariants confer an increased risk forTOF, both in non-
syndromic cases ofTOF and syndromic cases with 22q11.2 deletions 171 (Table 4). Newborn mice lacking 
Vegf die of anomalies reminiscent of 22q11 deletion syndrome with typical cardiac malformations such 
asTOF 172·• TBX1, the gene implicated in 22q11 deletion syndrome, is most likely a down stream target of 
the VEGF pathway as Tbx1 expression is down regulated in these mice. 
NFATC1 
NFATCl (Nuclear Factor of Activated T cells, cytoplasmic, Calcineurin-dependent 1) is a calcineurin-de-
pendent transcription factor belonging to the NFAT family of transcription factors. Nfatcl is involved in 
remodeling of endocardial cushions into mature heart valve leaflets by repression ofVegf expression in 
the myocardium underlying the site of prospective valve formation (Figure 1 ). Two of 21 patients with 
VSD were found to have a homozygous duplication of 44 nucleotides in intron 7 of the NFATC1 gene, 
whereas homozygosity for th.1s deletion was not observed in the control population, suggesting that 
NFATCJ is a low penetrance susceptibility gene forVSD 173 {Table 4). 
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Table 4 I Common variants with low penetrance contributing to non--syndromic CHM 
MTHFR Methylation cycle Various A222V, E429A 170,210 
MTHFD7 Methylation cycle TOF, AS R6SJQ 
"' 
MTRR Methylation cycle Various 122M 12.11).8 
SLC79A7 Methylation cycle Various c80A>G ,, 
NNMT Methylation cycle Various G>A in intron 1M;· n 
TCN2 Methylation cycle Various P259R 
" 
NPPA Vasoactive protein Conotruncal defects G664A "' 
NDS3 Vasoactive protein Co-no-truncal defects E298D-"* 
"' 
VEGF Polypeptide mitogen VSD, PTA, IAA, TOF -2578C>A, -1154G>A, -634G>C 171,172 
NFATC7 Transcription factor VSD Duplication of44bp in intron 7 m 
. Mutations in the open reading frame are described at the protein level. 
** Increased riskforCHM when exposed to periconceptional medicines and/or a low dietary nicotinamide intake. 
*"'*Increased risk for CHM in combination with maternal smoking. 
AS, aortic valve stenosis; IAA, interrupted aortic arch; PTA, persistent truncus arteriosus; TOF, tetralogy of Fallot; VSD, ventricular septal defect 
Chromosomal aberrations 
Chromosomal aberrations are well-known causes of syndromic CHM and are detected in 8-13% of chil-
dren with CHM by conventional cytogenetics alone 174• After the introduction of fluorescence in situ 
hybridization (FISH) additional deletions in patients with CHM were identified, with the 22q11.2 dele-
tion syndrome as the prime example of a frequent cause of CHM that escaped detection before the in-
troduction of FISH 175• With the recent introduction of array-based comparative genomic hybridization 
(array CGH) as a routine tool in diagnostics, many more chromosomal regions associated with CHM are 
being found. A high frequency of chromosomal imbalances was demonstrated in a selected group of 
patients with syndromic CHM 176• Newly recognized microdeletion/duplication syndromes associated 
with CHM are the 22q11.1 duplication syndrome 177, the 9q34 deletion syndrome 178, the 17p11.2 dele-
tion syndrome 179, the 16p11.2 deletion syndrome 180•181 and the 1 q21.1 deletion syndrome 182' 184• These 
microdeletions/duplications associated with CHM are good candidate regions to identify CHM genes. 
Some of the known microdeletion syndromes, such as the 22q11.2 deletion syndrome, can present 
with CHM without obvious dysmorphic features and/or mental deficit. The recently recognized 1 q21.1 
microdeletion syndrome has an even more variable phenotype with incomplete penetrance 182' 184• In a 
large series of 1 q21.1 deletion patients, 25% presented with CHM, including PDA, TA, CoA and BAV 183• 
This deletion was also found in 3 out of 505 patients with non-syndromic CHM 184• Overall a high fre-
quency of chromosomal deletions, duplications and copy number variations (CNV) was recently found 
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in a series of non-syndromic patients with CHM 185• These studies indicate that arrayCGH should be 
included in the diagnostic workup of patients with non-syndromic CHM. 
Somatic mutations 
Knudson has elegantly demonstrated how somatic mutations not present in the germline can contrib-
ute to genetic disease with his two-hit hypothesis 186• There has been much interest in somatic muta-
tions underlying cancer and this has been the subject of many reviews 187• These somatic mutations 
not only include mutations affecting nuclear DNA leading to activation of oncogenes or inactivation 
of tumor suppressor genes, but also epigenetic alterations of DNA, and mitochondrial DNA mutations. 
The concept of somatic mosaicism has also been demonstrated in many different skin disorders, and 
several other diseases188• Surprisingly, many years after Knudson's theory gained universal acceptance, 
the concept of somatic mutations remained largely confined to tumor biology and skin disease. This 
might explain why the candidate gene approach for many non-syndromic malformations, including 
CHM, has had little success: mutation analysis in most cases still is usually performed in constitutional 
DNA, whereas the mutations might be somatic and limited to the affected tissue. 
Over the last past years, the first somatic mutations confined to affected cardiovascular tissue have 
been reported in CHM. The genes in which somatic mutations have been found include GJA 7, NKX2.5, 
TBXS, GATA4, HEY2 and HAN01 "'·'"(Table 5). The group of Reamon-Buettner and Borlak has report-
ed the majority of somatic mutations in CHM, including mutations in NKX2.5, TBXS, GATA4, HEY2 and 
HAND7.1nterestingly, in several patients different mutations in the same gene with cumulative down-
regulation of transcription were reported 189•195• Although only a limited number of studies have been 
performed, most likely due to the scarceness of affected cardiac tissue, the abundance of somatic 
mutations reported by the group of Reamon-Buettner and Borlak contrasts with the limited number of 
mutations in other studies. No NKX2.5 gene mutations could be found in cardiac tissue from patients 
with BAV and associated aneurysm 196, and no somatic 22q11.2 deletions could be identified in heart 
tissue from patients with conotruncal heart defects without germ line 22q11.2 deletion 197• Recently, 
no evidence for somatic NKX2.5 mutations was found in a large series of fresh- frozen cardiac tissue 
taken near the septal defect of patients with ASD, VSD and AVSD 198• The latter authors suggested that 
the poor DNA quality from the formalin-fixed tissue used by the group of Reamon-Buettner and Borlak 
may account for the high amount of somatic mutations in their study 198, although differences in the 
location of tissue sampling might also be important. Evidently, the role of somatic mutations in CHM 
awaits further confirmation. 
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TableS I Somatic mutations contributing to non-syndromic CHM 
GJA7 Gap junction protein HLHS Gene conversion m 
NKX2.5 Transcription factor VSD, ASD, AVSD Various missense mutations 192.193 
GATA4 Transcription factor VSD,AVSD Various missense mutations 250,251 
TBXS Transcription factor ASD,AVSD Various missense mutations 
"' 
HEY2 Transcription factor AVSD T96A, D98A, L 1005 
'" 
HAND7 Transcription factor HLV,HRV A126fs 
"' 
*Mutations in the open reading frame are described at the protein level. 
ASD, atrial septal defect; AVSD, atrioventricular septal defect; HLHS, hypoplastic left heart syndrome; HLV, hypoplastic leftventride; HRV, hypoplastic right 
ventride; VSD, ventricular septal defect 
Table 6 ! Genes involved in non-syndromic CHM 
Incidence** 14/0.8 4 1.0 0.7 0.4 0.3 0.2 0.2 0.16 0.1 
Genes NOTCH7 NKX2.5r'! NKX2.5r'! GATA4 NKX2.5 GATA4 NKX2.5 NKX2.5 NKX2.5 ZIG 
GATA4 GATA4 MYOCD GATA4 CRELD7 THRAP2 NOTCH7 GOF7 GDF7 
TBX20 TBX20 JAG7 TBX7 CFC7 ZIG HAND7* CFC7 CFC7 
TBX7 MYH6 FOG2 GDF7 CFC7 GJA7* LEFTY2 
ACTC7 ACTC7 CFC7 NKX2.5* GDF7 ACVR28 
MYBPC3 MYHl NOTCH7 TBXS* THRAP2 NODAL 
TBXS MYBPC3 GOF7 HEYl* NKX2.5 
C/TED2 TBXsr'! TDGF7 PTPN77 CRELD7 
C/TED2 JAG7 
TW FOXH7 
flS, aortic valve stenosis; ASD, atrial septal defect; AVSD, atrioventricular septal defect; BAV, bicuspid aortic valve; CHM, congenital heart malformation; 
DORV, double outlet right ventricle; HLHS, hypoplastic left heart syndrome; PS, pulmonary valve stenosis; TGA, transposition of the great arteries; TOF, 
tetralogy ofFallot; VSD, ventricular septal defect 
*somatic mutations, (*)both germ line and somatic mutations 
**per 1000 live-births 
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The "multifactorial inheritance" hypothesis 
The overall recurrence risk of non~syndromic CHM (defined as the risk of a child with CHM after a previ-
ous child with CHM) is usually in the order of 2-10 o/o 199-206• Empirical risk studies have revealed higher 
recurrence risks for specific subsets of CHM, indicating that genetic factors may play a more prominent 
role in CHM such as ASD, AVSD, and LVOTO. Several studies have indicated a higher risk for offspring of 
a mother with CHM than for the children of a father with CHM 9.2-o?;ws. Theoretically, this could be due 
to maternal inheritance, imprinting, maternal environmental factors, but no exact data to explain this 
discrepancy have been reported. 
The "multifactorial inheritance'' hypothesis of common diseases suggests that the interaction and cu-
mulative effect of multiple genetic and environmental risk factors leads to disease. One of the argu-
ments underlying the multifactorial hypothesis is the observation that the overall recurrence risk of 
non-syndromic CHM is 2-10 %; as this is intermediate between the high risk present in monogenic cases 
and the negligible risk in case of non-genetic CHM, the existence of reduced-penetrance mutations in 
susceptibility genes has been suggested. However, only a limited number of common gene variants 
with low penetrance or rare variants with intermediate penetrance have been reported to date {Ta-
bles 2-4). Furthermore, few interactions of risk factors for CHM have been reported up to now. MTHFR 
polymorph isms might have an effect on heart development when present with other risk factors such 
as smoking, hyperhomoysteinaemie 209 or nutrient deficiencies 210• Some evidence of an increased risk 
of conotruncal defects in infants of mothers who smoked cigarettes periconceptional and who had a 
NOS3 gene variant has been reported 170• Maternal and fetal variants in theMTRR gene (c.66A>G) and in 
the transcobalamin 11 gene (c.776C>G) have been reported to be associated with an increased risk for 
different types of CHM in offspring only in combination with low maternal serum vitamin 812 12• The 
A allele in intron 1 of the NNMT gene causes an increased CHM risk only on a maternal background of 
low dietary nicotinamide intake and periconceptional use of certain drugs 11 • VEGF common variants 
associated with lower VEGF level confer an increased risk forTOF in patients with 22q11 deletions 171 , 
possibly due to the fact that TBX7, the gene implicated in 22q11 deletion syndrome, is a downstream 
target ofVEGF (Figure 1). Another example of gene-environment interaction is the increase in risk of 
ASD reported in offspring of women with low-activity variants of Glutathione-5-transferase when ex-
posed to specific solvents metabolized by Glutathione-S-transferase 211 • 
The NODAL signaling pathway is a paradigm for multifactorial inheritance of CHM. A minority of pa-
tients with heterotaxy 68 or heterotaxy-related HCM such as looping defects (TGA, DORV) "or CHM 
includingTOF show several mutations in genes belonging to the NODAL signaling pathway, including 
the NODAL, CFC7, FOXH7 and GDF1 genes 10• As the functional significance of each of these mutations 
could be demonstrated, the cumulative effects of multiple mutations may lead to reduced NODAL sig-
naling eventually resulting in CHM. 
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Conclusions 
The genetics of non-syndromic CHM remains unclear to a large extent: the low percentage of single 
gene mutations with high or intermediate penetrance argues against a prominent role of such muta-
tions in non-syndromic CHM, the existence of somatic mutations in CHM heart tissue is still a matter 
of debate, and common variants seem to have a limited contribution. Although more than 40 different 
genes have already been shown to be implicated in non-syndromic CHM, many human genes are ex-
pected be identified within the coming years taking into account the large number of genes that have 
been shown to play a role in mice cardiogenesis. It is expected that the massive sequencing power of 
next-generation sequencers will be instrumental in the identification of additional genes implicated in 
CHM. Furthermore, such studies might shed lights on the interaction of different genetic factors, and 
finally prove or refute the multifactorial model. 
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1.3 Aim and outline of the thesis 
This thesis presents clinical and molecular studies of patients and families with different congenital 
heart malformations (CHM) during a 10-years period between 1998 and 2008. Patients were examined 
in the Division of Obstetrics and Prenatal Medicine ofthe Department of Obstetrics and Gynaecology of 
the ErasmusMC (fetuses), in the outclinic of the Department of Pediatric Cardiology of the Sophia Chil-
dren's Hospital (children), in the outclinic of the Department of Cardiology at the Thorax Center of the 
ErasmusMC (adults), and in the Department of Clinical Genetics of the ErasmusMC (children and adults). 
The variety of cardiac phenotypes described in this thesis reflects the daily practice of the clinical ge-
neticist involved in genetic counseling of patients affected with CHM. Working at different departments 
(first as u!trasonographist practising fetal echocardiology, and later as a clinical geneticist) I had the 
opportunity to study CHM in patients at different ages (fetuses, children, and adults) and observe the 
'genetic link' between the different phenotypes present in family members sometimes known as 'iso-
lated' cases in the different departments. 
The aim of the studies in this thesis was to describe cardiac phenotypes in familial CHM, and identify 
disease genes involved in human CHM. A broad spectrum of syndromic and non-syndromic forms of 
CHM was studied, including laterality defects, left ventricular outflow tract obstruction (LVOTO) anoma-
lies, arterial malformations, and CHM in association with cardiomyopathies. 
Chapter1 reviews the genetic and environmental factors contributing to human congenital heart mal-
formations. 
Chapter 2 reports clinical and molecular studies in patients with laterality defects. The prenatal phe-
notype of Kartagener syndrome is described, and molecular studies on a subtype of Kartagener syn-
drome, acilia syndrome, are presented. A new syndrome with laterality defects and VACTERL associa-
tion is reported, and this syndrome is shown to be due to a new disease mechanism (repeat amplifica-
tion) in theZ/C3 gene. 
Chapter 3 describes multiple families with autosomal dominant inheritance of left ventricular outflow 
tract obstruction (LVOTO) and/or cardiac valve anomalies, and discusses possible pathogenetic path-
ways and disease genes involved in these CHM. 
Chapter4 delineates the clinical features of arterial tortuosity syndrome, and reports linkage analysis in 
three inbred families with this syndrome leading to the identification of the SLC2A 10 gene encoding 
GLUT1 0 as the disease gene involved in arterial tortuosity syndrome. 
Chapter 5 reports different genetic associations of CHM with cardiomyopathies. A new autosomal domi-
nant syndrome with laterality defects and cardiomyopathy could be linked to chromsome 6p. A severe 
type of early cardiomyopathy with septal defects is reported to be due to compound heterozygosity 
for mutations in a sarcomeric protein gene MYBPC3. Finally, another sarcomeric protein gene MYH7 is 
implicated in Ebstein anomaly and septal defects. 
Chapter 6 discusses the significance and implications of our studies and delineates future perspectives. 
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CHAPTER2 
Laterality disorders 
2.1 Introduction 
Laterality defects refer to a group of disorders indicating embryonic disruption of normal left- right {LR) 
patterning. The usual orientation of the heart and other organs is called "situs solitus': A complete mir-
ror image arrangement of all internal organs is called "situs inversus': Any LR arrangement other than 
situs solitus and situs inversus is called "heterotaxy" or"situs ambiguous': Heterotaxy is frequently asso-
ciated with "isomerism': a defect in the asymmetry of paired organs with distinct right or left anatomy. 
"Left isomerism" is characterized by bilateral left-sidedness with anomalies such as bilateral left atrial 
appendages, bilateral bilobed lungs, polysplenia, and congenital heart malformations (CHM). "Right 
isomerism" is characterized by bilateral right-sidedness with anomalies including bilateral right atrial 
appendages, bilateral trilobed lungs, asplenia, and CHM. However, a wide phenotypic spectrum is seen 
in heterotaxy, and patients can have a mixture of abnormalities of left or right isomerism. Over the 
past years several extensive reviews on the genetics of heterotaxy have been published H. It has been 
postulated that LR patterning genes not only play a role in complex laterality disorders, but are also 
implicated in isolated CHM, biliary tract anomalies, cystic renal disease and malrotation of the gut 6• As 
the phenotypes caused by defects in the determination of LR asymmetry in mice and man are strikingly 
similar, molecular studies in mice models can be of help to understand human disorders of LR pattern-
ing. Up till now more than 80 genes involved in the process of LR patterning have been identified in 
animal studies. Several excellent reviews concerning the establishment ofthe LR axis in various animal 
model systems have been published 7•13• 
2.1.1 Ciliary defects 
Cilia consist of a microtubule-based axoneme, a highly ordered structure of nine peripheral microtu-
bule doublets arranged around a central core that may or may not contain two central microtubules 
(9+2 or 9+0 axonemes). Most 9+0 cilia lack dynein arms, are non-motile and also called primairy cilia, 
whereas 9+2 cilia usually have dynein arms that link the microtubule doublets and are motile. The cili-
ary axoneme extends from the basal body-centrosome complex in the cytoplasm towards the tip of the 
cilia. Ciliary assembly and maintenance is accomplished by intraflagellar transport (1FT), which relies on 
the microtubule motor proteins kinesin 2 and cytoplasmic dynein to transport lFT protein complexes 
and their associated cargo up and down the length of the cilium 12• Cilia are present at the node, a local 
thickening ofthe blastoderm at the end of the primitive streak of the embryo (Figure 1). The leftward 
movement of fluid at the ventral node generated by the cilia, called nodal flow, is the essential proc-
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ess in symmetry break"1ng on the LR axis. How nodal flow leads to LR asymmetry is not yet clear 12•14• 
However, leftward nodal flow triggers Notch signaling, which is crucial for the asymmetric expression 
of Nodal in the left peri nodal region 15• 
Dysfunction of ciliary proteins causes impaired functioning of nodal cilia and nodal flow, leading to 
phenotypes that range from organ-specific diseases (e.g. polycystic kidney disease} to pleiotropic syn-
dromes (e.g. Meckel syndrome). Situs abnormalities are part of many of these phenotypes. Two distinct 
groups of human disorders are caused by ciliary defects: primairy ciliary dyskinesia (PCD) caused by 
defective 9+2 cilia, and the hepatorenal fibrocystic (HRFC) syndromes caused by defective 9+0 cilia. Ad· 
ditionally, many mice models with ciliary defects have been described (for reviews: see refs 12•16). 
2.1.1.1 Primary ciliary dyskinesia 
lmmotile cilia syndrome (ICS), also called primary ciliary dyskinesia (PCD), is a specific group of laterality 
disorders. PCD is typically characterised by recurrent respiratory tract infections, and infertility due to 
immotile sperm. In 50% of PCD patients situs inversus is also present, in which case PCD is referred to 
as Kartagener syndrome. PCD is diagnosed by electron microscopy of nasal ciliary biopsy, as it is caused 
by immotile or dysmotile 9+2 (motile) cilia present on the epithelium of the respiratory tract, oviduct, 
efferent ductules of the testis and ependymal lining of the brain 16• PCD is caused by defects in the 
structure of the ciliary axoneme, most commonly loss of the outer dynein arms. 
As the cilia are complex structures and more than 20 human genes are predicted to encode outer dy-
ne in arm subunits and associated proteins possibly necessary for outer arm assembly, it is not unex-
pected that PCD is genetically heterogeneous 17• Until recently molecular defects in four genes encod-
ing dynein components have been identified: ONAH5 18, DNA/1 1""22 , DNA/2 13 and DNAH11 24• Mutational 
analysis has demonstrated that 38% of PCD patients carry mutations in DNA/1 or DNAHS 25• Recently 
mutations in the KTV gene were identified in patients with PCD 26• The Ktu protein is required in the 
cytoplasm for the preassembly of dynein arm complexes before they become transferred to their func-
tional positions in the axe noma 26• Additionally, mutations in the TXNDC3 gene, encoding a thioredoxin-
nucleoside diphosphate kinase, that was shown to bind microtubules, was recently implicated in PCD 
patients with situs ambiguous and situs inversus totalis 27• Mutations in the X-linked retinitis pigmento-
sa GTPase regulator gene (RPGR), the gene mostfrequently"1mplicated in X-linked retinitis pigmentosa, 
have been found in patients with retinitis pigmentosa, PCD and abnormal situs characterized by partial 
dynein arm defects 28• About 6 % of Kartagener syndrome patients have no situs inversus but hetero-
taxy (ambiguous situs with mainly left isomerism), with CHM in more than half of these patients 29• 
In this thesis genetic studies are described in three families with acilia syndrome, an infrequent form 
of PCD characterized by total absence of cilia 30• In one of these families heterotaxy and CHM are also 
present 30• We further describe mild cerebral ventriculomegaly as an early sign of PCD in fetuses 31 • Later 
also Kosaki et al. 32 reported ventriculomegaly and situs abnormalities in 2 fetuses with Kartagener syn-
drome. Such ventriculomegaly is caused by impaired flow of the ependymal cilia 3334• Ventriculomegaly 
is not often documented in postnatal series of PCO, as most cases have no clinical symptoms, so this 
feature escapes attention. 
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2.1.1.2 Hepatorenal fibrocystic (HRFC) syndromes 
The primary or sensory 9+0 (immotile) cilia are present on nearly all cell types in mammals, including 
principal cells of the nephron, rod and cone photoreceptor cells, hair cells of the inner ear, olfactory 
sensory neurons and chondrocytes 16.35, Defects of the 9+0 cilia result in malformation syndromes with 
overlapping features, referred as hepatorenal fibrocystic (HRFC) syndromes 36• Features common to 
HRFC syndromes are hepatorenal fibrocystic disease, situs abnormalities with CHM, retinitis pigmen-
tosa, postaxial polydactyly and skeletal dysplasia. Disorders included in this spectrum are the polycystic 
kidney disorders, nephronophthisis, Meckel-Gruber syndrome, Joubert syndrome, Leber congenital 
amaurosis, Bardet-Biedl syndrome, orofaciodigital syndrome, short rib-polydactyly syndromes, Jeune 
syndrome, and Ellis van Creveld syndrome 36• Many of these syndromes show clinical overlap with each 
other, and are due to mutations in the same gene. 
2.1.2 Defects ofthe NODAL pathway 
Several excellent reviews provide an overview of the molecular network regulating the establishment 
of LR asymmetry through NODAL signaling'·''"'· Four highly conserved genes Nodal, Lefty7, Lefty2 and 
Pitx2 define the core of the NODAL signaling pathway (Figure 1 ). These 4 genes are all expressed asym· 
metrically near the midline or in the left lateral plate mesoderm at comparable developmental stages. 
The first mutations in patients with laterality defects were identified in the Z/C3 gene encoding a zinc 
finger transcription factor from patients with X-linked heterotaxy 38.Z/C3 mutations were later also been 
identified in males with isolated CHM (often transposition of the great arteries), isolated heterotaxy, 
and a combination of heterotaxy and midline developmental anomalies such as anal and vertebral 
anomalies 38-40. 
Figure 1 I Genetic pathway for lR patterning 
The leftward movement of fluid at the ventral node generated by the cilia, called nodal 
flow, is the essential process in symmetry breaking on the LR axis. An asymmetric signal 
initiates Nodal~leftyHefty2 regulatory loops in the left lateral plate mesoderm {LPM). Nodal 
activity induces Pita expression in the left LPM. The broken line represents the midline. 
Foxhl is a component of the Nodal-Lefty loops. Zic3 acts upstream of Nodal at the node. 
Adapted from refl7 with permission from Dr. Hiroshi Hamada. 
R 
Node 
••• ' •, ' ' 
L 
LPM 
Zic3 
' 
' 
' ' ' 
' ' ' 
' ' ' 
' ' ' 
' ' ' ~--- i : Foxh1 
' ' ' : v~ 
\;,; . .:_ ~~ /! c:~ft;2 
: _ Foxh1 Foxh1 
I _ __. 
' : 
' 
' L~ 
::2 
:::2: 
: • 
70 I CHAPTER 2 
Zic3 acts upstream of Nodal in the LR axis. Other human orthologs of the NODAL signaling genes have 
been associated with only a small percentage of human non-syndromic laterality disorders, and overall 
the specific genetic defect causing heterotaxy is known in less than 5% of the patients 41 -43• A few mu-
tations have been found in several components of the NODAL signal transduction pathway, including 
the ACVR28 ", NODAL", GDFT ", FOXH7 ", TDGFT (CR/PTO) ", CFC7 (CRYPTIC) "-", and LEFTY2" genes. 
Mutations in these genes can also give rise to CHM without laterality defects, or combinations of later-
ality defects with CHM. A limited number offamilies with autosomal recessive or autosomal dominant 
laterality defects have been reported 48-so. 
In this thesis a mutation in the ZIC3 gene is described in a patient with heterotaxy and VACTERL associa-
tion. VACTERL is an acronym for Vertebral anomalies, Anal atresia, Cardiac malformations, Tracheo-es-
ophageal fistula, Renal anomalies, and Limb anomalies. A spectrum of developmental anomalies strik-
ingly similar to that ofVACTERL association has been reported in mice with defective Gli-Shh signaling, 
a pathway that interacts with Zic genes 51 • This suggests that ZIC3 might be involved in the different 
developmental anomalies of the VACTERL association. The ZIC3 mutation in our family is a novel type 
of ZIC3 mutation, and consists of repeat amplification leading to elongation of the polyalanine stretch. 
In this thesis a new autosomal dominant form of left isomerism characterized by left bronchial isomer-
ism, azygous continuation of the inferior vena cava, polysplenia and intestinal malrotation is reported. 
The cardiac anomalies included noncompaction of the ventricular myocardium, bradycardia, pulmo-
nary valvular stenosis, and secundum atrial septal defect. The disease gene could be localized to chro-
mosome 6p, but has not yet been identified 52• 
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Mild fetal cerebral ventriculomegaly as a prenatal 
sonographic marker for Kartagener syndrome 
Marja W. Wessels1.2*, Nicolette S. den Hollander" and Patrick J. Willems4 
1 Department of Clinical Generics. Erasmus University Medical Centre, Rotterdam, The Netherlaruis 
1Department of Obstetrics and Gynaecolog:y. Erasmus University Medical Centre, Rotterdam, The Netherlands 
3 Department of Clinical Genetics, Leiden University Medical Centre, Leiden, The Netherlands 
4Synergene NV, Mechelen, Belgium 
Primary ciliary dyskinesia (PCD), also referred to a.s immotile-cilia syndrome or Knrugener syndrome, is a 
group of genetic disorders caused by defective cilia leading to chronic sinupulmon::uy infection, situs inversus 
and reduced fertility. Some PCD patients :llso have cerebral ventriculomeg:lly or hydroceph:llus. 
We report here two fetuses and one newborn with mild cerebral ventriculomeg:lly and a suspected and/or 
confirmed diagnosis of PCD. These cases demonstrate that mild fetal cerebral ventriculomegaly can be a 
prenatal sonographic marker of PCD, certainly in fetuses with situs inversus or a history of a previous sib 
with PCD. Copyright© 2003 John Wiley & Sons, Ltd. 
KEY woRDs: fetal cerebral ventriculomegaly: Kartagener syndrome: primary ciliary dyskinesia (PCD): prena-
tal diagnosis 
INTRODUCTION 
Primary ciliary dyskinesia (PCD) or immotilc-cilia 
syndrome is a genetically heterogeneous disease with an 
estimated incidence of l in 20.000 to 60.000 live births 
(Afzelius, 1976: Afzclius et al.. 2001). PCD is charac-
terized by recurrent or chronic sinupulmonary infections 
including sinusitis. rhinitis and bronchitis, which even-
tually leads to bronchiectasis. The infections are caused 
by dysmotility. immotility or the absence of cilia. Cilia 
are normally present on the epithelia lining the sinuses 
and the respiratory tract where they are responsible for 
the drainage of foreign particles and microorganisms. 
Reduced fertility is often present in PCD, certainly in 
male patients. as cilia are also present on the epithe-
lia of the female oviduct and the male vas deferens. 
Approximately half of the PCD patients present with 
situs in versus. in which case PCD is referred to as Karta-
gener syndrome (KS). Situs inversus in PCD has been 
suggested to be the consequence of defective monocilia 
that arc normally present on cells of the embryonic node. 
These cilia are thought to be instrumental in the embry-
onic movement of organs and the establishment of the 
left-right body axis (Nonaka et al.. 1998: Brueckner. 
2001: Hackett. 2002). PCD might therefore cause a ran-
dom situs with situs inversus in half of the patients. 
Occasionally. PCD patients also show hydrocephalus 
or mild enlargement of the cerebral ventricular sys-
tem and sulci (Greenstone et al .. 1984: Jabourian et al., 
1986: De Santi et al., 1990: Picco et al.. 1993). Also. 
the chronic headaches occurring in some PCD patients 
might be related to abnormalities in liquor circulation 
(Afzelius et at., 2001). The association of PCD with 
*Correspondence to: Marja W. Wessels, Department of Clinical 
Genetics, Erasmus University Medical Centre, West7.eedijk 112, 
3016 AH Rotterdam. The ~etherlands. 
E-mail: wessc:ls@kgen.azr.nl 
Copyright © 2003 John Wiley & Sons, Ltd. 
cerebral ventriculomegaly or overt hydrocephalus has 
also been described in dogs (Edwards et al.. 1989; Dhein 
et al., 1990; Daniel et al .. 1995), Wic-Hyd rats (Torikata 
et al., 1991: Shimizu and Koto. 1992: Nakamura and 
Sato. 1993). HpyJHpy mice (Bryan, 1983). mice with 
targeted disruption of the foxjl gene (Chen et al., 1998) 
and mice with an insertional mutation in the axonemal 
dynein heavy-chain gene. Mdnah5 (Ibaiiez-Tallon et al .. 
2002). This suggests a functional role in liquor circula-
tion for the cilia lining the ventricular ependyma of the 
brain and spinal cord in humans and other species. 
Prenatal diagnosis of PCD is sometimes possible 
by mutation analysis of one of the genes currently 
known to be involved in PCD (Pcnnarun et al., 1999: 
Guichard et al.. 2001: Olbrich et al., 2002). However. 
in the majority of cases. fetal ultrasound examination is 
the only method to detect PCD prenatally, if at least 
detectable structural anomalies such as situs inversus 
arc present. However. half of the patients with PCD 
do not show situs inversus. As ventriculomegaly or 
hydrocephalus is sometimes present in neonates or 
children with PCD. it might offer an additional prenatal 
sonographic marker for PCD. 
We present here two fetuses and one newborn with a 
suspected and/or confirmed diagnosis of PCD presenting 
with mild cerebral vcntriculomegaly. 
CASE REPORTS 
Family 1 
The healthy parents of family 1 were of Caucasian 
descent and unrelated (Figure 1). They were referred to 
our centre for prenatal diagnosis in their third pregnancy 
because of a previous child (II-2) with a primum 
atrial septal defect, aortic isthmus stenosis, absent right 
superior vena cava and a persistent left superior and 
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Figure !-Family pedigrees of the two families with an ~sociation of PCD and fetal ccrebrol ventriculomcgaly. Note the variability of the 
clinicul picture 
inferior vena cava connected to the coronary sinus. The 
congenital heart malformations did not necessitate sur-
gical repair. Case II-2 had recurrent atelectases of the 
right lung and mildly dilated lateral cerebral ventricles 
in the neonatal period. both of which disappeared later 
on. However. he had frequent upper-airway infections 
during his childhood. Occipitofrontal circumference and 
mental development were normal at the age of five 
years. The diagnosis of PCD was not made until a 
suspicion of PCD in the next pregnancy. In that preg-
nancy (II-3), a fetal anomaly scan at 19 weeks revealed 
a right-sided stomach and a central liver. a primum 
atrial septal defect and a persistent left superior vena 
cava. There also existed mild cerebral ventriculomegaly. 
with the width of the posterior hom of the lateral ven-
tricle measuring 13 rnm (normal upper limit: 10 mm). 
Amniocentesis revealed a normal female karyotype. and 
a 22q 11 deletion was excluded. PCD was suspected in 
sib II-2 in view of these ultrasound abnormalities and 
the presence of similar features with frequent upper-
airway infections. After counselling, the parents decided 
to continue the pregnancy. At 37 weeks. a girl weigh-
ing 2750 g was born with Apgar scores of 6 (1') and 
8 (5'). The prenatally diagnosed cardiac abnonnalities 
were confirmed. and in addition an absent inferior vena 
cava with azygous continuation was found. Abdominal 
Copyright © 2003 John Wiley & Sons, Ltd. 
abnormalities included a right-sided stomach. septated 
spleen with a small accessory spleen, central position of 
the liver with drainage of the left hepatic veins into a 
persistent left inferior vena cava and intestinal malrota-
tion with volvulus. The child suffered from respiratory 
difficulties, and atelectases of the lung developed. An 
ultrasound of the brain made in the first week of life 
showed cerebral ventricles within the nonnal size range. 
In view of the combination of cardiac and abdominal 
features compatible with a situs abnormality. neonatal 
lung atelectases and fetal and/or neonatal cerebral ven-
triculomegaly in one or both sibs, the diagnosis of PCD 
was suspected. Electron-microscopic examination of a 
nasal biopsy showed ciliary aplasia in both infants (II-
2 and II-3), confirming the diagnosis of PCD. The first 
child (Il-l) and the parents were healthy. but were not 
further investigated. 
Family 2 
A consanguineous couple (first cousins) of Moroccan 
descent was referred in the 1Oth pregnancy to our cen-
tre for prenatal diagnosis because of a previous child (II 
-6) with KS (Figure 1). The second child (II-2) died on 
day 2 after birth because of meconium aspiration. but 
Pmw:t Diagn 2003; 23: 239-242. 
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no prenatal or post-natal examination was pexformed. 
The sixth child (II-6), a girl. had situs inversus totalis 
and frequent upper-airway infections. This lead to the 
diagnosis of KS at the age of one month. This diag-
nosis of PCD was confirmed by nasal and bronchial 
biopsies showing impaired ciliary motility and abnormal 
cilia. Electron-microscopic evaluation revealed strongly 
abnormal cilia with deficiency of the inner dynein arms. 
radial spokes and nexin links. In the eighth pregnancy. 
a fetal anomaly scan at 16 weeks of gestation revealed 
hypoplasia of the left cardiac ventricle (II-8). Cerebral 
anatomy and thoracic and abdominal situs were nor-
mal. Amniocentesis revealed a normal male karyotype. 
The pregnancy was terminated. and the hypoplasia of 
the left ventricle was confirmed at autopsy, Addition-
ally, left-atrial isomerism and polysplenia were found. 
At that time, the diagnosis of PCD was not made. In 
the ninth pregnancy, ultrasound examination of the fetus 
(ll-9) revealed a normal situs but mild cerebral ventricu-
lomegaly, with the width of the posterior hom of the 
lateral ventricle measuring 13 mm. Amniocentesis was 
performed and a normal female karyotype was found. 
Virological studies on maternal blood were normal. A 
girl with a birth weight of 3535 g was born at term. 
Apgar scores were 3 (1') and 6 (5'). respectively. The 
child suffered from severe respiratory insufficiency due 
to meconium aspiration. and atelectases of the right mid-
dle lung lobe developed. She died after one day. No 
further diagnostic work."Up was pexformed. 
A fetal anomaly scan in the 19th week of the lOth 
pregnancy (ll-10) revealed situs inversus totalis. In view 
of these abnormalities and the presence of KS in ll-6, 
the tentative prenatal diagnosis of PCD was made in 
ll-10. The fetal cerebral ventricular width was normal. 
The parents decided to continue the pregnancy. 11-10 
was born at 41 weeks of gestation with a birthweight 
of 3640 g. and was hospitalised because of meconium 
aspiration and respiratory distress. The diagnosis of KS 
was confirmed by a nasal biopsy showing absent ciliary 
motility. The child was discharged from the hospital 
after 6 weeks. He had recurrent lung atelectases in the 
neonatal period. and upper-airway infections later on. 
In retrospect. it is very likely that apart from ll-
6 and ll-10. the fetus with hypoplastic left ventricle 
and left-atrial isomerism (II-8). and possibly the child 
with mild ventriculomegaly and post-natal respiratory 
distress (II-9). had PCD. The parents and the other 
children were reported to be healthy. but no further 
studies were performed. 
DISCUSSION 
We describe here two families \\lith probable autosomal 
recessive PCD associated with mild ventriculomegaly. 
In the first family, both sibs affected with PCD had 
mild dilatation of the lateral cerebral ventricles. In the 
second family. PCD was suspected in two sibs. of 
which one showed mild fetal ventriculomegaly, and 
was confirmed in two additional sibs. In all three 
cases. cerebral ventriculomegaly was mild, and was 
Copyright© 2003 John Wl\ey & Sons, Ltd. 
only retrospectively recognised to be a part of PCD. 
The ventricular dilatation in PCD is probably due to 
a dysfunction of the cilia that line the ventricular 
ependyma of the brain and ~"Pinal cord. It has not only 
been described in humans but also in dogs. rats and 
mice with PCD. Consequently. the beating of these cilia 
must be important in the circulation of liquor. Mild 
fetal ventriculomegaly can be caused by many factors 
leading to parenchymal loss of abnormal cerebrospinal~ 
fluid circulation. When diagnosed. additional prenatal 
tests (amniocentesis for karyotyping and virological 
studies. maternal platelet counts and virology) should 
be performed. As illustrated here, attention should also 
be paid to organ situs and structural heart defects in 
order to exclude PCD, certainly when a history of 
PCD in a previous child is present. Therefore. mild 
cerebral ventriculomegaly might be an early sign of 
PCD. This is important as PCD might be responsible 
for neonatal difficulties due to respiratory distress and/or 
meconium aspiration (Monnet. 1978: \Vhitelaw et al., 
1981: Losa et al.. 1995). or intestinal malrotation and/or 
congenital heart defects in case of situs ambiguus. To 
our knowledge. PCD has never been reported in post-
natal follow-up studies of fetuses with mild cerebral 
ventriculomegaly (Bromley et al .. 1991: Bloom et al .. 
1997: Vergani et al., 1998; Pilu et al .. 1999; Mercier 
et al.. 2001: Kelly et al., 2001), probably because PCD 
is not always recognised in the neonatal period (Losa 
et al., 1995). particularly not in the absence of situs 
inversus. This highlights the importance of a thorough 
diagnostic evaluation of fetal and neonatal abnormalities. 
Furthermore. a careful family history can lead to an 
etiologic dif~e<>nosis that was not considered in individual 
affected family members. certainly in diseases with a 
clinical spectrum as variable as that of PCD. 
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To the Editor: 
Primary ciliary dyskinesia (PCD or CILD) also 
called immotile cilia syndrome (ICS). is characterised 
by defective functioning of cilia leading to chronic 
sinupulmonary infections Wzelius. 1976; A...fzelius 
et al., :won Approximately half of the patients 
with PCD have situs inversus, in which case PCD 
is called Kartagener syndrome [Kartagener, 19331. 
PCD appears to be a condition with e::-..1:ensive 
genetic heterogeneity and 6 genes DNAll, DNA1l5. 
DNAFill, RPGR, OFDl, and TX.lv'DC3. which alto-
gether are responsible for about a third of PCD 
families, have been found so far to be implicated in 
PCD. Of the 11 specific PCD groups defined by 
Afzelius etal. [2001] one isacilia syndrome (AS). AS is 
an infrequent form of PCD characterised by total 
absence of cilia [Dudleyetal., 1982; Fonzi etal., 1982; 
G6tz and Stockinger, 1983; Gordon and Kattan, 
1984; Welch eta!., 1984; Babin and Kavanagh. 1985; 
Cerezo and Price, 1985; de Santi et al.. 1988; Phillips, 
1989; Richard eta!., 1989; Sofermanetal., 1996; Maiti 
eta!., 2000]. AS probably is a separate entity in PCD 
and the disease gene has not yet been identified 
[Maiti et aL, 2000]. 
In this study we analyzed several candidate genes 
in three unrelated AS families. The first family is an 
inbred Israeli family (Fig. 1) with two related sibships 
each having t\VO AS patients (three girls, one boy). 
that have been reported [Soferman eta!., 1996]. The 
parents of all four patients were consanguineous and 
descendants from a single ancestor. All four patients 
(III-5, III-6. IV-3. and IV-4) had been diagnosed with 
AS because of recurrent upper and lower respiratory 
tract infections, sinusitis and severe lung disease with 
widespread bronchiectasis (FEVl around 30%) 
with absence of cilia on respiratory epithelial cells. 
I\o heterota..'\."Y or cardiovascular malformation was 
reported but no real cardiovascular evaluation v.ras 
performed [Soferman et a!.. 19961. 
The second family is a nonconsanguineous 
Israeli family (Fig. 1) with tw'O of the three children, 
a girl (Il-l) and a boy (II-3) having AS. They suffered 
from recurrent otitis. sinusitis and pneumonia with-
out bronchiectasis. They both need bronchodilator 
therapy and have reserved lung function (FEVl 
around 70-80%) and bronchial hyperresponsive-
ness. The girl had a partial lobectomy (right side), 
whereas d1e boy had atelectases of the right lung. I'\o 
obvious heterota..'\."Y or cardiovascular malformation 
was present. 
The third family is a Dutch family with two AS sibs, 
a boy (II-2) and a girl (II-3), that have been reported 
[\Vessels et aL, 2003]. The parents are healthy 
and unrelated (Fig. 1). The fin."! child is healthy. 
The second child was born 'Wid1 transient mildly 
dilated lateral cerebral ventricles. He has absent right 
superior vena cava with persistent left superior and 
inferior vena cava connected to the coronary sinus, 
a primum atrial septal defect, and aortic isthmus 
stenosis. He also showed recurrent lung atelectases 
and respiratory infections. The diagnosis of PCD was 
only made when PCD was suspected in the ne::....1: 
•Correspondence to: Patrick j. Willems, MD, PhD, GEI\'D!A, Amer· 
ik:liei 62. 2000 Antwerp. Belgium. E-mail: willem.~patrick@skyn~t.be 
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pregnancy when heterota.>..')" was found at fetal 
ultrasound with a right-sided stomach and a central 
liver, a primum atrial septal defect, perslli1:ent left 
superior vena cava. There also existed mild cerebral 
ventriculomegaly, with the width of the posterior 
hom of the lateral ventricle measuring 13 mm 
(normal upper limit: 10 mm). After birth heterota."\y 
was confirmed; the cardiovascular anomalies con-
sisted of a primum atrial septal defect, persistent left 
superior vena cava, and absent inferior vena cava 
with azygous continuation. The abdominal situs 
anomalies included a right-sided stomach, intestinal 
malrotation with volvulus. central position of the 
liver with drainage of the left hepatic veins in a 
persistent left inferior vena cava, septated spleen 
with small accessory spleen. The child developed 
recurrent respiratory difficulties and atelectasis of 
the lung. PCD in both sibs was confirmed by 
electromicroscopic examination of a nasal biopsy 
showing ciliary aplasia in both. 
In these three AS families several candidate genes 
were analy-.ted in this study. In Family 1linkage to the 
DNA1-I5locus could not be excluded by haplotype 
analysis. Therefore, all SO coding exons including 
adjacent intron/e.\:on boundaries of DNAH5 were 
amplified and directly sequenced in an affected 
patient [Homef et al., 2006]. However, no DNAH5 
mutation was detected. In each of the three families 
all exons of the DNAJJ gene were screened 
for sequence variants by DHPLC in one affected 
individual, but no variants were found. In addition, 
D::--JA of a single affected individual in each of 
the families ~s also analyzed specifically for the 
occurrence of the IVS + 2_3insT mutation (also 
referred to as 219 + 3insT or c.4S + 2_ 4S + 3insD 
by restriction analysis using Hpal oni PCR products 
of e:xon 1 and adjacent intronic sequences. :Kone of 
the three families showed the IVS + 2_3insT muta-
tion, which accounts for rv60% of all DNAIJ 
mutations [Zariwala et al., 2006]. To exclude homo-
zygous DNAIJ mutations that DHPLC could not 
resolve. we performed genotype analysis using 
9 Hapmap tag Sl\TPs widely spaced on the entire 
length of DNAll, which is covered by a single 
linkage disequilibrium block (LD block) according 
to Hapmap (WWW'.hapmap.org). Heterozygous tag 
S:-.JPs genotypes indicated that the investigated 
patients of the three families were not homozygous 
for the LD block. Direct sequence analysis of the two 
coding exons 'With adjacent intronic regions of the 
FOXjl (I-IFH4) gene was performed in one affected 
patient from all three PCD families, but no mutations 
that could be disease-causing were identified. 
In conclusion, we could not find evidence for the 
involvement of DNAJJ, DNAH5. or FOX]J in any 
of our three AS families. In generaL about 10% ofPCD 
patients have mutations in DNAII [Zariwala et al., 
2006], and nearly a quarter (half of PCD families 
with outer dynein arms defects) have DNAH5 
mutations [Homef et al., 2006]. All DNAIJ and 
DNAH5 mutations lead to the absence of outer 
dynein arms, the most frequent abnormality 
observed in PCD [Zariwala et al., 2007], but not 
acilia. The FOX]l gene encoding the hepatocyte 
nuclear factor 3 or forkhead homologue 13 (formerly 
known as HFH-4 or FKHL 13 gene) on chromosome 
17 was a good candidate gene for AS for several 
reasons. Fir::.l, inactivation of the Foxjl gene in mice 
results in AS, infertility due to absence of flagella in 
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sperm and heterota..'\.y, the three important charac~ 
teristics ofhumanPCD [Chenet al., 1998; Brodyetal.. 
2000]. Second, inactivation of the Foxjl gene leads to 
reduced expression of left~right dynein. Third, Foxjl 
is expressed in respiratory epithelia and semini-
ferous tubules of the testes [Blatt et al.. 19991 We did 
not analyze the DNAHll, RPGR, TXl\1)C3, or OFDJ 
genes as these were unlikely to be involved in the 
pathogenesis of our families: DKAH11 mutations are 
rare [Schwabe et al., 2008]. mutations in the X~linked 
RPGR gene are associated retinitis pigmentosa., and 
mutations in the TXNDC3 or OFDJ gene have only 
been implicated in a single PCD family (Budny et al., 
2006; Duriez et al., 2007]. 
Of the 11 PCD groups defined by Afzelius et al. 
[2001] one specific group is acilia syndrome (AS). AS 
probably is a distinct entity within PCD as it breeds 
true in multiple families. The observation of AS in sibs 
of both sexes, consanguinity of some of the parents, 
and the presence of multiplex AS pedigrees in inbred 
families [GOtz and Stockinger, 1983; Soferman et al., 
1996] are compatible vrith an autosomal mode of 
inheritance. However, up to now no mutations have 
been identified in AS. and also not in this study. It is 
therefore likely that acilia syndrome consists of a 
separate entity within the heterogeneous group of 
PCDs. 
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Abstract 
We describe a newborn male with features of the VACTERL association, including anal atresia, laryngeal 
and esophageal atresia with tracheo-esophageal fistula, dextroposition of the heart with persistent left 
superior vena cava, and unilateral multicystic kidney. As the clinical picture of the VACTERL association 
overlaps with X-linked heterotaxy caused by ZIC3 mutations, we sequenced the ZIC3 coding region, 
and found a 6-nucleotide insertion that is predicted to expand the amino-terminal polyalanine repeat 
from ten to twelve polyalanines. This novel mutation was not present in the mother, nor in 336 chromo-
somes from 192 ethnically-matched controls. We hypothesize that this novel and de novo polyalanine 
expansion in the ZIC3 gene contributes to the VACTERL association in this patient 
Introduction 
Mutations in ZIC3, a zinc finger transcription factor gene located at Xq26, typically result in a spectrum 
of left-right asymmetry defects, including complex cardiac anomalies, altered lung lobation, splenic 
and hepatobiliary abnormalities, and gut malposition. Also renal, anal and lumbosacral anomalies are 
common. The combination of Z/C3-associated anomalies is referred to as X-linked heterotaxy (HTX1, 
MIM 306955) 1•5• However, also isolated congenital heart disease can be due to mutations in Z/C3.4 
Though usually unaffected, some female heterozygotes manifest abnormalities whose spectrum and 
severity is indistinguishable from affected males. 
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The VACTERLassociation, which comprises vertebral anomalies (V), anal atresia (A), cardiovascular mal-
formations (C), tracheo-esophageal fistula and/or esophageal atresia (TE), renal malformations (R) and 
limb defects (l) is a non-random association of defects with an unknown etiology in the majority of pa-
tients.5·71n several recent reviews the syndromes resembling VACTERL association have been discussed: 
these include Feingold syndrome (NMYC gene), Fanconi syndrome (FANC genes), CHARGE syndrome 
(CHDl gene), Pal lister-Hall syndrome (GL/3 gene), Anophthalmia-Esophageal-Genital syndrome (SOX2 
gene), Opitz G/BBB syndrome (M/07 gene), Townes-Brocks syndrome (SALL 7 gene) and Fryns syndrome 
(disease gene not identified yet) 8 9•10• VACTERL association phenotypically also overlaps with Z/C3-asso-
ciated X-linked heterotaxy: anal atresia and cardiac defects are common in both disorders, and typical 
VACTERL features such as tracheo-esophageal fistula, renal and vertebral anomalies have occasionally 
also been reported in Z/C3-associated heterotaxy (Table 1) 5• 
In the case presented here, we describe a novel ZIC3 mutation (elongation of the amino-terminal alanine 
repeat) in a patient with overlapping features between VACTERL association and X-linked heterotaxy. 
Case report 
A healthy Caucasian gravida 2 para 1 was referred for ultrasound examination at 31 weeks of gesta-
tion because of suspected polyhydramnios. Apart from polyhydramnios advanced ultrasonography 
revealed absent stomach filling, suggesting esophageal atresia, and a right multicystic kidney. Amnio-
centesis showed a normal male karyotype, and FISH analysis to exclude a 22q11.2 deletion was normal. 
In her previous pregnancy the mother delivered a healthy son of 4500 grams at 41 weeks of gestation. 
There were no congenital anomalies in the family of both nonconsanguineous parents. 
She went into premature tabor at 33 weeks, and a male infant with birth weight of 2060 grams (50th 
centile) was born by ventouse extraction because of failure to progress in the second stage of labor 
and fetal distress. The male newborn was hypotonic, bradycardic, and showed respiratory distress. Bag 
valve mask ventilation was not successful as no air entry into the fetal lungs could be established. Also 
oropharyngeal and nasopharyngeal intubation was not successful because of a blind-ending larynx, 
distal to the vocal cords. An attempt to put a tube in the proximal esophagus to ventilate the lungs 
through a possible fistula failed. A tracheotomy was established but nevertheless prolonged efforts to 
resuscitate were unsuccessful, and the patient died one hour after birth. 
External examination showed a proportionate male neonate with anal atresia and a sacral dimple. Post-
mortem MRI revealed a heart positioned in the right thorax with the apex of the heart towards the left 
indicating dextroposition of the heart, a persistent left superior vena cava, and myocardial hypertrophy 
of both ventricles (Figure 1 ). Both lungs, particularly the left lung, were hypoplastic. A normal trachea 
with bifurcation was seen, but there existed no connection to the larynx. The distal esophagus was 
identified, but had no connection to the proximal portion. The right kidney was multi cystic and posi-
tioned centrally in the lower abdominal region. The left kidney and the spleen showed a normal posi-
tion and aspect. The rectosigmoid was dilated, as seen in anal atresia. No abnormalities of the vertebral 
bodies or conus medullaris were observed. MRI of the brain showed normal infra- and supratentorial 
structures. Autopsy confirmed the laryngeal and esophageal atresia. A low tracheo-esophageal fistu-
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Ia was present The persistent left superior vena cava was connected to the coronary sinus. No other 
structural abnormalities of the heart were observed. A centrally located right dysplastic kidney with 
multiple cysts, and a blind-ending rectum with a possible recto-urethral fistula were found. Autopsy of 
the brain showed no abnormalities. A fibroblast culture showed normal chromosomal breakage after 
diepoxybutane (DEB) exposure, making Fanconi anemia unlikely. Dysmorphologic examination of the 
parents was normal. 
Molecular studies 
Bi-directional sequencing of all coding exons of the ZIC3 gene did not reveal mutations, apart from a 
6-nucleotide insertion within the portion of exon 1 that codes for a polyalanine repeat. The insertion 
sequence, GCCGCC, maintains the wild-type reading frame and codes for two additional alanines. The 
repeat therefore contained 12 instead of the normal 10 polyalanines. The polyalanine sequence of the 
mother of the patient was normal, and the GCCGCC insertion was not present, which suggests that the 
repeat amplication is de novo in the affected patient. Randomly selected controls, 44 males and 146 fe-
males, from the ethnically-matched population (Dutch Caucasian) were screened for variation in length 
ofthisZ/C3 polyalanine repeat. All336 X chromosomes showed a wild-type length of 10 repeats of the 
ZIC3 polyalanine repeat. 
Discussion 
We describe a male neonate with a combination of features resembling the VACTERL association, in-
cluding anal atresia, esophageal atresia with tracheo-esophageal fistula and a unilateral multicystic 
kidney. Dextroposition of the heart (heart positioned in the right thorax with the apex of the heart 
towards the left), with persistent left vena cava, abnormalities not typically seen in VACTERL, were also 
present. As this phenotype shared characteristics with ZIC3-associated heterotaxy, the ZIC3 gene (HTX1, 
MIM 306955) was analyzed and a de novo ZIC3 mutation was found. 
VACTERL association represents a spectrum of anomalies including vertebral defects, anal atresia, es-
ophageal atresia and/or tracheo-esophageal fistula, renal malformations and predominantly preaxial 
limb anomalies 1,., 3• This broad association has considerable overlap with other syndromes including 
X-linked heterotaxy due to a ZIC3 mutation. X-linked heterotaxy typically presents with heart defects 
characteristic of heterotaxy including common AV canal, double outlet right ventricle, transposition of 
the great arteries and abnormal pulmonary or systemic venous connection. Dextrocardia, indicating 
a mirror image position of the heart, is present is some patients 1.s. In our patient dextroposition of 
the heart was found, which could be a result of displacement of the heart, as can be seen in patients 
with lung hypoplasia. Intestinal malrotation, symmetric liver, abnormal lung lobulation, asplenia or 
polysplenia are frequently seen in patients with X-linked heterotaxy. Also midline malformations are 
common, and include imperforate anus, rectal stenosis, sacral agenesis, meningomyelocele, cerebel-
lar hypoplasia, and arhinencephaly 3.s. X-linked heterotaxy shares anorectal, renal and vertebral mal-
formations with VACTERL association (Table 1 ). However, laterality defects are rarely found in patients 
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with VACTERL association 11 • Nevertheless, all separate malformations within the VACTERL association 
have been reported in patients with laterality defects. In two large studies of patients with esophageal 
atresia and tracheo-esophageal fistula dextrocardia was reported in 3% of patients 14•12• Esophageal 
atresia can also be associated with other features of heterotaxy such as gut malrotation 12•15 and situs 
inversus 16•17• Esophageal atresia and tracheo-esophageal fistula are common in VACTERL association, 
but not in X-linked heterotaxy. Two patients that were initially diagnosed with VACTERL association 
were later shown to have a ZIC3 mutation 5•18• The first patient, described by Purandare et al. 18 showed 
features ofVACTERL, including lumbar and sacral agenesis, anal stenosis, fused kidneys and aqueduc-
tal stenosis with hydrocephalus without thoracic or abdominal situs anomalies. This patient did have 
a heart malformation consistent with heterotaxy including total abnormal pulmonary venous return 
and bilateral superior vena cava 18• The other patient had VACTERL association with typical vertebral, 
anal and renal malformation in combination with tracheo-esophageal fistula, but also dextrocardia, 
congenital heart malformations and asplenia.5 The anomalies present in these two VACTERL patients 
are very similar to those of the patient described here. The combination of the VACTERL association 
with heterotaxy is therefore suggestive of a ZIC3 mutation, certainly if the disorder is X-linked (Table 1 ). 
The presence oftracheo-laryngeal and/or esophageal anomalies in these 3 patients suggests that ZJC3 
plays a role in the development of the foregut. 
The majority of ZIC3 mutations reported to date consist of point mutations (nonsense, missense) or 
small insertion-deletions resulting in a frameshift, although rarely whole-gene deletions and X-auto-
some translocations have been described (Table 1) u.s.19• In our patient an insertion of GCCGCC in exon 
1 of the ZIC3 gene was identified. This mutation maintains the wild-type reading frame and codes for 
two additional alanines in the polyalanine stretch of ZIC3. The polyalanine stretch ofZIC3 is an almost 
perfect repeat where all alanines are encoded by GCC with the exception of the ninth alanine, which is 
encoded by GCT. As in some dynamic diseases repeat amplification occurs after transition of an incom-
plete to a complete repeat, we sequenced the alanine repeat from the mother of the patient, but the 
ninth repeat was normal (GCT). The ZIC3 repeat amplification is a novel mutation, not reported before 
neither in patients nor in controls. It is a de novo mutation as it was not present in the mother, whereas 
the patient is also the only affected family member. All randomly selected controls (336 X chromo-
somes) from an ethnically-matched Dutch-Caucasian population had 10 ZIC3 repeats. All together, the 
ZIC3 repeat amplification is most likely a disease-causing mutation. 
Polyalanine stretches have been predicted in about 500 human proteins, mainly transcription factors. 
Polyalanine domains in vertebrates are conserved between mammals and the polymorphic nature of 
sequences coding for polyalanine domains makes them prime candidates for mutations in genetic dis-
orders 20• Up to now, 9 human diseases have been described that are due to polyalanine stretch elonga-
tion 21 "23, and X-linked heterotaxy might be the tenth polyalanine repeat disease {Table 2). Nine of these 
disease genes, including ZIC3r encode transcription factors; the only exception is PABPN7, a nuclear 
protein involved in mRNA polyadenylation. Polyalanine stretch elongation of another ZIC gene family 
member ZIC2 is associated with holoprosencephaly 23-26• The ZIC3 repeat expansion described here is 
the smallest expansion(+ 2 residues) reported, together with the 2-residue polyalanine expansions in 
ARX and PABPN7 (Table 2). This polyalanine stretch of 12 residues is also the smallest polyalanine stretch 
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reported to be pathogenic, together with the 12-residue polyalanine expansion in PABPN1. 
Polyalanine tracts expansions in several transcriptions factors, including HOXD13, HOXA13, RUNX2, 
SOX3, PHOX28 and FOXL2 have been shown to induce cytoplasmatic mislocalisation and aggregation 
as well as nuclear aggregation 2U7-30• Several pathogenetic mechanisms have been proposed: i) Cyto-
plasmatic aggregation might be dependent upon repeat length as larger oligomers might be unable 
to pass through the nuclear pores, leading to loss-of-function of the transcription factor as it may not 
reach the target genes, 30 ii) Intranuclear aggregates might have a toxic gain-of-function affect, as has 
been suggested for PABPNT and ARX, 31 .32 iii) Aggregation might also induce a dominant-negative effect 
through the sequestration of the wild type protein or associated proteins in the aggregates. As ZIC and 
GU proteins interact, whereby GU proteins are translocated to the cell nuclei by coexpressed ZIC3 pro-
teins, 33 it is possible that formation ofZIC3 aggregates might also influence the function ofZIC3-related 
proteins such as GU3. 
In conclusion, we suggest here that Z!C3 might be the tenth gene implicated in polyalanine expansion 
diseases, and thatZ/C3 mutations may be present in patients with VACTERLassociation in combination 
with heterotaxy. 
The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of 
all authors, an exclusive licence (or non-exclusive for government employees) on a worldwide basis to 
the BMJ Publishing Group Ltd and its Licensees to permit this article to be published in Journal of Medi-
cal Genetics editions and any other BMJPGL products to exploit all subsidiary rights, as set out in our 
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Table 1 1 ZIC3 mutations in patients with features overlapping X·linked heterotaxy and VACTERl 
p.Arg183Gin M Asp tenia TGA 
Altered abdominal situs AVSD 
Pulmonary atresia 
p.Arg1S3Gin M Dextrocardia TGA Sacral agenesis 
Altered abdominal situs Pulmonary valve stenosis 
Mitral valve atresia 
c 1507insTT Situs inversus 
c.1507insTT M Situs ambiguus Not>pecified 
c.1507insTT M Situsambiguus Not>pecified 
c1507insTT f(2) Situs inversus 
p.Gin294X M(2) Situs ambiguus Not specified 
p.Cys270X M ~tusambiguus Not specified S?cral agenesis 
p.Cys270X M Situs ambiguus Not specified 
p.Cys253Ser NR NR NR lumbosacral spine 
abnormalities 
p.Gin249X M Altered abdominal situs AVSD 
Asplenia DORV, TGA 
Pulmonary stenosis 
TAPVR 
p.Gin249X M Dextrocardia AVSD Vertebral defect 
Asplenia Pulmonary atresia 
HlHS 
Bi!at;s~perio_rvena_cava 
pSer43X M Normal situs DDRV, TGA Fused lumbar vertebrae 
ASD, VSD 
Pulmonary stenosis 
Interrupted inferior vena 
cava 
Deletion Xq26 M Intestinal malrotation AVSD 
Midline stomach, liver left sUperior vena cava 
Asplenia 
Deletion Xq26 M Bilateral trilobated lungs AVSD, DORV, TGA 
Asp!enia lVOT obstruction 
Right stomach Bilatsuperiorvena cava 
Interrupted infer'1orvena 
cava 
Deletion Xq26 M Normal situs TAPVR,LVOT obstruction lumbar and sacral 
Bilats~peri9r vena cava agenesis 
Polyalanine M Dextroposition of the heart Bi!at superior vena cava 
expansion 
M/F Male/Female, ASD Atrial septal defect, AVSD Atrioventricular septal defect, DORV Double outlet right ventride, EA esophageal atresia, HLHS Hypoplastic 
left heart syndrome, LVOT Left ventricular outflow tract, NR, Not reported, TFTracheo~esophageal fistula, TAPVRTotaJ anomalous pulmonary veno1.1s retour, 
TGA Transposition of the great arteries, VSD Ventricular septal defect 
Posterior-placed anus 
Rectal stenosis 
Double ureter 
Anal malformation H.o~eshoekidney 
Renal hypoplasia 
Ureteral stenosis 
Anal malformation 
Anal malformation 
Anal malformation 
Horseshoe kidney 
Horseshoe kidney 
TF Anal-atresia Renal dysplasia 
Anal atresia 
Anal atresia 
Anal stenosis 
Anal stenosis Fused kidneys 
ENTF Anal atresia Multicystic 
laryngeal atresia dysplasia 
Arhinencephaly 
Biliary atresia 
Bilateral dubfeet 
.Adrenal aplasia ... 
Omphalocele 
. Cystic hygroma 
Radial dysplasia 
Bilatclubfeet 
Post. embryotoxon 
Extrahepatic biliary 
atresia 
Aqueductal stenosis 
with hydrocephalus. 
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Figure 1 I Postmortem coronal body MRI showing dextroposition 
of the heart, persistent left superior vena cava and normal position 
of liver stomach and spleen. The stomach is filled with air and 
pneumothorax is present after reanimation. 
Table 2 I Polyalanine expansions in human disease 
ZIG Heterotaxy (HTX1) with VACTERL-Iikefeatures 10--> 12 
ZIC2 Holoprosencephaly (HPES) 15-->25 
FOXL2 Blepha rophimosis-ptosis-epicanthus inversus (BPES) 14-->22,24 
PHOX2B Congenital central hypoventi!ation, Haddad syndrome 20-->25-33 
ARX West syndrome, Partington syndrome 16->18,23 
12-->20 
SOX3 Mental retardation with growth hormone deficiency 15-->26 
RUNX2 Cleidocranial dysplasia 17->27 
HOXA13 Hand-foot-genital syndrome 14-->24, 26 
12--> 18 
18-->24-30 
HOXD13 Synpolydactyly 15-->22-25, 
29 
PABPN1 Oculopharyngeal muscular dystrophy 10-->12-17 
(AD) 
10-->11 (AR) 
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Anomalies of the atrioventricular and semilunar heart valves account for almost one third of all congen-
ital heart malformations (CHM) 1• Cardiac valve anomalies can be part of well-defined syndromes such 
as Noonan syndrome 43 and Alagille syndrome 4.s, but the majority of cardiac valve anomalies is not 
associated with other organ malformations and represent non-syndromic forms. Many non-syndromic 
valvular defects are associated with other types of CHM, in particular Left Ventricular Outflow Tract 
Obstruction (LVOTO). 
The paucity of multiplex families with a dear Mendelian inheritance pattern of anomalies of the atrio-
ventricular and semilunar heart valves has precluded the identification of disease genes involved in 
these types ofCHM. Currently, only a few disease genes have been implicated in non-syndromic valvu-
lar defects and/or LVOTO. 
3.1.1 Signaling pathways in valvulogenesis 
Animal model studies have elucidated many genetic pathways that play an important role in cardiac 
valve malformation (for reviews: see refs 6 7), and many of these genes are candidate disease genes for 
human valvular defects8• Cardiac valve formation depends on a complex interaction between the myo-
cardium and the overlying endocardium, which undergoes an endothelial-to-mesenchymal transdiffer-
entiation (EMT) 7.1n the mouse localized swellings of the cardiac jelly appear in the atrioventricular and 
cardiac outflow tract, forming the cardiac cushions. These cushions consist of acellular swellings of ex-
tracellular matrix protein secreted from the myocardium, which becomes invaded by endocardial cells 
that are transformed into mesenchymal cells. This complex EMT process and the remodeling process 
require the interaction of multiple signaling pathways. The most relevant signaling pathways include 
the VEGF, NOTCH, WNT/beta-Catenin, and RAS/MAPK pathways'·'. As these signaling pathways exhibit 
extensive cross-talking with each other and other pathways it is not surprising that valvular defects are 
often found in combination with other CHM such as septal defects, chamber hypoplasia and LVOTO (for 
review: see ref 8). 
The importance of the RAS/MAPK signaling pathway was underscored by the identification of muta-
tions in the PTPN11, KRA5, 5051, BRAF, MEK1, MEK2, NF1 and HRA5 genes in patients with Noonan syn-
drome and related syndromes, altogether referred to as the neuro-facial-cutaneous syndromes 9• In 
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these syndromes pulmonary valve stenosis is a common finding, pointing towards a specific role of the 
RAS/MAPK pathway in pul mcnary valve development. 
Defects in the NOTCH signaling pathway play an important role in several human CHM. Mutations in 
the JAG7 gene encoding a NOTCH ligand Jagged1, and mutations in the NOTCH2 gene, encoding a 
NOTCH transmembrane receptor, lead to A!agille syndrome. This syndrome is also often associated 
with pulmonary valve abnormalities. NOTCH1 mutations are associated with aortic valve anomalies, 
such as bicuspid aortic valve (BAV) and aortic stenosis (AS), but can also lead to other CHM. The PSEN 
genes encoding presenilins, which act as the catalytic subunit of gamma secretase cleaving the Notch 
intracellular domain from Notch, have also been implicated in humans: PSEN2 mutations can lead to 
BAV in association with ventricular septal defect (VSD) 10• Also mutations in NOTCH signaling target 
genes may lead to CHM, and human HEY2 mutations have been found in cardiac tissue of patients with 
atrioventricular septal defects (AVSD) ,,_Mutations in several genes, including Hey1, Hey2, and Fgf8, are 
implicated in valve anomalies ·,n mice 8• 
Common human VEGFvariants confer an increased risk for tetralogy ofFallot(TOF), both in non-syndro-
mic cases ofTOF and syndromic cases with 22q11 deletions 12• Also murine mutations in several genes 
ofthis pathway (Nfatc1, eNos) lead to valve anomalies 8• 
Mutations in several genes of the WNT/~-Catenin pathway, including Has2, Hdf, and 8-Catenin, cause 
valvular defects in mice, but human mutations in this pathway have not yet been reported 8• 
Some additional genes involved in valvulogenesis have been discovered by genetic studies in patients 
with valvular defects. Mutations in the FLNA gene encoding filamin A have been identified as the cause 
of myxomatous valvular dystrophy, an X-linked valvular disease characterized by myxomatous degen-
eration, valvular regurgitation and secondary calcification of all four heart valves 13• Mutations in the 
CRELD1 gene, encoding a cell adhesion molecule that is member of a family of matricellular proteins, 
have been found in patients with AVSD 14• 
3.1.2 Left Ventricular Outflow Tract Obstruction (LVOTO) 
LeftVentricularOutflowTract Obstruction (LVOTO) comprises a spectrum ofCHM, including BAV,AS, co-
arctation of the aorta (CoAl and hypoplastic left heart syndrome (HLHS), representing 15-20% of medi-
cally significant CHM 15"17• Within one family all types of LVOTO may occur 18• Several human syndromes 
are associated with LVOTO. Thirty percent of patients with Turner syndrome have LVOTO, indicating 
that haploinsufficiencyofX-linked genes might play a role in LVOTO 19-21. Also the 11 q terminal deletion 
syndrome (previously called Jacobsen syndrome) is often associated with LVOTO, and it is therefore 
anticipated that cardiac genes in this chromosomal region might serve as good candidate genes for 
non-syndromic LVOTO 22.23 • Complex genetic inheritance involving several loci is likely in most non-
syndromic LVOTO 24-27 However, a limited numberoffamilies show autosomal dominant inheritance 8•18, 
as presented in this thesis. Only 4 genes have been implicated in human LVOTO. NKX2.5 mutations have 
been found in a few families with HLHS, CoA or interrupted aortic arch (IM) 18..:!9• NOTCH7 truncating 
mutations have been identified in familial calcific aortic valve disease in association with other CHM 30•31 • 
NOTCH1 missense mutations were also found in patients with LVOTO 32-34• As some of these missense 
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mutations were also present in the control group, albeit at a lower frequency, they might represent 
reduced penetrance mutations. Not all familial LVOTO is caused by NOTCH1 mutations as linkage analy-
sis in some families excluded the NOTCH7 gene 8•35.36 and suggestive linkage to other chromosomal 
loci including 2p23, 5q21, 10q21, 13q34, 16p12, and18q21, has been reported 353'. Also somatic muta-
tions have been found in LVOTO: gene conversion events between GJA 7 and its pseudogene have been 
found in heart tissue from patients with HLHS 38• Recently, a single recurrent mutation in the HAND7 
gene (c.376deiG -A 126fs) was detected in left and right ventricle tissue from a large fraction of hypo-
plastic left and right ventricles, indicating that HANDl function is impaired in human hypoplastic hearts 
39
.ln the majority of hearts the mutation was only found in the hypoplastic ventricle 39• Further studies 
are needed to determine the contribution of somatic mutations in LVOTO. 
In this thesis we describe several families with presumed autosomal dominant inheritance ofLVOTO.In 
addition, 21arge multiplex families with autosomal dominant inheritance of LVOTO in association with 
right-sided valve anomalies and septal defects are described, thereby extending the spectrum of car-
diac anomalies seen in LVOTO. The disease genes in these families remain unknown: NOTCH1 mutations 
were excluded, and a genome-wide linkage analysis is currently being performed. 
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Most nonsyndrom.ic congenital heart malforma-
tions (CHMs) in humans are multifactorial in 
origin. although an increasing number of mono-
genic cases have been reported recently. We 
describe here four new families with presumed 
autosomal dominant :inheritance of left ventricu-
lar outflow tract obstruction (LVOTO), consisting 
of hypoplastic left heart (HLHS) or left ventricle 
(HLV). aortic valve stenosis (AS) and bicuspid 
aortic valve (BA V), hypoplastic aortic arch (HAA.), 
and coarctationofthe aorta (Co-A). LVOTO in these 
families shovvs a wide clinical spectrum with some 
family members having severe anomalies such as 
hypoplastic left heart, and others only minor 
anomalies such as mild aortic valve stenosis. This 
supports the suggestion that all anomalies of the 
LVOTO spectrum are developmentally related 
and can be caused by a single gene defect. 
© 2005 Wilcy-Liss, Inc. 
KEY WORDS: left ventricular outflow tract 
obstruction; LVOTO; autosomal 
dominant; prenatal diagno-sis 
INTRODUCTION 
Historically, a congenital heart malformation (CHM) occur-
ring as an isolated feature (nonsyndromic heart malformation) 
has been considered as a multifactorial disorder with recur-
rence risks for first-degree relatives in the order of 1-18% 
[Nora and Nora., 1988]. Nonsyndromic CHM with monogenic 
inheritance is rare, although an increasing number of reports 
of single gene defects causing diverse forms of CH111 are being 
reported over the past years. 
*Correspondence to: Mur;ju W. Wessels, M.D., Department of 
Clinicul Genetics, Westzeedijk 112, 3016 AH Rotterd:un, The 
~etherlunds. E-mail: m.w,wessels@er:J.Smusmc.nl 
Received 12 May 2004: Accepted 16 December 2004 
DOl 10.1002/ajmg.a.30601 
© 2005 Wiley-Liss, Inc. 
Left ventricular outflow tract obstruction CLVOTO) includes 
obstructive anomalies of the left heart and aorta, such as 
hypoplastic left heart syndrome CHLHS) and hypoplastic left 
ventricle CHIN), aortic valve stenosis (AS) and bicuspid aortic 
valve CBAVJ, hypoplastic aortic arch (HAA), coarctation of the 
aorta (CoA), and occasionally interrupted aortic arch (IAA). 
The frequent occurrence of L VOTO in some human syn-
dromes (syndrom.ic LVOTO), and many animal models indicate 
that L VOTO is genetically very heterogeneous. Specific human 
syndromes frequently associated with LVOTO include Turner 
syndrome [Mazzanti and Cacciari. 1998], Kabuki syndrome 
[Digilio et al., 2001], ,Jacobsen syndrome [Grossfeld et al., 
2004], Holt-Oram syndrome [Bruneau et al., 1999], and 
Williams syndrome [Eronen et al., 2002]. L VOTO has also 
been reported in Alagille syndrome []McElhinney et al., 2002), 
Noonan syndrome [Marino et al., 1999; Sarkozy et al .. 2003], 
and DiGeorge/velocardiofacial syndrome (DGSNCFS). A 
few families with an autosomal dominant association of CoA 
and aplasia cutis have been reported [Dallapiccola et al., 1992; 
Bruel et al., 1999], whereas Cornel et al. [1987] reported a 
family with autosomal dominant CoA, deafness, and bilateral 
ptosis. Additionally, LVOTO anomalies have been reported in 
one family with Andersen syndrome due to mutations in the 
KCN-12 gene [Andelfinger et al., 2002]. 
N onsyndromic L VOTO anomalies usually occur sporadically 
or in familial patterns compatible with multifactorial inheri-
tance [Simonet al., 1974; Boon and Roberts, 1976; Brownell 
and Shokeir, 1976]. Only a small number of nonsyndromic 
cases with monogenic inheritance of L VOTO have been 
reported [Cough, 1961; Shokeir, 1971; Beekman andRobinow, 
1985; McDonald and Maurer, 1989; Nordenberg et al., 1989; 
Menahem, 1990; Gerboni et al., 1993; Grohman and Perga-
ment, 1996; Grossfeld, 1999; Stoll et al., 1999]. 
We describe here four new families 'With pre:o--umed auto-
somal dominant inheritance ofnonsyndromic LVOTO. 
CLINICAL REPORTS 
Familyl 
Patient 1. This male infant (II-2) was born at 41 weeks 
gestation after an unremarkable pregnancy. A routine ultra-
sound scan at 22 weeks had not revealed any abnormality. 
Birth weight was 3,910 g. On day 8, his condition suddenly 
deteriorated and he was admitted to the pediatric ward. X-rays 
showed an enlarged heart. EchocardiogTaphy demonstrated 
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Fig. 1. Podigroo~ of four families with probable auto~omu.l domino.nt inheritance ofLVOTO. 
persistent left superior vena cava CPLSVC), HIN. perimem-
braneous ventricular septal defect (VSD), atrial septal defect 
(ASD), and CoA with patent ductus arteriosus (PDA), Enlarge.. 
ment of the right atrium and ventricle, a coexisting sign of 
Co.A, was present. There was no evidence of other congenital 
malformations, and no dysmorphic features were observed. 
The CoA was surgically corrected and thePDAclosed. The ASD 
and VSD were closed surgically 4 weeks later. At the age of 
2 months, the baby died from left heart failure and pulmonary 
hypertension attributed to myocardial ischemia and mild re-
CoA At autopsy, the cardiac abnormalities were confirmed, 
and no other anomalies were found. 
Patient 2. In the next pregnancy (ll~3), a fetal echocar-
diographywas performed at 20 weeks because of the hb-tory of 
a previous child with a CHM: (Fig.l). The left ventricular width 
and diameter of the aortic valve were >2 SDs below the normal 
mean (Fig. 2), whereas the right ventricular width was normal 
[Sharland and Allan, 1992]. The ascending aorta and aortic 
arch were hypoplastic. No other fetal anomalies were detected. 
Amniocentesis to determine the fetal karyotype was offered, 
but declined by the parents. After 39 weeks, a female infant 
(II~3) with a birth weight of3,080 gwas born. 
Postnatal echocard.iography and catheterization confirmed 
the prenatal findings of relative HL V, a perimembraneous 
VSD, and HAA. No other congenital anomalies were identified, 
and no indication for limb defects such as occur in the Holt-
Gram syndrome were present. Three weeks after birth, 
surgical reconstruction of the aortic arch was performed. At 
operation, the HAA was confirmed. The diameter of the aorta 
was 5 m.m in the ascending part (normal values between 6.8 
and 8.9 m.m), 3 m.m between the left common carotic artery and 
the left subclavian artery (normal values between 5.6 and 
8.3 mm), and 2 m.m at the isthmus (normally between 4.9 and 
5.8 m.m). Postoperative recovery was complicated by sepsis, 
and 5 days after surgery bradycardia and hypotension resulted 
in the death of the child. At autopsy, the abovementioned 
cardiac anomalies were confirmed, and septic and ischemic foci 
of the myocardium were found. No other congenital anomalies 
were observed. 
Fig. 2. The fouzo..cham.bcrview of the heart ofputient 2 from fnmi.ly 1 ut 
26 WC'Cks demolllitrutcs vcntriculur discrcponcy with u normul-sizcd right 
ventricle but o .m:tollleft veotriclc. The left vcntrieulruo width ill only 6.6 = 
(>2 so~ below the normol moon). 
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Patient 3. In the fourth pregnancy Cll-4), a fetal echocar-
diography was performed at 20 weeks. A normal-sized left 
ventricle with a normal appearance of the ascending aorta was 
found. At 34 weeks, a normal-sized left ventricle was seen with 
a width of 12 mm. However, enlargement of the right atrium 
and ventricle with an abnormal ratio between the two 
ventricles suggested CoA, although the distal aortic arch could 
not be visualized well. The aortic root diameter and the flow 
across the aortic valve were normaL 
At 39 weeks, a girl (!I-4) with a birth weight of 4,010 gwas 
born. She had no dysmorphic features. Echocardiography 
revealed enlargement of the right heart and a relatively small 
left ventricle, a small secundum ASD, and a CoA with a 
hypoplastic isthmus. A successful repair of the CoA with end-
to-end anastomosis was performed 1 week after birth. At the 
age of3 year, the child is developing well, although the discre-
pancy in size between therightn.nd the left ventricle remained. 
Chromosome analysis showed a normal female karyotype, and 
a microdeletion of the 22q 11 region was excluded by fluorescent 
in situ hybridization CFISID. 
Patient 4. The father (l-1) was diagnosed in his childhood 
with ASD and PLSVC. Retrospective revaluation of the angie-
graphic recordings of the father also suggested a disproportion 
between the ventricles, with an enlarged right ventricle and a 
normal-sized left ventricle. After the birth of the first affected 
child, microsatellite analysis of the 22qll region was per-
formed in the father, and a deletion of the 22qll region was 
excluded. 
Additional family members. Echocardiography of the 
mother (I-2) was unremarkable. The oldest child (ll-1) was 
unaffected. The family history of both parents revealed 
no other family members with CHM or other congenital 
malformations. The parents of the father CI-1) were not 
investigated. 
Family2 
Patient I. This is the first child CTII-1) ofnonconsangui-
neous Caucasian parents (Fig. 1). He was born at term with a 
birth weight of 3,600 g after an unremarkable pregnancy and 
delivery. 
At the age of 1 year, he was evaluated because of an 
at.--ymptomatic heart murmur. A mild AS with a good ventric-
ular function was diagnosed. At the age of 4, the child was 
developing normal and no dysmorphic features were present. 
Chromosome analysis was normal. 
Patient 2. In the ne..'t pregnancy (ill-2), the mother un-
derwent fetal echocardiography in the 20th week of gestation 
because of the history of a previous child with CHM (patient 1). 
The four-chamber view revealed a small and poorly function-
ing left ventricle with endocardial fibroelastosis and restricted 
mitral valve movement. The ascending aorta was hypoplastic 
with a diameter of 1.3 mm (>2 SDs below the normal mean). 
A diagnosis of HLHS was made. Amniocentesis revealed a 
normal male karyotype, and FISH analysis to exclude a 22q11 
deletion was normal The pregnancy was terminated at 
21 weeks, and post mortem examination revealed a HLHS 
with left ventricular fibroelastosis, mitral valve stenosis, aortic 
valve atresia, HAA, andjuxtaductal CoA There were no other 
abnormalities or dysmorphic features. 
Pcdient 3. After the second pregnancy, both parents 
underwent cardiologic evaluation. The father (ll-1) was 
diagnosed with a thickened tricuspid aortic valve with mild 
AS and aortic regurgitation. The left ventricular function was 
good. The mother (ll-2) had no cardiac abnormalities. 
Patient 4. A brother of the mother Cll-3) was diagnosed at 
the age of 1 year with a tetralogy ofF allot (TO F) with a severe 
stenotic bicuspid pulmonary valve, overriding aorta, VSD, and 
PLSVC. He underwent repeated cardiac surgery. At the age of 
27, he has a normal psychomotor development without evident 
dysmorphic features. 
Other family members. The grandparents CI-1 and I-2) 
were not evaluated. 
Family3 
Pcdient 1. This patient CIII-2) was diagnosed in her 
childhood with mild mitral valve stenosis, BAV with regur-
gitation, and CoA (Fig. 1). She underwent corrective surgery at 
the age of6. Her first child is a healthy girl CIV-1). 
Patient 2. During the second pregnancy of patient 1, a 
20-week anomaly scan was performed because of her CHM. 
The four-chamber view was abnormal and revealed a poorly 
contracting HL V with a very small mitral and aortic valve, and 
diminished forward flow over both valves. The ascending aorta 
of the fetus (IV-2) was hypoplastic. Amniocentesis revealed a 
normal male karyotype, and a 22qll deletion was excluded 
by FISH. After genetic counseling, the parents decided to 
terminate the pregnancy. Autopsy showed moderate HL V with 
a small mitral valve and a small aortic ostium with a bicuspid 
valve. A PLSVC was connected with the coronary sinus. 
A premature closure of the foramen ovale was found. The 
ascending aorta was hypoplastic and a severe preductal CoA 
was observed. The left vertebral artery originated separately 
from the aortic arch. No other congenital abnormalities were 
found. 
Patient 3. A maternal uncle ofpatient 1 (ll-3) had a aortic 
valve replacement at the age of 57, but no more details are 
known. 
Patient 4. The sister of patient 1 CTII-3) showed aPLSVC 
without other structural heart defects. 
Additional family members. Cardiologic evaluation of 
the mother Cll-2) of patient 1 revealed no abnormalities. The 
parents CI-1 and I-2) of patient 3 were not investigated. 
Family4 
Patient 1. Patient CI-1) was diagnosed with severe 
AS and BAV after birth. A valvulectomy was performed in 
the first year of life. At the age of 13 years, moderate AS 
and poststenotic dilatation of the aorta was found, which 
progTessed in subsequent years. Now at the age of 30, he is 
awaiting aortic valve replacement and reconstruction of the 
ascending aorta. 
Patient 2. Patient 2 (ll-1) is a child of patient 1 (Fig. 1). 
At 20 weeks gestation, a cardiac anomaly scan was performed 
becauseofthe CHM of patient L HLH, a small mitral valve and 
diminished forward flow across the mitral valve were observed. 
The aortic valve measured 1 mm (>2 SD below the normal 
mean for gestational age). The ascending aorta and aortic arch 
could not be visualized well, suggesting HAA. Chromosome 
analysis including FISH of the 22qll region was normal. At 23 
weeks, the pregnancy was terminated. Post mortem examina-
tion was declined by the parents. 
Patient 3. In the next pregnancy (II-2), a 20-weekcardiac 
anomaly scan performed elsewhere had revealed no abnorm-
alities. Evaluation at 32 weeks gest:ltion revealed severe 
valvular AS, and the patient was referred to our unit for second 
opinion. A dilated, hypokinetic left ventricle without end-
ocardial fibroelastosis was observed. A normal-sized mitral 
valve with restricted opening was present. The aortic valve 
measured 4 mm (>2 SD below the normal mean), and was 
thickened and restricted in motion. High flow velocities 
(240 cm)sec) were found across the aortic valve. In view of 
this severe AS and poor left ventricular function, the child was 
delivered at 33 weeks by Caesarean section. Birth weight was 
2,140 g. Apgar scores were 3 and 2 at 1 and 5 min, respectively. 
Prostaglandin was administrated, and balloon valvoplasty 
was performed directly after birth. A restricted foramen ovale 
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was dilated using a Rashkind balloon septostomy technique. 
Balloon valvoplasty was repeated after a few weeks because of 
restenosis. At the age of 3 months, he had undergone a Ross 
procedure with homograft placement in the pulmonary valve 
position. At age 1 year, he is now stable with diuretics, ACE-
inhibitors, and enteral tube feeding. 
DISCUSSION 
We report on four families (Fig. 1) with multiple cases of 
nonsyndrom.ic left LVOTO. The three sibs in the first family all 
presented with relative HL V, and various deg:r-ees of hypopla-
sia of the aorta and/or CoA. In addition. they hadanASD and} 
or a perimembraneous VSD. The second fa.mily presented 
with mild valvular AS in the father and oldest son, whereas 
the second son had a HLHS and CoA. In the third family, the 
mother had CoA, the sonhadHLVwith CoAandHAA, and an 
uncle of the mother had an undefined abnormality of the aortic 
valve. The fourth family presented with severe valvular AS in 
the father and second son. The first child had a HL V and HAA. 
These families illustrate the wide clinical spectrum ofLVOTO. 
with some family members showing severe anomalies such 
~ 
HLHS HLHS 
CoA 
6 
CoA 
HLHS 
Family 1 ofShokeir (1971) 
~oA 
AS 
HLHS 
as HLHS. and others only minor anomalies such as mild AS. 
This supports the hypothesis that all the separate carcliovas~ 
cular anomalies of the LVOTO spectrum are developmentally 
related. This is also suggested by experimental animal studies 
generating altered flow through the embryonic heart by 
clipping of the aorta, which also leads to LVOTO [Harh et al., 
1973: Fishman et al., 1978]. This so-called flow theory is 
supported by observations of progression ofLVOTO in utero: 
structural defects of the left heart, which result in decreased 
left ventricular preload or increased left ventricular afterload 
alter normal blood flow and are associated with left ventricular 
hypoplasia [Allan et al .. 1989; Anderson and Brown, 1991; 
Danford and Cronican, 1992]. Thus, mutations in genes that 
affect embryonic hemodynamics may cause LVOTO. 
Nonsyndrom.ic LVOTO usually occurs sporadically, and a 
multifactorial origin has been proposed [Simon et al., 1974; 
Boon and Roberts, 1976; Brownell and Shokeir, 1976]. How~ 
ever. strong familial aggregation ofL VOTO has been reported 
by other investigators [Rose etal .. 1985;Boughman et al., 1987; 
Boughman, 1991; Ferencz et al., 1993]. Recently, an extensive 
study of first-degree relatives ofprobands with HLHS and CoA 
revealed a frequency of cardiac malformations that was much 
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Fig.,3. Families reporWd in the literature with 3 or moro first or B!.'COnd degree rela.tivcs affected with LVOTO. 
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higher than would be expected in a multifactorial model of 
inheritance [Loffredo et al .• 2004}. In the latter study, CH:M 
was detected in 19% of first degree relatives of pro bands with 
HLH, and in 9% of :first degree relatives ofprobands with CoA. 
Predominantly LVOTO and particularly BAV were found 
in these relatives. Only a limited number of families with 
presumed monogenic inheritance of nonsyndromic L VOTO 
has been reported in the literature (cited in Introduction) and 
those families that had three or more affected cases are pre· 
sented in Figure 3. LVOTO in our four families most likely 
shows autosomal dominant inheritance, with CH:M: in male 
and female patients in several generations and male-to-male 
inheritance in families 1, 2, and 4 (Fig. 1). 
Altogether the studies above suggest the existence of mono-
genic forms of nonsyndromic LVOTO. Three genes, G.JAl, 
NKX2.5, and ZIC3, have been involved in nonsyndromic 
LVOTO in humans. Somatic mutations in the human G.JAl 
gene encoding connexin43 have been found in cardiac tissue in 
a subset of patients with hypoplastic left heart and total 
anomalous pulmonary venous connections [Dasgupta et al., 
2001]. AE these findings have not yet been confirmed by other 
investigators, their significance is not yet clear, although a 
gene causing total anomalous pulmonary venous connections, 
and therefore decreased flow to the developing embryonic left 
ventricle, is consistent with the flow theory. More recently. 
germline mutations in the cardiac transcription factor gene 
NKX2.5 have been identified in a minority of patients "With 
LVOTO (3 patients on a total of 179 investigated), including 
one patient "With CoA, and two patients with HLHS [Elliott 
et al., 2003; McElhinney et al., 2003}. Ware et al [2004] 
recently reported HLHS without manifestations ofheterotaxy 
in two mules with a ZIC 3 mutation. 
Also the genes involved in syndromic LVOTO might be 
candidate genes for nonsyndromic L VOTO. DGSNCFS is 
clinically variable with IAA type B, truncus arteriosus, and 
TOF as the most common heart defects. Although the outflow 
tract defects in LVOTO are different from the spectrum of 
CHM in DGSNCFS, there is at least one patient "With HLHS in 
association with a 22qll deletion [Consevage et al., 1996). 
Furthermore, two patients with autosomal dominant LVOTO 
Gene 
Adam19 
Clp1 
Ecel 
Ednl 
Ednra 
Eln 
eNos 
Ephrin·B2 
Fgfll 
Foxcl 
Fox{"2 
Gjal 
Handl 
Jagge<ll 
Madh6 
NFATcl 
Nk:>.:2.5 
Egfr/Ptpnll 
Sema3C 
Tbxl 
Tbx5 
Zic3 
Mice 
Cardiac anomaly 
AS, PS, VSD 
HIN 
IAA*, VSD 
IAA*, VSD 
IAA•, VSD 
Obliterated art(lries 
BAV, AS, ASD, VSD 
Thickened semilunar and 
mitral valve 
HAA, HIN, DORV, defects LR axis 
IAA •, Co.A, VSD, vah•e anomalies 
IAA*, C{)A. VSD, valve anomalies 
Pulmonary outflow obstrudion 
HLV 
Thi{"kened valves, HAA 
Absent semilunar valves 
BAV,AS,ASD 
AS 
IAA *, truncus arWriosus 
t\AA, truncus arteriosus 
HLV,ASD 
TGA, dextrocardia, ASD, VSD 
TABLf: I. LVOTO Caused By Single Gene Defects in Mice and Man 
Reference 
Zhou et al. [2004] 
Huang et al. [2004] 
Yanagisawaet al. [1998] 
Kurihara et al [1995] 
Clouthier eta\. [1998] 
Li et al. [1998] 
Lee et a\. [2000] 
Cowan et al. [2004] 
Ahu·lssa eta!. [2002] 
Winnier et al. (1999] 
Winnier et al, [1999] 
Reaume et al. [1995] 
Firulli et aL l1998] 
Xue et aL [1999] 
Galvin et a!. [2000] 
Johnson eta\. [2002] 
Biben et a!. [2000] 
Chen et al. [2000] 
Feiner eta!. [2001] 
Merscher et al. [2001] 
Bruneau et al. [2001] 
Purandare et aL (2002] 
Gene 
ECEl 
ELN 
FKHL7 
FKHL14 
GJAI 
JAGGED) 
NK.Y2.5 
PTPNll 
TBXl 
TBX5 
ZTC3 
Man 
Cardiac anomaly Syndrome 
PDA, ASD,VSD Hirschprung disease 
SVAS, PAS, AS, CoA Williams syndrome 
Axenfeld-Rieger syndrome 
VSD, PDA, 'IOF LymphOOenm.(lisliachis 
syndrome 
HLHS, TAPVR Dt>afness, oculodentodigital 
dysplasia 
PS, 'fOF, AS, BAV, CoA Alagilie syndrome 
ASD, AVblock, TOF, HLHS 
PS, cardiomyopathy, CoA, Noonan syndrome 
mitral valve disease 
IAA*, VSD 22qll deletion syndrome 
ASD,VSD, conduction Holt·Oram syndrome 
defects, HLV, AS, mitral 
valve disease 
HLHS, heterota:'{y 
Reference 
Hofstra ct a!. [1999] 
Eronen et al. [2002] 
Nishimura ct al. [1998] 
Briceet a!. [2002] 
Dasgupta et al. [2001]; Liu 
eta!. [2001]; Paznekas 
et al. [2003] 
McElhinney et al. [2002] 
Guldmuntz eta!. [20011; 
Elliott eta!. [2003]; 
McElhinney et al. [2003] 
Marino et al. [1999] 
Gonget al. [2001]; Yagi 
eta!. [2003] 
Bruneau et al. [1999] 
Ware et al. [2004] 
AAA, a otic arch abnonnalilies; AS, aortic stenosis; ASD, atrial ~eptal defect;AV, atrioventricular; BAV, bicuspid aortic valve; CoA, wardation of the aorta; IL\A, hypoplastic aortic arch; HLHS, hypoplastic left 
heart syndrome; HL V, hypoplastic ld't vent-ricle; IAA, interrupted aortic arch; PS, pulmonal)' 6fenosis; PAS, pulmonary arterial slenwis; SV AS, supnwah'lilar aortic stem•sis; T AP\'R, total anomalous pulmonal)' 
venous r€tour; TO I>', tetralogy ofFallot; VSD, wnlricular septal defect. 
*Interruption betw.;>en left oommon carotid artery and left subclavian ariel)'. 
~ 
0 
"' 
~ 
~ 
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have IAA [Gerboni et al., 1993; Stoll et al., 1999], although the 
localization of the interruption in these patients is not clear. 
The TBXl gene, suggested to be responsible for abnormalities 
in DGSNCFS [Gong et al., 2001; ,Jerome and Papaioannou, 
2001; Lindsay et al., 2001; Merscher et al., 2001; Yagi et al., 
2003] might therefore be a candidate gene for nonsyndromic 
LVOTO. 
Although supravalvular aortic stenosis and pulmonary 
arterial stenosis are the most common CHMs in patients with 
Williams syndrome, aortic and mitral valve defects were 
diagnosed in 11% [Eronen et al., 2002]. Congenital BAV and 
AS are sometimes associated with dilated ascending aorta 
due to severe degeneration of the elastic network [Roberts and 
Roberts, 1991]. Such a postvalvular aortic dilatation was aLqo 
found in patient 1 from family 4. Thus, also genes involved in 
the elastin network might therefore be good candidate genes 
for nonsyndromic LVOTO. 
Holt~Oram syndrome is most commonly associated with 
ASD and VSD, but also LVOTO (including HLHS) has been 
described [Sletten and Pierpont, 1996; Bruneau et al., 1999]. 
Furthermore, TBX5, implicated in Holt-Oram syndrome, 
interacts with NKX2.5, which is involved in nonsyndromic 
LVOTO. 
LVOTO is very frequent in .Jacobsen syndrome, which is 
characterized by mental retardation, craniosynostosis, dys-
morphic facies, thrombocytopenia, growth retardation, and 
deletion of llq [Penny et al., 1995; Pivnick et al, 1996; 
Grossfeld et al., 2004]. About half of the patients have a CHM, 
most commonly LVOTO, and membranous VSDs. Five to ten 
percent of ,Jacobsen syndrome patients are born with HLHS, 
a frequency that is 1,000-2,000 times the frequency of the 
general population. Candidate genes for Jacobsen syndrome 
include JAM3, OBCAM, and Neurotrimin [Phillips et al., 
2002]. 
Many mice models present with L VOTO, displaying abnorm~ 
alities of left ventricular growth, mitral and aortic valve 
formation, and aortic hypoplasia and interruption (as listed in 
Table I). The genes implicated in these mice models might also 
be candidate genes for human L VOTO. 
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Only a limited number of families with clear monogenic inheri-
tance of nonsyndromic forms of congenital valve defects h:lve 
been described. We describe two multiplex pedigrees with a 
similar nonsyndromic form of heart valve anom:ilies that segre-
gate as an autosomal dominant condition. The first family is a 
three-generation pedigree with 10 f.unily members affected with 
congenital defects of the cardiac valves, including six patients 
with aortic stenosis and/ or aortic regurgitation. Pulmonary and/ 
or tricuspid valve abnormalities were present in three patients, 
and ventricular septal defect (VSD) was present in two patients. 
The second f.unily consists of 11 patients in three generations 
with aortic valve stenosis in seven patients, defects of the pulmo-
nary valves in two patients, and atrial septal defect (ASD) in two 
patients. Incomplete penctrnnce was observed in both families. 
Although left-ventricular outflow tract obstruction was present 
inmost fum.ilymcmbers, the co-ocCWTencewith pulmonaryvalve 
abnormalities and septal defects in both fumilies is uncommon. 
These families provide evidence that left-sided obstructive defects 
and thoracic aortic ancuxysm may be accompanied by right-sided 
defects, and even septal defects. These families might be instru-
mental in identifying genes involved in cardiac valve morpho-
genesis and malformation. © 2009 Wiky-u ...... Inc. 
Key words: aortic dihtation; autosomal dominant; bicu.~pid 
aortic valve; candidate genes; congenitttl heart malfomw.tion; heart 
valves; left-ventricuktt outflow tract obstruction; pathways; tho-
racic aortic aneurysm 
~NTRODUCT!ON 
Anomalies of the atrioventricular and semilunar heart valves and 
associated structures account for 25-30% of all congenital cardio-
vascular malformations (C"\'11) [Loffredo, 2000]. Most occur 
© 2009 Wllcy-Liss, Inc. 
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sporadically in a single patient without affected family members, 
and unassociated with other malformations (nonsyndromic). On 
the other hand, well-defined ~;mdromes with autosomal dominant 
inheritance, such as Noonan syndrome (caused by PTPNll, KRAS, 
SOSJ, or RAFJ mutations), and Alagille syndrome (caused by 
JAGGED! and NOTCH2mutations) are often associated with valve 
defects [McElhinney et al., 2002; McDaniell et al., 2006; Sznajer 
et al., 2007]. 
Only a limited number of families with dear monogenic inheri-
tance of non~;mdromic forms of congenital valve defects have been 
described. Familial non~;mdromic valve anomalies often include 
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either the left-sided heart valves (aortic and mitral valve) or the 
righhided heart valves (tricuspid and pulmonaryvalve). Left -sided 
valve anomalies can be part of a spectrum of anomalies of the left-
ventricular outflow tract referred to as LVOTO (left-ventricular 
outflow tract obstruction; also known as obstructive anomalies of 
the left-heart and aorta) [McBride et al., 2005; WesseL~ ct al., 2005; 
Garget al., 2006], but in some families they occur without other 
LVOTO anomalies [Rao ctal., 1969; McDonald and Maurer, 1989; 
Mcnahem, 1990]. In two fumilieswithL VOTO anomalies including 
bicuspid aortic valve (BAY) with calci:fic:ttion. Garget al. [2006] 
documented truncating mutations in NOTCH 1. Two patients in 
these families also exhibited right-sided heart malformations, 
including double outlet right-ventricle and tetralogy of Fallot. 
Bicuspid aortic valve underlies the majority of patients with aortic 
vo.lve disease and familial BAY has been described in single families 
suggesting autosomal inheritance [Emanuel et al., 1978; Glick and 
Roberts, 1994; Clementi et al., 1996; Huntington et al., 1997]. 
Studies on heritability of BAY support that genetic factors play a 
major role in BAY and demonstrate that BAV is often associated 
with other cardiovascubr malformations, in particular L YOTO 
anomalies and thoracic aortic aneurysm (TAA) [Cripe et al., 2004; 
McBride ct al., 2005; Loscalzo et al., 2007]. Locus heterogeneity for 
fumili<tl BAV has been established in several studies [ Goh et al., 
2002; Ellison et <tl., 2007; Martinet al., 2007], and genome-wide 
scans in families with BAV and/or associated CVM: has demon-
strated linkage to chromosomes 15q25-26, 18q, 5q, and 13q [Goh 
ct al., 2002; Martin et al., 2007]. 
Another frequent left-sided heart valve anomaly, mitral valve 
prolapse, can be inherited as an autosomal dominant tmit, and has 
been linked to chromosome 13 [Freed et al., 2003; Nesta et al., 
2005]. Familial right-sided v<tlve anomalies frequently represent 
syndromicforms ofCVM and onlyafewnonsyndromic families arc 
reported. Pulmonary stenosis (PS) is common in families with 
Noomn syndrome (PTPNJ 1 mutations), Watson syndrome (NFI 
mutations), and Alagille syndrome (JAGGED I mutations). Muta-
tions in PTPNII, however ,have not been convincingly shown to be 
present in patients with nonsyndromic PS [Sarkozy et al., 2003], 
although a few cases of possible nonsyndromic PS with JAGGED I 
mutations have been described [Krantzctal., 1999]. Nonsyndromic 
familial right-sided valve anomalies have only been described in a 
few small families. PS has been reported in some families with clear 
autosomal dominant inheritance [David, 1974; Ciuffo et al., 1985], 
and in some families with unknown mode of inheritance [Coblentz 
andMathivat, 1952; Lam.yetal., 1957;McCarron andPcrloff, 1974; 
Klinge and Laursen, 197S; El-Said et al., 1979; Udwadia et al., 1996], 
PS combined withASD in a large pedigree has been shown to be due 
to a mutation in the GATA4 gene [Garget aL, 2003]. Familial 
pulmonic v<tlve atresb and familial occurrence of tricuspid anom-
alies are very uncommon, and have only been described in a few 
fumilies [DiChiara et al., 1980; Chitayat et al., 1992; Kumar et al., 
1994; Grant, 1996; Grossfeld et al., 1997; Lin and Rosti, 1998; 
Bonnet et al., 1999]. 
Only a few families with combined left- and right-sided heart 
valve anomalies with monogenic inheritance have been described. 
A large family with autosomal dominant inheritance of mainly 
atrioventricular valve defects including Ebstein anomaly and atrio-
ventricular canal has been described by Schunkert ct al. [1997]. 
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Atrioventricular septal defects (AVSD) (also known as endocardial 
cushion defects) can be inherited as an autosomal dominant trait 
with variable C.'q)ression and incomplete penetrance. These valve 
anomalies can be due to mutations in the gene encoding the cell 
adhesion molecule CRELDl [Robinson et al., 2003], and a second 
locus is located on chromosome lp31-p2l. A few families with X-
linked valvular dysplasia, a condition chawcterized by myxoma-
tous degeneration, valvular regurgitation and secondary calcifica-
tion affecting all four heart-valves have been described [Kewbury-
Ecob et al., 1993; Kyndt et al., 1998]. Recently mutations in the 
FLNA gene -encoding :filamin A were identified in these families 
[Kyndt et al., 2007]. 
The paucity of multiplex families with a dear Mendelian inheri-
tance pattern of nom-yndromic cardiac valve malformation has 
precluded the identification ofhuman genes specifically involved in 
cardiac valve morphogenesis and malformation. We describe two 
families with a similar autosomal dominant form of congenital 
heart malformation mainly consisting of cardiac valve anomalies. 
CUNlCAL REPORTS 
The pedigree of family 1 is shown in Figure 1. 
Patient 1. The index patient (II-1) visited our Department of 
Oinical Genetics for genetic counseling. She had aortic valve 
replacement at the age of 42 because of a severely stenotic BAV. 
She received two new aortic valve prostheses in the following 30 
years, and at the age of 60 she developed atrial fibrillation. Three of 
the five children of patient II -1 were healthy, and cardiologic 
examination including ECG and echocardiogmphy revealed no 
abnormalities. Two other children (Patients 2 and 3) are affected. 
Patient 2. One of the five children (III-4) of Patient II-I was 
asymptomatic until he presented with progressive dyspnea at the 
age of44. Echocardiography revealed a BAV, a dilated left-ventricle 
with thickening of the posterior wall, and left-ventricular 
dysfunction. 
Patient 3. Another son (III~S) of Patient II-1 was diagnosed 
with a BAV with mild stenosis and regurgitation, and mild dilata-
tion of the aorta at the age of26 years. An X-my of the thorax showed 
an elongated aorta. At the age of 36 years the aortic valve was 
stenotic, calcified and thickened, and mild tricuspid regurgitation 
was present. His left-ventricular function remained good. Chro-
mosomal analysis showed a normal male karyotype. A micro-
deletion of the 22qll (TBXI gene) and 7qll23 (elastin gene) 
region was e."\cluded by fluorescent in situ hybridization (FISH). 
Patient 4. A sister (II-2) of Patient II-1 was diagnosed with 
valvular aortic stenosis and regurgitation, mitral stenosis with 
regurgitation, and tricuspid regurgitation. She underwent three 
operation for aortic and mitral valve prostheses between the age of 
40 and 44 yC<ltS. At the age of 45 years a tricuspid valve correction 
was performed. She died at the age of SO. In four of her five children 
cardiologic examination including ECG and cchocardiography 
revealed no abnormalities. 
PatientS. A daughter (III-7) ofPatientii-2 was diagnosed with 
moderate mitral valve regurgitation at the age of 50 years. 
Patient 6. A brother (11-4) of Patient Il-l was diagnosed with 
aortic valve regurgitation and received an aortic valve replacement. 
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FIG. 1. Pedigrees oftwo families with autosomal domlnal'lt:fnh&rltanee of congenital valve anomalles.AR. aortic valve regurgitation; AS, aortic: 
valve stenosls;ASD, atrial septal defeet; BAV, bicuspid aortic: valve'; CVM CordiOVIIscularmalformatlon; HCM, hypertrophic cardiomyopathy; 
MR, mh:ral valvt regurgitation; PS, pulmonary valve stenosis; PA, pulmonary atresia; TAA, thoracleaortlc: aneut!Jsm; VSD, ventricular septal 
defect. 
Patient 7. The son (patient III~ 14) ofPaticnt II-4 was diagnosed 
with :l.ortic stenosis. Surgical correction was performed at the age of 
9 years. He died 1-day after surgery. 
PatientS. Oneofthethrecdaughters ofPaticnt Il-5 (paticntiii-
18) underwent valvulotomy for a severely stenotic BAV at the age of 
9 years. She also received a mitral valve prosthesis for severe mitral 
valve regurgitation. 
Patient 9. The brother of Patient III-18 (patient III-21) was 
operated at the age of 5 years for a VSD and valvular PS. He 
developed a re-stenosis and pulmonary valve regurgitation. 
Patient 10. A son (IV-I) of an asymptomatic sister of Patient 
III-18 was diagnosed with a perimembranous VSD at the age of 4 
months. 
Fam~ly 2 
The pedigree of family 2 is shown in Figure 1. 
Patient 1. The parents of Patient (III-15) visited our Depart-
ment of Clinical Genetics for genetic counseling when their daugh-
ter was born with pulmonary atresia with intactventricular septum, 
double-chambered right ventricle an ASD. The aortic valve showed 
no abnormalities. Surgical correction was performed in the first 
year and again at the age of 5 years. At the age of 7 years an 
obstructive fibromuscular bundle in the right ventricle was re-
moved, and a small tricuspid valve with prolapse of the leaflets was 
found during operation. The chordae were abnormally long and 
attached directly to the ventricle wall without papillary muscles. 
Chromosomal analysis showed a normal female karyotype. A 
microdeletion of the 22qll region and 7qll.23 region were ex-
cluded by FISH. Cardiac evaluation of both parents of patient 1 
showed no abnormalities, the a!>")'ffiptomatic mother (II-8) was 53 
years at examination. 
Patient 2 The son (III-17) of a brother of the mother ofPatient 
III-15 was diagnosed at birth with aseverevalvu.hr and infundibu-
lar PS with intact ventricular septum and a secundum ASD. Surgical 
correction was performed at the age of 1-year. After a second 
operation at the age of 6 he died from hypoxic encephalopathy. 
Patient 3. The father (II-10) of Patient III-17 underwent 
cardiologiccvaluation at the age of 35 years because of the f.:uni-
lialCVM, and a valvular aortic stenosis was diagnosed. Chromo-
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somal analysis and FISH of the 22qll region showed no 
abnormalities. 
Patient 4. A brother (11-4) ofPatient II- I3 was diagnosed at the 
age of 31 years with a severe valvular aortic stenosis and regurgita-
tion and dilatation of the ascending aorta. At the age of32 years his 
severely calcified aortic valve was replaced by a Bjork Shiley 
prosthesis. Chromosomal analysis and FISH of the 22qll region 
showed no abnormalities. He died suddenly at the age of SO years. 
Patient 5. The daughter (III-9) of Patient II-4 was evaluated at 
the age of7 years for a cardiac murmur, but was thought to have no 
abnormality. After giving birth to an affected child (N -1) she was 
re-evaluated and was diagnosed as having a stenotic BAV. 
Patient 6. Patient III-9 gave birth to a girl (Patient N-1) with 
critical valvular aortic stenosis who died several days after birth. 
Patient 7. A son (IIJ-8) of Patient 11-4 was diagnosed with a 
severe valvular aortic stenosis and received aortic valve 
replacement. 
Patient 8. A brother (II-3) of Patients 11-4 and II-10 was 
examined at the age of 47 years because of the familial CVM: 
cchocardiography revealed a mildly stenotic, thickened BA V, with 
mild dilatation of the ascending aorta. At the age of 58 years the 
aortic root diameter was 53 mm and there was an ascending aorta 
aneurysm measuring 61 mm. There was left-ventricular hypertro-
phy. A Ben tall procedure including replacement of the ascending 
aorta and proximal aortic arch was performed. A severely calcified 
aortic valve was replaced. Pathological examination showed a 
calcified aortic valve and wall. Intima fibrosis was present and mild 
medial degeneration. The elastin fibers showed no abnormalities. 
The daughter of this patient (III-11) showed no abnormalities on 
cardiologic examination, including echocardiography. 
Patient 9. A son (Ill-S) of Patient II-3 was examined by the 
cardiologist and had mild dilatation of the ascending aorta (43 mm) 
without valvular abnormalities, left ventricular dysfunction or 
hypertrophy. 
Patient 10. A daughter (III-11) of a sister (II-5) of Patients II-8 
died 12 days after birth with an enlarged heart. 
Patient 11. Cardiologic evaluation of the mother (II-5) of 
patient 10 at the age of 43 years revealed no abnormalities, but 
re-evaluation at the age of 57 years showed a sclerotic aortic valve 
with moderate regurgitation. 
Additional family members. Cardiologic evaluation (echocar-
iography and ECG) ofhealthy family members in generation II (Il-
2. II-6, II-7, 11-8,11-9 and II-11) showed no abnormalities. These 
healthy family members were bet'Ncen 39 and 64 years of age at the 
time of examination. The grandparents in gencration I were not 
investigated. The grandfather died of a cardiac arrest at the age of 57 
years. 
MOLECUlAR STUDE~$ 
Linkage analysis using polymorphic microsatellites D9Sl826, 
D9S158, and D9S1838 flanking the NOTCH I gene was performed 
in both families. This e:'i:cluded NOTCH I as the disease gene in both 
families since multiple recombinants were found. Additiomlly, 
sequence analysis of all coding exons and intron-exon boundaries 
of the NOTCH I gene was normal in one affected patient in each 
family. 
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DISCllSSJON 
W c describe !'No families with autosomal dominant inheritance of 
isolated CVM mainly involving the cardiac valves. None of the 
affected family members showed signs of a connective tissue 
disorder or malformation syndrome. Among the 10 affected family 
members of the first family, 6 were diagnosed with an abnormal 
stenotic and/or insufficient aortic valve. In three patients, regurgi-
tation of the mitral valve was present, Pulmonary valve abnormality 
was diagnosed in one f:unily member. In the second f.:tmily, 
abnormal semilunar valves were present in nine family members, 
seven with abnormal aortic valves, and two with defects of the 
pulmonary valves (Table I). Different cardiologists evaluated pa-
tients and BAV may not always be reported if present. In both 
families, septal defects were present in several patients, which we 
believe may be part of the spectrum since thcyco-e:·cisted with valve 
anomalies in several family members. In the first family, one patient 
had a VSD and PS. In the second family, an ASD was present in a 
patient with PS and in a patient with pulmonary atresia. No other 
congenital abnormalities or dysmorphic features were present in 
any of the patients, indicating that the CV11 in these families is 
nonsyndromic. In both families, autosomal dominant inheritance 
is well supported since there are three affected gencrations with 
male-male inheritance and expression in both females and males. 
Nonpenctrance is present in one obligate carrier in both families. In 
family 2, patient II~2 was unaffected at the age of 43 years but 
showed moderate aortic valve regurgitation 14 years later at the age 
of 57. Patient II~S showed no abnormalities at echocardiography at 
the age of 53. She has a tri-leafletaorticvalveandnormal function of 
cardiac valves and the left-ventricle. 
Autosomal dominant inheritance of nons)'11dromic congenital 
valve anomalies has only been described in a limited number of 
families. In most cases consistence of valve anomalies of either 
predominantly left- or right-sided structures of the heart is present, 
In both presented families predominantly aortic valve anomalies 
were observed, although right-sided malformations such as pul-
monary and tricuspid valve anomalies were present in some 
patients. This observation is also documented in other studies with 
smaller families (for instance only !'No persons affected) where 
patterns of inheritance are not always clear [Gillet al., 2003; Lewin 
et a.!., 2004; Martin et al., 2007]. In a recent study demonstrating 
high heritabilityofhypoplasticleft-heart syndrome (HLHS) a high 
percentage ofHLHS probands had both left- and right-sided valve 
dysplasia suggesting that HLHS is a severe form of valve malfor-
mation and anomalies of the left- and right-sided valves may have a 
common etiology [Hinton ct al., 2007]. 
Human genes known to be involved in valvulogenesis include 
genes associated with elastogenesis and collagen synthesis, as elastin 
and collagen arc major components of semilunar and atrioventric-
ular valves. As mutations in most of these genes are associated with 
syndromic forms of CV1v1 they are unlikely to be involved in our 
families with nomyndromic CV11. Familial BAV and aortic valve 
stenosis in association with TA.A is a well-recognized entity. 
Loscalzo et al. [2007] suggested that altered TGFB signaling might 
play a role in BAV with T AA as several aneurysm syndromes, 
including Marfan syndrome [Neptune et al., 2003], Loeys Dietz 
syndrome [Loeys et al., 2005], and arterial tortuosity syndrome 
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[ Couck.e et al., 2006] arc a.ssociatcd with upregulation of the TGFB 
pathway leading to loss of elastic fiber integrity. However, TGFBRl 
and TGFBR2 gene analysis in 13 families with BAV and TAA 
revealed no mutations in [Losc:llzo etal., 2007]. Recently mutations 
in the gene ACTA2, encodingvascubr smooth muscle cell a~ actin, 
were identified as a major cause of autosomal dominant inherited 
T M. Interestingly multiple familymembers in 4 out of 14 described 
families withACTA2 mutations showed BAV, indicating that genes 
encoding sacromeric proteins might be good candicate genes for a 
subset of familial L VOTO [Guo et al., 2007], 
Eb.stin mutations in our families are unlikely as they predomi-
nantly cause supravalvular aortic stenosis, although aortic valve 
stenosis can also occur. Furthermore, right-sided valve momilies 
and ASD/VSD are rarely described in patients with elastin muta-
tions [Metcalfe ct al., 2000; Eronen et al., 2002]. 
Only a few genes have been involved in nonsyndrornic CVM with 
a monogenic mode of inheritmce; these include the NOTCH I, 
Elastin, NKX2.5, NKX2.6, GATA4, CREWJ, MYH6, ACTAO, 
TBX20, and FLNA genes [for reviews: Bruneau, 2008; Ransom and 
Srivastava, 2007; Weism:.mn and Gclb, 2007]. Mutations in 
NOTCHl have been found in two families with BAV, aortic valve 
stenosis, aortic valve olcification and other L VOTO anomalies 
[Garget al., 2006]. Interestingly one patient with AS and BAV al$o 
had ascending aortic dilatation. In both our families NOTCH I was 
excluded as the disease gene by linkage analysis using polymorphic 
microsatellites (D9S1826, D9S158, D9Sl838) flanking the 
NOTCH I gene that showed multiple recombinants in both fami-
lies. Additionally, sequence analysis of all coding exons and in-
tron--exon boundaries was normal in an affected family member in 
both families. 
Human NKX2.5 mutations can cause a number of different 
cardiac phenotypes [McElhinney et al., 2003; Elliott et al, 2003], 
including ASD/VSD and LVOTO, but anomilies of the semilunar 
valves, as observed in 17/21 of the patients in our families, are not 
often described [Majumdar et al., 2006]. A NKX2.5 mutation was 
excluded in both our families by mutation analysis in one affected 
family member. GAT A4 mutations can lead to nonsyndromic ASD 
and other CVM including PS [Garget aL, 2003], whereas gross 
deletions of the 8p23 region encompassing the GATA4 gene arc 
associated with a variety of cardiac anomilies, mainly PS and ASD. 
However, in contrast to our fumilies left-sided cardiac anomilies 
are uncommon in these patients, although aortic/mitral regurgita-
tion was reported in 1118 patient of the families described by Garg 
et al. [2003]. So far, no good candidate genes have been reported for 
our families, therefore a genome-wide linkage analyses has been 
initiated in both families. 
Mature valve structures arise from endothelial cells of the 
endocardial cushions [Lincoln et aL, 2004]. The endocilrdial 
cushions are formed by endothelial-mesenchymal transdifferen-
tiation of a subset of endothelial cells that invade the a-rracellular 
matrix and differentiate into mesenchymal cells [Armstrong 
:l.Ild Bischoff, 2004]. Valve leaflets eventually consist of a single 
endothelial cell layer and a central layer consistent of collagen, 
elastin, and glycosaminoglycans [Maron and Hutchins, 1974]. 
The endocardial cushion tissue contributes not only to the 
formation of valves, but also to the formation of membr:l.Ilous 
septa [Schroeder et aL, 2003]. This might explain why some 
1181 CHAPTER 3 
WESSElS ET AL 221 
Gene 
Wnt!P·Catenin signaling 
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Hdf [Cspg2, versican] 
jJ.carenin 
Notch signaling 
Norch1 
Hesr2 
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£phrin82 
FgfB 
£ce11Ece2 
Vegf signaling 
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Nfarc1 
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Tie 2 {T£K} 
eNos 
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Bmp-Tgf-P signaling 
Bmpr2 
Bmp4 
BmpG/1 
A/k3 
Madh5 [Smad5) 
Perlecan [HSPG2} 
Fibulin-4 
Erb signaling 
ErbB1 [Egfr, Her1] 
£rb83 (He<3/ 
HB·fGF 
T:1ce [Adamt?) 
fJ Meltrin [Adam19] 
Egfr1Prpn11 
GATA transcription fa~ors 
GATA4 
Fog 1 
Fog2 
Nkx2.S 
Pirx2 
Sox transcription factors 
Sox4 
Sox9 
Fox transcription factors 
Foxpt 
Foxct 
Foxc2 
Various 
£phA3 
Pdgf-a[patch mutation} 
Pdgf·b 
Apoe 
Cent 
Periostin 
Chm1 
Cxcr? 
Cardiac anomaly 
Absence of cardiac jellijendocardial cushions 
Absence of endocardial cushion swelling 
Lack of heart cvshion formation 
Hypoplastic cardiac cushions 
Dysplastic AV valves, ASO, VSD 
Dysplastic atrioventricular and pulmonary valves 
TA, VSO, TOF 
Thickened aortic, pulmonar\1 and mitral valve 
Single AV valve, hypoplastic arch arteries, OORV 
Abnormal AV valve formation, truncus arteriosus 
Endocardial cushion defects 
Absent semilunar valves 
Hyperplastic valve tissue 
Endocardial cushion defects 
BAV,AS,ASO, VSO 
AV valve dyspl;;~sia 
Absent semilvnar valves, truncus arteriosvs 
Variable 
Hypoplastic cardiac cushions 
Hypoplastic cardiac cushions 
Thickened valves 
Malformed semilunar valves, TGA 
Thickened aortic valvular leaflets 
Enlarged thickened semilunar and AV valves 
Hypoplastic cardiac cushion 
Enlarged malformed semilunar and AV valves 
S:n!arged semilunar and AV valves 
Immature valves, VSD 
Semilunar valve h~perplasia 
Common AV v;;~Jve 
Common AV valve, DORY 
TA, PS, AV canal, ASD, VSO, TOF 
BAV, AS, ASD 
Enlarged endocardial cushion 
Semilunar_valve defects, truncus arteriosus 
Hypoplastic endoca'rdial cushions 
Thickened endocardial cushion 
Valve anomalies, IAA. CoA, VSD 
vorve anomalies, JAA, CoA, vso 
Hypoplastic endocardial cushions 
Septal_ and valve defects 
AV valve malformation, VSO 
Sclerotic, stenotic aortic valves 
Atrioyentricular septal defects 
AV valve_,abnormalides,- ASD 
Thickened, calcified, stenotic aortic valves 
Semilvnar 'valve, malformation, VSO 
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FIG. 2. Molecular pathwa~s and their cross-talking involved in cardiac morphogenesis. {COJorflgure can be viewed ln the onllne Issue, which Is 
available at www.lntel'!lelenee.wlley.com.J 
patients in our families have septal defects apart from valve 
anomalies. 
In contr:lst to the sparse knowledge about the genes involved in 
human valve formation and malformation much more is known 
about valvulogcncsis in mice. In mice signal transduction pathways 
including Wnt/f}-catenin, Vcg£ Notch, Bmp-Tg$, and Erb, and 
transcription factors including different GATA, FOX :md SOX 
transcription factors have been implicated in heart cushionlvalve 
formation (Table II, Fig. 2). These different signaling pathways 
exhibit e)..1ensive cross-t:illcing, resulting in a complex integrated 
process of cardiac valve morphogenesis [for review: Schroeder et al., 
2003; Armstrong and Bischoff, 2004]. These mouse models could 
provide functional candidate genes for fumilies with cardiac valve 
anomalies once positional genetics approaches have localized the 
human disease gene. 
The two multiplex fumilies in this report may facilitate identifi-
cation of human genes specifically involved in cardiac valve mor-
phogenesis and aortic w:ill disease. The co-occurrence of aortic and 
pulmonary valve abnormalities and aortic aneurysms in these 
families supports a common genetic etiology in some forms of 
left- and right-sided valve anomalies, and c:>..lJands the phenotype of 
LVOTO. 
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CHAPTER4 
Arterial malformations 
4.1 Introduction 
During the past decade genetic studies of the cardiovascular system in syndromes such asMarfan syn-
drome (FBN7 gene encoding fibrillin) ', Loeys-Dietz syndrome (TGFBR1/2 genes encoding TGF~ recep-
tors 1 and 2) 2.-4, Ehlers-Danlos syndrome (COL3A1 gene encoding collagen 3 and FLNA gene encoding 
Fila min A) 5•6 and arterial tortuosity syndrome (SLC2A 10 gene encoding GLUT1 0) 7•8 have provided in-
sights into the pathogenesis of arterial aneurysms (Tables 1 and 2). The TGF~ signaling pathway plays a 
central role in the pathogenesis of many of these aortic wall disorders, making this pathway the primary 
pharmacological target for the development of new treatment strategies for arterial wall disorders 9•10• 
Apart from the TGFI3 signaling pathway also sarcomeric protein genes of smooth muscle cells have 
been implicated in familial aortic aneurysm, as mutations in the MYH11 gene encoding smooth muscle 
cell myosin heavy chain and in the AGA2 gene encoding smooth muscle cell a-actin have been identi-
fied in familial thoracic aortic aneurysm/dissection (TAAD) 11 •12• These 2 pathways seem to interact as 
treatment of cardiomyocytes with TGF() 1 leads to increased expression of sarcomeric proteins 13• 
4.1.1 Syndromic aortic aneurysms 
4.1.1.1 Marfansyndrome 
Marfan syndrome is the "classical" arterial aneurysm syndrome with a prevalence of 1 per 5,000. The 
aneurysms located in the ascending aorta are caused by cystic medial degeneration due to mutations 
in the fibrillin-1 (FBN1) gene located on chromosome 15q. Fibrillin-1 is a large 350-kDa glycoprotein 
that is a major component of the microfibrils that make up the elastic fiber. It has a repetitive domain 
structure containing calcium-binding motifs (epidermal growth factor precursor-like) and motifs that 
bind to TGF~, thereby linking fibrillin to the TGF~ pathway. Fibrillin-1 is thought to play a role in the 
TGF() signaling cascade via its interaction with latentTGF()-binding protein (LTBP). LTBP bindsTGF() via 
an LTBP-associated protein {LAP), forming what is known as the large latent complex 14• Mutations in 
FBN1 likely disrupt the targeting and sequestration of the large latent complex due to an inability of 
LTBP to bind to the microfibrils. The increased level of available TGF~ leads to an increase in TGF() activ-
ity, which is responsible for the development of symptoms. These mutations result in both a decrease 
in the amount of elastin in the aortic wall and a loss of elastin's normally highly organized structure. As a 
consequence, the aorta exhibits markedly abnormal elastic properties leading to progressive increases 
in stiffness and dilatation 15• 
1281 CHAPTER 4 
Apart from Marfan syndrome, FBN1 mutations may also result in a wide range of overlapping clinical 
entities, including MASS (mitral valve, aorta, skeleton, and skin) syndrome, isolated ectopia lentis, Weill-
Marchesani syndrome, Shprintzen-Goldberg syndrome, and familial aortic aneurysms. Many excellent 
reviews of Marfan syndrome have been published 1•16-18• 
4.1.1.2 Loeys·Dietz syndromes 
Loeys-Dietz syndrome type 1 is characterized by the triad of hypertelorism, bifid uvula I cleft palate, 
and generalized arterial anomalies including tortuosity, aneurysm and dissection. Affected patients 
have a high risk of aortic dissection or rupture at an early age in childhood 19·=w. Histological studies of 
the aortic wall reveal loss of the elastin content and disarray of elastic fibers, along with increased col-
lagen deposition. Loeys-Dietz syndrome type 2 also has generalized arterial anomalies but less facial 
features, similar to Ehlers-Danlos syndrome type IV. Both Loeys-Dietz syndromes are due to autosomal 
dominant inactivating mutations in the TGFBR7 and TGFBR2 genes encoding receptors 1 and 2 for trans-
forming growth factor beta. These inactivating mutations lead to a paradoxa! upregulation of the TGF!) 
pathway. 
TGFBR1 and TGFBR2 mutations have been found to cause a large spectrum of genetic disorders, in-
cluding Loeys-Dietz syndrome type 1, Loeys-Oietz syndrome type 2, some patients with Marfan-like 
syndrome (Marfan syndrome type 2) and Ehlers-Danlos syndrome type 4 2"", and a minority of patients 
with non-syndromic familial TAAD 21 .22. 
4.1.1.3 Ehlers-Danlos syndromes 
Ehlers·Danlos syndrome type IV (vasculartype) 
The vascular type of Ehlers-Danlos syndrome, EDS type 4, is an autosomal dominant condition charac-
terized by extreme fragility of skin, blood vessels, intestine, gravid uterus, and lungs. Visceral rupture, 
easy bruising, wide and atrophic scars, joint laxity, and translucent skin characterize the phenotype. 
Vascular complications include aneurysm and/or dissection of major or minor arteries. The sites of arte-
rial rupture are throughout the vascular tree, including arteries in the thorax and abdomen, head and 
neck and extremities. EDS 4 can be caused by mutations in the COL3A1 gene that affect the integrity 
and/or synthesis of the precursor procollagen molecules of type 3 collagen. Approximately 5-10% of 
FAA families without obvious Ehlers-Oanlos syndrome exhibit linkage to the COL3A 1 gene, and might 
exhibit a COL3A1 mutation 22• Some patients with EDS 4 have TGFBR1 or TGFBR2 mutations: these pa-
tients are sometimes referred to as Loeys-Dietz syndrome type 2, although few symptoms of the typical 
Loeys-Dietz syndrome type 1 are present. 
Ehlers-Danlos syndrome type 6 (kyphoscoliotic type) 
Ehlers-Danlos syndrome type 6 (kyphoscoliotic form) is characterized by abnormal skin (hyperexten-
sibility, scars, easy bruising), joint laxity, muscle hypotonia, progressive scoliosis, glaucoma, retinal de-
tachment and increased risk of rupture of the globe, and aortic dilation 23.24 • Patients are at risk for aortic 
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dissection and rupture of medium-sized arteries 23• Ehlers-Danlos syndrome type 6 is caused by defi-
cient activity of the procollagen-lysine, 2-oxoglutarate 5-dioxygenase 1 (lysyl hydroxylase 1) enzyme 
due to mutations in the PLOD7 gene. 
Ehlers~Danlos syndrome with nodular heterotopia 
Periventricular heterotopia with Ehlers-Danlos syndrome is an X-linked condition, which is lethal in 
most males in the prenatal or neonatal period. Affected females exhibit nodular brain heterotopia and 
an Ehlers-Danlos-like syndrome characterized by joint hypermobility, hyperextensible skin, high palate, 
subarachnoid hemorrhage, visceral hernia, and vascular anomalies: the latter include aortic dilatation 
and aneurysm, patent ductus arteriosus {PDA), and bicuspid aortic valve (BAV) can be present 5.25• The 
disorder is caused by loss-of-function mutations in the X-linked FLNA gene encoding filamin A, an actin-
binding protein involved in cytoskeletal organization. 
4.1.1.4 Cutis laxa 
Cutis laxa is a condition characterized by redundant, pendulous, and inelastic skin. It is genetically het-
erogeneous, and mutations have been found in the ELN gene encoding elastin (autosomal dominant 
cutis laxa), the ATP7A gene encoding Cu-transporting ATPase (X-linked cutis laxa, Ehlers-Danlos syn-
drome type 9, Occipital horn syndrome), the FBLN4 gene encoding Fibulin 4 (autosomal recessive cutis 
laxa), and the FBLNS gene encoding Fibulin 5 (autosomal recessive and autosomal dominant cutis taxa) 
26
.27• Vascular tortuosity and aneurysm can be present in all forms, but is most prevalent in patients 
with FBLN4 or FBLNS mutations 28• The corresponding fibulins are essential in elastic fiber formation in 
connective tissue. Transgenic Fibulin 4-deficient mice show aortic aneurysm and dissection, arterial 
tortuosity, and aortic valve anomalies with disturbed TGFI) signaling 29• 
4.1.1.5 Arterial tortuosity syndrome 
Arterial tortuosity syndrome (ATS) is a rare autosomal recessive disorder characterized by tortuosity, 
elongation, stenosis and aneurysm formation of the major arteries, due to disruption of elastic fibers 
in the medial layer of the arterial wall 7• Non-vascular abnormalities include arachnodactyly, joint lax-
ity or contractures, micro-rethrognathia, hypertelorism, cleft palate and/or bifid uvula. These clinical 
findings are reminiscent of Loeys-Dietz syndrome. Further studies have shown that tortuosity of large 
and middle-sized arteries is present in all patients, but other aortic abnormalities also occur including 
aortic root dilation, localized arterial stenosis, and long stenotic arterial stretches 30.31• The prognosis of 
ATS may be more favorable than reported before as milder cases may have been underdiagnosed 31 • 
In this thesis clinical and molecular studies of ATS patients are described. We first reported the clinical 
features in three consanguineous multiplex families with 11 affected AT$ patients, and reviewed the 
literature on ATS 7• Using our largest consanguineous multiplex ATS family a genome-wide screen with 
homozygosity mapping was then performed, and linkage of the ATS gene to chromosome 20q13 was 
found 32• Further narrowing of the candidate region to a 1.2Mb region containing 7 genes, let to the 
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identification of the disease gene: Mutations in 6 ATS families were found in one of these genes, the 
SLC2A 70gene encoding the facilitative glucose transporter GLUT1 0 '·Although fragmented elastic fib-
ers were observed in some areas of aortic wall in ATS patients, the predominant observation in mutant 
mice with missense mutations in SLC2A 70was elastic fiber proliferations including both thickened and 
increased elastic fibers in the lamina interna, lamina media and adventitia of middle size arteries 33• 
In older mice deranged elastic fibers and disruption of internal elastic lamina was seen in some ar-
eas of the aortic wall. This raises the question whether the long stenotic stretches of the aorta that 
are observed in some ATS patients might be due to elastic fiber proliferations 31 • No arterial tortuosity, 
aneurysms, or arterial stenosis was observed in these mice, possibly due to the milder missense muta-
tions versus nonsense mutations in ATS patients. GLUT1 0 deficiency was found to be associated with 
upregulation ofTGFB signaling in the arterial wall of AT$ patients, a finding also observed in Loeys-Dietz 
syndrome, which also presents with aortic aneurysms and arterial tortuosity. The precise interaction 
between GLUT1 0, a glucose transporter and the TGF~ signaling pathway remains elusive (Figure 1). 
Figure 1 I Possible link between GLUT10 and the TGF~ signaling pathway 
In ATS patients with a loss-of-function mutation in SLC2A 7 0 leading to GLUTlO deficiency decorin expression is decreased and versican expression is in-
creased. Normally glucose is transported into the smooth muscle cell nucleus by GLUTlO, activating decorin transcription by binding to a response element in 
its promotor. Decorin then b'mds to and inactivates TGF~ extracellularly, attenuat'mg signaling via the TGF~-$mad pathway. Loss of GLUT10 may reduce nuclear 
glucose levels resulting in a decreased expression of decorin and upregulation ofthe TGF~-Smad pathway by loss of inhibition. As a resultversican expression 
is increased, which might inhibit elastic fiber assembly. 
With permission of Prof.Dr.lng.Paul Coucke 
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4.1.1.6 Other syndromes associated with aortic aneurysm 
Congenital contractural arachnodactyly (CCA) or Beals syndrome is an autosomal dominant connective 
tissue disorder, comprising marfanoid habitus, flexion contractures, severe kyphoscoliosis, abnormal 
pinnae, and muscular hypoplasia. CCA is caused by mutations in the FBN2 gene encoding fibrillin-2. 
Only in severe CCA cases there exists aortic root dilatation and sometimes even interrupted aortic arch. 
Autosomal dominant Polycystic Kidney Disease (APKD) is characterised by bilateral renal cysts, and usu-
ally also cysts in other organs including the liver and pancreas. Intracranial aneurysms, dilatation and 
dissection of the aortic root, and mitral valve prolapse might also be present 34• APKD is caused by muta-
tions in the PKD1 gene encoding polycystin-1 or in the PKD2 gene encoding polycystin-2. 
In approximately 50 % of patients with Turner syndrome MRI angiography shows elongation of the 
transverse aorta with kinking in the juxta-ductus region (pseudo-coarctation) 35.36• Aorta aneurysm is 
seen in up to 30% of Turner syndrome patients 37, and the risk is higher in Turner patients with CHM, 
such as bicuspid aortic valve (BAV) and coarctation of the aorta 38• 
Another disease associated with aortic aneurysm is fibromuscular dysplasia (FMD), which can occur as a 
familial trait. It is characterized by medial hyperplasia of the middle sized arteries, leading to"string-of-
beads'stenotic arterial appearances, predominantly in the renal and internal carotic arteries 39• 
4.1.2 Non-syndromic aortic aneurysms 
Aortic aneurysms represent a common vascular condition with life-threatening implications, and a 
leading cause of morbidity and mortality 40• The mortality following rupture of an aortic aneurysm ex-
ceeds 75%. Overall, abdominal aortic aneurysms {AAA) are more frequent than thoracic aortic aneu-
rysms (TAA), with the most common location of aortic aneurysm being the infrarenal abdominal aorta, 
followed by the ascending thoracic aorta. Familial inherited aneurysm are most often TAA located in 
the ascending aorta {60%), followed by aneurysms of the descending aorta (40%) 15• TAA have a higher 
mortality rate (97%) than AAA, genetic factors play a more important role in their pathogenesis, and 
they are more often caused by monogenic mutations than AAA. 
4.1.2.1 Familial thoracic aortic aneurysms 
Overall, 15% to 20% of thoracic aortic aneurysm (TAA) and/or aortic dissection {AD) cases (also referred 
to as TAAD) may be familial 41 •42• Non-syndromic familial TAAD is genetically heterogeneous. Five loci 
with 3 genes have been identified: these include AAT1 at chromosome 11 q23.2-q24 ", AAT2 at 5q13-
q14 "', AAT3 at 3p25-p24 (TGFBR2 gene)', AAT4 at 16p13 (MYH11 gene)" and AAT6 at 10q22-q24 
(AGA2 gene) 12• Some families are not linked to these loci thereby indicating that additional loci forTAA 
must exist 4348• A subset of patients with an AaA2 or MYH71 mutation also presents with PDA. AaA2 
mutations may additionally lead to BAV. Although classified under non-syndromicTAAD, patients with 
AITA2 mutations sometimes show additional clinical features such aslivido reticularis and iris flocculi. 
1321 CHAPTER 4 
4.1.2.2 Familial thoracic aortic aneurysms with bicuspid aortic valve and LVOTO 
TAA can be present in families with left ventricular outflow tract obstruction {LVOTO) anomalies, includ-
ing BAV 49..s0• Also, aortic dilatation is found in approximately 50% of patients with BAV 15'51 • NOTCH7 
mutations are found in a small subset of patients with LVOTO anomalies 52• In this thesis we performed 
linkage analysis in two large families with LVOTO anomalies {including TAA in several family members) 
and excluded NOTCH1 as the disease gene, indicating that other genes contribute to this spectrum of 
CHM so. 
4.1.2.3 Familial abdominal aortic aneurysm 
Genetic studies of abdominal aortic aneurysm (AAA) indicate that approximately 15% of the patients 
with AAA have a positive family history for AAA. This fraction may be higher when more complete 
screening of family members would be performed. Familial AAA can present as a syndromic disorder 
such as Marfan, Ehlers-Danlos or Loeys-Dietz syndrome, as described above (Table 2). In these syn-
dromes aneurysms are not only present in the thoracic aorta but also in the abdominal aorta. Familial 
AAA can also be non-syndromic, and a few families with autosomal dominant and recessive AAA have 
been described. Different loci for AAA have been identified through genome wide association studies, 
including loci on chromosome 19q13 (AAA 1) ", 4q31 (AAA2) 53 and 9p21 (AAA3)"' (Table 1). The AAT1 
locus on chromosome 11 q23-q24 not only causes TAA but also AAA 43• No disease gene for AAA has 
been identified yet. 
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Table 1 ! Syndromicand non~syndromicforms of familial aortic aneurysms 
Syndromicforms 
Marian syndrome AD 15q21 FBN7 
Loeys-Dietz syndrome type 1 AD 9q33 TGFBR7 
Jp22 TGFBR2 
Loeys-Dietz syndrome type 2 AD 9q33 TGFBR7 
(Ehlers-Danlos syndrome type 4) Jp22 TGFBR2 
Ehlers-Danlos syndrome type 4 AD 2q31 COL3A7 
Ehlers-Danlos syndrome type 6 AR lp36 PLOD7 
(Kyphoscoliotic type) 
Ehlers-Danlos syndrome with X-linked Xq28 FLNA 
periventricular nodular heterotopia 
Cutis laxa syndrome AR llqll FBLN4 
AR 14q32 FBLNS 
Arterial tortuosity syndrome AR 20q13 SLC2A70 
Non"'S}'I1dromicforms 
Familial thoracic aortic aneurysm/dissection AD llqll (AATl) 
(TAAD) AD Sqll (AAT2) 
AD Jp22 (AATJ) TGFBR2 
AD 10q22 (AAT6) AGA2 
AD 9q33 TGFBR7 
Thoracic aortic aneurysm with PDA AD 16p13 (AAT4) MYH77 
Familial LVOTO with TAA AD 9q34 NOTCH7 
Abdominal aortic aneurysm (AAA) AD 19qll (AAAl) 
AD 4q31 (AAA2) 
AD 9p21 (AAAJ) 
AD llq2l (AATl) 
AR ? 
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Table 2 I Discriminating features in familial aortic aneurysms 
Cardiovascular 
Aorticroota neurysm/ dissection +++ +++ + + + 
Other aneurysm/ dissection +1- +++ ++ ++ + 
Arterial tortuosity +++ + 
Arterial stenosis/occlusion 
ASD ++ 
PDA ++ 
BAV + 
Craniofadal 
Hypertelorism +++ 
Bifid uvula/cleft palate ++ +I-
Micro~retrognathia ++ +++ 
Eye 
Myopia +++ + + 
Ectopia lentis +++ 
Skin/joints 
Velvet skin ++ + + ++ 
Skin laxity + + + ++ 
Dystrophic scars ++ + + ++ 
Inguinal hernia ++ ++ + + + 
Joint laxity ++ ++ ++ + + 
Arachnodactyly +++ ++ 
Contractu res +I- ++ + + 
Other 
Visceral rupture/perforation + + ++ 
Developmental delay + 
Other Craniosynostosis 
Open space indicates that the feature was not scored. 
LOS, loeys-Dietz Syndrome; LR, Livedo Reticularis; ASD, Atrial Septal defect; PDA: Patent Ductus Arteriosus; BAV, Bicuspid Aortic Valve 
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Features FLNA FBLNH SCL2A10 MYH11 ACTA2 
Cardiovascular 
Aorticrootaneurysm/ dissection + + + + + 
Other aneurysm/dissection + + + 
Arterial tortuosity ++ +++ 
Arterial stenosis/occlusion + + 
ASD 
PDA + + + 
BAV + + 
Craniofacial 
Hypertelorism + ++ 
Bifid uvula/deft palate + 
Micro-retrognathia + + 
Eye 
Myopia + 
Ectopia lentis 
Skin/joints 
Velvet skin + + ++ 
Skin laxity + + ++ 
Dystrophic scars + 
Inguinal hernia + + ++ 
Joint laxity + + ++ 
Arachnodactyly + + 
Contractu res + 
Other 
Visceral rupture/perforation 
-? 
Developmental delay +I- -? 
Other Seizures Emphysema lris flocculi, 
LR 
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Arterial tortuosity syndrome (ATS) is a rare 
condition with autosomal recessive inheritance 
characterized by connective tissue abnormalities. 
The most specific clinical findings are- cardio-
vascular anomalies including tortuosity~ length· 
ening. aneurysm. and stenosis formation of major 
arteries. Also ventricular hypertrophy is frequent-
ly present. Other anomalies are skin hyperexten· 
sibility and cutis laxa. joint laxity or eontractures 
of the joints, and inguinal herniae. Histology 
shows disruption of elastic fibers of the media. 
These features suggest that ATS is a connective 
tissue disorder.A biochemiealormolcculardefeet 
has not yet boon identified. We describe here 
nine additional ATS patients from three consan-
guineous Moroccan families and review a total 
of 35 patients with this uncommon condition. 
rtJ 2004 Wllcy-Liss. Inc. 
KEY WORDS: arterial tortuosity; ATS; aneur-
ysms; pulmonary stenosis; joint 
la.'rity; hyperextensibility: cutis 
laxa: clastic fibers 
INTRODUCTION 
Arteriu.l tortuosity syndrome (ATS) (OMIM: 208 050) is a rare 
disorder, with only 26 ATS patients reported (Table I. and 
references therein). Tortuosity of most of the major and middle 
arteries. including the aorta, the carotid, renal, and pulmonary 
arteries is the most specific feature. Arterial aneurysms, and 
stenosis of the pulmonary arteries und the aorta are also 
characteristic features, and ventricular hypertr-ophy is often 
present. The majority of patients also have congenital involve-
ment of the skin, with softness, hyperextensibility, or cutis 
laxa, but no bru.Lqability. AdditionalATS abnormalities typical 
of a connective tissue disorder are la.xity and! or contractures of 
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joints, arachnodactyly, inguinal :lii.d/or umbilical herniae, and 
relaxation of the diaphragm leading to hiatal hernia. Most 
patients have an elongated face with micrognathia. Other 
facial features might include downslanting palpebral fissures, 
blepharophimosis. and a beaked nose. High-arched and/or cleft 
palate can be present. In addition, hypotonia is sometimes 
observed (Table 1). Histopathology reveu.ls fragmentation of 
the internal elastic membrane and elastic fibers of the tunica 
mediaofthe large arteries [Ertugrul, 1967; Beuren etul, 1969; 
Lees et ol., 1969; Wagstaff et al., 1970; Welch et al., 1971; Ades 
et al.. 1996; Pletcher et ul., 1996; Franceschini et al., 2000; 
Rivera et al, 2000], whereas the elastin network in fibroblasts 
derived from .:1 skin biopsy was reported to be normal [Al Fadley 
et al., 2000], Biochemical studies of collagen are normal [Ades 
etal., 1996; Pletcheret al., 1996; Franceschini et al., 2000], and 
the primary defect at the protein or molecular level inATS has 
not yet been identified. 
Defects in the elastin network are also found in a group of 
ill-defined connective tissue disorders having overlapping 
features with ATS (Tables I and II), These include autosomal 
recessive cutis laxa type 1 COMIM 219100) which is due 
to mutations in fibulin 5 [Loeys et al., 2002], progeroid 
Ehlers-Danlos syndrome which is caused by mutations in 
the B4GALT7 gene encoding the 13-1.4-galactosyltrunsferase 
1 enzyme [Okajimaetal., 1999], andseveralconditionswithout 
identified primary gene defect, including autosomal recessive 
cutis laxa type 2 with growth and developmental delay COMIM 
219200), wrinkly skin syndrome COMIM: 278250), gerodermia 
osteodysplastica (OMI:YI 231070), and De Barsy syndrome 
(01:UM: 219150). Cutis laxa type 2 with growth and develop-
mental delay was originally described by Reisner et al. [1971] 
as a new entity with congenital cutis la:w.,joint la."'Citywith hip 
dislocation. growth retardation, and psychomotor delay. 
Additional patients with this form of cutis laxa have been 
reported by Sakati et al. [1983] and Patton et al. [1987]. 
However, many of these patients were later reclassified as 
examples of Costello syndrome [Patton and Baraitser, 1993]. 
Moreover, the original patients of Reisner et al. [1971] were 
republished 2 years later by other authors [Gazit et al, 1973] 
as the first patients with wrinkly skin syndrome [Zlotogora, 
1999]. The latter syndrome is characterized bywrinklingofthe 
skin of the abdomen, the hands and feet, increased creases of 
the palms and soles, joint laxity, spinal deformities, pre- and 
post-natal growth retardation, and psychomotor delay [Gazit 
et al., 1973; Karrar et nl., 1983; Casamassima et al., 1987; 
Hurvitz et al., 1990; Kreuz und Wittwer, 1993; Azuri. et ul., 
1999; AL-Gazali et al., 2001]. This illustrates the overlap 
between cutis la.xa type 2, Costello syndrome, and wrinkly skin 
syndrome. Al-Gazali et al. [2001] recently suggested that the 
clinical spectrum of these disorders can be further extended to 
~ 
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TABLE I. Clinical Features in ATS Patients 
Arterial anomalies "' Joints ~ 
~ 
Stenosis Arachno Pectus Facial Other 
'fortuosity Aneurysm A. Pulrn. Skin Hemia Laxity Contractures dactyly deformity anomalies findings 
+ + HP VH 
+ + HES + BN,HP,M VH 
+ + + HES 
' 
VH 
+ + Cutis Jaxa + SHT 
+ + HES I + M VH,H 
+ 
' 
+ Cutis laxa + I 
" + + + Soft + BN,HP,M VH,SH'l' 
+ + + Cutis Iaxa + + 
' 
BN,DP,M VH,AT 
+ + VH 
+ + Soft + I· DP,M 
+ + + CP VH, hamartoma 
+ + + + HP,M 
+ + Soft j j + LF,M, HP Keratoconus, H, RD 
+ + M AT 
+ + HES + + LF,M Kyphoscoliosis 
+ + HES + + LF,M 
+ I· HES + LF,M 
+ + !!ES + + LF,M SHT 
+ + HES + + LF,M SH'I' 
+ HF.S + + LF,M 
+ + HES + + LF,M 
+ + m:s + + LF,M 
+ + HES I + LF,M 
+ + BJ·~S + + LF,M Hip dislocation 
+ + HES + + LF,M 
+ + HES + + LF,M 
+ + HES I + + + CP,M,BP RD 
+ + Soft + + + + BN, HP, DP, BP 
+ Cutis laxa + + BN 
+ Soft + + LF,HP 
+ + HES + + + LF,HP MR, HP, AC, ST, RD, VH 
+ Redundant + LF,M, CP MR, H, AC, ST, AT, RD 
+ 
' 
+ MR, H, AC, RD, 8'1', A'I' 
+ Cutis laxa + + M,HP H,AC 
+ Cutis Iaxa + I M,CP H,AC 
35/35 11/35 21/35 29/35 8/35 26/35 15/35 9/35 7/35 
(100%) (31%) (60%) (83%) (23%) (74%) (43%) (26%) (20%) 
1arophimosis; CP, cleft palate; DP, downslantingpalpabral fissures; H, hypotonia; HES, hyperextensibility of the skin; HP, high palate; LF, long 
relaxation of diaphragm~hiatal hernia; SHT, systemic hypertension; ST, strabismus; VH, ventricular hypertrophy; yrs, years; mos, months. 
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include gerodermia osteodysplastica, another disorder of the 
elastin network with similar clinical features [Bamatter et n.l., 
1950; Hunter et al., 1978; Hunter, 1988; Lisker et al., 1979; 
Al-Torki et al., 1997]. Also De Barsy syndrome [De Barsy et al., 
1968; Karnes et al., 1992] and ATS show overlap. However, 
the main features of ATS including tortuosity, lengthening, 
stenosis, and aneurysm of multiple nwjor arteries, are in-
frequent in these conditions. 
The mode of inheritance of ATS syndrome is probably 
autosomal recessive as parental consanguinity and increased 
recurrence risk in siblings has been observed in many pedi· 
grecs (Table 1), although ATS might be heterogeneous with 
involvement of different genes and modes of inheritance. 
We describe here nine additional patients with ATS from 
three consanguineous fumilies from Moroccan descent and 
review the characteristics of all the patients previously re-
ported in order to delineate this rare disorder. 
CLINICAL REPORTS 
Faxnily 1 
Patient 1. This was the third child CV-3) of healthy 
Moroccan consanguineous parents (Fig, 1, family 1). The older 
sibs were reported to be healthy. This pregnancy was un-
eventful until the 34th week when ultrasound examination 
revealed a stomach located in the thorax. A diaphragmatic 
hernia was suspected. Amniocentesis was performed, and 
cytogenetic analysis showed a normal, female karyotype. The 
parents continued the pregnancy, and a girl with a birth weight 
of 3,735 g was born in the 39th week. She was intubated and 
transferred to the neonatal unit, where a hiatal hernia W3E 
found by radiography. She was also noticed to have an umbi-
lical hernia and dysmorphic features, including a cleft of the 
soft palate, hyperlax skin, long fingers, blepharophim.osis, 
telecanthus, and micrognathia. Echocardiogram of the heart 
revealed tortuosity and lengthening of the aorta. Also the 
carotid arteries were tortuous. Angiographic studies confirmed 
the tortuosity of the thoracic and the abdominal aorta, Also 
the superior mesenteric arteries were tortuous. The pulmon-
ary arteries were not visualized. Because of the suspicion of 
Ehlers-Danlos syndrome, a skin biopsy was taken for collagen 
analysis. This showed a normal electrophoretic pattern of 
collagen type ill, and a normal collagen type I to ill ratio. Seven 
weeks after birth the girl developed severe ileus, for which 
laparotomy was performed. This showed necrosis of the com-
plete small bowel, probably due to arteriopathy of the mesen-
teric artery. Two days later the child died. Permission for 
autopsy was not obtained. ATS was diagnosed retrospectively 
in view of the typical urteriopathywith tortuosity, and laxity of 
the joints and skin. 
Faxnily2 
Patient 1. This was the second child (IV-2) born to healthy 
Moroccan parents that were first cousins (Fig. 1, family 2), and 
originated from the same town as family 1. The first pregnancy 
ended with a spontaneous miscarriage at 12 weeks gestation, 
and the oldest child is a healthy son. This girl was born after an 
uneventful pregnancy n.nd birth at 42 weeks. At the age of 
4 months, a systolic heart murmur was found on routine 
examination. Cardiologic evaluation revealed stenosis and 
tortuosity of the peripheral pulmonic arteries, together with 
tortuosity of the abdominal aorta. Hyperlax:ity of the joints, 
especially of the wrists and fingers, was present. She also pre-
sented with dysmorphlc features, including a large forehead, 
downslanting palpebral fissures, blepharophimosis, hyperte-
lorism (with outer and inner canthal distances at the 97th 
percentile), flat suprao.Qrbital margins, a short and beaked 
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Family 2 
10 •,t 
F1:1mily 3 
Fip;. 1. Pedigre<lH of the thr<X> eon:=1guineou~ urtcrin.J. tortu0>1ity t<yndromc (ATSJ fumilie!l originating from the =e I'<'gion in the north of Morocco. A 
common unC!'><tor wruo not found, but lli likely. In family 3, thcro mtl &..-.:patient>! with ATS, nnd fiVl' pnti<:mtl< with nn udditiono.l di'>Cu..-<e with mcntnl 
l'<'tnrdution. Three puticnttl aY-3, TV-4, N-G) hnv<' both di..eruocH. (). ATS: n uddltionnl di!;cU>~e; $,Down eyndromc. 
nose, a long philtrum, a high palate, pectus excavatum, and 
long fingers (Fig. 2A). Bilateral inguinal herniae were present. 
The skin was very soft, and she had atopic eczema. Height, 
weight. and OFC were normal. Psychomotor development was 
also normal. At the age of 3 yeru-s, heart catheterization 
revealed multiple stenoses of the peripheral pulmonary 
arteries, pulmonary hypertension, hypertrophy of the right 
ventricle, tortuosity of the abdominal aorta and the coronary 
urteries. At the age of 4, she developed Staphylococcus aurcus 
sepsis. leading to decompensation and death. The parents 
refused autopsy. 
Patient 2. This patient is the youngest child in this fa.m.ily 
(IV -3) .In view of the congenital abnormalities of her sister, she 
was evaluated by a pediatrician at the age of9 days.Apartfrom 
mild hypotonia no abnormalities were noted. Ultrasound 
evaluation of the heart and major arteries revealed tortuosity 
of the pulmonary arteries and the ascending and descending 
aorta. Clinical examination at the age of 18 months revealed 
dysmorphic features including periorbital fullness, down-
slanting palpebral fissures, a beaked nose, long fingers, and 
flat feet. Hyperln..'City of the joints, especially of the wrists and 
fingers, was present. The skin was hyperlax in the abdominal 
region and hands (Fig. 2B). Her psychomotor development was 
normal. 
Family3 
This consanguineous fa.m.ily originates from the same area in 
north Morocco as the first two families, although the three 
families could not be traced back to the same ancestors (Fig. l, 
fa.m.ily 3). The healthy parents are first cousins. ATS was 
diagnosed in six ofthe 11 children (IV-2 IV-3, IV-4, IV-5, IV-9, 
IV-10). The youngest child has Down syndrome and complete 
atrioventricular septal defect with double outlet right ventricle 
and pulmonary atresia. Five children of this sibship (IV-1, 
IV-3. IV -4, IV -5, IV -6) have mental retardation, which probably 
represents :mother unknown disease. Only the six sibs with 
ATS ure described here. 
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Patient I. This is the second child CIV~2) and one of a pair 
of fraternal twins. She weighed 2,800 g after an uneventful 
pregnancy and delivery. Long fingers and toes were noted at 
birth. She ww hospitalized at the age of 1 month because 
of suspected pyloric stenosis, which was corrected by pylor-
omyotomy. At that time hypotonia, nystagmus and mild 
psychomotor delay were noted. Stenosis of the peripheral 
pulmonary arteries was suspected. Echocardiography at the 
age of2 years showed an enlarged aortic root, tortuosity of the 
wcendingaorta. and an elongated, tortuous pulmonary artery. 
Physical examination at the age of 15 years showed a high-
arched palate, an elongated face with a long nose, a relatively 
short philtrum and chin, long fingers and toes, acrocyanosis, 
and cubitus valgus. There ww mild joint laxity of the elbows. 
MRI of the brain showed tortuosity of the large cerebral 
arteries without other brain abnormalities. She developed 
normally and attended a normal school. 
Patient 2. IV..S is the twin brother of IV-2. He weighed 
2,800 g at birth. Dysmorphic features observed in the first 
year of life included hypertelorism, convergent strabismus, 
micrognathia, high~arched palate, large ears, long fingers, 
hyperlaxity of the joints of the hands, adducted thumbs. 
acrocyanosis, and clubfeet. A Nissen fundoplication ww per-
A 
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formed because of abnormal rela..;:ation of the diaphragm at 
16 months. At the age of 2 years, hypotonia with paresis of 
the lower extremities and psychomotor retardation became 
evident. Echocardiography and angiography showed tortuous 
and dilated pulmonary arteries, an enlarged ascending aorta, 
and tortuosity of the descending aorta, subclavian, carotic, and 
renal arteries. Two bladder diverticulae were noticed. He dev-
eloped flexion contractures of the hips and spasticity of the legs 
and became wheelchair~bound later on. At the age of 15 years, 
MRI of the bruin showed tortuosity of the large cerebral 
arteries, diffuse atrophy of the cerebellar hemispheres and 
supratentorial ventriculomegaly with severe white matter 
loss (Fig. 3A). Chromosome analysis showed n. normal male 
karyotype. Acetylcholinesterase receptor antibodies were ab-
sent. He hw severe mental retardation and is unable to sit 
unsupported or walk. 
Patient 3. The fourth child in this family (IV-4), ww 
born with a weight of 4,010 g after an uneventful pregnancy of 
42 weeks. Asphyxia and cyanosis were noted at birth. Apgar 
scores were 3 and 4 at 1 and 5 min, respectively. Congenital 
anomalies were present. including cleft palate (soft and hard), 
micrognathia. hypertelorism, convergent strabismus, large 
ears, and acrocyanosis. Her skin WSf3redundant. At 13 months, 
81 
Fig. 2. Photoj:7nph~ of HOme of the ATS patient.>. A: Patient IV-2 from fmnily 2 ~how~ n lnr~ forehead, dowru;lantingpulpebrul fu<~ure<~.lx•ukcd nO><C, 
micrognathia, and ccr.cma at tho a~ ofS months. B: Pntiont IV-3 from fmnily 2 <~how:.< periorbital fullnc~~. lurgc forohend, and u bcukQd noso CBll. The 
ubdominul <~kin i:; hyperlwc: CB2l. C: Patient rv.g from fumily 3 at tho ugo of 15 montllli (Cl=d C2) =d 6 )'{lam (C3). Alurgo forehead, pc~riorly rotated earn 
=d ~kin lmcity i:; evident (C2l. D: Pationt IV-10 from fmnily 3 at the a~ of 5 yonr11. Notice tho lon;: fuco with micrognathia. 
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hypotonia and delayed early milestones were reported, Echo-
cardiography and angiography at the age of 2 years showed 
tortuosity and elongation of the pulmonary arteries, thoracic 
and abdominal aorta as well as the abdominal arteries. She 
had a large hiatal hernia. She was lost to follow up in the 
subsequent years, but she was evaluated again at the age of 
14 years. MRI of the brain showed microcephaly with slight 
enlargement of the occipital horns of the lateral ventricles, und 
white matter loss. Arterial tortuosity was observed, especially 
of the vertebral and basilar arteries, and of the middle cere· 
bral arteries (Fig. 3B). Other features included long fingers, 
adducted thumbs, and cyunosis. Chromosome unalysis showed 
a normal female karyotype. At the age of 17 years, she is 
severely mentally retarded, hypotonic, and unable to stand or 
walk. 
Patient 4. This child (IV·5) was born at 38 weeks with a 
weight of2, 700 gas twin A of a pair of fraternal twins. He was 
asphyxiated after birth. Apgar scores were 1 and 5 at 1 and 
5 min, respectively. Dysmorphic features including hyper. 
telorism, low set ears, adducted thumbs, long fingers, and 
clubfeet were noted. Severe hypotonia was present, whereas 
psychomotor delay became evident later. He had a hiatal 
hernia with feeding difficulties. A Nissen operation was per· 
formed attheageof3months. Thirteen months later he died at 
home. At autopsy bilateral bronchopneumonia was found. The 
large arteries showed severe tortuosity (Fig. 4). 
Patient 5. The ninth child (IV-9), was born after an un-
eventful pregnancy and delivery with a birth weight of 3,000 g. 
Hypotonia and hyperla.xity of skin and joints were present 
from birth on (Fig. 2,C2). Echocardiograpby and angiography 
showed tortuosity und elongation of the pulmonary artery, 
ascending and descending aorta, carotid and vertebral arter-
ies. Arterial aneurysms or stenoses were not found. CT scun of 
the brain showed tortuosity of the left vertebral artery. At the 
age of 5 years, she showed mild psychomotor delay with 
hypotonia, ptosis of the right eye, torticollis, and muscular 
atrophy. Dysmorphic features included frontal bossing, small 
nose, large posteriorly rotated ears, bilateral simian creases, 
joint hyper laxity, and pectus carinatum (Fig, 2C). 
Patient 6. She is the tenth child (IV-10) in this sibship of 
11. She was born after 42 weeks of gestation 'With a birth weight 
of 4,060 g. Dysmorphic features, including microretrognathia, 
large enrs, medial cleft palate, and clubfeet were noticed after 
birth (Fig. 2D). The joints and skin were hyper lax and pectus 
carinatum was present. She was hypotonic. Chromosome anal-
ysis showed a normal female karyotype, and FISH analysis 
showed no deletion of22q11. At age 5 years, she is developing 
normally and attending a normal school, 
Additional family members. In this Sl'bship of 11 there are six 
children 'With ATS (IV-2, IV-3, IV-4, IV-5, IV-9, and IV-10), 
4 'Without ATS (IV·6, IV-7, rv.s, IV-11), and one patient in 
which no studies of the arterial system were performed UV-1). 
At least five patients UV-1, IV-3, IV-4, IV-5, IV-6) have a 
separate disease with psychomotor retardation, microcephaly, 
and adducted thumbs. The youngest sib UV·ll) has Down 
syndrome due to trisomy 21. 
Arterial malformations 1145 
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ADDITIONAL STUDIES 
Electromyogram studies in several patients from family 
3 were normal, excluding myotonic dystrophy. Cytogenetic 
analysis performed in several patients from all three families 
were normal. Biochemic:ll. studies of collagen in cultured 
fibroblasts showed normal amounts of collagen, with norm:ll. 
ratio of collagen I to collagen ill, and a nornutl pattern on 
electrophoresis. Serum copper values in patient 2 from family 
3 were normal, excluding Menkes disease. Homocystinuria 
was e."<cluded in several patients from family 3 by the finding of 
normal homocysteine values in urine. 
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Fig-. 3. :MR.ung-iogruphy ofputient~ IV-3 (A) und IV-4 (Bl from fumily 3 oiliowingtortuo:;ityofthe ccrebrul urteri('K. 
DISCUSSION 
The three families reported here most likely have ATS in 
view of the typical clinical picture mainly characterized by 
extensive tortuosity with aneurysm and stenosis formation of 
A 
multiple major arteries. k ATS is a very rare disorder, we 
reviewed all cases reported in the literature (Table I), 
Approximately 35 patients from 21 families (including our 
cases) have been reported so far, The major arteries of all of 
these patients show a degree of tortuosity and lengthening, 
B 
Fig:. 4. An,c:iogrnphy of the pulmonary nrt('rie~ (A), und norta with large urtorio~ (B) ofpnti.cnt IV-G from family 31!howingtortuollity und lengthening. 
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which is much more severe than in other connective tissue 
disorders such as Menkes disease, Ehlers-Danlos syndrome, 
Marfan syndrome, and homocystinuria. Also aneurysms and 
stenoses mainly confined to the aorta and the pulmonary 
arteries are present in many ATS patients. Apart from arterial 
involvement, ATS is characterized by abnormalities of the skin 
including hyperextensibility and cutis laxa (without hemor-
rhagic diathesis or hypertrophic scar fonnation). Laxity of the 
joints and contractures are also present in many patients. 
Inguinal herniae and abnonnal relaxation of the diaphragm 
leading to the development of hiatal herniae necessitating a 
Nissen operation me also features of this connective tissue 
disorder. Additionally, a typical phenotype with an elongated 
face, micrognathia, high palate. arachnodactyly, and pectus 
anomalies are also frequent. The ventricular hypertrophy and 
hypertension reported in many ATS patients might be caused 
by the arterial involvement. 
The clinical picture in our family 3 is complex: six (possibly 
seven) of the 11 sibs have ATS, one patient has Down syndrome 
related to the advanced maternal age (42 years), and five sibs 
have a neurologic disease with severe psychomotor retarda· 
tion. The latter is most likely caused by another unknown 
disease with autosomal recessive inheritance because severe 
psychomotor retardation is infrequent in ATS, and there is 
no cosegregation of ATS and psychomotor retardation in our 
family: three patients have ATS but no psychomotor retarda-
tion CIV-2, IV-9, IV-10), and one patient has retardation but no 
ATS (IV-6). Furthennore, psychomotor retardation is only 
present in family 3 but not in family 1 and 2, although the three 
families most likely share a common mutation in the putative 
ATS gene (Fig. 1). Severe psychomotor retardation without 
ATS is also present in four sibs from a consanguineous sibship 
that has a common ancestor with family 3. Acrocyanosis was 
evident in the six ATS patients from family 3, but not in the 
other sibs without ATS. 
Consequently, it might be a feature of ATS, although it has 
only been recorded once in the ATS literature [Pletcher et aL, 
19961. Cleft palate was present in the ATS patient from family 
1. and in three patients from family 3 of whom two have ATS. 
This might suggest that it belongs to the ATS spectrum. 
However, cleft palate was also present in a patient without ATS 
in family 3, and it has only once been documented in the ATS 
Arterial malformations ]147 
literature [Ades et al., 1996]. Consequently, it is uncertain that 
cleft palate is a feature of ATS. High-arched palate, to the 
contrary, more likely belongs to the ATS spectrum as it was 
observed in four of our ATS cases, and in many ATS patients 
reported in the literature [Ertugrul, 1967; Lees et al, 1969; 
Pletcher et al, 1996; Franceschini et al., 20001. 
The clinical severity of ATS is very variable: although the 
disease is fatal before the age of 5 years in 41% of cases, some 
patients have very limited symptoms. The diagnosis might not 
only been missed, but may be misdiagnosed as Ehlers-Danlos 
syndrome or cutis laxa. 
ATS is an autosomal re~ssive disorder with consanguinity 
in more than half of the parents of the 35 patients. In view 
of the presence of arteriopathy, joint abnonnalities, herniae, 
and skin hyperextensibility, ATS can be considered a con-
nective tissue disorder. This is consistent with the finding 
of histologic abnormalities of the elastin network [Ertugrul, 
1967; Lees et al., 1969: Beuren et al., 1969; Wagstaff et al., 
1970: Welch et al., 1971: Ades et al., 1996: Pletcher et al., 1996: 
Franceschini et al., 2000; Rivera et al, 2000] .Jill mnjor arteries 
are of the elastic type and contain a large amount of elastic 
tissue that is necessary for stretching during systole and recoil 
on blood during diastole. Practically the whole tunica media 
of these vessels consists of elastic tissue circumferentially 
organized in concentric elastic membranes composed of elastic 
fibers. In most ATS cases histologic studies of the larger 
arteries show fragmentation of the elastic membranes, but 
biochemical studies have not revealed any abnonnality [Ades 
et al, 1996; Pletcher et al., 1996: Franceschini et al., 2000), 
Although it is very likely that ATS is due to a defect of the 
elastin network, the disease gene(s) and defective protein(s) 
are still unknown. Human disease with impaired eln.stogenesis 
can reffillt from many defects along this pathway (Table ill). 
The identification of the ATS gene by functional genetics has 
been precluded by the absence of a biochemical defect, whereas 
the positional cloning was hampered by the absence of suitable 
families amenable to linkage analysis. However, the inbred 
multiplex families described here offered the possibility to 
identify the ATS gene by positional genetics, Recently, the 
disease gene responsible for ATS in our families and an addi-
tional Italian inbred family [Gardella et al., 20041 was mapped 
to 20q13 [Coucke et al., 20031. 
TABLE III. Dioorders of the Elastin Network 
Gene mutation 
Fibrillin 1 
Fibrillin 2 
Elastin 
Lysyl hydroxylase 
Unknown 
ATP7A 
~-Gnlnctosidnse 
oo:-Iduroniduse 
Unknown 
Fibulin 5 
Unknown 
Unknown 
Unknown 
Unknown 
Unknown 
Protein deficiency 
Fibrillin 1 
Fibrillin 2 
Elastin 
Lyey-l hydroxylase 
Lysyl oxidase 
Lysyl o:xido...qc 
Elastine-binding protein 
Elastine-binding protein 
El.ustine-binding protein 
Fibulin 5 
Unknown 
Unknown 
Gnknown 
Unknown 
Unknown 
Disease 
Murfun syndrome 
Congenital contrncturnl n.ro.chnodactyly 
Supravalvular aortic :otenosi:o 
Williums syndrome 
Cutis lnxa 
Intracranial aneurysm (?) 
Ehlers-Danlos type 6 
Ehlers-Danlos type 5 
Menkes diseuse 
Occipital horn di.'lCase 
X-linked cutis l= 
GMI gnngliosidosis 
Morquio syndrome 
Hurler syndrome 
Costello syndrome 
Cutis la:ro type 1 
Cutis lu.'W. type 2 
Wrinkly skin syndrome 
Gerodermia osteodysplusticu 
De Bun."')' syndrome 
ATS 
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Homozygosity mapping of a gene for arterial tortuosity 
syndrome to chromosome 20q 13 
P J Coucke, M W Wessels, P Van Acker, R Gardella, 5 Barlati, P J Willems, M Colombi, 
A De Paepe 
Background: Arterial tortuosity syndrome (ATS} is on 
uncommon connective tissue disorder of unknown_ oetiology. 
The most prominent feature is tortuosity of the Iorge arteries, 
but lengthening, stenosis, and aneurysm formation are also 
frequent, 
Methods: We performed o genomewide screen- by homo· 
zygosity mopping of three consanguineous, multiplex 
families, two from Morocco, and one from lfcly, whieh 
included 11 ATS patients. The 1wo families from Morocco 
moy possibly hove a common ancestor. 
Results:: We mopped the ATS gene to chromosome 20q 13. 
Recombinotions within on extended haplotype of_ 11 micro· 
satellite markers localised the ATS gene between markers 
0205836 and 0205109, on interval of9.5 eM.. 
Conclusions: Cloning and compleling functional-and struc-
tural analysis of the ATS gene moy provide new insights into 
the molecular mechanisms of elostogenesis. 
Arterial tortuosity syndrome (ATS; MIM 203 050) is a rare connective tissue disorder characterised by generalised tortuosity, elongation, stenosis, .:md .:mcur-
ysms of the major arteries.,_, Skin <lnd joint abnormalities, 
including hypcrcxtensibility or hypcrla..xi.ty of the skin, joint 
la..·dty or contr<lctures, .:md inguinal hemiJ.s, reminiscent of 
other connective tissue diseases, can also be observed, Other 
phenotypic J.bnormalities include micrognJ.thiu, elongated 
fJ.ce, high palate, beaked nose, sliding herni.:t, .:md venoicul<lr 
hypertrophy. Histopathological studies show abnormalities of 
the e!J.stin network in the large J.rteries.>·• 7 
The mode of inheritance of ATS is autosomal recessive, but 
the discJ.Se gene has not yet been identified. Recently, the 
elastin gene and some collagen genes involved in connective 
tissue disease were excluded as c.:mdidate genes in ATS.'" 
Until now, a very limited number of ATS pJ.tients have been 
described, .:md few multiplex families have been published. 
However, some inbred multiplex families originating from 
Morocco'' .:md Italy'" have recently been reported. Such 
families make it possible to localise the ATS gene by 
positional genetics. This study reports the localisation of the 
ATS gene by homozygosity mapping in two, and probJ.bly 
three, inbred families. 
PATIENTS AND METHODS 
Families 
The three families, which included 11 ATS patients, 
originated from Morocco and Italy. All three families arc 
inbred and the parents of all patients arc cons.:mguineous 
(fig l), The two Moroccan families (family 1 with six affected 
individuals (N-2, N-3, N-4, N-5, IV-9, .:md N-10) and 
family 2 with one affected individual (V-3)) might have a 
J Med Genet 2003;40:7 47-751 
common ancestor as they originate from the same town in 
north Morocco. The clinical picture in these patients consists 
of tortuosity of the aorta, .:md pulmonary, subdavi.:m, and 
renal anerics, as shown by echocardiography, angiography, 
and/or CT scan (t<tble 1 }. Additional clinical features present 
in some of these patients were hypcrlax skin and joints, and/ 
or dilation, .:meurysms, .:md stenosis of the pulmonary 
arteries .:md ascending J.orta. All these clinical manifestzttions 
fit the spectrum of ATS, J.S reviewed by Wesscls.v The 
phenotype of one individual (N-1) in the Morocc.:m family l 
(fig 1) is unde<lr because no studies of the major arteries 
could be performed. The Italian family, originJ.ting from 
south Sicily, has four affected individuals (IV-1, N-2, N-4, 
N-5). All patients show tortuosity of the major arteries, and 
two p<ltients (IV-4 and N-5) also show severe pulmonJ.ry 
artery stenosis. Y<lriable cutaneous, joint, and f<tcial mani-
festations were observed in all patients (table 1). 
Occasiomlly, gastric and inguinal hernias, intestine elonga-
tion. and keratoconus were present. 
The pJ.rents and brother of the ATS patients were clinically 
normal. The clinicJ.l features of the different patients of all 
three families arc described in det<til elsewhere.'' '0 
Venous blood was taken for genetic studies from <lil ll 
affected individuals, their parents, and healthy siblings. 
Informed consent was obtJ.ined in e<lch instance from the 
subject and/or a legal gu.:rrdi.m. 
DNA analysis and pooling strategy 
Genomic DNA was extracted from peripheral blood leuko-
cytes by a standard technique. 
A genome se.:uch was performed in family 1. To increase 
the speed of the tot<tl genome screen, the DNA sJ.mples of the 
six affected individuals of this Morocc.:m family were pooled. 
As it is criticill th<lt the pool contains equal quantities of D~A 
from each individual, D:-JA qu.:mtification was measured by 
ultraviolet light spectroscopy, followed by quantification on 
lo/o ag.:uose gels with a lambda quantification standard. Each 
individual sample was diluted to 50 ng/)Jl stock solution to 
avoid viscous solutions. Finally, a control PCR was performed 
on each sample to make sure that they all yielded the same 
amount of amplified product. Equimolar amounts of each 
s<lmple were then combined, .:md the sample pool was 
assessed empirically by comparing alleles for several poly-
morphisms between pooled and individual samples ( datJ. not 
shown). 
Homozygosity mapping 
A set of 400 highly polymorphic micros<ltellitc markers (ABI 
PRISM™ Linkage Mapping Set Version 2; Applied 
Biosystems, Foster City, CA., USA} with an average spacing 
Abbreviations: ATS, arterial tortuosity syndrome; EDS, Ehlers·Donlos 
syndrome 
www.imedgenct.com 
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Figure 1 Pedigrees oF the three consanguineous families. Pedigrees 1, 2, onQ 3 represent the Moroccan family 1, Moroccan family 2, and the Italian 
family respectively. Affected individuals ore denoted by dosed symbols, unaltacted family members by open symbols, and individuals with unknown 
phenotype by open symbols with a question mark. Hoplotypes for the chromosome 20 markers ore shown below eoch family member for whom DNA 
was avoilobfe. lhe soi1d portion of the bars 'Indicates the" hoplotypes linked to the gene for ATS. 
of 10 ccntimorg:ans (o\1) was analysed on a capillary 
sequencer (ABBIOO; Applied Biosystems). A pooled DNA 
sample, containing cquimol.:rr amounts of six affected 
individuals of family l, was analysed. The data wcrc 
processed using Genescan .:md Gencrnapper software 
(Applied Biosystems). After the finding of suggestive lod 
www.imedgenet.com 
scores in family l, the Dr--'A of all individuals of the three 
f.:tmilics w.:ts further analysed with microsatellitc markers 
from the Gen<:!thon genetic map. Markers were investigated 
on m ABBlOO capillary sequencer, md alleles were 
numbered <:~ccording to length, with the shortest allele being 
assigned number 1. Haplotypes were constructed, assuming 
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Table 1 Clinical features of fue ATS poh"ents 
Artorlol Qnomalie$ 
"'""'" """' Fornily lndividuol ... Torhlcl$ily Arlericll stenosis Skin Hcmio;~ Joint laxily dodyly dcfol'mlly Other findi!IS$ 
Podigroc: IV-2 18y • HES 1 IV-3 18y • • Soh IV-4 17y • Redundont 
IV-5 17m • W-9 9y • Cu~~ loxo IV-10 8y • Cutis loxo Podigroc: V-3 2m • HES 
' 
Podigreo !V-1 
3 
2\y • Soh 
!V-2 16y • Soh 
IV-4 2\y • + 
""'" W-5 19y + • Loxily 
HES, hyporoxtonsibilily of the skin; m, month~; y, }'(IQ!'$. 
the minim.:~! number of recombin.:~tions, by tracing segreg.:~~ 
tion of .:~llelcs in the families using the published marker 
order (fig I). 
MLI~K was used to e.:tlculate t'No-point lod scores between 
the ATS locus .:~nd the m<:~rkers. The analysis w<:~s performed 
under the .:~ssumption of <:~utosomal recessive inheritance of 
the phenotype Vlfith complete penetrance. Individual IV:l of 
pedigree l was considered to h<:~ve an unknown phenotype in 
the linkage .Jnalysis. The influence on the lod score is 
therefore 0, but the inclusion of this sample was helpful in 
the reconstruction of the haplotypes. Equal.:~llelc frequencies 
were used in the linkage calcul.:~tions. Although the use of 
incorrect .:tllele frequencies may lead to false positive evidence 
of linkage under certain conditions, the power to detect true 
linkage remained unaffected, The frequency of the ATS was 
set at 0.0000 l. UNKMAP was used to perform multipoint 
linkage analysis using the marker order: centromere 
-D20SS36-l.9 cM-D20SS91-7.6 c.'v1-D20SI09-tclomere. 
Mutation screening of the beta GlcNAc beta 1, 4-
galactosyltransferase 5 Gene (B4GALT5) 
PCR products for each of the nine exons of the B4GALT5 gene 
were obtained for an affected individual of e.:~ch of the three 
families (familyL IV~9; family2, V~3; f.:~mily3, N-4). 
Mutation screening was performed by direct sequencing of 
the PCR products using dye terminator chemistry (Applied 
Biosystems). 
RESULTS 
Genomewide scan 
To map the ATS gene, a genomcwide scan was performed by 
homozygosity mapping using pooled DNA from s.ix affected 
individuals of family 1 (fig 1). Homozygosity mapping of 
autosomal recessive conditions in inbred families is b.:~sed 
upon the fact that affected subjects vvill be homozygous for 
polymorphic markers in and <:~round the disease locus due to 
inbreeding. In our genome scan, 400 polymorphic micro-
satellite m.:~rkers, equally spread over the genome, were 
.:~nalysed. In the pool of six patients from family 1 this yielded 
10 different markers with a single allele ll.:~nked at both sides 
by a m<trker with. at most, two different .:tlldes. 
Subsequently, these 10 markers were typed for CJ.ch 
individual member from family l. This revealed a two-point 
lod score of 4.11 at a = 0 for m;:~.rker D20S 178 loc.Jted in 
-
+ 
• 
+ 
• • l.ong foee, high polotc 
• • long foeo, high polotc 
• Long foeo, mkr¢gnothio, 
doft poloto 
• 
• • Micrognothio, high poloto 
+ + Mlerognothio, deft polote 
• • + Mi<:rognothio, deft polote, blophorophimo$is, ortcriol 
oneurysm 
+ Soft nosol cortilogo, 
mierognothio, 
hypothyroidism 
• Soft nmol cortilogc, 
tnierognothio, korotoconus, 
hypothyroidhm 
• Soft nosol cortilogc, 
micrognothio 
+ Soft Mt.Cll cortilogo, 
mierognothio 
chromosome 20ql3, whereas the other nine markers revealed 
lod scores lower th.:tn 1.5. Further analysis of the chromo· 
some 20ql3 region was performed in all three ATS families 
using additional m<:~rkers (fig 2) originating from the 
Ceo 
3.1 
t 0205119 
D20S836 
1.9 
D20S891 
20q12 
20ql3.1 
5.3 
20q13.2 
D20S176, D20S866 
20ql3.3 2.3 
0.9 
D20S109 
D20S869, D20S 196 
2.4 
0205893 
2.1 
D20S840 
44
1 + D2D51DO 
Tel 
Figure 2 linkage map of tho morkers used in the analysis. The genetic 
distances between tho marker!. wore deducod from tho Genethon linkage 
map'•, ond ore indicated in eM. The candidate region for ATS syndrome 
is indicated in bold. 
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Table 2 Two-point lod scores for markers at 20q 13 
w~ .. 
MoM 
-
'"' 1 
Pod 2 Pod3 Z....... combin.d 
0205119 0.06 2.29 0.59 1.16 4.04 
020$836 0.06 2.46 0.59 1.14 4,19 
D20S891 0.00 4.11 075 3.13 7.99 
D20S176 0.00 2.17 0.75 2.19 S.ll 
0205866 0.00 2.18 0.68 us 4.04 
0205109 0.04 3.80 0.50 0.00 4.30 
020$869 0.03 237 0~7 ,,. 440 
0205196 0.04 201 0.65 0.33 299 
0205893 OJ3 0.81 0.36 0.20 1.37 
02058.40 0.14 0.79 -o.09 0.69 1.39 
0205100 0.28 0.]9 0.17 ...0.02 0.3A 
Pod, pcdi9rcc. 
G~nCthon genetic map. This yielded a combined ma..ximum 
lod score of 7.99 at e = 0 for D20SS91 (table 2}. 
Lod scores calculated for the three f.nnilies separately 
yielded a ma.:cimum of 4.11, 0.75, and 3.13 at 8 = 0 for marker 
D20SS9I for the Moroccan family I, the Moroccan family 2 
(the two possibly related f.:unilics), <md the Italian family, 
respectively (table 2). This suggests that the ATS gene in both 
the large Moroccan family 1 and the ItJ.lian family maps to 
this region on chromosome 20ql3. The positive lod scores in 
the Moroccan f.:unily 2 with a single ATS patient is also 
compatible with linkage to the silille region. 
Normal haplotypes, as identified in carrier parents, were 
different from those segregating with the disease. The 
unaffected subjects were heterozygous or homozygous for 
the normal haplotypes. The individual with the unknown 
phenotype (individual N-1 in Moroccan family 1) was 
homozygous for the disease haplotype, and might be affected. 
Multipoint linkage calculations between the ATS locus and 
markers D20S836, D20SS9L and D20Sl09 revealed a max-
imum lod score of 7.99 at marker D20SS9I (fig 3 ). 
Haplotypcs were constructed, revealing key recombinants 
between marker D20SS36 and the ATS gene at the proximal 
side (Moroccan family I and Italian f.:unily), and between 
marker D20SI09 and the ATS gene at the telomere side 
lOr 
'I 
·-§ 4 
] 
'I 0 ['0 
-2 
-10 10 20 
Genetic distance (eM) 
Figure 3 Multipoint linkage analysis between ATS and three 
chromosome 20q markers. Curves indicate the likelihood that the ATS 
locus is at the map location with respect to the adjacent markers shown 
below tho horizontal axis. The relative genetic position of 0205836 was 
arbitrar'1fy Paced at zero. 
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(Italian family) of the chromosome (fig I). These recombina-
tional events localise the gene for ATS between D20SS36 and 
D20SI09 in a genetic interval of9.5 eM on the GCnCthon map 
(fig 2). On the draft sequence of the human genome in the 
::-Jational Center for Biotechnology Information (NCBI) 
database, this linkage interval corresponds to a physical 
candidate region of approximately 4.1 Mb. 
Condidote gene study in region of interest 
A computer search in the human genome resources of NCBI, 
ENSEMBL. and UCSC revealed over 30 positional candidate 
genes within the linkage interval between markers D20S836 
and D20Sl09 on chromosome 20q. One of these, B4GALT5 
(EC 2.4.1.22), encodes for beta 4 galactosyl transferase, one 
of the galactosyl transferases involved in the bios}Tithesis of 
glycosaminoglyc.:ms.'' This group of enzymes catalyses the 
transfer of galactose to galactose beta-L 4-N-acetylglucosa-
mine, during the formation of different glycoconjugates and 
saccharide structures. Mutations in another member of the 
gal<tctosyl transfer<tse gene family, B4GALT7 (EC 2.4.1.133), 
have been identified in patients with a progcroid variant of 
Ehlcrs-Danlos S}Tidrome (EDS).iZ-1" As progeroid EDS disease 
shares some of the features of ATS, the B4GALT5 gene was 
considered a good candidate gene for ATS. Direct sequencing 
of the nine exons of B4GALT5 from an affected individual of 
each of the three ATS families showed no sequence 
alt<..-rations in the coding region. A substitution in intron 3 
(IV$3-16 C-T) was identified in the two Moroccan families, 
and segregated completely with ATS in both. However, this 
mutation is an unconunon polymorphism in the Moroccan 
population (frequency of the T allele is 0.07). Other positional 
candidate genes arc PRKCBPL NCOAJ, PRE)(, ARFGEF2, 
GSElL, STAU, ARPC3B, DDX27, KCNBl, and PTGIS, among 
others. However, none of these genes is an obvious functional 
candidate for ATS. 
DISCUSSION 
In this study we describe the mapping of the gene for arterial 
tortuosity syndrome (ATS) to a small region on chromosome 
20ql3. Initially, a genomcwide scan was performed on a DNA 
Silillple pooled from six affected individuals from a large 
eonsangu.ineous Morocc<tn fa.mily. A single region on the long 
arm of chromosome 20 was shared by all patients, The 
homozygosity mapping w<ts confirmed by linkage analysis in 
three consanguineous ATS kindreds with a total of 11 
patients. Multipoint linkage analysis yielded maximum lod 
scores of 7.99 at marker D20SS91 on chromosome 20ql3. 
Analysis of key rccombinational events indicated a linkage 
region of 9.5 eM on the Gt:--nCthon genetic map (fig 2), which 
represents 4.1 Mb on to the physical map of chromosome 
20ql3. 
As only three ATS families were investigated, we cannot 
exclude genetic heterogeneity. However, as ATS is <t rare 
disorder, but two and possibly three families are linked to the 
same locus, it could be speculated that there is only a single 
ATS locus. 
Based on the different databases, the candidate region for 
ATS contains over 30 predicted genes. Although the 
theoretical search for pl.:tusible functional candidate genes 
for ATS is highly speculative, genes (or homologues of 
structural genes) involved in the c.xtr<tcellular matrix are 
possible c.:mdid.:ttes, particularly those involved in the 
elastogencsis pathway. All major arteries contain a large 
amount of elastic fibres consisting of elastin, which together 
with the fibrlllins and microfibril associated proteins arc 
responsible for elasticity." Mut<ttions in FBNl (Marfan's 
S}TidrOme), FBN2 (Beal's S}Tidrome), elastin (Williilills' 
S}Tidrome), fibulin 5 (cutis Jaxa type I) and ABCC6 (PXE) 
all give rise to abnormalities in the elastic network. However, 
Arterial malformations 1153 
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these disease genes arc not located in the linkage interval of 
ATS on chromosome 20q. 
B4GALT5, a functional candidate gene for ATS located in 
the co.ndidate interval was excluded by mutation analysis in 
the p.:~tients. None of the remaining positional candidate 
genes has an obvious relationship 'Nith the extracellular 
matrix or the elastogenesis p.:~.thway. The mouse syntenic 
region of human chromosome 20q13 is located on chromo-
some 2q; however, no extra obvious co.ndid.:~.tc genes for ATS 
have been localised to this region. 
In conclusion, we h.:~ve identified .:1 locus for ATS on 
chromosome 20q13, which is on imponant step in the 
identification of the ATS gene. Cloning o.nd completing 
functional and structural o.nalysis of the ATS gene may 
provide new insights into the molecular mechanisms of 
elastogenesis. 
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Mutations in the facilitative glucose transporter GLUTlO 
alter angiogenesis and cause arterial tortuosity syndrome 
~ 
] Paul J Coucke1, Andy Willaertl, Marja W Wessels2, Bert Callewaert1, Nicoletta Zoppi3, Julie De Backer\ 
~ Joyce E Fox4, Grazia M S Mancini2, Marios KambourisS, Rita Gardella3, Fabio Facchetti6, Patrick J Willems7, 
::o Ramses Forsyth8, Harry C Dietz9, Sergio Barlati3, Marina Colombi3, Bart Loeys1 & Anne De Paepe1 
~ Arte<;al tortu.,;ty >yodwmo (ATS) ;, oo aut.,omal ""'""';" 
1i d;wde< <har.>cte<;,.d by tortu.,;ty, oloogotioo, '"""';' aod 
:E aneurysm formation in the major arteries owing to disruption 
a. of elastic fibers in the medial l<tyer of the arterial wall1• 
E Previously, we used homozygosity mapping to map a candidate 
0 locus in a 4.1-Mb region on chromosome 20q13.1 (ref. 2). 
g' Here, we narrowed the candidate region to 1.2 Mb containing 
:C seven genes. Mutations in one of these genes, SLC2A10, 
~ encoding the facilitative glucose transporter GlUT1 0, were 
~ identified in six ATS fumilies. GLUT1 0 deficiency is associated 
2: with upregulation of the TGF~ pathway in the arterial wall, a 
3 finding also observed in loeys-Oietz syndrome, in which aortic 
~ aneurysms associate with arterial tortuositY\ The identification 
We report that loss-of-function mutations in a third member of the 
SLC2A family. SLC2AIO, cause arterial tortuosity syndrome (ATS: 
~ ::;~~::~i~i:~~~:~~~i~':F:~~~::i~~:;y~u~:!~ 
® link between GlUTlO and type 2 diabeteso~-,s. 01.1r data 
could provide new insight on the mechanisms causing 
:'re microangiopathic ch~ges associated. with di:met~ and ~~-~est that therapeutic compounds mtervenmg w•th ~{;f~ signaling represent a new treatment strategy. 
OMIM 208050). an autosomal recessive condition1 ch=cteri:t.ed by 
tortuosity of the Llrge o.nd medium-sized .meries (Fig. la), often 
resulting in death at young age. Other typical features include 
aneurysms of large arteries and stenosis of the pulmonary artery, in 
association with f-acial features (Fig. I b) and severn! connective tissue 
manife:.'tations. Hi~'topathological findings include fTagmentation of 
the clastic fibers in the tunica medi.l of the large arteries (Fig. lc) lO-u. 
Previously, homozygosity mapping in 21 members of two consangui-
neous families with ATS originating from Morocco (family 1) and 
Italy (family 4: Fig. Id) assigned the gene to chromosome 20ql3.1 
{ref. 2). Subsequently. this locali7..ation was confirmed in four smaller 
fumilics originating from Morocco (families 2 and 3) and the Middle 
&~1: (fumily 5 o.nd 6). Key recombinants delineated a candidate linkage 
interval of 4.1 Mb between markers D20S836 o.nd D20S109. We 
performed further fine mapping in three families (families l-3} 
originating from the same region in Morocco, under the assumption 
that one recessive ance:.'tral mutation might have cau.scd ATS in these 
families. Families 1 and 2, but not fumily 3, shared haplotype:; between 
markers D20S888 and ).I.SATll (Fig. le}, a region of 1.2Mb contain· 
ing seven genes (SLC13A3, TP53RK, SLC2AIO, EW, PRKCBPI, 
NCOA3. SULF2) o.nd one pseudogene (RPLJSAP). We sequenced 
these genes directly and identified homozygous mutations (dd~-tion, 
no=n>e. missense) in the SLC2AIO gene in ill six families (Fig. 2a.,b). 
In fumilics I and 2, we found a homozygou:; no=n.>e mutation 
SlOG-+ A (Wl70X) in all clinically affected individuaL-;. All affected 
individuals in furnilies 3 and 4 were homozygous for framcshift 
mutations 96ldclG (V32lfsX39l) and 1334dc!G (G445fuX4S4), 
re:;pectivdy. Both mutations result in a premature stop codon. The 
affected individuaL~ from families 5 and 6 shared the same homo-
zygou:; misscn.'iC mutation, 243C-G (S81R). Both families had a 
common haplotype between markers ).I.SATl o.nd ).I.SAT7, indicating a 
Facilitative glucose tramportcrs (GLUTs), encoded by a fumily of 
SCL2A genes, are responsible for the uptake of several monosacchar-
ides, including glucose. fructose, m;umose, galactose and glucosamine. 
So fur, mutations in tv.·o of these genes have been linked to genetic 
disorders with intuitive relevance to altered glucose metabolism. 
Heterozygous mutations in SLC2Al cau:;e a defect of glucose tro.nsport 
into the brain. resulting in on epileptic encephalopathy with low 
spinal-fluid glucose lcvcls6• Homozygous mutations in SLC2A2 have 
been shown to cause Fanconi-Bickcl ~yndrome, characterized by 
hepatorenal glycogen accumulation, nephropathy and diarrhe;i, 
whereas heterozygous mutations in this gene result in non-insulin 
dependent diabetes mellitus~.9. 
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!!! Figure 1 CliniCJI ;;~nomaiies in ATS <:~nd pedigrees. (a) MR angiogr.Jphy showing typical ortcrlal tortuosity of the cerebral arteries in ;m individual with 
::1 ATS (IV:4 in family 1) in comparison with a healthy aged-matched control. (b) Typical facial phenotype with micrognathia, elongated face, down-slanting 
~ palpebral fissures, blopharophlmosis and a beaked nose (individual IV:4 in family 1). (c) Org:.mlzatlon of clnstic fibers in a control and In <:~n individual w·~h 
(l:) ATS, as shown by orcein staining. AorUl clastic laminae in the media of an individuJI with ATS arc coarser, less abundant and more disorganized thJn in 
g control JOrt<l. M<lgnlfication: 400x. (d) Pedigree structure of the six ATS families. Symbols: circle, female: square, male; open symt.>ol, unaffected; filled 
('I symt.>ol, affected; slash line, deceased; double relationship line, consanguinity. Asterisks indicote that DNA, fibroblasts or Doth arc available. (e) Ideogram 
@ of chromosome 20 showing the Initial linkage Interval, the final candidate region and haplotyp(ls for chromosome 20ql3.1 markers In the candidate region 
in families 1-3. 
~founder mutation in these fumilies (dut:l not shown). We assume that 
the btter mutation causes dise<t.o;e on the basis of the following 
arguments: (i) SerSI is evolutionarily strictly conserved in GLL'TIO 
(Fig. 2b); (ii) an uncharged amino acid is changed to a positively 
charged amino acid in the third tran.mJ.cmbr.me domain and (iii) the 
mut:ltion was absent in 200 control chromosomes. All parents of 
affected individu:ili (in fumilies I--6) were heterozygous for the 
re;pective mutations. 
The presence of homozygous loss-of-function mutations in at le<1st 
four ATS fumilies identifies SLC2AJO as the gene re:;pons.ible for ATS. 
The gene contains five exons and encodes GLl.7fiO, a 541-residue 
glucose tran~;porter1 4-- 16• Human GLL'TlO has been shown to fucilitatc 
o-glucose, o-galactose and 2-deoxy-o-glucose transport when 
expressed in Xenopus !.aevis oocytes4. GLUTIO is an outlier within 
the GLUT family because of its longer e.xofacialloop and differences 
in motif characteristics for glucose tr.msporters. sugg~'ting that 
GLUTlO may hnve addition:ll functions, different from other GLUT 
family mcmbers4.5. 
Tissue expression :malysis has uncovered a widespread distribution 
of SLC2A10 mR."JA, mainly in liver, pancreas and adipose tissue4.5•17• 
We studied mR.~A and protein expression of GLUTIO in cultured 
skin fibrobla:,is and vascul.:tt smooth muscle celL~ (VSMC~) from 
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individu:ili offected with ATS and from controls. Quantitative PCR 
(Q-PCR) of sample!; deriwd from individtuils with ATS homozygous 
for premature stop codon mut:ltions demom.trated J. near-absence of 
SLC2A10 mRNA in VSMCs a_~ well as in fibroblasts (Fig. 2.;), a_~ 
expected by virtue of clearance of mutant tr.mscripts by the nonsense-
mediated mRNA decay (:t\'MD) pathway. We observed norrn:ll 
SLC2AJO mR.~A expression in samples derived from an individu:ll 
with ATS homozygous for the 243C-.G missense mutation. We 
observed (peri)nuclear localization of GLUTIO in norm:.U individuab, 
but there was no detectable GLUTlO signal in individuals with ATS, 
as shown by immunofluorescence analysis of cultured skin fibro-
blasts and VSMCo; (Fig. 2d). An addition:ll argument to suggest 
a nuclear localization of GLL'TIO is the low dissociation constant 
(Km ::= 03 mM), which is compatible with the glucose concentrntion 
in the cytoplasm4. 
The SLC2AJO gene has previously been considered a_~ a candidate 
gene for diabetes bec.:tusc of its function in glucose transport and its 
m:~.p position, which coincides with a type 2 diabetes locus~.5. 
However, a cau..<>al role for SLC2Al0 in diabetes has not been dcmon-
strated1~·19. Theoreticilly, homozygous mut:ltions in SLC2AJO could 
lead to ATS. whereas heterozygous mutations could le<1d to diabetes. 
an:llogous to the situation where homozygou.o; mutations in SLC2A2 
a 
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••••• 2 Figure 2 SLC2A10 (GLUTIO) mutJtion and expression dat.:l. {a) $LC2A10 muttttions. identified in families 1-6. (b) Location of GLUTlO muttttions at a ~ :;chematlc rcprc<...cntrltion of the GLUTlO protein. GLUTIO contains 12 hydrophobic tr.:msmembrane domains (ovals) wit~ a hydrophilic endof;;~cial loop 
z between tr..msmembrane domains 6 and 7 anc! a large exofacialloop cont.:Jining a potentl<:~l N·llnkcd glycosylation site between transmembr.me domains 
<.0 9 and 10. E:volutional)' conservation of the substituted ami nc acid observed in families 5 and 6 in GLUTIO is shewn. (c,d) SLC2A10 (GLUTlO) expression & in the control nnd in individu.:~ls with ATS. (c) mRNA expression of SLC2A10 as determined by Q-PCR in VSMCs and skin fibroblasts. In VSMCs in 
@) individuals with ATS, the level of mRNA was severely reduced. In skin fibroblasts, the individual carl)'lng 3 homozygous nonsense mutation nlso shewed 
a signitlcant reduction (P < 0.05) compared wit~ the control, tllrt the individual homozygous for J missense mutation did not show any reduction. Bnrs 
Indicate the 95% confidence interv.:~l of the mCJn expression lcvcl. (d) Immunofluorescence nnalysis of GLUTlO in VSMCs and skin fibroblasts. Expression 
~ol GLUTlO was nearly absent in VSMCs and fibroblasts lrom lndividuJis with ATS, JS compared with the control, The fluorescence signal in heterozygous 
~ndivldUJis was approxim:rtely halt th~t of the controls. MngnifiC<ltion: l.OOOx. 
!e:ld to F:mconi-Bickcl syndrome7 md hetcrorygou.s mutntioru; to 
dillbctes8. However, this hypothesis is unlikely, given that we did not 
observe :m incrcnscd frequency of dmbetes in the heterozygotes from 
the ATS fumilics. 
There is substantial phenotypic overbp bctwccn ATS :md a newly 
identified genetic condition called Locys-Dictz syndrome (LOS: 
OML.\1 609192) tha.t associates arterial tortuosity with aneurysm 
formntion3• Other findings in common between the two condition..~ 
include arnchnodactyly, joint Laxity or contractions, microretro-
gnathio., hypertclorism, cleft pilitc and/or bifid uvuh (Table 1). 
LOS is caused by heterozygous loss--of-function mutntion..~ in the 
genes encoding the type 1 or type 2 TGF~ re<:eptors (TGFBRI or 
TGFBR2). 'I'lm le:1ds to a parndo:cical increase in TGF~ signaling 
in the Jrteri:ll w:ill, a.~ evidenced by increased phosphorybrion 
<:~nd nuclear trarulOClrion ofSmnd2 (pSmnd2), n down~tr= effector 
of the TGF~ signaling p.:~thway, :md increased expression of down-
~tr= targets of TGF~ such as connective tissue growth fuctor 
(CTGF} and collagen~3 . Because of the clinical overlnp with LDS.. 
we investigated whether the TGF~ pnthway is involved in the 
pathogenesis of ATS. 
Im.munosto.ining for pSmad2 and CTGF (Fig. 3a) in the arterial 
w:ill of nn individwl with ATS demoru.tr.J.ted incren.~cd sign;ll intensity 
compared with control specimens, similar to the increase observed in 
individuals with LDS3. In ngreement with the in vivo observations, Q-
PCR measurements showed n significantly higher stcndy-sute mRKA 
expression kvcl for CTGF (Fig. 3b) in cultured VSMCs of the 
individual with ATS compnred with controls {P < 0.05), indica.tive 
of uprcguhtion of TGF~ signaling. 
The m~-chanisms by which muurions in SLC2AJO !e:J.d to TGF~ 
nctivation nre uncle.u'. Noubly, the expression of decorin, a protcogly-
c:m inhibitor of TGF~ signalini0, is regubted by a defined glucose 
re.-ponse clement in its gene promoter21. Therefore, we ~'tudicd the 
expression of dccorin in cultured VSMCs of individu<lls with LDS. 
individunls with ATS and controls (Fig. 4). Decorin expression w.1s 
severely reduced in cultured VSMCs of individuals with ATS us com-
pared with controls, us shown by immunofluorescence suining 
(Fig. 4:t.). Q-PCR experiments using VS:!V!Cs confirmed the reduced 
expression of dccorin mR.'lA in individuals with ATS {Fig. 4b). The 
~J>Ccifi.C decrease of decorin expression in individuals with ATS, in 
contr.l.St to individuals with LDS, might indicate divergent mechanisms 
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Table l Clinical comparison of individuals with ATS and individuals 
with LOS 
Symptoms 
Arterial anomalies 
TortUOSity 
Aneurysms 
Stenosis a. pulmonnl;s 
Aneurysm n. pulmonalls 
Ske:ctol anomalies 
Contr~cturcs 
Pectus deformity 
Joint lw:lty 
Ar<.~chnodactyly 
Facial anom;;rlics 
Hypcrtclorlsm 
ATS LDS 
-
-
.. 
~ for upregubtion of TGF~ signnling in these two conditions. t->.'otably, 
~ we did not observe :my differences in <'.'--pression between fibroblasts of 
:C individu<lls with ATS and those of healthy controls (data not shown). 
J:. Given the (peri)nuclear JOQlization of GLUTlO, a decrease in intr.J.-
~ cellular glucose and fu.ilure of glucose-mediated tr:mscriptional upre-
.;:l gulation of the decorin promoter seems to be unique to AT$. In 
;i: contr.J.st, primary alteration.~ in the TGF~ receptors lead to inO'e<.l.....OO 
~ TGF~ signaling in LDS. In order to determine the specificity of 
re the decorin response, we monitored the r::xpres,..;;lon of versican, a 
9 
Figure 3 lmmunost~ining and Q-PCR analysis for phosphorylated Smad2 
and CTGF in nrterlal tissue. (a) Three controls and individual 5.1V:5 with 
ATS were exomincd. Note the incrwscd intensity of nucleJr phosphorylntcd 
Sm<.~d2 ;;nd cxtracelluiJr CTGF. Scalo bars, 10 .,m. (b) Expression levels of 
CTGF In VSMCs oi affected individual IV:l oi inmily 4 and two controls Jr. 
stcndy-statc conditions, as mcnsurcd by Q-PCR. CTGF shows fourfold higher 
expression in the individual with ATS. Bars lndiCJtc the 95% confidence 
interval of the me.Jn expression leV{!I. 
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Figure 4 Immunofluorescence Jnd Q-PCR analysis of decorin and ~crslcan 
in VSMC. (a) In indl~iduai4.1V:l with ATS, expression of decor;n is nearly 
absent, as compared with control VSMCs. Magr.iiication: l,OOOx. 
(b,c) Q-PCR analysis lor (b) dccorin Jnd (c) versiCJr. in VSMCs of an 
Individual with ATS compared with Jn individual with LDS and two controls. 
The expression oi decorin mRNA in the Individual with ATS Is significantly 
lower (P < 0.05} than in the LDS patient and the controls, whereas 
the expression of versican Is significantly ~igher (P < 0.05) in the 
lndivldunl with ATS and the Individual with LDS compared with controls. 
B<Jrs indicate tho 95% confidence interval of the me<~n expression level. 
protcoglycm that is known not to be strongly regulated by glucose but 
whoso cx-pression is driven by TGF~22• As predicted from our 
pathogenetic model, samples from patient_~ w-ith either ATS or LDS 
showed incr=cd expression of versican (Fig. 4<). An inhibitory role 
of versican on elastic fiber assembly has been proposedn, perhaps 
providing a mechanism for fuiled elastogoncsis in both ATS and LDS . 
Although TGF~ signaling is disturbed in cells and connective tissue 
derived from individual!; with AT$, other mechanisms leading to 
abnormal m:atrh: deposition cannot be excluded. Impaired uptake or 
tran~-port of other monosaccluridcs could hinder glyco~ybtion events 
important for the production of mature glycoprotein;; and protcogly-
cans. essential structural components of the arterial wall :md con-
nective tissue in gcner<ll. 
We were surprised to identiJY a glucose transporter gene responsible 
for a connective tissue disorder. 1\'o other connective tissue disorder, 
with the exception of pseudoxanthoma clasticurn (cuused by a muta-
tion in ABCC6), is known to be caused by a transporter protein 
dcfc<f!"1. No dear function of tho ABCC6 tran..~-porter ho.s been identi-
fied, and the underlying pat..i.ogenic mechanism leading to d.b"turbed 
elastin homeostasL~ in PXE L~ unknown. Insights derived from the study 
of ATS may prove relevant to other di-;ordcrs related to fuiled intr.J.-
ccllul:u- tran..~port of glucose. Indeed, the microangiopathic changes und 
£brosis seen in diabetic retinopathy, nephropathy and peripher.U 
va.-=lar di~se correlate with incrCJ....OO TGF~ sign:ilini5• Diabetes-
associated arteriolar tortuosity is seen in tissues undergoing po~"tnatal 
angiogenesis, including the retinal :md coronary microcirculatio!l---. 
perhaps rr::ca.pitulating events occurring on a broader scale during 
=bryogcnesis in ATS. These data suggest that untagoMm of TGF~ 
signaling may contribute to therapeutic advances in a wide v.uicty of 
genetically determined :md acquired di.<.erden;, including AT$. 
METHODS 
Pntients. Approprilltl' informed con,cnt, including specific com.ent to publish 
thl' photo> in Figure lb. WOI.' obtained from :ill pntirnt' involved in the study. 
Dct:llled diniccl description• of five ATS familie&. except for family 6, hJVC been 
4$5 
. 
pt!bli...h<:d previo<.~sly1 • 12.:'0. DNA was o:tmcted from pcriphcrnl blood and/or 
cultur~d 'kin fibroblast>. Skin fibrobl<~st> were cultured ln Dulbccco\ modified 
Eagle\ medium (DME..\1) 'tlpplemented with 15% fetal bovine ><:rum (FBS) in 
the pr=ncc of annbiotia<. Va_'<CU);JJ" smooth muscle cdls (VSMCI) were 
obtained from the ~ortk medi.l from individual N:l with AT$ in family 4 
and from :rn individt.k!l with LDS (TGFBRl mutation, R487P)J and were 
cultured ln >mooth muxle b:NJ medium supplemented 5% FBS, 0.2% 
fibmbln.'t growth fuctor (FGF), 0.1% insulin, 0.1% cpldermal growth fuctor 
(EGF), and 0.1% gentunicin 'ulfute/amphotericin. Pur.Ufin-cmbedded aortic 
ti.\sue wa,, available only from individual IV:S ln family 5. 
£ MlaoMUellitc and sequence analysio;. Miao)o..ctdlite markers in the ATS ~ linkage region on chromosome 20ql3.! (rc£ 2) were taken from the Marshfield 
~ map or designed based on the Wnple t=dem repeat finder in the University of 
.a CalitOmi~ S.mta Cruz genome brow:;cr (j.ISATl-11). We carried out gcnotyping 
_§ on an Applied BiO>)"tem~ Prism 3100 Genetic Anal)'7.er (Applied Biosystems). 
1: 111e dam were prore..o;cd u>ing Gcru:sCilll wftware {Applied Bio,ystems). 
8 We amplified all coding cxons from all >eVen gene:. in the ATS linkage i ~g;n ~~~~~:~~ZS~~"~C:ta~~~RK~!~1: ·~~~~ ~~~s~ 
.::: exon.' (Supplementary Table l online). Sequencing'""'-' performed using the ~ BigDye v3.1 ET termil1<ltor cycle MX!Uencing kit (Applied Bio')"~>lerm;). 
~ Sequencing reactions were l0:1ded onto an Applied Bio>!"'tems Pri>m 3100 
a. Genctic Analyt.er. 
~ 
c. Immunosuining. For GLL'TlO ill!d decorin analysis in VSMC~ and skin 2 fibroblru.~ by immunofluorescence microscopy, we grew 1 x 11? VSMC' or 
(!; 'kin fibroblast-. from controL> and from individuals with ATS for 71 h in 
01 complete medium. To rumlp.e GLU'TlO, the celli. were washed in PBS. 
~ pCTITJe<~bili:t.cd. in 0.5% Triton X-100 und 3% parnform.aldchydc for 2 min. 
!! fixed for 20 min in 3% p=formaldehyde, incubated tOr 30 min at room 
~ ;~:;:~" ~!:~~~~~~:C::%r~;~~nc:~~~cd n::;:~;tT~ ·~: 
~ decorin level5, the cells wew fixed in 3% paraform.aldchyde for 10 min, wa:<hed 
:J twice for 5 min in PBS and incubated for ·10 min at room temperature (21 ''C) ~ with 20 J.LS ml-: monoclonal ant:tbody to decorin (done 115402, R&D 
~ System>). Next, the VSMC' ill!d fibroblast' were inrubated for 1 11 at room 
g temperature (21 '"C) with rhod;J.min<XOnjugated anti-rabbit lgG (!:SO in l% 
@ BSNPBS) und anti-mou.-.: lgG (1:100 in 1% BSA!PBS), ro-pectivdy; 
w...<;hed in PBS; mounted in 1:1 PBS-!;iycerol solution on sin.'-' ~!ides and 
photogrnph~d with a Zei.'>.< Axiovert lOSIH fluor=ncc microscope. Q=ti-
~-t.ltivc evaluation of the fluorescence w-1.~ performed "-' previously report<:<~l7. 
~or GLUT!O, quantitative C\".lluation ""-' repeated on 20 randomly ,elected 
cells for eaci1 cell 'train. Image' were digitb.ed to measure the cell and th~ 
nude.U" ~rc-.1s unci the integrated opti<.:al den.,itr (100) corresponding to the 
fluore.eence signals. 
For immunohistochemi<.:al >t1ining for CTGF and pSmad2 in arterial ti:,,ue, 
we ~ected represcnwtive specim~'I1S of formalin-5xed, paraffin-embedded 
arterial media of three healthr control lndividual, and one individual with 
ATS. From these 'pecimens, 5-).Ul'l thick paruffin section.~ were cut, dcp=ffi-
nized and rehrdro~ted. The.-.: ti>sues wew prctreated with a protease-! enzr-
matic 'o!ution (Ventuna). For immunoht~tochemical analysis, we u.-.:d 
ant:tbodie> directed. ai;Uin.<t pSmad2 and CTGF (Alpha Diag;no>tic, Ccll Signal-
ing Technology and Abc;Jm, =-pcctivdy) and previou.,ly decnbed methods3• 
Light microscopy""'-~ pctfonned on an Olympu.' BX45 micro.cope. 
Q-PCR. Rl'\A ""'-' L..ol:tted u.'ing the R.'Jen.''Y Mini Kit (Qia[:cn) • .md cDl\A """ 
>)'l'lthe>i7.cd. u:;ing SuperScript ll Revcn<e Tran.=ipta.-.e Kit with random 
h=er primer> (Invitrogen) in a total volume of 20 j.Ll. TWo microlit~"" of 
eDNA (l:lO dilution) and 250 nM gene-specific primers were u.-.ed with the 
Q-PCR Core Kit for SYBR Green l (Eurogentec) !Or Q-PCR on a GencAmp 
5700 Sequence Detector (Applied Bim;ystems). The Q-PCR program consbted 
of 40 cycle.< with 15 sat 95 'C :md l min at 60 'C, followed by a &-<.'<Ociation 
nm to determine melting curves. We carried out all reactions in duplicate and 
nor:nafu:ed them to the geometric mean of three reference genes {GAPDH. 
HPKfl and YWHAZJ. We used fibroblast~ from controls and individuab with 
ATS and VSMC<, obt1ined from aortic media from two control,, from 
456 
Arterial mJiformations ]159 
individual IV:l with ATS (from li1milr 4) and from un individual with LDSJ. 
W~ grew cells in 6-cm dishes to 80% confluence. E:..-pw.>ion b·eL, were 
determined in three independent cxpcrimen~ for each cell line. Differential 
gene cxpreM>ion ""'-'considered significant when the difference wm. at lca.'t SO% 
and the 95% confidence interval of the mean cxpres.>ion lc••eb did not overlap 
(equivalent toP< 0.05). 
Acccs:<ion codes. GenBmk; SLC2AIO eDNA, ~M_030m; SLC2AJO coding 
region, :-IT_011362. 
/1/crc; Suppktr1""Ul'Y information i.< r:nai/abk on tk ,>,'flturc Gcncrh:s website . 
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CHAPTERS 
Cardiomyopathies with congenital heart 
malformations 
5.1 Introduction 
The contractile unit of cardiovascular muscle is made up of different sarcomeric proteins (Figure 1). 
Hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM) and restrictive cardiomyopathy 
(RCM) can be caused by mutations in several sarcomeric protein genes, including the genes encoding 
alpha cardiac myosin heavy chain (MYH6), beta cardiac myosin heavy chain (MYH7), cardiac myosin-
binding protein C (MYBPC3), cardiac troponin T (TNNT2), cardiac troponin I (TNN/3), essential myosin 
light chain (MYL3), regulatory myosin light chain (MYL2), alpha tropomyosin (TPM1), and alpha cardiac 
actin (ACTO). Noncompaction cardiomyopathy (NCCM), also referred to as left ventricular noncom pac-
tion (LVNC), can be caused by mutations in some of the sarcomeric protein genes, including MYH7, 
ACTC1 and TNNT2 1-6. Recently, mutations in sarcomeric protein genes have also been implicated in 
congenital heart malformations (CHM), including septal defects, and Ebstein anomaly {For review: see 
Refl. 
5.1.1 Cardiomyopathies with heterotaxy 
Familial heterotaxy is an infrequent condition that has only been reported in a few families s-10• Muta-
tions in several genes, including LEFTY2 11,NODAL 1z.13,ACVR2B 14, CFC7 15•16,FOXH7 16, GDF7 17, TDGF1 16, 
CRELD1 18 and NKX2.5 19 have been identified in patients with heterotaxy, but overall only a minority of 
heterotaxy patients have demonstrable mutations 13•16• Monogenetic inheritance of heterotaxy with 
cardiomyopathy has not yet been reported in the literature, although some patients with situs inversus 
or heterotaxia also have hypertrophic or non compaction cardiomyopathy 2o-26• 
In this thesis a new family is described with autosomal dominant inheritance of noncompaction of the 
ventricular myocardium, CHM including pulmonary valve stenosis, atrial septal defect {ASD) and per-
sistent azygous continuation and heterotaxy consisting of left bronchial isomerism (or bilateral bilobar 
lungs), polysplenia and intestinal malrotation. Linkage analysis yielded suggestive lod scores for this 
new syndrome with DNA markers on chromosome 6p 27• In a few recent reports similar patients are 
described confirming that this association is a new recognizable syndrome 28,29• 
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5.1.2 Cardiomyopathyies with septal defects 
Several genes encoding transcription factors are implicated in the development ofnon-syndromic sep-
tal defects: ASD can be caused by mutations in TBX5 30, NKX2.5 31 , TBX20 32 and GATA4 33, whereas VSD 
can be caused by mutations in TBX5 30 and TBX20 32• The first link between sarcomeric proteins and CHM 
was provided by Ching et al. 34 who reported mutations in the MYH6 gene in patients with ASD with 
or without cardiomyopathy. Recently, several other authors have reported patients with septal defects 
due to mutation in sarcomeric protein genes, including MYBPC3 3s-37 (this thesis), MYHr (this thesis) and 
ACTC1 S.Js. 
Familial HCM mainly affects adults, and is usually caused by autosomal dominant mutations in genes 
encoding sarcomeric cardiac muscle proteins. Also young children with severe hypertrophic cardio-
myopathy have been reported, and 7 % of them have 2 mutations in one of the sarcomeric protein 
genes 39, which suggests that a gene-dosage effect might be responsible for manifestations of HCM at 
a younger age. Few neonatal cases with severe cardiomyopathy due to homozygous or compound het-
erozygous truncating mutations in MYBPC3 have been described previously. Several of these patients 
present with additional CHM, including septal defects and patent ductus arteriosus 35'37• 
In this thesis two unrelated neonates are described with a severe form of cardiomyopathy resembling 
left ventricular noncom paction associated with septal defects. Molecular studies showed that both pa-
tients were compound heterozygous for two common loss-of-function mutations in the sarcomeric 
protein gene MYBPC3 encoding cardiac myosin-binding protein C. This demonstrates that the MYBPC3 
gene is involved in left ventricular noncompaction, and also plays a role in septal development. In the 
family with NCCM, Ebstein anomaly, ASD and VSD, discussed in paragraph 5.1.3 and Chapter 5.5 a MYH7 
mutation was found. This confirms that different sarcomeric protein genes are involved in septation. 
5.1.3 Cardiomyopathyies with Ebstein anomaly 
Ebstein anomaly of the tricuspid valve is a rare anomaly, occurring in less than 1% of CHM 40.1t is char-
acterized by adherence of the septal and posterior leaflets of the tricuspid valve to the underlying 
myocardium, apical displacement of the tricuspid annulus, and dilatation of the atrialized portion of 
the right ventricle, whereas the attached chordae are usually thin and ill formed 41 • Ebstein anomaly is 
frequently associated with other forms of CHM: in 70-90% ASD is present 42-44, and occasionally pulmo-
nary or aortic valve stenosis or atresia, mitral valve abnormalities, transposition of the great arteries, 
or conduction system anomalies, including accessory conduction pathways (eg Wolff-Parkinson-White 
syndrome) occur 43-46. NCCM is present in almost 20% of patients 47•48• 
Although most cases of Ebstein anomaly occur sporadically, familial occurrence has been reported in 
approximately 20 families. As many of these families consist of only two affected patients the pattern 
of inheritance is not always clear, and only a few pedigrees with clear autosomal dominant inheritance 
has been described. In some of these families Ebstein anomaly is associated with NCCM 1,49-62• Only in 
a minority of cases the disease gene has been identified, with a few mutations in the NKX2.5 and TBXS 
genes being reported 63.64. 
In this thesis we report a clinical and molecular analysis of a Caribbean family with an autosomal 
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dominant form of Ebstein anomaly associated with septal defects and NCCM. Mutation analysis of the 
MYH7 gene revealed a novel missense mutation in the ATP-binding domain of the sarcomeric cardiac 
B-myosin heavy chain protein. Subsequently, in another of our NCCM families with a MYH1 mutation we 
found a hypertrabeculated left ventricle with mild Ebstein anomaly in a 12-year-old girl, and confirmed 
she also carried the familial MYH7 mutation 2• This corroborates the observation that sarcomeric protein 
genes are not only involved in different cardiomyopathies including NCCM, but also in the develop-
ment of congenital heart malformations. 
Figure 1 I Musde cell with the different proteins 
implicated in hypertrophic cardiomyopathies 
Components of the thick myosin filament including 
Myosin-binding protein C (MYBPG), Regulatory and 
Essential light chains (MYL2, MYL3), and Myosin heavy 
chain (MYH7), components of the thin actin filament 
including Actin (AGC), Tropomyosin 1 (TPMl), Troponin 
I (TNNI3), Troponin C (TNNCl), and Troponin T (TNNT2), 
mitochondrial transfer RNAs for glycine/isoleucine/ 
lysine (MTIG, MTII, and MTIK), caveolin 3 (CAV3), 
Noncatalytic AMP-activated protein kinase gamma 
2 (PRKAG2), lysosomal proteins including Alpha 
galactosidase (GlA), Lysosome-associated membrane 
protein 2 (lAMP2), and Transthyretin (TTR). From 
www.genedx.com www.genedx.com with permission. 
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Noncompaction of the ventricular myocardium 
is associated with de novo mutation in the beta-
myosin heavy chain gene 
Budde et a!. (2007) 
PLoS ONE 2: e1362 
Homozygosity for a novel splice site mutation in 
the cardiac myosin-binding protein C gene causes 
severe neonatal hypertrophic cardiomyopathy 
Xin et al. (2007) 
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Alpha-cardiac actin mutations produce atrial 
septal defects 
Matsson et a!. (2008) 
Hum Mol Genet 17: 256--265 
The contractile unit of cardiovascular muscle is 
made up of different sarcomeric proteins. Muta-
tions in nine of these genes are known to cause 
hypertrophic cardiomyopathy (HCM): this in-
cludes the genes encoding alpha cardiac myosin 
heavy chain (MYH6), beta cardiac myosin heavy 
chain (MYH7). cardiac myosin-binding protein C 
(MYBPC3), cardiac troponin T (TNNT2), cardiac 
troponin I (TNNJ3), essential myosin light chain 
(MYL3), regulatory myosin light chain (MYL2), 
alpha tropomyosin (TPMI), and alpha cardiac 
actin (ACTCI). After the identification in 1991 of 
HCM-causing mutations in the cardiac ~-myosin 
heavy chain gene (MYH7), more than 400 
different mutations in these nine genes have been 
associated with HCM (1). OveralL mutations in 
MYBPC3 and MYH7 are the most frequent (for 
review. see 2). Mutations in several of these 
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sarcomeric protein genes. including TNNT2, 
TNNI3, MYBPC3, MYH6, MYH7, ACTCI 
and TTN. can also lead to dilated cardiomyop-
athy (DCM). DCM is a very heterogeneous form 
of cardiomyopathy that can be caused by 
mutations in more than 20 different genes (for 
review, see 3). Additionally, non-compaction 
cardiomyopathy (NCCM) can be caused by 
mutations in some of the sarcomeric protein 
genes, including MYH7 and MYBPC3 (4-7). 
NCCM is characterized by left ventricular 
hypertrophy with deep trabeculations vvith or 
vvithout associated left ventricular dilation. This is 
believed to be due to an arrest of myocardial 
morphogenesis (for review, see 8). 
Recently, congenital cardiovascular malforma-
tions including atrial septal defect (ASD). ven-
tricular septal defect (VSD). Ebstein anomaly, 
patent ductus arteriosus (PDA) and aortic 
aneurysms have been reported in families vvith 
mutations in sarcomeric protein genes (5. 9~12) 
(Table 1). 
Septal defects 
Several genes encoding transcription factors are 
implicated in the development of non-syndromic 
septal defects: ASD can be caused by mutations 
in TBX5 (13)- NKX2.5 (14)- TBX20 (15) and 
GATA4 (16), whereas VSD can be caused by muta-
tions in TBX5 (13) and TBX20 (15). Mutations in 
some of these transcription factors can also lead 
to cardiomyopathies. NKX2.5 mutations can cause 
progressive cardiomyopathy (17), TBX20 muta-
tions are implicated in DCM (15), and expression 
ofGATA proteins regulates cardiomyocyte hyper-
trophy in several mice models (18. 19). although 
human GATA4 mutations are not known to 
cause cardiomyopathy (20). These transcription 
factors interact with each other and regulate 
expression of sarcomeric genes such as A CTC 1, 
MYH7 and MYH6 (19, 2L 22) (Fig. 1). The first 
link between sarcomeric proteins and congenital 
cardiovascular malformations was provided by 
Ching et al. (22). who reported mutations in 
MYH6 in patients with ASD with or without 
cardiomyopathy. Recently. several other authors 
have reported patients vvith a combination of 
cardiomyopathy and congenital cardiovascular 
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Fig. 1. The dual role of sarcomeric proteins in cardiovascular 
tissue. On the one hand. sarcomeric proteins determine the 
structure and contractile force cardiovascular tissue. 
whereas on the other hand, they have recently been implicated 
in congenital cardiovascular malformations of the heart and 
major arteries. As some of these sarcomeric protein genes 
arc downstream t:lrgcts of these transcription factors. it is 
possible that mutations in these transcription factors exert 
their effect through impairment of sarcomeric function. 
malformations caused by a mutation in a sarco-
meric protein gene (Table 1). Budde et al. (5) 
described a family with NCCM associated with 
congenital heart malformations caused by a 
mutation in MYH7. Three of 12 affected family 
members had NCCM with both ASD and 
Ebstein anomaly, and one family member had 
NCCM with ASD. Xin et al. (10) reported a large 
cohort of Old Amish children with severe lethal 
HCM caused by homozygous truncating muta-
tions in MYBPC3: several of these patients had a 
VSD. Compound heterozygosity for two trun-
cating mutations in MYBPC3 was also shown 
to lead to severe lethal NCCM with ASD or VSD 
in three unrelated newborns (7, 23). A fourth 
sarcomeric protein, :x-cardiac actin (ACTCJ), has 
been implicated in a family with isolated ASD/ 
VSD (24). a family with isolated ASD (1 0), and 
a family with ASDJVSD in combination with 
HCM/NCCM, respectively (ll). 
Ebstein anomaly 
Non-syndromic Ebstein anomaly is characterized 
by the downward displacement of the attachment 
of the septal and posterior leaflets of the tricuspid 
valve. A deletion of the transcription factor 
NKX2.5 because of a microdeletion of 5q35 has 
been found in a patient with syndromic Ebstein 
anomaly (25). No genes responsible for non-
syndromic Ebstein anomaly have been found yet, but 
transcription factor genes might be good candidate 
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genes as these are implicated in many different 
congenital heart malfonnations. Additionally, sar-
comeric protein genes are good candidates as 
a mutation in MYH7 was recently described in 
a family with Ebstein anomaly and NCCM (5). 
which is a frequent association (26, 27). 
Aortic aneurysm and PDA 
Aortic aneurysms can be caused by several genes 
of the transforming growth factor~ (TGF~) signal-
ing pathway, such as fibrillinl (FEN 1), trans-
forming growth factor ~ receptor 1 (TGF{JRI) 
and 2 (TGF[3R2) and the glucose transporter 
GLUTIO (SLC2Al0) (28). Mutations in these 
genes lead to upregulation of the TGF~ signaling 
pathway. Some patients with arterial tortuosity 
syndrome caused by SLC2AJO mutations also 
show cardiomyopathies (29). Interestingly, treat-
ment of cardiomyocytes with TGFBl leads to 
increased expression of sarcomeric proteins, such 
as beta cardiac myosin heavy chain (MYH7). 
resulting in cardiac hypertrophy (30). Also the 
sarcomeric protein genes MYHJJ and ACTA2 
are implicated in some forms of familial aortic 
aneurysms (Table 1). Mutations in the MYHll 
gene lead to thoracic aortic aneurysm andfor 
dissection (T AAD) associated with PDA (9). 
Recently, mutations in the smooth muscle o:-
actin gene ACT A2 were also shown to cause 
TAAD (12). Both the ACTA2 and MYHll genes 
encode sarcomeric proteins of smooth muscle 
cells (SM Cs) that are crucial in the structure and 
contractile force of the aorta. Not only patients 
with a MYHll mutation but also a minority of 
the patients with a ACTA2 mutation show PDA. 
As closure of the ductus arteriosus at birth 
requires SMC to contract, impaired contractile 
force of SMCs might lead to PDA. In a small 
proportion of patients with a ACTA2 mutation, 
bicuspid aortic valves are present (12). 
Conclusions 
It is well knovro that mutations in genes encoding 
sarcomeric proteins lead to different forms of 
ventricular cardiomyopathy, including HCM, 
DCM and ventricular non-compaction. Recently, 
several of these genes have also been implicated 
in the development of various congenital cardio-
vascular malformations such as septal defects. 
Ebstein anomaly, aortic aneurysm and PDA. 
Several models have been proposed to explain 
how dominant mutations in sarcomeric protein 
genes disturb sarcomere structure and function 
and lead to cardiomyopathies: (i) haploinsuffi-
18 
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ciency because of inactivation of one allele, (ii) 
dominant-negative effect of a mutant protein that 
interferes with normal protein function (protein 
suicide) and (iii) gain-of-function of the mutant 
protein that has acquired novel functions. It is 
unclear which of these three theoretical alter-
natives is correct, but most research supports the 
idea that incorporation of mutant protein with 
altered mechanical properties into the normal 
sarcomere is central in the pathogenesis (9). Also 
the effect of these mutations at the biomechanical 
level is still a matter of debate: some studies 
suggest a decrease in the motor function of the 
sarcomere and compensatory hypertrophic res-
ponse. whereas others suggest augmented myosin 
motor function resulting in hypertrophy. In any 
case. inefficient ATP utilization. increased energy 
consumption. and disrupted Ca2+ homeostasis 
seem to lead to myocyte disarray. apoptosis and 
premature death of myocytes resulting in cardio-
myopathies (31. 32). The aortic pathology caused 
by ACTA2 and MYHll mutations with disarray 
of SMCs, and focal SMC hyperplasia (9, 12, 33) 
is reminiscent of the myocyte disarray and hyper-
trophy in cardiomyopathies caused by mutations 
in sarcomeric protein genes. It remains unclear, 
however, how deficiencies in the sarcomeric pro-
tein network could lead to congenital cardiovas-
cular malformations such as septal defects and 
valve anomalies. 
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Abstract We report a three-generation family with nine 
patients affected by a combination of cardiac abnonnalities 
and left isomerism which. to our knowledge. has not been 
described before. The cardiac anom::tlies include non-com-
paction of the ventricular myocardium. bradycardia. pul-
monary valve stenosis. and secundum atrial septal defect 
The laterality sequence anomalies include left bronchial 
isomerism. azygous continuation of the inferior vena cava. 
polysplenia and intestinal malrotation. all compatible with 
left isomerism. This new syndrome is inherited in an auto-
somal dominant pattern. A genome-wide linkage analysis 
suggested linkage to chromosome 6p24.3-21.2 with a maxi-
mum LOD score of 2. 7 at marker D6S276. The linkage 
interval is located between markers D6S470 (telomeric 
side) and D6SI610 (centromeric side). and overlaps with 
the linkage interval in another family with heterotaxy 
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reported previously. Taken together, the genomic region 
could be reduced to 9.4 eM (12Mb) containing several 
functional candidate genes for this complex heterota."-Y 
phenotype. 
Introduction 
Ken-compaction of the ventricular myocard is a congenital 
cardiomyopathy. presenting with arrhythmias. heart failure 
or cardio-embolic events. It usually involves the apical, 
mid-btera.l and mid-inferior ventricular segments of the left 
ventricle. Non-compaction cardiomyopathy is a heteroge-
neous disorder that can be isolated, or associated with other 
anomalies. Isolated left ventricular non-compaction 
(LVNC) can be X-Iinked (Bleyl etal. 1997a. b) or auto-
somal dominant (Kurosaki et a.l. 1999: Sasse-Klaassen et al. 
2003). LYNC is frequently associated with neuromuscular 
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disorders and mitochondrial disorders (Stollbcrgcr and Fm-
stercr 2006). Mutations in the G4.5 gene (fafazzin) have 
been identified in patients with X-linked isolated LVNC 
(Chen et al. 2002: D'Adamo ct al. 1997: Xing et al. 2006). 
This gene ha.<> also been implicated in X-linkcd infantile 
cardiomyopathy, and X-linked endocardial fibroelastosis or 
Barth syndrome. L VNC may also be part of the phenotypic 
spectrum of the larninopathies due to a mutation in lamin 
A!C (Hermida-Prieto et al. 2004). Mutations in WB3 
(Cypher!ZASP) were described in a subset of patients with 
L VNC (Vatta ct al. 2003). 
Non-compaction of the ventricular myocardium has also 
been described in association with congenit::l.l heart malfor-
mations. including obstructive right- and left-ventricular 
anomalies. ventricular septal defect (VSD) and atrial septal 
defect (ASD) (Cavusoglu ct al. 2003: Dagdevircn et al. 
2002: Jchida et al. 2001: Sengupta eta!. 2001). In a Japa-
nese family with this typ:; of non-compaction cardiomyopathy 
a mutation in the rx-dystrobrevin gene (DTNA) has been 
identified (Ichida et al. 2001). 
Autosomal dominant heterotaxy is a very infrequent 
condition that has only been reported in a few families with 
variable expression and non-penetrance (Alonso et al. 
1995; Casey etal. 1996: Vitale etal. 2001). Mutations in 
several genes. including LEFTYA (Kosaki etal. 1999a). 
NODAL (Gebbia et al. 1997). ACVR2B (Kosaki et al. 
1999b). CFCJ (Bamford etal. 2000). CREWJ (Robinson 
eta!. 2003) and NKX2.5 (Watanabe et al. 2002) have been 
identified in a few patients with heterotaxy. 
In this report we describe a three-generation family with 
non-compaction of the ventricular myocardium. congenital 
heart malformations. and heterotaxy consisting of left 
isomerism with left bronchial isomerism. azygous continuation 
of the inferior vena cava.. polysplenia and intestinal 
malrotation. Linkage analysis yielded suggestive lod scores 
for this new syndrome with markers on chromosome 6p. 
Methods 
Genomic DNA was isolated from peripheral blood follow-
ing standard procedures (Miller et al. 1988). DNA (20 ng) 
was amplified in 7.5 p.L PCR reactions. using I x Gene-
Amp PCR Gold buffer. 1.5 mM MgC12• 10 pmol of each 
primer (forward primer labeled with FA.M. TET or HEX). 
250 !J.M dNTPs and 0.4 U of AmpliTaq Gold DNA poly-
merase (Applied Biosystems). PCR products were loaded 
on an ABI3100 automated sequencer. data were analyzed 
using the GencMapper v 2.0 software (Applied Biosys-
tems). 
A systematic genome scan with short tandem repeat 
polymorphisms (STRs) from the Cooperative Human Link-
age Center (CHLC) Human Screening Set/Weber version 6 
~Springer 
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was performed. Additional markers for fine mapping were 
obtained from the G61Cthon marker set (see ~Electronic­
database- section). 
There were only limited amounts of DNA from individu-
als in generation IV (Fig. 1) due to their young age. and 
from the decensed patient ill-4 only DNA from paraffin-
embedded tumor tissue was available. Therefore. for the 
initial genome scan we used DNA samples from patients TI-
l. ll-3. ll-5. III-I and ill-2. and from an unaffected individ-
ual IT-2. Chromosomal regions with positive LOD scores 
were further investigated by including DNA samples from 
additional affected family members IV -2. IV -3. IV -4. and 
ill-4. 
Two-point linkage analysis was performed using the 
:MLINK and LINKMAP programs of the LINKAGE pack-
age (version 5.1). Maximum LOD and location scores were 
calculated for each marker a.o;:suming the disease in this 
family to be an autosomal dominant disorder with pene-
trances varying from 50 to 99%. and with a gene frequency 
of l :10.000. No phenocopies were allowed and equal allele 
frequencies of the genotyped markers were u~ in the cal-
culations. Haplotypes were constructed based on the mini-
mal number of recombinations. 
Web resources: for genetic maps: http://www.ncbi.nib. 
gov; for marker information: http://gdbwww.gdb.org/. 
Results 
Patient reports 
The family is presented in Fig. 1 :and Table I. 
Patients IV-2. IV-3. IV-4 (triplets) 
The parents of a triplet pregnancy (Fig. 1) were referred to 
our Center for Prenatal Diagnosis after detection in another 
hospital of fetal bradycardia. The Caucasian couple was 
non-consanguineous and had a healthy 4-yea.r-old son (IV-
1). Oomiphene citrate treatment for ovu1a.tory dysfunction 
had resulted in this triplet pregnancy. Ultrasound examina-
tion at 20 weeks gestation showed tri*amniotic triplets with 
persistent bradycardia between 90 and 100 beats per minute 
in all three. Growth parameters were normal for gestational 
age in all three fetuses. 
The female fetus IV-2 was diagnosed with biventricular 
hypertrophy. an enlarged main pulmonary artery and severe 
pulmonary valve stenosis. Doppler flow examination 
revealed a severely reduced flow across the pulmonary 
valve. and tricuspid valve regurgitation of more than 2.5 m 
per second. Azygous continuation of the inferior vena cava 
was observed (Fig. 2). The second fetus (IV-3) also had 
bradycardia and moderate hypertrophy of both ventricles 
Hum Genet (2008) 122;595-603 
Fig. 1 Pedigree of the nine 
affected patients with autosomal 
domin::mt inheritance of non-
compaction/cardiomyopathy. 
left isomerism. and congenital 
henrt malfonmtions. Haplo-
typcs for the 6p markers arc giv-
en below the different family 
members. The disease-associ-
ated haplotype is indicated in 
bold; recombin::mts are present 
in individuals 11-2. 11-3. and III-
1. The haplotypes were con-
structed for I-l. I-2, 11-5 ::md his 
wife II 
III 
IV 
~~ ==-tt!ylnon.:o"'i>adJon 
(Jl Con~ltal !l8afl matrormatlon 
~Lottpulme>naryi\101Tl1111om 
~ ~~=':.:,alm:ygO<> ,_'" <U>d I or 
(Fig. 3). The third fetus (IV-4) showed bradycardia but no 
other abnormalities. Amniocentesis was offered to the par-
ents but declined. In the following weeks fetal heart rates 
were monitored and persistent bradycardia (90-1 00 beats 
per minute) was observed in the three fetuses. At 25 weeks 
gestation the pulmonary valve stenosis in fetus IV-2 had 
developed into functional pulmonary valve atresia with 
severe myocardial thickening of the right ventricle. At that 
time fetus IV-3 showed small bowel dilation suggestive of 
intestinal obstruction. The stomach was located in a normal 
position. The triplets were born vaginally at 34 weeks after 
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an induced delivery because of progressive CTG (cardioto-
cographic) abnormalities in fetus IV-3. Patient IV-2, a 
female, had Apgar scores of 8 and 9 after l and 5 min, 
respectively, and her birth weight was 1.870 g. Cardiac 
anomalies included sinus bradycardia. a small hypertrophic 
right ventricle. pulmonary valve atresia with intact 
ventricular septum. secundum ASD and azygous continuation. 
Prostaglandin infusion was given to maintain patency of the 
ductus arteriosus. Echography of the abdomen showed 
intestinal malrotation. Cardiac function and systemic circu-
lation became progressively insufficient and she died of 
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Table 1 Clinical feature~ of the Symptoms Patient.~ 
family members 
IV-2 IV-3 IV-I m-2 III-I Ill -I II-5 II-1 II-3 
~ oncompaction/cardiomyopathy + + + + + + + + 
Conduction ahnormaliJies 
Bradycardiu/sick sinus syndrome + + + + + + + + 
Bundle branch block + + + 
Congenital heart malformation 
ASD secundum + + + + 
Pulmonary valve stenosis + + + 
Situs abnormalities 
Bronchial left isomerism + + 
Azygous continuation of the vena cava inferior + + + 
Abdominal situs ambiguous 
Polysplenia 
FiJ:,. 2 Pren:u.nl ultrasound demonstrated uzygous continuation of the 
inferior vena cava in fetus IV-2 
cariliac failure 2 weeks after birth. Autopsy showed atrial 
situs solitus, concordant atrio-ventricular and ventriculo-
arterial connections with pulmonary valve atresia. intact 
atria1 and ventricular septa, a small dysplastic tricuspid 
valve, a small right ventricle with a hypertrophic wall and 
endocardia.! fibroelastosis. abnon:n:l.l trabeculations in the 
left ventricle and :mteroseptal hypertrophy. Additionally. 
bilateral bi-lobed lungs (bronchial left isomerism). a cen-
trally placed liver. intestinal malrotation and polysplenia 
were found. Microscopy of the cardiac conduction system 
revealed a normally placed sinus node with minimal fibro-
sis. The atrial transitional zone showed edema and fibrosis. 
The penetr.l.ting bundle was absent. as was the connection 
between the branching bundle and the right bundle branch. 
The second triplet. a boy (IV-3) was born with a weight 
of 1.305 g ( <P5). and Apgar scores of 7 and 8 after 1 and 
5 min. respectively. External examination showed glandu-
lar hypospadias. He also showed sinus bradycardia at 60-
70 beats per minute after birth. Echocardiography revealed 
t;l Springer 
+ + + 
+ + + + 
Fig. 3 Prenatul ultrJ$OUnd demonstrated biventricular hypertrophy in 
fetus IV-3 
mild hypertrophy of both ventricles and mild valve pulmo-
nary stenosis. Re-evaluation of the echocardiography 
showed increased tr.l.beculisation of the left ventricle. 
Echography of the abdomen revealed polysplenia. whereas 
a ciliated small bowel associated with jejunal atresia with 
intestinal malrotation and volvulus were found at explor-
atory laparotomy. Primary anastomosis was performed 
after partial bowel resection and repair of the intestinal mal-
rotation and midgut volvulus. 
His brother·s (IV-4) birth weight was 1.920 g. Sinus bra-
dycardia persisted after birth. and cchocardiogrn.phy 
showed increased tra.beculisation of the left ventricle. He 
was diagnosed with mild intestinal malrotation (caecum in 
the right upper abdomen). No polysplenia was found. 
Patient ///-2 
The father (III-2) of the triplets (Fig. 1) was known to have 
had bradycardia from the age of 11 years. Investigation at 
Hum Genet (2008) 122:595--603 
the age of 22 following an episode of palpitations identified 
sinus bradycardia. paroxysmal atrial fibrillation and left 
ventricular hypertrophy. He had been lost to cardiologic 
follow-up for a few years, until the birth of the triplets. Car-
diologic re-evaluation revealed sinus bradycardia. junc-
tional escape beats with episodes of atrial fibrillation, 
dilation of both atria, a small secundum ASD. and non-
compaction of the left and right ventricular myocard 
(Fig. 4). Echography of the abdomen showed a normal 
position of the stomach, liver. gallbl::uider and spleen. A 
chest X-ray showed absence of the fissura minor and bilat-
eral long hyparterial bronchi. consistent with left bronchial 
isomerism (Fig. 5). This was confirmed on aCT of the tho-
rax which also demonstrated a large azygous vein with an 
incomplete inferior vena cava. Clinical examination 
revealed no dysmorphic abnormalities. Chromos-ome analy-
sis revealed a normal male karyotype. and a 22q 11.2 dele-
tion was excluded by FISH. 
Patient 111-1 
The sister of patient III-2 (III-1) was diagnosed at the age of 
3 years with pulmonary valve stenosis, a large secundum 
ASD and interrupted inferior vena cava with azygous con-
tinuation. Valvulotomy and later pulmonary valve replace-
ment were performed. At the age of 15, sick sinus 
syndrome required pacemaker implantation. At 32 years 
the ECG demonstrated a complete left bundle branch block. 
Echocardiography revealed an enlarged left atrium and left 
ventricle with left ventricular non-compaction of the myo-
card. The right atrium and ventricle were enlarged. Poly-
splenia and malrotation of the gut was prescnL Bronchial 
situs was normal. 
Fi~ 4 Apical three-chamber 
view of the heart of patient III-2 
~howing prominent trabecula-
tion of the left ventricle on two-
dimensionul contr •.1.st echocurdi-
ography (B) 
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Fi~ 5 Linkage intervals in our family and the family described by Vi-
taleet al. (200!) The linkage region in our family is located in a29 Mb 
interval between D6S470 and D6SI610. The linkage intcrvul in the 
family reported by Vitale et a.L (200 I) is situated between D6S 105 and 
D6S 1960. The smullest region of overlap (SRO) between both region~ 
i~ a 12Mb interval between D6S!05 and D6Sl610 
Patient !!1-4 
A brother of the father of the triplets (III-4) was diagnosed 
at the age of 20 years with a grossly enlarged. hypokinetic 
heart with biventriculnr hypertrophy. sick sinus syndrome 
and atrial fibrillation. He died of a malignant anaplastic 
large-cell lymphoma at the age of 29. Autopsy was not per-
formed. 
Patient 11-5 
The grandfather of the triplets (II-5) had no medical history 
until he was hospitalized because of severe heart failure 
f:d Springer 
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after a pulmonary infection at the age of 59. He was diag-
nosed with cardiomyopathy. ECG showed atrial fibrillation 
with ventricular response of70 beats per minute and a com-
plete left bundle branch block. 
Echocardiography showed dilatation of both atria and a 
dilated and hypokinetic left ventricle. Both ventricles 
showed apical hypertrOphy with hypertrabcculation. A 
small secundum ASD was found. At the age of 62 he sud-
denly died. Autopsy confirmed the cardiac abnormalities 
and accessory spleens were found. The heart showed exces-
sively prominent trabeculations and deep intert:rabecular 
recesses of the left ventricle. consistent with non-compac-
tion of the left ventricular myocard. Microscopy of the con-
duction tissue revealed that the penetrating bundle was 
present. but there existed discontinuity between the A V 
node and the penetrating bundle. The right bundle branch 
was interrupted. 
Patient JJ-1 
A sister of the grandfather (Il-l) was asymptomatic. how-
ever cardiologic evaluation showed complete left bundle 
branch block on ECG. Echocardiography demonstrated a 
dilated. hypokinetic left ventricle with non-compaction of 
the myocard. Bronchial and abdominal situs were normaL 
Patient JJ-3 
The brother of the grandfather (II-3) was asymptomatic. 
Cardiologic evaluation revealed a sinus arrhythmia of 53 
beats per minute. Echocardiography was suggestive for 
non-compaction of the right ventricle. but not conclusive. 
No abnormalities of bronchial or abdominal situs could be 
identified. 
Additional family memhers 
Cardiologic examination. ECG. echography of the heart 
and abdomen. and a chest X-ray were performed in two 
additional asymptomatic sibs (ll-2 and II-4) of the grandfa-
ther. but no abnormalities could be detected. 
Link:lge analysis 
We performed a semi-automated systematic genome scan 
in this family. and obtained positive LOD scores for adja-
cent markers on chromosome 6 (D6S422 and D6S276) and 
chromosome 12 (DJ2S336. DJ2Sl617. Dl2S345, 
Dl2S326. Dl2S35J and DJ2S79). Further analysis of these 
regions by saturation with additional markers and the inclu-
sion of adclitional individuals (Fig. I) confirmed the 
findings for chromosome 6. but not for chromosome 12. 
Two-point linkage analysis yielded a maximum LOD score 
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of 2.70 at 0 = 0 for marker D6S276 (Table 2). Changing 
allele frequencies of the polymorphic markers and setting 
the penetrancc at 50% did not significantly alter LOD and 
location scores. To extract the full information from the 
genotypic data. haplotypes for 15 adjacent markers on chro-
mosome 6 were constructed by parsimony. and several 
recombinants that defined the limits of the cliscase suscepti-
bility region were detected. The recombination event in 
inclividual II-3 suggests that the linkage region is limited by 
marker D6SJ6JO on the centromeric side (Fig. 1). This 
individual is probably affected in view of his bradycarclia 
and echocardiography suggestive of non-compaction of the 
right ventricle. A recombinational event for marker 
D6SJ574 in patient ID-l (who is clearly affected) limits the 
critical region on the telomeric site. If we assume the dis-
ease to be fully penetrant. unaffected inclividual II-2 shows 
a recombination between D6S470 and D6S399 on the tela~ 
meric side. In that case the critical region is flanked by 
D6S470 (telomeric side) and D6Sl6JO (centromeric side). 
and spans approximately 35.5 eM (29Mb. National Center 
for Biotechnology Information. NCBI build 36.2) (Figs. 1. 5). 
Discussion 
The common finding in all nine affected members from this 
three-generation family (Fig.. 1) is non-compaction of the 
ventricular myocard (Fig. 4) with conduction abnormalities. 
In most affected individuals the cardiomyopathy involves 
both ventricles. 
Non-compaction cardiomyopathy is caused by an arrest 
in the normal development of the myocard. resulting in a 
thickened left ventricular wall with deep intcrtrabecular 
recesses. Characteristics on echocardiography have been 
Table 2 Two-point lod scores for markers on chromosome 6p 
Recombin!ltion frnction (0) 
Marker 0.00 0.01 0.05 0.10 0.20 0.30 0.40 
Telomeric 
06$1574 -5.00 -1.04 -0.00 0.37 0.55 0.46 0.25 
06S309 0.40 0.66 0.97 1.03 0.87 0.59 0.28 
065470 -0.86 -0.57 -0.16 0.02 0.11 0.09 0.03 
0151263 0.36 0.35 0.31 0.27 0.17 0.08 0.02 
D6S259 0.44 0.43 0.38 0.33 0.23 0.!5 0.07 
D6Sl567 0.68 0.66 0.59 0.50 0.32 0.17 0.05 
D6S422 1.10 !.07 0.96 0.81 0.53 0.27 0.07 
D6SJ05 1.03 1.01 0.93 0.83 0.63 0.43 0.22 
06S276 2.70 2.65 2.46 2.20 !.64 1.02 0.40 
06$291 0.58 0.56 0.49 0.40 0.25 0.12 0.03 
D6SI610 -4.76 -0.97 -0.38 -0.17 -0.01 0.04 0.02 
Centromeric 
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defined as non-compacted trabecular cndocard with deep 
endomyocardial spaces. 
Although non-compaction of the ventricular myocard is 
characterized by a hypertrophy of the left ventricle. the right 
ventricle might also be affected in some cases. Microscopic 
examination of the heart at autopsy in two deceased patients 
from our family (patients IV-2 and TI-5) revealed exces-
sively prominent tmbeculations with deep intertrabecular 
recesses, which is characteristic for non-compaction of the 
ventricular myocard. also referred to as spongy myocar-
dium (lchida et al. 2001: Kurosaki et al. 1999: Rigopoulos 
et al. 2002). The disorder was initially misdiagnosed as 
hypertrophic cardiomyopathy in our family. Eight of the 
nine patients in this family also had cardiac arrhythmia. in 
most cases sinus bradycardia. whereas both autopsy cases 
showed nodoventricular discontinuity and a right bundle 
branch block. Non-compaction of the ventricular myocard 
is often associated with conduction defects, most commonly 
bundle branch block and tachyarrhythmias (Ichida et al. 
2001: Kurosaki et al. 1999: Ritter et al. 1997). In our family. 
non-compaction of the ventricular myocardium was not iso-
lated as structural heart malformations were present in five 
of the nine patients. including secundum ASD and/or abnor-
malities of the right sided valve structures such as pulmo-
nary valve stenosis/atresia and tricuspid valve dysplasia. 
L VNC is a heterogeneous disorder. associated with neu-
romuscular and mitochondrial disorders and often has a 
genetic basis. Mutations in G4.5 (Tafaz;:in) (Chen et al. 
2002: D'Adamo etal. 1997: Xing eta!. 2006). DTNA 
(alpha-dystrobrevin) (Ichida etal. 2001). LDB3 (Cypher! 
ZASP) (Vatta et al. 2003) and Lamin A/C (Hermida-Prieto 
et al. 2004) have been described in a minority of patients. 
In the majority of L VNC cases the disease gene is 
unknown. An autosomal dominant pattem of inheritance is 
present in most cases (Sasse-Klaassen et al. 2003), and one 
form of autosomal dominant LVNC has been mapped to 
human chromosome llpl5 (Sasse-Klaassen et al. 2004), 
but the disease gene has not yet been identified. Non-com-
paction of the ventricular myocardium can also be caused 
by deletion of chromosome 5q encompassing the NKX2E 
gene (Pauli et al. 1999). and trabecular muscle overgrowth 
is found in some patients with a NKX2E mutation 
(Pashmforoush et al. 2004). Mice lacking Nk:x2e specifi-
cally in the ventricular chambers show extensive trabeculae 
and myocardial non-compaction (Pashmforoush et al. 
2004). Targeted inactivation of the murine Fkbpl2 (Shou 
et al. 1998). PBP (Crawford et al. 2002), Peg] gene (King 
et al. 2002). Jmj (Lee et al. 2000) TACE (Shi et al. 2003) 
and BmplO (Chen et al. 2004) genes lead to non-compaction 
of the ventricular myocard. 
Apart from non-compaction of the ventricular myocard. 
situs abnormalities are typical of our family. At least six of 
the nine patients had anomalies compatible with the left 
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isomerism spectrum. including left bronchial isomerism. 
azygous continuation of the inferior vena cava, polysplenia 
and intestinal malrotation. The association of non-compac-
tion with bronchial/abdominal situs abnormalities has not 
yet been reported in the literature. although some patients 
with situs in versus also have hypertrophic cardiomyopathy 
(Agirbasli et al. 2000) or subaortic hypertrophic stenosis 
(Befeler 1975: Cochran and Wanamaker 1975: Wells and 
Befeler 1975). The association of situs abnormalities with 
azygous continuation of the inferior vena cava. and sick 
sinus syndrome without left atrial isomerism is typical in 
this family, and has only been reported in a few Japanese 
patients (Fukuzawa et al, 1993: Kakura et al. 1998: Nogu-
chi et al, 1997). However, cardiomyopathy or noncompac-
tion of the ventricular myocard as present in our family, 
was not reported in these patients (although one patient 
had cardiomegaly) (Noguchi et al. 1997). As a mild pheno-
type with sinus bradycardia and abdominal ambiguous 
situs with mild or no other cardiac anomalies. is present in 
some family members (e.g .. patients IV-4 and TI-3) 
(Table 1), the phenotype of these Japanese patients and 
that of the family reported here could be due to allelic 
mutations. Recently. a patient with non-compaction of the 
left ventricle and dextroversion was reported (Friedman 
et al. 2007). and Friedberg et al. (2005) described seven 
fetuses with non-compaction of the ventricular myocard 
and heterotaxy. including left atrial appendage. heart block 
and various structural heart malformations. Overall. non-
compaction of the ventricular myocard is clinically and 
genetically heterogeneous. and a disease-causing mutation 
has been identified in only a small fraction of patients 
(Xing ct al. 2006). 
Only a few families with autosomal dominant laterality 
defects have been reported (Alonso et al. 1995: Casey et al. 
J 996: Vitale et al. 2001 ). and in these families congenital 
heart malformations in association with left-right axis 
malformations are present. In humans. a few genes have 
been associated with heterotaxy, with mutations found in a 
minority of patients. These genes include ZJC3 (Gebbia 
et al. 1997) LEFTYA (Kosaki et al. 1999a). NODAL 
(Gebbia etal. 1997) ACVR2B (Kosaki eta!. 1999b) and 
CFCJ (Bamford et al. 2000). Recently single cases with 
Nkx2.5 (Watanabe et al, 2002) and CRELDJ (Robinson 
et al. 2003) mutations were reported. Additionally, Vitale 
et al. (2001) found suggestive linkage (LOD scores of 
2.95) to chromosome 6p21 in a large five-generation fam-
ily with autosomal dominant inheritance of left-right axis 
malformations. This chromosomal 6p region was also the 
only region with suggestive linkage in our family. The 
candidate regions in these two families as defined by 
recombination events are overlapping (Fig. 5). The candi-
date interval in the family described by Vitale et al. (200 I) 
is located between D6SJ05 (telomeric boundary) and 
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D6SJ960 (centromeric boundary). whereas the candidate 
region in our family is located between D6S470 (telomeric 
boundary) and D6Sl6JO (centromeric boundary). As both 
families have autosomal dominant heterotaxy. a very infre-
quent dlsordcr, it is possible that both conditions are alle-
lic. although cardiomyopathy or non-compaction of the 
ventricular myocard. pulmonary stenosis, ASD and sinus 
bradycardia were not reported in the clinical description of 
the family of Vitale et :11. (200 1 ). 
If we assume that the ~e disease gene causes these 
two forms of hcterotaxy, this gene must be located between 
D6SJ05 (telomeric side) and D6SJ6JO (centromeric side) 
in a region of approximately 9.4 eM (12Mb) (Fig. 5). This 
interval contains a few interesting functional candidate 
genes. including the kinesin-like 2 gene (KNSL2). the axo-
nema.\ dynein heavy chain 6 (DNAH6), the axonem:.J 
dynein heavy chain 8 gene (DNAH8). and the tubulin beta 
gene (TUBB), These genes are good candidate genes as 
dyneins, tubulins and kinesins have been a.<:sociated with 
heterotaxy. The region also includes the NOTCH 4 gene. 
which plays a critical role in heart development. Notch sig-
n:lling may be required for endoco.rdi:ll cushion differentia-
tion and/or va..;;culo.r smooth muscle cell development 
(Annstrong and Bischoff :?:004; Noseda et al. :?:004). Notch 
signaling is. also required for normo.Jleft-right determina-
tion in mice (Pr.Gemeck eta.\. 2003). It is therefore possible 
that NOTCH4 is implicated in non-compaction and/or 
hetrotaxy. 
To our knowledge, the autosomal dominant complex of 
anomalies with non-compaction of the ventricular myocard. 
congenito..l heart mo..lformations and left isomerism has not 
been reported before, although different autosomo..l domi-
nant combinations of several features of this new syndrome 
have been described previously. The three-generation pedl-
gree with male-to-male transmission supports autosomo..l 
dominant inheritance of an unknown mutant gene affecting 
cardiac morphogenesis. 
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Abstract 
Aims Familial hypertrophic cardiomyopathy is usually caused by autosomal dominant mutations in 
genes encoding sarcomeric cardiac muscle proteins. The disease mainly affects adults, but young chil-
dren with severe hypertrophic cardiomyopathy have been reported. We describe here two unrelated 
neonates with a severe form of hypertrophic cardiomyopathy, and performed molecular studies to 
identify the genetic defect. 
Methods and Results Two unrelated ne-onates with lethal cardiomyopathy were studied at the clinical, 
pathological and molecular leveL Both patients were compound heterozygous for two common loss-
of-function mutations in the MYBPC3 gene. One of the patients also presented with a ventricular septal 
defect, whereas the other patient had an atrial septal defect. 
Conclusions Whereas heterozygous mutations in sarcomeric protein genes usually lead to hypertroph-
ic cardiomyopathy with clinical symptoms starting in child- or adulthood, homozygosity or compound 
heterozygosity for 2 truncating mutations in the MYBPC3 gene can cause severe neonatal cardiomy-
opathy with features of left ventricular noncompaction. Furthermore, mutations in sarcomeric protein 
genes seem also to be implicated in congenital heart malformations. 
Introduction 
Hypertrophic cardiomyopathy (HCM) is a major cause of sudden cardiac death in people younger than 
35 years of age under physical stress, and a major cause of mortality and morbidity in the elderly, with 
an estimated prevalence of 1 in 500 individuals according to echocardiographic criteria. In approxi-
mately 60% of cases a mutation in one of the sarcomeric contractile protein genes is found 1.2. 
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Familial HCM is usually transmitted as an autosomal dominant condition due to heterozygous gene 
mutations with incomplete penetrance. After the identification in 1990 of HCM-causing mutations in 
the cardiac ~-myosin heavy chain gene (MYH7) 3A, mutations in genes encoding proteins involved in 
the sarcomere, cytoskeleton and Z-disk, calcium handling, mitochondrial and lysosomal functions have 
been associated with HCM 5•6• More than 400 different mutations have been found in the genes that 
encode sarcomeric proteins, such as 13-cardiac myosin heavy chain (MYH7), cardiac myosin-binding pro-
tein-( (MYBPC3), a-cardiac myosin heavy chain (MYH6), regulatory myosin light chain (MYU), essential 
myosin light chain (MYL3), cardiac troponin T (TNNT2), cardiac troponin I (TNN/3), tropomyosin (TPM7), 
cardiac actin (AUC7), and titin (ITN) (see: http://cardiogenomics.med.harvard.edu). 
Partly due to the genetic heterogeneity, interfamilial clinical variability in HCM is high. Also intrafa-
milial variability is considerable, and it has proven difficult to establish good genotype-phenotype 
correlations in HCM. In addition to the primary genetic defect, the effects of modifier genes or ad-
ditional mutations in other sarcomeric genes may contribute to the phenotypic expression of HCM 7• 
Childhood-onset cardiac hypertrophy is also genetically determined in the majority of cases, and two 
thirds of familial cases of childhood-onset cardiac hypertrophy are caused by a mutation in one of the 
sarcomeric protein genes 8• 
Here we describe two unrelated children with severe cardiomyopathy, ventricular noncompaction and 
septal defects, due to compound heterozygosity for truncating mutations in MYBPC3, resulting in neo-
natal death. 
Methods 
Ginical diagnosis 
Two unrelated families with an index patient with severe neonatal cardiomyopathy were studied after 
informed consent at the clinical, pathological and molecular level. Clinical evaluation included clinical 
history and physical examination, electrocardiography (ECG) and 2D and M-mode echocardiography. 
Non-compaction of the left ventricle was diagnosed based upon 3 echocardiographic criteria defined 
by Jenni et al., 9 including i) a thick non-compacted (NC) endocardial layer in end systole at the paraster-
nal short-axis views (ratio NC/C >2) with numerous, excessively prominent trabeculations and deep 
intratrabecular recesses, ii) that are perfused on color Doppler studies and iii) predominantly apical 
localization. 
Pathologic studies 
Microscopic examination and electronmicropscopy of cardiac autopsy material of patient 1 was per-
formed with standard techniques. 
Molecular analysis 
Genomic DNA of the patients was isolated from blood samples. All coding regions and intron-exon 
boundaries of the MYBPC3 gene were analyzed by direct sequence analysis. Sequence analysis of M13-
tagged PCR products was carried out on an ABI3730xl capillary sequencer using Big-Dye Terminator 
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v 3.1 chemistry (Applied Biosystems). (Details of methods and primer sequences are available on re-
quest.) Analysis of sequence data was performed using SeqScape analysis software (v2.5, Applied Sic-
systems). In addition to sequence analysis, MLPA analysis of the MYBPC3 gene was carried out (MRC 
Holland SALSA MLPA kit P1 00) to detect possible genomic rearrangements. Exons of the MYBPC3 gene 
were numbered 1-34 according to international standards with the Adenine of the translation initiation 
start site (ATG) numbered+ 1 and the ATG in exon 1 (www.HGVS.org). Subsequently, using the same 
techniques, the complete coding regions and intron-exon boundaries of 8 other sarcomeric genes 
(MYHl, TNNT2, TNN/3, MYU, MYL3, TNNC, TPM1 and AaC1) were analyzed to exclude that additional 
pathogenic mutations in these genes contributed to the phenotype observed in the patients. 
Results 
Patient 7 
This male patient was born after an uncomplicated pregnancy at40 weeks gestation with a birth weight 
of 3110 grams and Apgar scores of 9/9. He was the second child of healthy Dutch non-consanguineous 
parents. At the age of 1 week cyanosis was noticed during crying and the child experienced feeding 
difficulties. At the age of 5 weeks he was hospitalized because of feeding problems, perspiration and 
facial cyanosis. X-thorax showed a grossly enlarged heart. Echocardiography revealed a moderately 
dilated left ventricle with severe systolic dysfunction. The apical wall of the left ventricle was excessively 
thickened with prominent hypertrabeculation. The left and right atria showed mild dilatation. A small 
secundum atrial septal defect (ASD) was also present. He was treated for heart failure with Furosemide, 
Captopril, Carnitine and Digoxin. Viral serology showed no abnormalities. Metabolic screening of urine, 
including oligosaccharide spot test, was normal. Plasma carnitine and amino acid levels were normal. 
After stabilization, the child was released from hospital, but two weeks later he was readmitted to the 
hospital presenting with a pallor color and progressive feeding problems. X-thorax and echocardiogra-
phy revealed further enlargement of the heart (heart-thorax ratio± 0.7) with severe hypertrophy with 
a fractional shortening of the left ventricle of less than 10%. The child died from cardiac failure at the 
age of 12 weeks. Macroscopic examination of the heart revealed severe cardiomegaly and dilatation 
with a total weight of 115 gr (normal weight at this age: 30 gr). Right ventricular thickening was noted, 
especially of the LV posterior wall. Also the anterior wall of the left ventricle was severely thickened, and 
showed abnormal trabeculation and multiple intertrabecular recesses as seen in non-compaction car-
diomyopathy. The secundum ASD was confirmed. No other congenital malformations were found. Mi-
croscopic examination of cardiac tissue (Figure 1 A) showed myofibrillar disarray in both the ventricular 
septum and the left ventricular wall. No significant amount of interstitial fibrosis was observed. Hyper-
trophic myocytes with a diameter varying between 20 and 30 micrometers (normal 12 micrometers) 
and multiple vacuoles on electron microscopy were suggestive of a glycogenesis (Figure 1 B). As the 
echocardiography images and ECG were not suggestive of Pompe disease and urine oligosaccharide 
analysis was normal, no a-glucosidase enzyme or molecular assay was performed. 
Sarcomere mutation analysis was initiated by screening of the complete coding region and intron-exon 
boundaries of the MYBPC3 gene. This analysis revealed that the patient was compound heterozygous 
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for the c.2373dupG mutation and the c.2827C> T (p.Arg943X) mutation. Mutation analysis of additional 
sarcomeric genes (MYH7, TNNT2, TNN/3, MYU, MYL3, TNNC, TPM7 and ACTC7) did not result in the iden-
tification of additional pathogenic mutations. Large deletions of mitochondral DNA, and several mito-
chondrial missense mutations associated with hypertrophic cardiomyopathy were excluded. Mutation 
analysis in both parents identified the c.2373dupG mutation in the mother and the p.Arg943X mutation 
in the father (Figure 2). 
At the time of diagnosis of cardiomyopathy in their newborn child, both parents had no cardiac symp-
toms. Echocardiography revealed no abnormalities in the mother at age 32 years and the father at age 
31 years. ECG in the father showed mild repolarisation abnormalities (ST-elevation of 0,5 mm in V1 fol-
lowed by a negative Tin V1-V4). Re-evaluation of both parents after 7 years, revealed moderate septal 
hypertrophy (HCM) with an interventricular septum of 14 mm in the mother, and interventricular septal 
measurements at the upper limit of the normal range (12 mm) in the father. Family history indicated 
that there were several family members with cardiac symptoms, sudden death, and/or diagnosed with 
HCM on both sides of the family (Figure 2). 
Patient2 
This male patient was born at 38 weeks gestation with a birth weight of 3345 gr. He was the second 
child of non-consanguineous parents. He experienced feeding problems in the first weeks of life. At the 
age of four weeks dyspnoea was noticed and he was referred to the hospital. He was mildly hypotonic. 
A grossly enlarged heart was observed on the X-thorax and low oxygen saturation blood levels were 
found. He was referred to the pediatric cardiology center for further evaluation. Echocardiography re-
vealed moderately dilated ventricles with severe diastolic and systolic dysfunction. Hypertrabeculation 
with flow perfused intertrabecular recesses was present in both ventricles, including the apical walls 
{Figure 3). An apical muscularVSD was visualized, although deep recessal flow complicated interpreta-
Figure 1 J A. M"1aoscopic examination of postmortem heart musde from paf1ent 1. Hypertrophic myocytes with myofibri!lar disar~<~ytypical of HCM due to 
sarcomeric protein mutations, was present albeit without significant amount of interstitial fibrosis. 
B. Electron micrograph showing a large, irregularvacuole 
111:1 
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Figure2 I Pedigree of patient 1 who had severe neonatal cardiomyopathy (II) due to compound heterozygosityforthe c.2373dupG and p.Arg943X mutations 
in the MYBPC3 gene. On both sides of the pedigree, there are multiple affected individuals with adult HCM (<J [))that are heterozygous for one of the 
mutations. 
tion of the imaging. A muscle CT scan showed no signs of atrophy, and a muscular biopsy revealed no 
congenital myopathy. Biochemical studies, including lactate, pyruvate, creatine kinase, amino acids, 
carnitine and sialotransferrines levels, and metabolic screening of urine, including oligosaccharides, 
were normal. Viral serology showed no abnormalities. The patient was treated for heart failure with 
Furosemide, Captopril and Digoxin. He deteriorated at the age of 12 weeks, and died. 
The complete coding region and intron-exon boundaries of the MYBPC3 gene were analyzed. Com-
pound heterozygosity for the c.2373dupG and the c.2827C> T (p.Arg943X) in the MYBPC3 gene was 
found. Molecular analyses of other sarcomeric genes (MYH7, TNNT2, TNN/3, MYL2, MYL3, TNNC, TPM1 
and AGC1) revealed no additional disease-causing mutation. The parents declined pathological stud-
ies of the heart of their deceased child, nor did they decide on further cardiologic evaluation for them-
selves or pedigree analysis. 
Discussion 
Here we describe two unrelated newborns with severe cardiomyopathy resulting in neonatal death due 
to compound heterozygosity for null mutations in the MYBPC3 gene. Although initially their cardiomy-
opathies were described as severe atypical HCM, HCM with left ventricular non-compaction (LVNC) was 
considered after re-evaluation of serial ultrasounds and pathologic examination. LVNC is a genetically 
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heterogeneous disease associated with mutations in TAZ(G4.5) 10, OTNA 11, LOB3 12, SCNSA and LMNA 13 
in a limited number of families 14• Recently, LVNC was shown to be due to heterozygous mutations in 
genes encoding sarcomeric proteins, including G-cardiacmyosin heavy chain (MYH7) ts.ta, alpha-cardiac 
actin (AGC) 18•19 and cardiactroponin T (TNNT2) 18.Here we report that mutations in another sarcomeric 
protein gene MyBPC3 also lead to LVNC, as we previously reported 20• This suggests that LVNC, HCM, 
dilated cardiomyopathy (DCM) and restrictive cardiomyopathy (RCM) are allelic diseases that share 
similar pathophysiological mechanisms. 
ln the majority of patients with familial cardiomyopathy due to a mutation in one of the genes encod-
ing sarcomeric proteins, a single autosomal dominant mutation is found. In contrast our 2 patients 
are compound heterozygotes for 2 truncating MYBPC3 mutations, suggesting a cumulative effect of 
these mutations. Mutations in the MYBPC3 gene, encoding cardiac myosin binding protein C, are one 
of the most common genetic causes of HCM in many populations, found in approximately 20-40% 
of individuals with HCM 21•23• Autosomal dominant mutations in the MYBPC3 gene, mostly truncating 
mutations and sometimes missense mutations, give rise to HCM with an age of onset after the third 
decade, moderate left ventricular hypertrophy and a favorable prognosis 24• A.s mutations in MYBPC3 
(and MYH7) are the most common genetic cause of familial HCM 8, compound heterozygous or ho-
mozygous mutations should be considered in a neonate which presents with severe HCM or LVNC, 
even in the absence of symptoms in the parents or a negative family history. This is shown here where 
both patients with severe neonatal cardiomyopathy are compound heterozygotes for the 2 most fre-
quent HCM mutations in the Netherlands, the c.2373dupG mutation and the p.Arg943X mutation. The 
c.2373dupG mutation alone accounts for nearly one-fourth of all HCM cases in the Netherlands, and 
has previously been shown to be an important founder mutation in the Dutch 25 population and also 
to be present in other 21 .26 populations. The mutation creates a new aberrant splice donor site leading 
to skipping of exon 24, resulting in a frame shift after p.Gin791 and a premature stop 27• No truncated 
protein product from the c.2373dupG allele could be detected in the sarcomere using antibodies, sug-
gesting that the truncated protein was unstable, or the aberrant transcript was degraded by cell sur-
Figure3 I Echocardiographicstudies in patient2showing cardiomyopathy 
with LV noNompaction. The four chamber shows excessive trabeculation 
(arrows) at the apical left ventricular wall, whereas the right ventricular 
wall also showed numerous deep trabeculae and recesses. 
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veil lance mechanisms such as nonsense mediated decay 28• The second mutation found in both our 
patients is the p.Arg943X mutation. This mutation was identified as an additional founder mutation in 
the Dutch population (D.O. unpublished results). P.Arg943X is a nonsense mutation in exon 27, leading 
to a premature stop codon and protein truncation beyond domain C 7 of MYBPC3. Even in the absence 
of nonsense mediated decay of the mutant MYBPC3 mRNAs the p.Arg943X mutation is thought to lead 
to reduction in MYBPC3 due to protein instability and/or loss of the (-terminus of MYBPC3 that binds 
myosin thick filaments and titin, which is required for normal MYBPC3 incorporation into the A-band of 
the sarcomere 29• As a consequence, in our patients no MYBPC3 protein is expected to be incorporated 
into the sarcomere, which might explain the early and severe presentation of the cardiomyopathy in 
both patients._ 
In larger series approximately 3-5% of HCM patients are compound or double heterozygotes for two 
disease-causing mutations in the same or different sarcomeric protein genes 21 .22• However, most of 
these mutations are missense mutations of which the pathogenic nature is not always easy to establish. 
In these patients generally a more severe HCM phenotype is seen, characterized by an age of onset 
around the second decade or in childhood {Table 1) 21.2ua-39• In a recent study on sarcomeric protein 
gene mutations in childhood-onset HCM 6 out of 84 children (7 %) had compound mutations 8• This 
suggests that a gene-dosage effect might be responsible for manifestations at a younger age. 
Not only clinical features such as the neonatal onset of severe symptoms, but also the pathology of the 
heart in patient 1 initially suggested a metabolic origin eg glycogenesis (Figure 1).1t is known that mu-
tations in genes regulating glycogen metabolism, including AMP-activated protein kinase 2 (PRKAG2) in 
Wolff-Parkinson-White associated cardiomyopathy, lysosome-associated membrane protein 2 (LAMP2) 
in Danon disease, -galactosidase (GLA) in Fabry's disease, and acid -1,4-glucosidase(GAA) in Pompe's 
disease can cause left ventricular hypertrophy that mimics HCM 40• Conversely, metabolic diseases 
might also be misdiagnosed in patients with HCM due to sarcomeric protein mutations, as shown in our 
patient. Mutations in genes regulating glycogen metabolism cause myocyte hypertrophy by stimulat-
ing glycogen-filled vacuoles but cause neither myocyte disarray nor interstitial fibrosis, which typically 
occur with defects of sarcomere-protein genes. 
Few neonatal cases with severe cardiomyopathy due to homozygous or compound heterozygous trun-
cating mutations in MYBPC3 have previously been described 21 •34.37.38• A homozygous splice site muta-
tion p.Asp1064GiyfsX38 in MYBPC3 (leading to a frame shift and premature truncation) was recently 
described in 3 neonates with severe neonatal HCM that all died at the average age of 3-4 months in 
an inbred Old Order Amish pedigree with severe HCM 37• This homozygous MYBPC3 mutation was also 
reported in another cohort of 10 neonates with severe infantile HCM from Old Order Amish descent, 
suggesting that this mutation is a founder mutation in the Amish 38• It is remarkable that several of 
the affected neonates from the Old Order Amish with homozygous truncating mutations in MYBPC3, 
present with septal defects including apical muscularVSO, and ASD and patent ductus arteriosus. Sep-
tal defects were also present in the neonates with severe HCM due to compound heterozygous trun-
cating mutations described by Lekanne et al. 34 and the two cases described here. Recently, different 
congenital heart malformations (septal defects, patent ductus arteriosus, aortic aneurysm and Ebstein 
anomaly) have been reported in families with mutations in sarcomeric protein genes, including MYB-
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PC3, MYH6, MYH7, MYH71, and AGC1 16,19.37,41-43• This suggests that sarcomeric cardiac muscle proteins 
are not only involved in cardiomyopathies but also in congenital heart malformations 44• 
In conclusion, the absence of functional MYBPC3 from the sarcomere can lead to a phenotype of severe 
HCM with features of ventricular noncompaction and septal defects, which appears to be lethal in the 
postnatal period. 
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Table 1 I Patients with cardiomyopathy due to 2 mutations in the MYBPC3 gene, and! or additional sarcomeric protein genes* 
MYBPC3 mutation with mutation in other sarcomeric gene 
MYBPC3 I p.Arg273His MYH7 I p.Arg719Gin 
MYBPC3 I p.Asp605Asn MYH7 I p.Giu894Giy 
MYBPC3 I c2373dupG MYH7 I p.Arg694Cys 
MYBPC3 I p.Giu1096X MYHl I p.Giu4S3Lys 
MYBPC3 I p.Aia833Thr TNNT2 I p.Arg286His 
MYBPC3 I p.Val2561le TNNT2 I p.Arg92Trp 
MYBPC3 I p.Arg943X TNN/3 I p.Ser166Phe 
MYBPC3 I p.Phe111JIIe TPM7 lp.lle172Thr 
MYBPC3 I p.Arg495Gin TNN/3 I p.Arg141Gin 
Compound heterozygote or homozygote mutations in MYBPC3 
MYBPC3 I p.Pro873His MYBPC3 I p.Pro873His 
MYBPC3 I p.Arg810His MYBPC3 I p.Arg810His 
MYBPC3 I p.Arg502Trp MYBPC3 I p.GiySArg 
MYBPG I p.Aia954fs MYBPC3 I p.Giu258Lys 
MYBPG I p.Aia627Val MYBPC3 I p.Aia627Val 
MYBPC3 I p.Pro873His MYBPC3 I p.Asp745Giy 
MYBPC3 I p.Giu542Gin MYBPC3 I p.Aia851Val 
MYBPC3 I p.Gin76X MYBPC3 I p.His257Pro 
MYBPC3 I p.Thrl 0285er MYBPC3 I c.3490+2T ~G 
MYBPC3 I p.Arg502Trp MYBPC3 I p.Ser358Asn 
MYBPC3 I p.lle154Thr MYBPC3 I p.Asp605del 
Double truncating mutations in MYBPC3 
MYBPC3 I p.Gin76X MYBPC3 I p.Gin76X 
MYBPC3 I c.1624+ 1G>A MYBPG I c.2373dupG 
MYBPC3 I p.Arg943X MYBPC3 I p.Giu1096fs 
MYBPC3 I p. Asp1064GiyfsX38 MYBPC3 I p. Asp1064GiyfsX38 
MYBPC3 I p.Arg943X MYBPC3 I c2373dupG 
MYBPC3 I p.Arg94JX MYBPC3 I c237JdupG 
*The pathogenicity of some of the missense mutations listed here is uncertain 
*"~More severe HCM and highest incidence of myectomie as compared to patients with singleMYBPG mutations12 
·-magnosis at a younger age [between 0.2 and 37.4 yrs) as compared to patients with single MYBPG mutations11 
HCM 
HCM 
HCM 
HCM 
HCM 
HCM 
HCM 
HCM 
Childhood HCM-
HCM 
HCM 
HCM 
HCM 
HCM 
HCM 
HCM 
HCM 
Childhood HCM•-• 
Childhood HCM . , 
Childhood HCM·*'» 
Neonatal HCM 
Neonatal HCM 
Neonatal HCMJVSD 
Neonatal HCMIASD, VSD 
Neonatal HCMIASD 
Neonatal HCM/VSD 
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Moderate /severe 35 and 15 y~ 
" 
.. 
- " 
- ·- " 
Severe 33 and 56 y~ 
'"' 
-
H< 
" 
"* 
ll 
-
.... 
" 
- - " 
Before 15 yrs 
Moderate /severe 27y~ " 
Severe 39y~ 
" 
*' *' 
ll 
*' *' 
ll 
Severe 47yrs 
" 
Severe 29yrs 
" 
Severe 34y~ 
" 
Mild symptoms 24y~ 
" 
Before 15 y~ 
Before 15 yrs 
Before 15yrs 
Death 9 months 
" 
Death 5 weeks 3 days 
" 
Death 6 weeks 2 weeks 
" 
Death 6 weeks-7 months 1-3 weeks 
"'' 
Death 3 months 5weeks This study 
Death 3 months 4weeks This study 
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Abstract 
Background Ebstein anomaly of the tricuspid valve occurs in less than 1 o/o of all patients with a con-
genital heart malformation. Many cases appear sporadic, but familial cases with autosomal dominant 
inheritance have been reported. No disease gene involved in Ebstein anomaly has been identified yet. 
Methods and Results We describe a large family with autosomal dominant inheritance of Ebstein 
anomaly in association with ventricular septal defect and noncompaction cardiomyopathy. A novel 
heterozygous missense mutation was identified in the MYHl gene encoding the sarcomeric cardiac 
13-myosin heavy chain. 
Conclusions The association of Ebstein anomaly with ventricular septal defect and noncompaction car-
diomyopathy is an autosomal dominant condition that can be caused by mutations in the MYHl gene. 
This indicates that this sarcomeric protein, which is implicated in familial cardiomyopathy, also plays a 
role in the development of the tricuspid valve and atrial and ventricular septum. 
Introduction 
Ebstein anomaly of the tricuspid valve is a rare congenital heart malformation (CHM) occurring in less 
than 1 o/o of CHM '. It was first described by Wilhelm Ebstein in 1866, and in 1927 Alfred Arnstein sug-
gested the name Ebstein anomaly. This anomaly is characterized by adherence of the septal and pos-
terior leaflets of the tricuspid valve to the underlying myocardium, apical displacement of the tricuspid 
annulus, and dilatation of the atrialized portion of the right ventricle, whereas the attached chordae 
are usually thin and ill formed 2• Ebstein anomaly is frequently associated with other forms of CHM: in 
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70-90% an interatrial communication '1s present, and occasional find'mgs include pulmonary or aortic 
valve stenosis or atresia, mitral valve abnormalities, transposition of the great arteries, or conduction 
system anomalies, including accessory conduction pathways (eg Wolff-Parkinson-White syndrome) J..s_ 
Noncom paction cardiomyopathy (NCCM) is present in almost 20% of patients 6•7• 
Environmental as well as genetic factors may play a role in the etiology of Ebstein anomaly. Maternal 
exposure to benzodiazepines and maternal lithium therapy may increase the risk of Ebstein anomaly 
1
.a. Several chromosomal anomalies and inherited animal models with Ebstein anomaly have been re-
ported 9"17• Although most cases of Ebstein anomaly occur sporadically, familial occurrence has been 
reported: several reports of sibs 1s-25 or multiple family members with Ebstein anomaly in different 
generations 19.26-31 suggest that Ebstein anomaly might be caused by autosomal recessive or dominant 
mutations. The association of Ebstein anomaly with NCCM of both the left and the right ventricle32 has 
been reported in several cases 7.33-39, and also a few familial cases with autosomal dominant inheritance 
of this association have been described 32.4°_ 
Here we report a clinical and genetic analysis of a family with an autosomal dominant form of Ebstein 
anomaly associated with noncompaction cardiomyopathy. Mutation analysis of the MYH7 gene en-
coding the sarcomeric cardiac f3-myosin heavy chain revealed a novel missense mutation in the ATP-
binding domain. 
Methods 
Clinical Evaluation 
The proband, his father and paternal uncle were examined at 2 tertiary referral centers (Erasmus Medi-
cal Center Rotterdam and Leiden University Center, The Netherlands). Two other family members were 
studied at the Texas heart Center Houston, USA. Additional family members were investigated by vari-
ous cardiologists. 
The diagnosis of left ventricular noncompaction was made based upon echocardiographic criteria es-
tablished by Jenni et al. 41 (with the exception of the presence of a CHM). Informed consent was ob-
tained from all participants. 
Medical records of the deceased children and participating family members were reviewed by one of 
us(MWW). 
Molecular Analysis 
Genomic DNA of the proband's father (patient IV-5) and his brother (IV-4) was isolated from periph-
eral blood samples. All coding regions and intron-exon boundaries of the MYH7 gene were analyzed 
by direct sequence analysis. Sequence analysis of M13-tagged PCR products was carried out on an 
ABI3730xl capillary sequencer using Big-DyeTerminatorv 3.1 chemistry (Applied Biosystems). Details 
of methods and primer sequences are available on request. An.:~ lysis of sequence data was performed 
using SeqScape analysis software (v2.5, Applied Biosystems). Subsequently, using the same techniques, 
the complete coding regions and intron-exon boundaries of MYBPC3, TNNT2, TNN/3, TNNC7, TPM7, and 
AGC7, the Z-disk genes TCAP and CSRP3, the (a-handling genes CALM7, CASQ2, CALR3, PLN, SLN, SRI, 
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LMNA and NKX2-5 were analyzed to exclude that additional pathogenic mutations in these genes con-
tributed to the phenotype observed in the patients. 
Results 
Clinical Evaluation 
The family presented here (Figure 1) was first referred to us because of the prenatal diagnosis of mild 
Ebstein anomaly in a fetus (patientV-1) at 22 weeks of gestation. No tricuspid regurgitation was present 
and the pregnancy continued uneventfully. A girl was born at term in good condition with a weight 
of 4400 grams. The prenatal diagnosis of Ebstein anomaly was confirmed by echocardiography. At the 
present age of 2 years the child has mild Ebstein anomaly without tricuspid regurgitation or ventricular 
wall thickening. She is developing normally without medication. 
The father of patientV-1 (IV- 5) had no medical history or signs of cardiac disease. After the diagnosis of 
Ebstein anomaly in his daughter he was referred for cardiac evaluation at the age of 40. Clinical exami-
nation including ECG, echocardiography and MRI revealed NCCM. A paternal uncle (patient IV-7) of the 
proband died at the age of one month because of a severe congenital heart malformation. At autopsy 
(records from 1972) a grossly enlarged heart was found, with dilated and hypertrophic ventricles. A 
ventricular septal defect (VSD) of 8 mm was present just beneath the insertion of the septal leaflet of 
the tricuspid valve. The aorta was in a slightly anterior position. Lung edema was seen with thin-walled 
dilated arteries and dilatation lesions, as seen in pulmonary hypertension. 
Another paternal uncle of the proband (patient lV-4) was diagnosed with mild Ebstein anomaly at the 
age of 1 0 years. At the age of 40 echocardiography showed tricuspid leaflets inserting 21 mm below the 
mitral valve. Severe mitral regurgitation and decreased systolic function were present. Both the right 
and left atria were enlarged. A small right ventricle with hypertrabeculation, and a left ventricle with 
hypertrabeculation and many crypts were present, confirming NCCM of both ventricles. An aneurysm 
of the perimembraneous interventricu Jar septum was observed, but no septal defect was visualized 
(Figure 2). 
The paternal grandparents of the proband were consanguineous (first-degree cousins). The paternal 
grandfather of the proband (lll-6) was asymptomatic, but was never evaluated by a cardiologist. His 
sister (patient 111-3) has atrial fibrillation and cardiomyopathy with left ventricular dysfunction and heart 
failure. A brother (patient Ill-S) was diagnosed with a VSD. He died suddenly at the age of 40. Another 
brother of the paternal grandfather was asymptomatic but had three children with a CHM. The first 
born, a girl (patient lV-1 ), was diagnosed at birth with a grossly enlarged heart, pulmonary valve steno-
sis, severe Ebstein anomaly with a hypoplastic right ventricle and a large right atrium. She died at the 
age of 3 weeks during cardiac surgery. Autopsy confirmed the cardiac malformations. The second girl 
(patient IV-2) was born with a weight of 4050 grams and had no clinical symptoms. She was examined 
at the age of three weeks because of the family history of congenital heart malformations. She was 
diagnosed with a grossly enlarged heart with a VSD, patent ductus arteriosus, double-chambered right 
ventricle and left ventricular hypertrophy. At the age of 5 months and 2 years the child was in good 
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condition, according to the medical files and family history she did not receive further cardiological 
follow up. The third child (patient IV-3), a boy, was born with a weight of 3450 grams. Within the first 
days a systolic murmur was heard. At the age of 2 months he was admitted to the Texas Heart Insti-
tute for cardiac evaluation. Catheterization revealed a patent foramen ovate, a small VSD with a large 
trabeculated left ventricle, and a double-chambered right ventricle with and a smooth-walled atrialized 
sinus portion. He was treated for congestive heart failure. At the age of2 years he was reevaluated and 
primary closure of the VSD and atrial septal defect (ASD) was performed. The VSD was a type 2 and of 
moderate size (6-7 mm) with pedunculated aneurysm. An unusual anatomy of the tricuspid valve was 
noted, w"1th a leaflet overlaying the septal defect, as seen in Ebstein anomaly. The 2 sibs IV-2 and IV-3 
are alive at the age of 33 and 32 years, respectively, but no further cardiac evaluations have been per-
formed since childhood. 
The paternal grandmother (111-7) died suddenly at the age of 45 years. She had experienced heart pal-
pitations during the last years of her life. No medical records of cardiac evaluations could be obtained 
from her or her sibs. Her brother was operated before the age of 50 years because of heart valve insuffi-
ciency. One sister had a history of cardiac palpitations and a heart murmur. A daughter of another sister 
has an enlarged heart, but no detailed information could be obtained. It is unclear whether the CHM 
present in IV-4, IV-5 and IV-7 was inherited through the father 111-6 or the mother 111-7. 
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Figure 1 1 Pedigree of the family with Ebstein anomaly, septal defects and NCCM 
Ill 
IV 
v 
Blackened family members are affected with CHM: 4 family members have Ebstein anomaly, 5 have septal effects, 2 have NCCM and several others have 
cardiomyopathy. It is unclear whether the NCCM and/or CHM present in IV-4, lV-5 and IV-7 was inherited through the father 111-6 or the mother 111-7. The 
p.Phe230Ser mutation was present in patients IV-4and IV-5. 
Abbreviations: AF, atrial fibrillation; ASD, atria! septal defect; DCM, dilated cardiomyopathy; DCRV, double-chambered right ventricle; HCM, hypertrophic 
cardiomyopathy; LV, left ventricle; PA, pulmonary atresia; PFO, patent foramen ovale; PDA, patent ductus arteriosus; NCCM, non compaction cardiomyopathy; 
RV, right ventricle; SO, sudden death; VSD, ventricular septal defect. 
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Molecular Analyses 
Molecular diagnostic work-up of patient IV-4 with Ebstein anomaly and NCCM included sequencing of 
all coding regions and the intron-exon boundaries of the following genes: the sarcomeric genes MYH7, 
MYBPC3, TNNT2, TNN/3, TNNC1, TPM1, and AaC1, the Z-disk genes TCAP and CSRP3, the (a-handling 
genes CALM7, CASQ2, CALR3, PLN, SLN, SRI and FKBP18, and NKX2-5 and LMNA. No disease-associated 
mutation could be found in all these genes. A heterozygous missense mutation c.689T>C in exon 8 
of the MYH7 gene was identified, predicting the substitution of a phenylalanine by a serine at amino 
acid position 230 (p.Phe230Ser). This mutation was also identified in his brother (patient IV-5) who has 
NCCM, and in the affected proband (patientV-1) with Ebstein anomaly. No other family members were 
available for molecular testing. 
Figure 2 ! Echocardiogram (+chambered view, 
apex up) of patient IV-4 with NCCM and Ebstein 
anomaly. Prominent trabecufations are i1sible, 
mainly in the left ventricular apex and an apical 
displacementoftheseptal and posterior leaflet from 
the atrioventricular ring. 
The c.689T>C (p.Phe230Ser) mutation is a novel mutation, neither present in the literature nor in any 
database. In our own data set of more than 200 sequenced MYH7 genes we never encountered this 
mutation. The phenylalanine residue at position 230 shows complete cross-species conservation un-
til zebrafish (Figure 3), and computer prediction software (SIFT) identifies this missense mutation as 
pathogenic. 
Discussion 
We describe an extended Caribbean family with autosomal dominant inheritance of non-syndromic 
congenital heart malformations. Ebstein anomaly was present in 4 and sepal defects in 5 family mem-
bers. Several family members were diagnosed with cardiomyopathy, and in two patients NCCM was 
diagnosed. 
Familial Ebstein anomaly is rare and only around 20 families have been described in literature. 
As many of these families consist of only two affected patients the pattern of inheritance is notal-
ways dear 18' 25• Only in a few families autosomal dominant inheritance of Ebstein anomaly has been 
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described. Balaji et al. 30 described a family with an autosomal dominant association of Ebstein anomaly 
with joint anomalies (restricted finger extension and extension limitation of larger joints). Schunkert 
et al. 42 described a family with autosomal dominant inheritance of Ebstein anomaly with valvulosep-
tal defects and atrioventricular canal. Some families with autosomal dominant inheritance of Ebstein 
anomaly also show NCCM 32.40.43. Multiple loci for Ebstein anomaly have been suggested from studies 
in humans and animals. In humans Ebstein anomaly has been reported in patients with mutations in 
the NKX2.5 44 and TBXS genes 45• Also several chromosomal abnormalities are associated with Ebstein 
anomaly, including 1 p36 deletion, 8p23 deletion, trisomy 9p, 10p13-14 deletion, 11 q deletion, 15q du-
plication, trisomy 21, and 22q11 deletion/duplication. As most of these chromosomal abnormalities 
were occasional findings it is unclear whether the chromosome imbalance was responsible for Ebstein 
anomaly 9"17 (for review: see Miller et al.11 ). In Labrador retrievers autosomal dominant tricuspid valve 
malformation is clinically similar to Ebstein anomaly in humans, and a gene locus has been mapped to 
a region of canine chromosome 9, which is syntenic to human 17q12-q23 15• Finally, several knockout 
mice exhibit cardiac abnormalities similar to the anomalies seen in humans with Ebstein anomaly. Mice 
with targeted deletion of Alk3, a type 1 A receptor for Bone Morphogenetic Proteins (BMPs), signaling 
proteins involved in endocardial cushion formation, reveal displacement and adherence of the poste-
rior leaflet of the tricuspid valve, as seen in human Ebstein anomaly 16• Mice with null mutations of peri-
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Figure 3 I Alignment of the regions flanking the novel p.Phe230Ser and the known 
p.Leu30161n mutation in MYHl. The alignment illustrates the evolutionary conservation of 
the mutated MYHl residues p.Phe230 and p.Leu301, and the respective flanking amino acids 
across species. 
Figure 4 I Position of the p.Phe230Ser and p.Leu301Gin mutations 
·ma protein model of the myosinheavychain 
A. Visualisation of the clustering of amino add changes found in patients 
with NCCM and/or Ebstein anomaly in a protein model ofthe 30 structure of 
the chicken myosin heavy chain Sl fr.Jgment (PDB code 2MYS). 
B. Close up view ofthe ATP binding site and the residues homologous to the 
human MYH7 gene. Mutations in the ATP binding site resulting in NCCM 
are indicated. The mutated residues p.Phe230 and p.Leu301 described here 
are indicated in red. Other positions in this area known to be mutated with 
NCCM are shown in brown. The sulfate in the ATP binding site is indicated 
in yellow, the catalytic serine residue p.Ser322 in margenta. The ATP/ 
Mg2+ ( or.Jnge) is from a myosin structure of the slime mold Dictyosteflum 
diS<oideum (PDB code 1MMG). 
(The p.Phe230Ser mutation is situated in a hydrophobic pocket formed 
by the side chains of residues p.A!a229, p.lle285, p.Met349, p.Trp438, and 
p.Met439. 
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ostin, an extracellular matrix protein involved in atrioventricular valve formation, show various tricuspid 
valve anomalies resembling human Ebstein anomaly 17• 
Apart from the autosomal dominant inheritance of Ebstein anomaly, our family is also unusual in that 
Ebstein anomaly is associated with NCCM in two family members (patient IV-4 and IV-5), and cardiomy-
opathy is present in several additional family members. As cardiological examinations in the deceased 
children took place in 1973/1974, and echocardiography records or pathological specimens were no 
longer available for re-valuation, it is unclear whether myocardial abnormalities in these children would 
have fitted the diagnosis NCCM. Patient IV-3 might also have had NCCM as he was diagnosed with 
a large trabeculated left ventricle and double- chambered right ventricle at the age of two months. 
The association of Ebstein anomaly and NCCM is well known, and NCCM is present in up to 20% of 
patients with Ebstein anomaly 6•7• As this association is also reported in families compatible with auto-
somal dominant inheritance this might be a specific subgroup of Ebstein anomaly with a monogenic 
origin 32.40.43• NCCM is genetically heterogeneous as mutations in several genes, including the TAZ-G4.5 
gene encoding taffazin46, the Cypher-ZASP gene (LDB3) encoding LIM domain binding protein 3 47, and 
the DTNA gene encoding a-dystrobrevin,48 have been reported, albeit in a limited group of patients 
49
.5°. Several studies 43.51•54 indicate that NCCM can also be caused by mutations in sarcomeric protein 
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genes that are also implicated in different cardiomyopathies (hypertrophic, dilated and restrictive). Re-
cently, Budde et al. 43 described a large family with autosomal dominant NCCM (12 family members) 
and Ebstein anomaly (4 family members) caused by a p.Arg281Thr mutation in the MYH1 gene. Three 
of the four patients with Ebstein anomaly also had an ASD. To investigate the possible involvement in 
our family of one of the genes known to be implicated in familial cardiomyopathies, we sequenced 
the complete coding regions and intron-exon boundaries of a large number of sarcomeric and other 
candidate genes, and identified a novel missense mutation c.689T>C (p.Phe230Ser) in the MYH7 gene. 
In another of our NCCM families with a MYH7 mutation (p.Leu301 Gin) described by Hoedemaekers 
et al. 52 we recently found a hypertrabeculated left ventricle with mild Ebstein anomaly in a 12-year-
old girl, and confirmed she also had the familial p.Leu301 Gin mutation. The observations in these 3 
families indicate that a subset of cases with Ebstein anomaly, in particular those associated with NCCM, 
may be due to mutations in the MYH7 gene encoding cardiac B-myosin heavy chain gene. As NCCM is 
not reported in all familial cases of Ebstein anomaly, other genes might be involved. However, NCCM 
can be overlooked, indicating that serial examinations are mandatory in patients with familial Ebstein 
anomaly, even with mild valvular abnormalities to monitor development of cardiomyopathy. Further 
studies are needed to explore the contribution of sarcomeric mutations in isolated and familial cases of 
Ebstein malformation, with or without NCCM. 
MYH7 mutations are very common in familial forms of cardiomyopathy, including hypertrophic cardio-
myopathy (HCM), dilated cardiomyopathy (DCM), restrictive cardiomyopathy (RCM), and distal myopa-
thies with mild cardiac involvement such as Laing distal myopathy, central core disease and myosin 
storage myopathy. Most mutations leading to the different cardiomyopathies are located in the head 
and neck regions, much more than in the rod region, whereasMYH7 mutations leading to d'1stal myopa-
thies with limited cardiomyopathy are located in the rod region. Seven of the 9 MYH7mutations associ-
ated with NCCM, including the p.Phe230Ser mutation in our family, cluster in the head region of MYH7, 
more in particular in the ATPase active site encoded by exons 8-11 of MYH7.43,s1,s2The ATPase active site 
is an evolutionary conserved region of MYH7 (Figure 4A and 4B). The p.Phe230 residue is located in a 
hydrophobic pocket formed by the side chains of residues p.Ala229, p.lle285, p.Met349, p.Trp438, and 
p.Met439. Thus this residue keeps the (-terminus of the helix p.Asp218 to p.Phe230 (which is close to 
the ATP binding site) in proper place. Substitution of the p.Phe230 residue by the smaller and highly 
polar serine side chain would disturb this hydrophobic cluster (Figure 4C). As the ATPase active site is 
required for normal force production, impaired force generation might play a role in the aetiology of 
the abnormal tricuspid development and the septal defects seen in these families. 
Ebstein anomaly is characterized by downward displacement of the posterior and septal tricuspid leaf-
lets with a normally positioned anterior leaflet. This is interesting from an embryonic point of view as 
the anterio-superior leaflet of the tricuspid valve originates from different structures than the inferior 
and septal leaflets: the anterior-superior leaflet develops out of the endocardial tissue of the atriov-
entricular canal and the outflow segment, whereas both the septal and posterior leaflets develop out 
of the endocardial cushion and ventricular musculature. The two latter leaflets are formed by dela-
mination from the underlying myocardium; a process that includes formation of the papillary muscles 
attached to the leaflets and that takes place during weeks eight through 12. In Ebstein anomaly this 
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process is disturbed, and the septal and inferior leaflets remain "plastered" to the ventricular myocar-
dium, reminiscent of the topography of the developing tricuspid valve in week eight of development 55• 
NCCM is regarded as a developmental arrest in the same embryonic period, when the ventricular myo-
cardium is remodeled and transformed from noncompacted to compacted. We therefore suggest that 
Ebstein anomaly and NCCM can both be caused by the same developmental arrest between week eight 
and 12, and therefore sometimes occur together. It has also been established that the development of 
the tricuspid valve is associated with septation, and the ventricular wall in Ebstein anomaly reveals a de-
crease or total absence of myocardial fibers in the inlet portion of the interventricular septum 55.56. The 
presence of septal defects in several members of our family suggests that the MYH7 protein also plays 
a important role in septation, and that this developmental process occurs in the same embryologi-
cal time window as ventricular compaction and formation of the tricuspid valve. This corroborates the 
earlier observation that mutations in sarcomeric protein genes such as MYH6 and AUC7 not only cause 
different cardiomyopathies including NCCM, but also developmental defects resulting in congenital 
heart malformations 54•57•58• 
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In the past decade significant progress has been made in the dissection of the molecular biology of car-
diagenesis. An important contribution to this understanding was made by the identification of disease 
genes implicated in syndromic forms of congenital heart malformation {CHM). These human genes 
identified important molecular pathways that could be further studied in animal models leading to the 
identification of more candidate genes for human CHM. Examples of this approach are the discovery of 
the network of transcription factors in Holt-Oram syndrome and related disorders, the TBX1 pathway 
in neural crest-related disorders, the RAS-MAPK pathway implicated in Noonan syndrome and related 
disorders, the NOTCH pathway in Alagille syndrome and related disorders, and the TGFB signaling path-
way in Marfan syndrome and related disorders. However, only a minority of CHM without additional 
malformations (non-syndromic CHM) is caused by mutations in these genes. As non-syndromic CHM 
is much more frequent than syndromic CHM, the future challenge is to identify genes implicated in 
non-syndromic CHM. Most non-syndromic CHM occurs sporadically, and extended families with clear 
monogenic inheritance of non-syndromic CHM are scarce, thereby precluding the identification of dis-
eases genes involved in non-syndromic CHM by a classical positional genetics approach. 
In this thesis families with monogenic forms of syndromic CHM (arterial tortuosity syndrome, X-linked 
heterotaxy, and Kartagener syndrome) and non-syndromic CHM (LVOTO, valvular defects, cardiomy-
opathy, and Ebstein anomaly) were studied at the clinical level to delineate the phenotypes and at the 
molecular level to identify the genetic defect in known or novel disease genes. It is clear from several 
studies in this thesis that specific associations of different CHM may result from the same genetic de-
fect: the association of heterotaxy with VACTERL anomaly caused by repeat amplification in the ZIC3 
gene (Chapter 2), the association between cardiomyopathy and septal defects caused by mutations 
in the MYBPC3 and MYHl genes (Chapter 5), the association of cardiomyopathy with Ebstein anomaly 
and/or septal defects caused by mutations in the MYH7 gene {Chapter 5), and the association between 
cardiomyopathy and heterotaxy caused by an unknown gene on chromosome 6 (Chapter 2). These as-
sociations could only be recognized through family studies, as different family members had different 
forms of CHM. 
Different genetic strategies were used in this thesis to search for genes involved in cardiovascular 
anomalies in both syndromic and non-syndromic families. The gene for Arterial tortuosity syndrome 
was identified after homozygosity mapping in several consanguineous families from an inbred North 
African population {Chapter 4). Homozygosity mapping is a very successful method to identify auto-
somal recessive disease genes in inbred families. However, families with autosomal recessive forms of 
CHM are rare, and most monogenetic CHM has an autosomal dominant mode of inheritance. Linkage 
analysis in autosomal dominant diseases requires large pedigrees with multiple affected family mem-
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bers in multiple generations. However, extended families with clear autosomal dominant inheritance 
ofnon-syndromic CHM are scarce. Although autosomal dominant pedigrees with noncom paction and 
heterotaxy (Chapter 2), and LVOTO with valve defects (Chapter 3) could be identified, only sugges-
tive linkage to large chromosomal regions containing multiple candidate genes could be obtained, 
as the families were too small to yield high lad scores. To identify the disease gene in those families 
two approaches will be followed. The first approach will be a traditional positional genetics approach: 
additional families with the same type of CHM will be used to narrow down the linkage region. This 
approach requires identification of families with similar phenotypes presumably caused by the same 
disease gene. However, as most cardiac phenotypes are genetically heterogeneous and many genes 
involved in cardiogenesis have pleiotropic effects, it is not always obvious to classify CHM. The second 
approach is using next-generation sequencing. Whereas sequencing of large candidate regions ob-
tained after initial linkage studies used to be too time- and cost consuming, this has recently become 
a realistic approach by the development of new technologies for high-throughput massive parallel 
sequencing on so-called "next-generation sequencers': Next-generation sequencing of large linkage 
intervals will facilitate the identification of CHM genes in autosomal dominant families such as pre-
sented in our thesis. 
Although the families with non-syndromic CHM studied in this thesis are amenable to positional clon-
ing of the disease gene, they are unique families. Overall, most non-syndromic CHM occurs sporadi-
cally. Only in a low fraction (less than So/o) of non-syndromic CHM single gene mutations with high 
penetrance have been found. As adequate genetic counseling of these families requires identification 
of the genetic defect, the most prominent challenge is to identify these mutations. The traditional ap-
proach of serial sequencing of candidate genes is very costly and time-consuming, and therefore ineffi-
cient. Also here next-generation sequencing holds great promise. For many genetically heterogeneous 
diseases including non-syndromic CHM, diagnostic sequencing platforms consisting of a large series 
of candidate genes are constructed that can be sequenced on next-generation sequencers. These plat-
forms allow the parallel sequencing of billions of nucleotides, so that many genes can be simultaneous-
ly sequenced in many samples at low cost. The first platforms for hypertrophic (HCM) and dilated (DCM) 
cardiomyopathy are already available and diagnostic platforms for CHM most likely will follow. It is 
anticipated that such technologies will facilitate the sequencing of entire genomes-exomes at relatively 
low cost 1• There is little doubt that next-generation sequencing will be instrumental in the dissection 
of the genetics of non-syndromic CHM. However, as the recurrence risk of non-syndromic CHM is rela-
tively low, only a small proportion of CHM might prove to have a true monogenetic origin being caused 
by a single mutation. It is likely that next generation sequencing will yield rare variants with unknown 
significance, often novel, missense mutations in many CHM patients. Even if the functional importance 
of (each of) these rare variants can be determined by functional studies, the difficulty will be to deter-
mine the combined penetrance of these variants, as many wilf have reduced penetrance. It has been 
hypothesized that non-syndromic CHM is most likely due to multifactorial inheritance involving a mul-
titude of common variants that may be superposed on unfavorable environmental factors (Chapter 1 ). 
Nevertheless, until now little evidence for"multifactorial model" has been provided for human genetic 
disease, including CHM. Polymorphisms in genes encoding different enzymes MTHFR, MTHFD1, MTRR, 
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SCL 19A 1 and NNMT known to be implicated in the methylation cycle through the conversion of homo-
cysteine into methionine by a 1-carbon {methyl) transfer, have a limited effect on the risk of CHM, and 
represent common variants with low penetrance. No Genome-Wide Association Studies {GWAS) for 
CHM have been reported, but not much is expected from such approach as GWAS for several common 
disorders have shown that "common variants" contribute little to its genetic basis 2• Interestingly, so-
matic mutations not present in non-cardiac tissue have been found in affected cardiac tissue in a large 
fraction of CHM. The concept of somatic mutations leading to non-inherited genetic disease has been 
established in cancer by Knudson 40 years ago, but has not yet been convincingly proven for CHM as 
these studies originate from a single research group, and therefore await confirmation. 
How can patients benefit from the progress of understanding the molecular and genetic mechanisms 
involved in cardiogenesis? Clinical geneticists counseling patients and families with CHM are confront-
ed with 3 main questions: i) What is the genetic defect leading to this CHM, ii) What is the recurrence 
risk, and is prenatal diagnosis possible, and iii) Is there any (future) treatment for this genetic disease? 
The first 2 questions can be answered when the disease gene and disease-causing mutations are identi-
fied given the difficulties addressed above. Identification of the genetic defect may also pave the way 
towards therapeutic strategies interfering with the molecular pathways involved in specific CHM. This 
is illustrated by the clinical trials with drugs interfering with the TGFj3 pathway in patients with Marfan 
syndrome and related disorders with aortic pathology 3• Apart from the development of specific treat-
ments for specific forms of CHM caused by specific genes, there might be broader therapeutic implica-
tions. The large network of transcription factors including GATA, TBX, FOG, HAND and NKX not only acts 
as a developmental regulator of cardiogenesis, but is also re-employed in the adult heart in response 
to acute injury, or longstanding ischemia. Here they are thought to mediate the re-expression of the 
"fetal program" of cardiac genes 4• There is currently great interest in the therapeutic manipulation of 
these transcription factors in the adult heart to promote cardiac repair. Obviously, such strategies in-
clude drug-induced orientation of stem cells into specific cardiac cell types that can be used for cellular 
replacement in the damaged heart 56. 
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Congenital heart malformations (CHMs) are among the most common congenital defects, occurring 
in 8 out of 1000 live births. In the past decade significant progress has been made in the identification 
of genes implicated in the signaling pathways involved in cardiovascular development Human syn-
dromes with CHM (syndromic CHM) have been instrumental in the discovery ofthese disease genes 
and developmental pathways. More recently, also a number of disease genes have been identified in 
families with non-syndromic CHM. Several of these disease genes have been discovered through posi-
tional genetics starting from multiplex families with CHM. In this thesis clinical and molecular studies 
of a broad spectrum of syndromic and non-syndromic forms of CHM are reported, including laterality 
defects (Chapter 2), left ventricular outflow tract obstruction (LVOTO) anomalies (Chapter 3), arterial 
malformations (Chapter 4), and CHM associated with cardiomyopathies (Chapter 5). 
In Chapter 1 the most important forms of syndromic CHM with the different cardiovascular signaling 
pathways are summarized. Also the etiological factors implicated in non-syndromic CHM, including 
environmental factors, disease genes with high-penetrance mutations, susceptibility genes with inter-
mediate- or low-penetrance mutations, and somatic mutations are reviewed. 
In Chapter 2 clinical and genetic studies in patients with different forms of laterality defects are re-
ported. Laterality defects refer to a group of disorders with embryonic disruption of normal left- right 
patterning. They can be subdivided into two groups: malformations caused by ciliary defects (includ-
ing primary ciliary dyskinesia and hepatorenal fibrocystic syndromes), and malformations caused by 
defects in the nodal signaling pathway. Families with defects in both of these subgroups are reported 
in this thesis. 
Two fetuses and one newborn with mild cerebral ventriculomegaly and a suspected and/or confirmed 
diagnosis of primary ciliary dyskinesia (PCD) are described. These cases show that fetal cerebral ven-
triculomegaly can be a prenatal sonographic marker of PCD, certainly in fetuses with laterality defects 
or a history of a sib with PCD. 
Three families with acilia syndrome, which is an infrequent form of primary ciliary dyskinesia (PCD) 
characterized by total absence of cilia, are reported. No evidence could be found for the involvement of 
the DNA! or DNAHS genes that are commonly involved in PCD. Consequently, it is very likely that a cilia 
syndrome forms a separate entity within the heterogeneous group of PCD. 
A newborn with features of X-linked heterotaxy and VACTERL association is reported. In this patient 
we identified a 6-nucleotide insertion in the X-linked heterotaxy gene ZIC3 that is predicted to expand 
the amino-terminal polyalanine repeat from ten to twelve polyalanines. It is likely that this novel and 
de novo polyalanine expansion in the ZIC3 gene causes the VACTERL association in this patient. ZIC3 is 
thereby the tenth gene implicated in polyalanine expansion diseases. 
In Chapter 3 various families with autosomal dominant inheritance of Left Ventricular Outflow Tract 
Obstruction (LVOTO) are reported. LVOTO in these families shows a wide clinical spectrum with some 
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family members presenting with severe anomalies such as hypoplastic left heart syndrome, and others 
with only minor anomalies such as mild aortic valve stenosis. This supports the notion that all anoma-
lies of the LVOTO spectrum are developmentally related and can be caused by a single gene defect. 
Two additional large pedigrees with autosomal dominant inheritance and incomplete penetrance of 
LVOTO in combination with heart valve anomalies are reported. These families provide evidence that 
left-sided obstructive defects and thoracic aortic aneurysm may be accompanied by right-sided heart 
defects and septal defects. The disease genes in these families remain unknown: NOTCH1 mutations 
were excluded, and genome-wide linkage analysis is currently being performed. 
In Chapter 4 clinical and molecular studies of arterial tortuosity syndrome (ATS) are reported. ATS is 
a rare autosomal recessive condition characterized by cardiovascular anomalies including tortuosity, 
aneurysm and stenosis of major arteries. Nine new ATS patients from three consanguineous Moroccan 
families are described, and a clinical review of a total of35 patients with this infrequent disease is pre-
sented. In collaboration with the University of Ghent, Belgium, a genome-wide screen by homozygosity 
mapping of these three consanguineous multiplex families was performed, which resulted in the map-
ping of the ATS gene to chromosome 20q13 in a candidate region of 1.2Mb region containing 7 genes. 
Mutations in one of these genes SLQA 10, which encodes the facilitative glucose transporter GLUT10, 
were identified in 6 ATS families. GLUT1 0 deficiency is associated with upregulation ofTGFB signaling in 
the arterial wall, a finding also observed in Loeys-Dietzsyndrome, which is a similar syndrome with aor-
tic aneurysms and tortuosity. Therapeutic compounds intervening with TGFB signaling might represent 
a new, attractive treatment strategy for such disorders. 
In Chapter 5 the association of cardiomyopathies with congenital heart malformations, including het-
erotaxy, septal defects and Ebstein anomaly, is described. 
A three-generation family with nine patients affected by CHM and left isomerism is reported. The car-
diac anomalies include noncompaction of the ventricular myocardium, bradycardia, pulmonary valve 
stenosis, and secundum atrial septal defect. The laterality sequence anomalies include left bronchial 
isomerism, azygous continuation of the inferior vena cava, polysplenia and intestinal malrotation, all 
compatible with left isomerism. This new syndrome has an autosomal dominant pattern of inheritance. 
A genome-wide linkage analysis suggested linkage to chromosome 6p. 
Two unrelated neonates with septal defects and a lethal cardiomyopathy were shown to be compound 
heterozygous for two common loss-of-function mutations in the sarcomeric MYBPC3 gene. Whereas 
heterozygous mutations in sarcomeric protein genes usually lead to hypertrophic cardiomyopathy 
with clinical symptoms starting in adulthood, homozygosity or compound heterozygosity for 2 trun-
cating mutations in the MYBPC3 gene can lead to severe hypertrophic cardiomyopathy with ventricular 
noncompaction and septal defects. 
A large family with autosomal dominant inheritance of Ebstein anomaly in association with ventricular 
septal defects and non compaction cardiomyopathy is reported to have a mutation in the MYH7 gene. 
This further indicates that sarcomeric proteins, which are implicated in familial cardiomyopathies, also 
play a role in CHM. 
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In Chapter 6 the results of this thesis are discussed and put in perspective. As adequate genetic coun-
seling of families with CHM requires identification of the genetic defect, the most prominent challenge 
is to identify these mutations. However, only in a minority of families a disease-causing mutation can 
currently be identified. New technologies of high-throughput parallel sequencing on"next-generation 
sequencers" hold great promise for the identification of disease genes and mutations: these new tech-
nologies offer cost-effective sequencing of large linkage intervals in families such as presented in this 
thesis in order to identify the disease gene, or panels with large series of candidate genes in order to 
identify the disease-causing mutation. Eventually, next-generation sequencing of whole genomes or 
exomes will identify all variants contributing to non-syndromic CHM. 
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Congenitale hartafwijkingen zijn de frequentste aangeboren aandoeningen met een prevalentie van 8 
op de 1000 levendgeboren kinderen. De laatste jaren is er grate vooruitgang geboekt in de identificatie 
van de genen die een rol spelen in de verschillende signaaltransductie netwerken die betrokken zijn 
bij de hartontwikkeling. Humane syndromen met hartafwijkingen (syndromale hartafwijkingen) heb-
ben een belangrijke rol gespeeld bij de opheldering van deze genen en signaaltransductie netwerken. 
Recent heeft ook onderzoek in families met niet-syndromale hartafwijkingen tot de identificatie van 
ziektegenen geleid. Meerdere van deze genen werden ontdekt door positionele klonering in families 
met vele personen met een aangeboren hartafwijking. 
In dit proefschrift worden klinische en mo!eculaire studies beschreven in families met uiteenlopende 
vormen van syndromale en niet-syndromale hartafwijkingen. Samengevat betreft het onderzoek in fa-
milies met lateralisatieafwijkingen (Hoofdstuk 2), hartafwijkingen van de linker hart structuren (LVOTO) 
(Hoofdstuk 3), arterh?le afwijkingen (Hoofdstuk 4), en aangeboren hartafwijkingen in combinatie met 
cardiomyopathieen (Hoofdstuk 5). 
ln Hoofdstuk 1 worden de meest belangrijke vormen van syndromale hartafwijkingen en de bijbeho-
rende signaaltransductie netwerken samengevat. De verschillende etiologische factoren betrokken bij 
niet-syndromale aangeboren hartafwijkingen, waaronder omgevings-factoren, ziektegenen met hoog 
penetrante mutaties, ziektegenen met verminderd of laag penetrante mutaties en somatische muta-
ties, worden besproken. 
In Hoofdstuk2 worden verschillende klinische en moleculaire studies in path?nten met lateralisatieaf-
wijkingen beschreven. Lateralisatieafwijkingen zijn een groep van aandoeningen waarbij er een versto-
ring is van de normale links-rechts asymmetrievan de organ en en vaatstructuren in het lichaam. Erzijn 
twee subgroepen lateralisatieafwijkingen: aandoeningen die veroorzaakt worden door een verstoorde 
opbouw en/offunctie van de trilharen of cilia (waaronder primaire ciliaire dyskinesie en hepatorenale 
fibrocysteuze syndromen), en aandoeningen die veroorzaakt worden door verstoring van de werking 
van het zogenaamde NODAL signaaltransductie netwerk. In deze thesis worden families beschreven 
met lateralisatieafwijkingen die behoren tot beide groepen. 
Twee foetussen en een pasgeborene met mil de verwijding van de achterhoornen van de zijventrikels 
van de hersenen en een bevestigde en/ofvermoedde diagnose van primaire ciliaire dyskinesie (PCD) 
worden beschreven. Deze casussen illustreren dat een milde cerebrate ventriculomegalie een prena-
tale marker kan zijn voor PCD, in het bijzonder als er ook een lateralisatieafwijking aanwezig is of een 
voorgaand kind met PCD. 
Drie families met het acilia syndroom, een zeldzame vorm van PCD waarbij er afwezigheid is van de tri!-
haren, worden gerapporteerd. Moleculaire studies toonden geen aanwijzingen voor mutaties in DNA/7 
en DNAHS, de 2 genen die het vaakst betrokken zijn bij PCD. Het is daarom zeer waarschijnlijk dat acilia 
syndroom een aparte entiteit is binnen de heterogene groep van PCD. Omdat mutaties in het Foxj1 
gen in de muis acilia syndroom veroorzaken, werd dit gen in onze families onderzocht, maar mutaties 
werden niet gevonden. 
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Een pasgeborene met kenmerken van de X-gebonden vorm van heterotaxie en VACTERL associatie 
(anus atresie, larynx- en oesophagus atresie met tracheo- oesophageale fistel, dextropositie van het 
hart, persisterende vena cava superior links en een unilaterale multicysteuze nier) wordt beschreven. 
In deze patient werd een insertie van 6 nucleotiden in hetZ/C3 gen ge'ldentificeerd, welke leidt tot een 
polyalanine expansie van 1 0 naar 12 alanines. Deze nooit eerder beschreven en de novo mutatie is zeer 
waarschijnlijk de oorzaak van de VACTERL associatie in deze patient.Z/C3 is daarmee het 1 Qd~ gen in de 
groep van polyalanine aandoeningen. 
In Hoofdstuk 3 worden verschillende families met autosomaal dominant overervende linkszijdige 
obstructieve aangeboren hartafwijkingen (LVOTO) gepresenteerd. LVOTO in deze families bestaat uit 
een breed spectrum van aangeboren hartafwijkingen, waaronder ernstige aanlegafwijkingen zoals 
onderontwikkeling van de linker hartkamer (hypoplastisch linker hart) maar ook milde afwijkingen, 
zoals een bicuspide aortaklep. De observatie dat dit brede spectrum van hartafwijkingen kan worden 
veroorzaakt door een enkele mutatie ondersteunt de hypothese deze afwijkingen gerelateerd zijn in 
de embryonale hartontwikkeling. 
Twee families met autosomaal dominant overervende LVOTO met wisselende expressie en penetrantie 
worden beschreven. Hoewel er bij de meeste aangedane familieleden LVOTO bestond, werden ook an-
dere aangeboren hartafwijkingen geobserveerd, zoals septale defecten en afwijkingen van de rechts-
zijdige hartstructuren zoals pulmonaalstenose. Dit wijst erop dat LVOTO ook met rechtzijdige hartaf-
wijkingen geassocieerd kan zijn. 
In Hoofdstuk 4 worden klinische en moleculaire studies in families met arterial tortuosity syndroom 
(ATS) gerapporteerd. ATS is een autosomaal recessief overervende aandoening gekenmerkt door aan-
geboren afwijkingen van de grote en middelgrote slagaders, zoals kronkeling (tortuosity), verwijding 
(aneurysma) en vernauwing (stenosis) van de aorta en andere arterien. Negen patienten met ATS af-
komstig uit 3 families worden beschreven, en de tot 2004 gepubliceerde patienten met ATS worden 
besproken.ln samenwerking met het Universitair Ziekenhuis Gent, Belgie, werd middels een genoom 
scan homozygositeits mapping verricht in 3 consanguine Marokkaanse families, vermoedelijk afkom-
stig uit dezelfde regio in Marokko. Dit resulteerde in de lokalisatie van het ATS gen in een kandidaat 
regio van 1.2 Mb regio op chromosoom 20q13.1 waarin 7 genen waren gelegen. Tenslotte werden in 6 
ATS families mutaties ge.identificeerd in het SLC2A 10 gen, dat codeert voor een glucose transport eiwit 
GLUT1 0. GLUT1 0 deficientie is geassocieerd met upregulatie van het TGF~ netwerk in de arterie wand, 
een bevinding die ook wordt geobserveerd in het Loeys-Dietz syndroom, een vergelijkbaar syndroom 
met aorta aneurysma en kronkeling. Deze observatie biedt mogelijk een aanknopingspunt voor medi-
camenteuze therapie metTGF~ antagonisten zoals Losartan. 
In Hoofdstuk 5 wordt gerapporteerd over de associatie van cardiomyopathieen met aangeboren hart-
afwijkingen waaronder lateralisatieafvvijkingen, septale defecten en Ebstein anomalie. 
Een drie-generatie familie met 9 patienten met aangeboren hartafwijkingen en links isomerisme wordt 
beschreven. De cardiale afwijkingen betreffen noncompaction cardiomyopathie, bradycardie, pulmo-
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naalklep stenose en atrium septum defect. De lateralisatieafwijkingen betreffen bronchiaal links iso-
merisme, azygos continuatie van de vena cava inferior, polysplenie en malrotatie van de darmen, allen 
passend binnen het spectrum van links isomerisme. Met een genoom wijde scan werd in deze familie 
vermoedelijke koppeling gevonden met de chromosoom 6p21 regia. 
Bij twee pasgeborenen met septale defecten en lethale cardiomyopathie wordt heterozygotie voor 
twee vaak voorkomende truncerende mutaties in het MYBPC3 gen vastgesteld. Heterozygote mutaties 
in genen die coderen voor sarcomeer eiwitten leiden meesta! tot klinische symptomen op vo!wassen 
leeftijd, terwijl homozygote mutaties of heterozygotie voor twee truncerende mutaties in het MYBPC3 
gen !eiden tot een ernstige cardiomyopathie met kenmerken van noncompaction en met septa!e de-
fecten. 
In een grate familie met autosomaal dominant overervende Ebstein anomalie in associatie met non-
compaction cardiomyopathie en septale defecten wordt een mutatie in het MYH7 gen beschreven. Dit 
ondersteunt eerdere observaties dat defecten in sarcomeer eiwitten een rol spelen bij het ontstaan van 
aangeboren hartafwijkingen. 
ln Hoofdstuk 6 worden de resultaten van de studies van deze thesis besproken. Aangezien voor een 
adequaat genetisch advies aan patienten en/of families met aangeboren hartafwijkingen identificatie 
van de ziekteveroorzakende mutatie(s) van groot belang is, zijn technieken voor kost-effectieve de-
tectie van deze genmutaties essentieel. Nieuwe technieken zeals next-generation sequencing bieden 
grate mogelijkheden om deze mutaties op te sporen. Sequencing van grate linkage intervals in families 
zeals gepresenteerd worden in dit proefschrift wordt mogelijk zodat nieuwe ziekte genen ge·identifi-
ceerd kunnen worden. Grote panels van kandidaat genen voor aangeboren hartafwijkingen kunnen 
in individuele patienten worden geanalyseerd. Uiteindelijk zal deze next-generation sequencing ook 
toelaten om complete genom en of exomen van patienten te sequencen om zo de ziekteveroorzakende 
mutatie(s) te identificeren. 
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Hypertrabeculated heart musculature of the sa!amandra. 
From; On che hEwt and arterial Mches of salamandra macuiosa iaur. and 
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the young specimens consists in a homogeneous connective tissue, 
becomes fibrous in t.r,_e older animals. 'VVr e cannot discover any 
muscular elements in this structure. The dorsal and ventral valves 
are in a fevv larvae connected by a small endocard ridge at tbe 
left lateral ostium edge. In the adult animals this ridge is more 
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F~g. 13. Transverse section through the heart of adult Salamandra maculosa 
Laur. 
v., ventricle; s.c., sulcus coronarius; a.v.r.~ auriculo-ventricular ring; d.v., 
dorsal valve; v.v., ventral valve; La., left atrium; s.v., sinus venosus; v.p., 
pulmonary vein; p., pericardium. 
even take t...lJ.e structure of a left lateral valve. The cavity of the 
ventricle is, from the ostium atrio-ventriculare to the entrance 
of t..'le bulbus cordis, more or less L-shaped. This space is sur-
rounded by a spongy musculature, consisting of septa arranged 
chaotically and enclosi.c"J.g larger or smaller chambers (fig. 13). 
This spongy structure is developed most strongly in the apex 
of the ventricle a.'"ld in the cranial part of t..1.e ventricle especially 
most strongly on the ventral and ventrally right veritricle walL 
This latter spongy structure, in the cranial part of tc'le ventricle 
only, is in specimen nor oniy very feebly developed (fig. r2). In 
that specimen the musculature is not yet cross-striped (fig. r4, A). 
The septa change gradually in:o the ventricle wall ( corticalis). 
This ventricle wall consists L'l younger animals of a very tl:>.in 
epicardial layer, connected with the myocardium, into which the 
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Hollander, Titia Cohen-Overbeek, Ernst Schoonderwaldt, Irene Groenenberg, Margreet Husen, Anne-
Marie Westerve!d, en 'de meiden' van het secretariaat. Vee! dank aan diegenen die families verwezen 
voor verder onderzoek. Vee! heb ik in die jaren oak geleerd van Dr. Frans Los. Beste Frans, vaak heb ikje 
moeilijke situaties in aile rust zien oplossen, met grate deskundigheid.lk kon altijd om je hulp vragen, 
waarvoor dank. 
Het uitwerken van deze thesis kwam tot stand tijdens mijn werkzaamheden op de afdeling Klinische 
Genetica. Jeannette Hoogeboom, een van mijn 'opleiders': Lieve Jeannette, naar je pluis niet-pluis ge-
voel heb ik altijd geluisterd (nog steeds). lk ben je ook dankbaar voor wat je hebt neergezet in het 
Amphia Ziekenhuis, jouw enthousiasme voor het vak is daar zeker overgenomen ! Dank ook voor je 
extra supervisie op maandag. Marleen Simon, mijn kamer-maatje. Lieve Marleen, je hebt Ianger dan 
verwacht een dee I van de genetische zorg in het Amphia ziekenhuis op je genom en en daarbij ook nog 
dagelijkse beslommeringen met mij gedeeld op onze chaotische kamer.lneens stond er dan een plant-
je op mijn buro, ging je mijn 10 beschimmelde koffiekoppen afwassen of hingen er kerstballen aan 
mijn lamp. Dank! Ingrid van de Laar, mijn cardio maatje. Lieve Ingrid, vanaf 2005 gingen we intenser 
samenwerken en het is mede dankzij jou dat we in de afgelopen jaren zoveel hebben kunnen opbou-
wen bin nen de cardiogenetica. Doordat jeer in slaagde een Hartstichting beurs te krijgen kwamen er 
middelen om aan meerfamilies verder te werken. Je bent een fantastische collega en ik verheug me er 
op nog lang sa mente werken; nu benjij aan de beurt l LieveJudith V.,een jaar lang heb jeje ingespan-
nen voor de cardio counselingen en ik heb een beroep moeten doen op je zelfstandigheid. Doordat 
a lies zo goed liep heb je voor rust gezorgd en mij heel erg geholpen, dankje.lk hoop natuurlijk datje 
uiteindelijk binnen het cardioteam blijft. Dr Grazia Mancini, lieve Grazia, dank voor je inspanningen en 
betrokkenheid bij de ATS familie. 
Ook de overige coli ega's wil ik bedanken voor de collegialiteit en goede sfeer: Alice Brooks, Anja Wag-
ner, Ann eke Maat-Kievit, Fred Petrij, Gretel Oudesluijs, Rogier Oldenburg, Margriet Collee, Marieke van 
Dooren, Robert-Jan Galjaard, Lutgarde Govaerts, Yolande van Bever, en natuurlijk de assistenten, psy-
chologen en genetisch consulenten. 
Fred, dank voor al je inspanningen om de organisatie van de cardiogenetica te verbeteren. 
Het secretariaat en administratief medewerkers wil ik bedanken voor aile hulp en gezelligheid. Vooral 
Agnes natuurlijk, een rots in de branding. 
Prof.dr. Ben Oostra, beste Ben, dank voor de mogelijkheden die je biedt om binnen het DNA research lab 
aan cardiovasculaire afwijkingen te werken. En dat we dit in samenwerking met Dr. Aida Bertoli-Avella 
kunnen doen ! Dear Aida, dankzij jouw inspanningen !open de projecten rondom de verschillende 
'cardio-families: en het is altijd een plezier om met jete overleggen. Dr Dennis Dooijes, Beste Dennis, 
heel jammer vind ik het datje weg gaat;je hebt de hele cardio DNA diagnostiek in Rotterdam opgezet 
en het loopt perfect dankzij jou. Ookje enthousiasme bij nieuwe bevindingen zal ik missen, maar we 
hebben nog het een en ander af te maken en blijven hopelijk samenwerken. Prof.dr. Peter Heutink en 
Bianca de Graaf dank ik voor het werk aan de lateralisatie familie. 
Het cardiogenetica team is breder en heeft kunnen groeien dankzij het enthousiasme en de energie 
van de cardiologen en kindercardiologen van hetThoraxcentrum en Sophia kinderziekenhuis. De afge-
lopen jaren is de samenwerking sterker geworden mede dankzij de inspanningen van collega's die de 
pati€nten naar ons verwijzen. Dr Jolien Roos-Hesselink, dear Jolien, mede dank zij jouw toenemende 
verwijzingen van pati€nten en families met aortapathologie, is er de afgelopen jaren een groot bestand 
opgebouwd van families met LVOTO en aneurysma's. We hebben allerlei plannen en ik heb zin in de 
voortzetting van onze samenwerking! Ingrid Frohn-Mulder, kindercardiologe. Lieve Ingrid, al vanaf de 
tijd bij de Prenatale Diagnostiek overleg ik metje, en ben jij ons belangrijkste aanspreekpunt geworden 
voor de cardiogenetica in het Sophia kinderziekenhuis. Omdatje ook in de zorg rondom de (familiaire) 
cardiomyopathieen actief betrokken bent bij de 'vrijdag cardiogenetica bespreking: sla je een brug 
tussen kinder- en volwassen cardiologie. Dank je ook voor het gezellige overleg bij jou thuis ! Hierbij 
bedank ik tevens de andere cardiologen betrokken bij de volwassen cardiogenetica, Prof.dr. Folkert 
ten Cate en Dr. Michelle Michels, voor hun bijdrage aan het onderzoek in de verschillende families met 
(noncompaction) cardiomyopathie, beschreven in deze thesis. De volwassen cardiogenetica poli is de 
afgelopen jaren steviger neergezet dankzij de inzet van Dr. Danielle Majoor-Krakauer en het vele werk 
dat Judith Phefferkorn, genetisch consulente, heeft verricht. Lieve Judith, door jouw inzet en betrok-
kenheid bij de families met cardiomyopathieen loopt de volwassen cardiogenetica poli zo geed, je hebt 
bergen werk verzet. OokYvonne Hoedemaekers en Conny van de Meer hebben een belangrijk aandeel 
geleverd! 
Mieke Kerstjens-Frederikse en de'Groningse groep'dank ik voor de NOTCH1 analyses in de LVOTO fami-
lies en de samenwerking met betrekking tot LVOTO afwijkingen; hopelijk gaan we die nog uitbreiden. 
Aile mede-auteurs wil ik bedanken voor hun bijdrage. 
Prof.dr Paul Coucke, beste Paul, dank je voor het (DNA) werk wat jij en je collegas van het Universitair 
Ziekenhuis Gent hebben verricht in de Rotterdamse ATS families. Daarnaast dank ikjou en Veerle voor 
de vriendschap en gastvrijheid die je hebt geboden aan mij, coli ega's en familie! 
In 2005 begon ik als buitengewoon staflid in het Amphia Ziekenhuis, nadat Prof.dr. Hanne Meijers mij 
vroeg een poli op te zetten in samenwerking met de gynaecologen en kinderartsen. Beste Hanne, ik 
ben je heel dankbaar dat je me destijds deze mogelijkheid bood, het heeft mij veel plezier en voldoe-
ning in mijn werk bezorgd. 
Dr. Roger Heydanus, dr. Dimitri Papatsonis, en dr. Simone Lunshof, gynaecologen van de Prenatale Di-
agnostiek in het Amphia ziekenhuis. Beste Roger, Dimitri en Simone, dank voor aile verwijzingen en de 
prettige samenwerking. Dank ook voor jullie flexibiliteit om deze laatste maanden wat meer ruimte te 
krijgen voor het afronden van dit proefschrift en jullie belangstelling hiervoor. Helmi, Miranda en Mar-
gie, dank voor jullie perfecte (en gezellige) ondersteuning van de prenatale-genetica poli, waardoor 
het elke keer weer zo plezierig is om aan het spreekuur te beginnen. 
De kinderartsen waarmee ik intensief samenwerk dr. Stella de Man en dr. Coranne Aarts. Lieve Stella, 
jou wil ik bedanken voor de manier waarop je ruimte schept om, in een gezamenlijk spreekuur, sa men 
nate den ken over genetische diagnostiek bij kinderen met een ontwikkelingsachterstand/aangeboren 
afwijkingen. lk denk dat we een vrij unieke formule hebben! Dank ook voor alle fijne gesprekken, je 
bent meer dan aileen collega voor mij. Lieve Cora nne, ookjou dank ik voor de fijne samenwerking. 
Carla Verkooijen, lieve Carla, je bent van onschatbare waarde voor de kinder-genetica poli in het Amp-
hia en ik benje heel erg dankbaar datje mijn zaken ook'een beetje in de gaten houdt: 
De mann en van de'Erasmus room of Horror': Tom de Vries Lentsch en Ruud Koppenol. Beste Tom, het 
spijt me voor de'puinhoop' die ikje aanleverde, waardoor je heel hard hebt moeten werken.lk ben je 
enorm dankbaar voor je professionele hulp! Ruud, ookjij bedankt voor je bijdrage, en voor de brood-
nodige humor! Graag geen poppetjes op mijn promotiedag. 
Ueve Aswin, jou vriendschap is nog steeds heel belangrijk! 
Lieve Carolien, a! jaren zijn we vriendinnen en hebben lief en leed gedeeld. Bijna elke maandag logeer 
ik bij je en hierdoor heb ik niet aileen heel efficient kunnen werken maandagavond, maar kon ik ook 
elke week metje bijpraten, en de kids zien. Dankje datje er altijd bent voor mij. 
Mijn paranimfen en vriendinnen Alice Brooks en Nicolette den Hollander.lk ben heel blij datjullie naast 
mij staan. Lieve Alice, Stelling 10 gaf je mij, en het typeert ook meteen wat wij hebben. Bij jou kan ik 
terecht voor aile 'matters of the heart tijdens het werk en daarbuiten! Dank voor je vriendschap, die 
mU heel dierbaaris. Lieve Nicolette,je bent als familie voor mij. Ontelbare keren heb je me meed inge-
sproken en goede raad gegeven. Wat moet ik zonder jou? Dank voor a lies watje voor mij, Patrick en 
Stijn betekent! 
Mijn familie en (be!gische) vrienden dank ikvoor aile steun, aandacht, belangstelling en afieiding. Lieve 
Els, Godelieve, Suzanne en Maja, ikzie jullie vee! te weinig maar ik denk vaak aan aile goede momenten, 
jul!ie zijn een deer van mij. 
Mijn peter en meter, die ook voor mij zorgen. Lieve Piet, dank voor aile troost en steun die je me gaf. 
Liesbeth, jouw liefde en steun aan mama, papa, de rest van de familie en aan mij is ongelofelijk. Door 
jou (en papa) kon ik af en toe ongestoord verder werken, heel erg bedankt. Je bent een ware oma voor 
Stijn. Mama zou er blij om zijn. 
Lieve papa, dankje voor a lies watje voor mij hebt gedaan. Jouw en mama's liefde voor de natuur was 
een rode draad door ons Ieven thuis en daarna.lk hoop datje dit ook aan Stijn kunt meegeven. Dankje 
dat jeer voor Stijn altijd bent, hij is dol op opa ! 
lk began en sluit af metjou. Lief Patje, compafiero, dankje ....... voor a lies 
